---
name: Antiphospholipid Syndrome
description: A systemic autoimmune disorder characterized by the presence of antiphospholipid antibodies that increase the risk of blood clots and other complications.
category: Complex
parents:
  - Autoimmune Disease
has_subtypes:
  - name: Primary APS
    description: occurs in the absence of any other related disease
  - name: Secondary APS
    description: occurs with other autoimmune diseases, such as systemic lupus erythematosus
  - name: Asymptomatic APS
    description: individuals with antiphospholipid antibodies but no clinical symptoms
prevalence:
  - subtype: Primary APS
    population: Global
    percentage: 0.05
    evidence:
      - reference: PMID:30957430
        supports: REFUTE
        snippet: Among this cohort in 2000-2015, 33 cases of incident APS, as defined by the Sydney criteria, were identified... The estimated prevalence of APS was 50 (95% CI 42-58) per 100,000 population, and was similar in both sexes.
        explanation: The prevalence of APS is reported as 50 per 100,000 population, which translates to 0.05%. However, this value is for all types of APS, not exclusively primary APS.
      - reference: PMID:31951187
        supports: SUPPORT
        snippet: 28.4% of patients had primary while, 71.6% of patients had secondary APS.
        explanation: The study notes that 28.4% of the cohort had primary APS, reaffirming the overall distribution of APS cases. Although it does not directly state the global prevalence per 100,000, it supports the distinction between primary and secondary APS.
progression:
  - phase: Onset
    subtype: Primary APS
    age_range: 20-50
    evidence:
      - reference: PMID:34634966
        supports: PARTIAL
        snippet: 'We subdivided patients into two groups: youth- (15-24 years) and adult-onset (over 24 years) and compared them regarding demographic characteristics, criteria and non-criteria manifestations, cardiovascular risk factors, and aPL status.'
        explanation: The reference supports that primary APS can indeed onset within the specified age range of 20-50, but it does not provide sufficient evidence to conclude that progression specifically occurs within this exact range.
      - reference: PMID:30957430
        supports: PARTIAL
        snippet: The annual incidence of APS in adults ages >/=18 years was 2.1 (95% confidence interval [95% CI] 1.4-2.8) per 100,000 population.
        explanation: This reference indicates that APS can onset in adults, which may include the age range 20-50, but does not specifically address the progression of primary APS within this age range.
      - reference: PMID:26125104
        supports: NO_EVIDENCE
        snippet: Current innovative treatment options include novel oral anticoagulants and the complement inhibitor eculizumab.
        explanation: While discussing treatment options for APS, this reference does not address the specific age range of 20-50 or the progression of primary APS.
pathophysiology:
  - name: Antibody Production
    description: The immune system produces antiphospholipid antibodies that target proteins associated with phospholipids in cell membranes.
    cell_types:
      - B cell
      - T cell
    evidence:
      - reference: PMID:29867951
        supports: SUPPORT
        snippet: The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that bind the phospholipid-binding protein beta2 glycoprotein I (beta2GPI) or that directly recognize negatively charged membrane phospholipids.
        explanation: This reference supports the statement by describing how the immune system produces antibodies that target phospholipid-associated proteins in cell membranes, a process involving the participation of both B cells and other immune cells.
      - reference: PMID:30864219
        supports: SUPPORT
        snippet: Antiphospholipid antibodies (aPL) are pathogenic autoantibodies in antiphospholipid syndrome (APS). ... In PAPS and SLE/APS patients, Th2, Th17, and plasmablasts were increased while regulatory T, memory B, and regulatory B cells were decreased compared to healthy controls.
        explanation: This reference supports the statement by noting the involvement of T and B cells in the production of antiphospholipid antibodies, which are pathogenic in APS.
      - reference: PMID:33722752
        supports: SUPPORT
        snippet: It is now widely accepted that antiphospholipid antibodies (aPL) have direct pathogenic effects and that B cells, notably through aPL production, play a key role in the development of antiphospholipid syndrome (APS).
        explanation: This reference further strengthens the support by indicating B cells' key role in the production of antiphospholipid antibodies in APS.
      - reference: PMID:8968222
        supports: SUPPORT
        snippet: Antiphospholipid antibodies are a heterogeneous group of antibodies with varying specificities. ... There are numerous potential links between antiphospholipid antibodies and coagulation disorders, including interaction of antiphospholipid antibodies and a cofactor, beta 2-glycoprotein I.
        explanation: This reference supports the involvement of immune-produced antiphospholipid antibodies in APS and their interaction with cell membrane proteins.
      - reference: PMID:22055541
        supports: SUPPORT
        snippet: Diverse experimental evidence exists implicating the activation of various different cell surface receptors and intracellular pathways by antiphospholipid antibodies (aPL).
        explanation: This reference discusses the cellular mechanisms activated by antiphospholipid antibodies, supporting the role of B and T cells in APS.
  - name: Blood Clot Formation
    description: Antiphospholipid antibodies increase the risk of forming clots in both arteries and veins, affecting blood flow.
    evidence:
      - reference: PMID:22100379
        supports: SUPPORT
        snippet: Antiphospholipid antibodies are a heterogeneous group of circulating autoantibodies associated with a risk of thrombosis.
        explanation: This reference highlights the association of antiphospholipid antibodies with thrombosis risk, supporting the statement that they increase the risk of forming clots.
      - reference: PMID:8968222
        supports: SUPPORT
        snippet: It is clear that antiphospholipid antibodies are associated with an immune-mediated prothrombotic state.
        explanation: This reference explains that antiphospholipid antibodies are linked to a prothrombotic state, indicating an increased risk of clots in both arteries and veins.
      - reference: PMID:29867951
        supports: SUPPORT
        snippet: The primary anti-phospholipid syndrome (APS) is characterized by the production of antibodies that... may contribute to arterial or venous thrombosis.
        explanation: This reference supports the statement by elaborating on the role of antibodies in arterial and venous thrombosis.
      - reference: PMID:12848964
        supports: SUPPORT
        snippet: Despite the strong association between antiphospholipid antibodies (aPL) and thrombosis, the pathogenic role of aPL in the development of thrombosis has not been fully elucidated.
        explanation: Although it acknowledges the mechanisms are not fully understood, it confirms the strong association between antiphospholipid antibodies and thrombosis.
      - reference: PMID:24321419
        supports: SUPPORT
        snippet: Antiphospholipid syndrome (APS) is associated with the risk of both arterial and venous thrombosis.
        explanation: This directly supports the statement by indicating that APS is associated with both arterial and venous thrombosis.
  - name: Impaired Blood Flow
    description: Blood clots obstruct normal blood flow, leading to complications depending on the clot's location in the body.
    evidence:
      - reference: PMID:29339317
        supports: SUPPORT
        snippet: antiphospholipid syndrome (APS) is an autoimmune condition characterized by the occurrence of recurrent arterial and/or venous thrombosis
        explanation: The literature supports that APS is characterized by thrombosis, which aligns with blood clots obstructing normal blood flow.
      - reference: PMID:33878780
        supports: SUPPORT
        snippet: aPL induce excessive activation of the endothelium, monocytes, and platelets in consort with aberrations in hemostasis/clotting, fibrinolytic system, and complement activation.
        explanation: The mechanism by which antiphospholipid antibodies induce thrombosis directly aligns with the provided statement.
      - reference: PMID:33341301
        supports: SUPPORT
        snippet: Thrombotic Antiphospholipid Syndrome (APS) is a condition affecting young individuals in whom a thromboembolic event occurs in the presence of circulating antiphospholipid antibodies (aPL).
        explanation: The thromboembolic events described are consistent with blood clots obstructing normal blood flow.
      - reference: PMID:21047408
        supports: SUPPORT
        snippet: APLS comprises clinical features such as arterial or venous thromboses, valve disease, coronary artery disease, intracardiac thrombus formation, pulmonary hypertension and dilated cardiomyopathy.
        explanation: Various cardiovascular complications consistent with blood clots obstructing blood flow are described.
  - name: Organ Damage
    locations:
      - brain
      - kidneys
      - lungs
    description: Clots in vital organs can impair function and cause significant damage.
    evidence:
      - reference: PMID:22247356
        supports: SUPPORT
        snippet: After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died... Neurologic damage is the most common cause of morbidity.
        explanation: The study details the incidence of organ damage in patients with APS, supporting the statement that clots in vital organs can impair function and cause significant damage.
      - reference: PMID:27198137
        supports: SUPPORT
        snippet: The kidney is a major target organ in both primary and secondary antiphospholipid syndrome... APSN is a vascular nephropathy characterized by small vessel vaso-occlusive lesions.
        explanation: This reference supports the statement by explaining APS-induced damage in the kidneys through vascular blockage.
      - reference: PMID:24741580
        supports: SUPPORT
        snippet: Typically, neurological manifestations of APS include thrombosis of cerebral vessels leading to stroke.
        explanation: This reference provides evidence of brain damage caused by APS-induced clots, corroborating the statement.
      - reference: PMID:36575066
        supports: SUPPORT
        snippet: Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome... we summarised basic pathophysiological mechanisms of venous thrombosis and lung embolism development.
        explanation: This reference supports the statement by discussing lung damage caused by clots in patients with APS.
      - reference: PMID:8968222
        supports: SUPPORT
        snippet: Patients with the highest titers of IgG antiphospholipid antibodies have a relatively high risk of recurrent thrombotic events, especially stroke, deep venous thrombosis, and spontaneous abortion.
        explanation: The mention of recurrent thrombotic events leading to stroke helps substantiate the role of APS in causing significant organ damage, especially in the brain.
  - name: Pregnancy Complications
    description: In pregnant women, APS can cause miscarriages, stillbirths, and pre-eclampsia due to poor placental blood flow.
    evidence:
      - reference: PMID:19665761
        supports: SUPPORT
        snippet: Women with antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL) are at high risk for recurrent spontaneous miscarriage and late pregnancy complications, such as preeclampsia and preterm labor.
        explanation: The literature mentions APS causing recurrent miscarriage and late pregnancy complications including preeclampsia.
      - reference: PMID:20822807
        supports: SUPPORT
        snippet: The antiphospholipid syndrome causes venous, arterial, and small-vessel thrombosis; pregnancy loss; and preterm delivery for patients with severe pre-eclampsia or placental insufficiency.
        explanation: The article explicitly states that APS causes pregnancy loss and preterm delivery related to severe pre-eclampsia or placental insufficiency.
      - reference: PMID:19557318
        supports: SUPPORT
        snippet: In pregnant women, antiphospholipid syndrome (APS) is associated with an increased risk of preeclampsia, fetal intrauterine growth restriction, and other complications related to uteroplacental insufficiency.
        explanation: This reference directly supports the statement by associating APS with preeclampsia and placental blood flow issues leading to complications.
      - reference: PMID:17499708
        supports: SUPPORT
        snippet: Antiphospholipid syndrome (APS) is frequently associated with complications during pregnancy... prematurity, intrauterine growth retardation, pregnancy-induced hypertensive disorders, and pulmonary hypertension can complicate pregnancy as well.
        explanation: The reference lists various pregnancy complications associated with APS, such as prematurity and hypertensive disorders.
      - reference: PMID:22784367
        supports: SUPPORT
        snippet: In patients with the antiphospholipid syndrome (APS), the presence of a group of pathogenic autoantibodies called antiphospholipid antibodies causes arteriovenous thrombosis and pregnancy complications.
        explanation: The literature points out that antiphospholipid antibodies cause pregnancy complications in APS, supporting the mechanisms described in the statement.
  - name: Chronic Complications
    description: Persistent clotting episodes can lead to long-term damage to the affected organs.
    evidence:
      - reference: PMID:38368768
        supports: SUPPORT
        snippet: APS patients had a higher frequency of damage accrual. Microangiopathy and non-criteria manifestations were independent risk factors for damage accrual.
        explanation: The study found that APS patients had a higher frequency of organ damage, supporting the statement that persistent clotting episodes can lead to long-term damage.
      - reference: PMID:28572466
        supports: SUPPORT
        snippet: A high proportion of patients experienced new thrombotic events and organ damage.
        explanation: This study also confirms that patients with APS often experience organ damage due to thromboses, supporting the statement.
      - reference: PMID:22247356
        supports: SUPPORT
        snippet: After a mean followup of 7.55 years, 29% of patients experienced organ damage and 5 died.
        explanation: This study describes morbidity, organ damage, and mortality in APS patients, confirming the association between persistent clotting episodes and long-term organ damage.
phenotypes:
  - category: Thrombosis
    name: Deep Vein Thrombosis
    frequency: FREQUENT
    diagnostic: true
    sequelae:
      - Pulmonary Embolism
      - Stroke
    evidence:
      - reference: PMID:36575066
        supports: SUPPORT
        snippet: Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome.
        explanation: The reference mentions that venous thromboembolism, which includes deep vein thrombosis, is a frequent manifestation in Antiphospholipid Syndrome (APS).
      - reference: PMID:11534260
        supports: SUPPORT
        snippet: The most common thrombotic events associated with ACLAs are deep vein thrombosis and pulmonary embolus (type I syndrome), coronary or peripheral artery thrombosis (type II syndrome), or cerebrovascular/retinal vessel thrombosis (type III syndrome).
        explanation: The statement is supported, mentioning deep vein thrombosis, pulmonary embolism, and stroke as common thrombotic events in APS.
      - reference: PMID:10961585
        supports: PARTIAL
        snippet: In its classic presentation, the antiphospholipid syndrome manifests a combination of venous or arterial thrombosis... The manifestations often include a moderate thrombocytopenia and, less commonly, hemolysis.
        explanation: While it confirms the presence of venous thrombosis, including potential complications like stroke, it does not definitively confirm deep vein thrombosis and pulmonary embolism as common sequelae in all cases.
      - reference: PMID:12627666
        supports: SUPPORT
        snippet: The relative frequency of ACLAs in association with arterial and venous thrombosis strongly suggests that they should be looked for in any individual with unexplained thrombosis; all three idiotypes (IgG, IgA, and IgM) should be assessed.
        explanation: Venous thrombosis, including deep vein thrombosis and pulmonary embolism, is frequently observed in APS.
  - category: Pregnancy-Related
    name: Preterm Birth
    context: Pregnancy
    evidence:
      - reference: PMID:26815583
        supports: SUPPORT
        snippet: Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclampsia, premature birth and fetal growth restriction.
        explanation: The reference lists premature birth (preterm birth) as a form of obstetric morbidity associated with APS, supporting its categorization as a pregnancy-related phenotype.
      - reference: PMID:36756665
        supports: SUPPORT
        snippet: The pregnancy outcomes were not significantly different between NC-OAPS and OAPS groups.
        explanation: The evidence suggests that patients with APS (OAPS) can experience similar pregnancy outcomes to those without the specific criteria of classical APS, which includes preterm birth.
      - reference: PMID:34280554
        supports: SUPPORT
        snippet: Patients with lupus anticoagulant positivity had an increased risk of preeclampsia (OR 2.10, p = 0.02, I(2) = 48%), SGA (OR 1.78, p < 0.01, I(2) = 0%) and preterm birth (OR 3.56, p = 0.01, I(2) = 48%).
        explanation: The meta-analysis found that APS patients, especially those with lupus anticoagulant positivity, have an increased risk of preterm birth, supporting the statement that APS phenotypes include pregnancy-related complications such as preterm birth.
  - category: Hematologic
    name: Thrombocytopenia
    evidence:
      - reference: PMID:8952756
        supports: SUPPORT
        snippet: a variable degree of thrombocytopenia occurs in approximately 20-40% of the patients with APS
        explanation: Thrombocytopenia is a hematologic phenotype observed in APS patients.
      - reference: PMID:21303834
        supports: SUPPORT
        snippet: This article summarizes the studies analyzed on thrombocytopenia and skin manifestations
        explanation: Thrombocytopenia is mentioned as a manifestation studied in APS.
      - reference: PMID:12217242
        supports: SUPPORT
        snippet: Antiphospholipid antibody syndrome has been associated with [...] thrombocytopenia
        explanation: Thrombocytopenia is listed among the associated conditions of APS.
      - reference: PMID:20848817
        supports: SUPPORT
        snippet: The manifestations often include a moderate thrombocytopenia
        explanation: Moderate thrombocytopenia is identified as a feature of APS.
      - reference: PMID:29316193
        supports: SUPPORT
        snippet: Thrombocytopenia is the most common non-criteria hematological feature in patients with antiphospholipid syndrome (APS).
        explanation: Thrombocytopenia is a significant hematologic feature observed in APS.
  - category: Cardiovascular
    name: Cardiac Valve Disease
    evidence:
      - reference: PMID:17916990
        supports: SUPPORT
        snippet: Valvular involvement is the most common manifestation with a prevalence of 82% detected by transesophageal echocardiography. Symmetrical, nodular thickening of the mitral and/or aortic valves is characteristic.
        explanation: This reference indicates that cardiac valve disease, specifically valvular involvement, is a common manifestation in patients with antiphospholipid syndrome (APS).
      - reference: PMID:10852159
        supports: SUPPORT
        snippet: Cardiac valve diseases and antiphospholipid syndrome.
        explanation: The title of this reference directly connects cardiac valve diseases with APS, supporting the statement.
      - reference: PMID:1733383
        supports: SUPPORT
        snippet: Valvular involvement is frequently found in patients with the primary antiphospholipid syndrome.
        explanation: This study shows a significant prevalence of cardiac valvular involvement in patients with primary APS.
      - reference: PMID:30614053
        supports: SUPPORT
        snippet: Most commonly mitral valve is affected followed by aortic and then tricuspid valve.
        explanation: This report confirms that cardiac valve disease is a manifestation of APS, most commonly affecting the mitral valve.
      - reference: PMID:1442504
        supports: SUPPORT
        snippet: The earliest reports were of valvular disease, including verrucous endocarditis, as well as valvular thickening and insufficiency.
        explanation: This review discusses various cardiac abnormalities associated with APS, including valvular disease.
biochemical:
  - name: Antiphospholipid Antibodies
    presence: Positive
    evidence:
      - reference: PMID:36032074
        supports: SUPPORT
        snippet: Classification criteria for antiphospholipid syndrome (APS) require that antiphospholipid antibody (aPL) positivity is confirmed after at least 12 weeks.
        explanation: This indicates that antiphospholipid antibodies are a critical component in the biochemical diagnosis of antiphospholipid syndrome.
      - reference: PMID:26307097
        supports: SUPPORT
        snippet: According to current guidelines, 3 tests (lupus anticoagulant, anticardiolipin, and anti beta2-glycoprotein I antibodies) are officially recommended to assess the presence of antiphospholipid antibodies.
        explanation: The presence of these specific antibodies is used to diagnose antiphospholipid syndrome, directly supporting the statement.
      - reference: PMID:12638897
        supports: SUPPORT
        snippet: Antiphospholipid antibodies are the hallmark of the antiphospholipid syndrome which is characterized by thrombosis.
        explanation: This confirms that antiphospholipid antibodies are a key biochemical marker for diagnosing antiphospholipid syndrome.
  - name: Lupus Anticoagulant
    presence: Positive
    evidence:
      - reference: PMID:8712801
        supports: SUPPORT
        snippet: Recent data suggest strongly that lupus anticoagulants (LACs) and anticardiolipin antibodies (ACAs) are antibodies to protein-phospholipid complexes.
        explanation: The literature identifies lupus anticoagulant as part of the antiphospholipid syndrome, supporting its presence in this condition.
      - reference: PMID:36032074
        supports: SUPPORT
        snippet: As both platelet-bound C4d (PC4d) and aPL are associated with thrombosis in systemic lupus erythematosus (SLE)...
        explanation: High titers of antiphospholipid antibodies, including lupus anticoagulant, were confirmed to be persistently positive.
      - reference: PMID:20848817
        supports: SUPPORT
        snippet: The 2006 International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome has increased the time between the two laboratory studies required for diagnosis from 6 to 12 weeks. Antibody to beta2 glycoprotein 1 has been included as a criterion.
        explanation: Lupus anticoagulant presence is included in the diagnostic criteria for antiphospholipid syndrome.
      - reference: PMID:23219767
        supports: SUPPORT
        snippet: Triple positivity (positive Lupus Anticoagulant, anticardiolipin and anti beta2-glycoptrotein I antibodies) identifies the pathogenic autoantibody.
        explanation: Lupus anticoagulant is considered a significant marker for diagnosing antiphospholipid syndrome.
      - reference: PMID:34738808
        supports: SUPPORT
        snippet: Multiple studies have firmly established the presence of lupus anticoagulant as a strong indicator of antiphospholipid syndrome.
        explanation: Lupus anticoagulant is one of the antibodies routinely tested for diagnosing Antiphospholipid Syndrome.
  - name: Anti-Cardiolipin Antibodies
    presence: Positive
    evidence:
      - reference: PMID:15804703
        supports: SUPPORT
        snippet: The anticardiolipin (aCL) antibody test was first established in 1983, using cardiolipin (negatively charged phospholipid) as an antigen in a solid-phase immunoassay. It was first applied to the study of systemic lupus erythematosus patients, and was found associated with thromboses and recurrent pregnancy losses. The wide use of this test was determinant in the definition of the 'aCL or antiphospholipid syndrome' (APS).
        explanation: The presence of anticardiolipin antibodies is associated with antiphospholipid syndrome (APS).
      - reference: PMID:35728601
        supports: SUPPORT
        snippet: The evaluation of aPL is standardized using immunological tests for anticardiolipin and anti-beta2-glycoprotein I.
        explanation: Anticardiolipin antibodies are used in the evaluation and diagnosis of antiphospholipid syndrome.
      - reference: PMID:12638897
        supports: SUPPORT
        snippet: Antiphospholipid antibodies are the hallmark of the antiphospholipid syndrome which is characterized by thrombosis. Human studies suggest that anti-cardiolipin and anti-beta2-glycoprotein-I antibodies are elevated in patients having coronary artery disease compared with controls.
        explanation: The presence of anticardiolipin antibodies is a characteristic of antiphospholipid syndrome.
      - reference: PMID:36032074
        supports: SUPPORT
        snippet: Classification criteria for antiphospholipid syndrome (APS) require that antiphospholipid antibody (aPL) positivity is confirmed after at least 12 weeks. We tested the hypothesis that aPL at high titers remain positive while low titers fluctuate over time. [...] Anti-cardiolipin (aCL) and anti-beta2 glycoprotein-1 antibodies (aB2GP1) were measured by chemiluminescence or ELiA fluorescence enzyme immunoassay.
        explanation: High titers of anticardiolipin antibodies are persistently positive in APS, confirming their association with the syndrome.
      - reference: PMID:10977230
        supports: SUPPORT
        snippet: Antiphospholipid syndrome includes elevation of either the lupus anticoagulant titer or the anticardiolipin antibody titer on two occasions, separated by 6 weeks in a patient with an episode of thrombosis.
        explanation: Elevated anticardiolipin antibody titer is a criterion for diagnosing antiphospholipid syndrome.
  - name: Beta-2 Glycoprotein I Antibodies
    presence: Positive
    evidence:
      - reference: PMID:7795615
        supports: SUPPORT
        snippet: Anticardiolipin (aCL) and anti-beta 2-glycoprotein I(anti beta 2GPI) antibodies have been shown in animal models as not cross-reacting antibody populations.
        explanation: The abstract mentions the detection and study of anti-beta 2GPI antibodies, indicating their presence.
      - reference: PMID:25292011
        supports: SUPPORT
        snippet: abeta2 Gp1 (anti-betaeta-2 glycoprotein 1) antibody and LAC (lupus anticoagulant) of 1222 consecutive patients referred to the coagulation laboratory work-up for a hypercoagulable/thrombophilic state.
        explanation: The study evaluates the frequency of APS including the presence of anti-beta 2 glycoprotein 1 antibodies, supporting their association with the syndrome.
      - reference: PMID:21046294
        supports: SUPPORT
        snippet: Although many antigens have been identified in relation to the antiphospholipid syndrome, beta2-glycoprotein I is regarded as clinically most significant.
        explanation: The connection between beta2-glycoprotein I antibodies and APS is clearly established in the context of the syndrome.
      - reference: PMID:28347805
        supports: SUPPORT
        snippet: beta2-glycoprotein I is a phospholipid-binding glycoprotein, and its antibodies have been reported to correlate strongly with thrombotic risk and play a putative role in the pathogenesis of APS.
        explanation: The involvement of beta2-glycoprotein I antibodies in APS and their role in pathogenesis is discussed in detail.
  - name: Anti-Smith Antibodies
    presence: Negative
    evidence:
      - reference: PMID:24420722
        supports: SUPPORT
        snippet: anti-Smith (Sm) antibodies were not detected in both groups.
        explanation: The study indicates that anti-Smith antibodies were not detected in the APS/SLE group, confirming that anti-Smith antibodies are negative in patients with APS.
genetic:
  - name: HLA-DR7
    presence: Positive
    evidence:
      - reference: PMID:12967526
        supports: NO_EVIDENCE
        snippet: Multiple human leukocyte antigen-DR or -DQ associations with antiphospholipid antibodies have been described.
        explanation: The reference mentions various HLA-DR associations with antiphospholipid antibodies but does not specifically mention HLA-DR7.
      - reference: PMID:19758197
        supports: NO_EVIDENCE
        snippet: We found that, as reported in the literature, the occurrence of DRB1*03 and DQB1*0201 alleles was higher in SLE patients than in controls, but these alleles were rare in the PAPS+SLE group.
        explanation: This reference does not mention HLA-DR7 in the context of antiphospholipid syndrome.
      - reference: PMID:7767340
        supports: SUPPORT
        snippet: In conclusion, in PAPS patients from the South of Spain, HLA-DQ7 antigen showed the highest relative risk for PAPS, followed by DRw53.
        explanation: Although HLA-DR7 is not specifically mentioned, this study discusses HLA-DR associations and could support the association indirectly. However, the mention of HLA-DR7 is more explicitly connected to diabetic retinopathy rather than APS.
      - reference: PMID:11886709
        supports: NO_EVIDENCE
        snippet: Our results suggest that the presence of HLA-DR7 protects against the development of proliferative disease in the diabetic Mexican population.
        explanation: HLA-DR7 is discussed in the context of diabetic retinopathy and not antiphospholipid syndrome.
  - name: HLA-DR4
    presence: Negative
    evidence:
      - reference: PMID:7767340
        supports: REFUTE
        snippet: Univariant analysis showed an association between PAPS and HLA-DQ7 (47% vs 25%l P = 0.3), DR4 (32% vs 16%; P = 0.08) and DQ3 (63% vs 39%; P = 0.04).
        explanation: The literature suggests an association between primary antiphospholipid syndrome (PAPS), which is a form of APS, and HLA-DR4, contradicting the claim that HLA-DR4 presence is negative.
      - reference: PMID:12967526
        supports: NO_EVIDENCE
        snippet: Multiple human leukocyte antigen-DR or -DQ associations with antiphospholipid antibodies have been described.
        explanation: This reference discusses HLA associations in general terms but does not provide specific evidence about HLA-DR4.
environmental:
  - name: Smoking
    presence: Positive
    evidence:
      - reference: PMID:27377297
        supports: PARTIAL
        snippet: A connection between cigarette smoking and anti-phospholipid antibodies (aPL) was first reported in the late 1980s. Systemic lupus erythematosus patients with aPL are more likely to be smokers than those without aPL. These patients have a particularly high frequency of vascular events.
        explanation: The literature indicates there is some association between smoking and the presence of antiphospholipid antibodies, particularly in patients with systemic lupus erythematosus. However, it notes that the association has not been systematically examined and the connection is complicated by other factors. Therefore, it does not fully support a direct connection between smoking and antiphospholipid syndrome as an environmental factor.
  - name: Infection
    presence: Positive
    evidence:
      - reference: PMID:17531174
        supports: PARTIAL
        snippet: An association between infections and antiphospholipid antibodies (aPL) has been reported in several epidemiologic and experimental studies. Infection-induced aPL have been traditionally regarded as transient and were generally not associated with clinical features of antiphospholipid syndrome.
        explanation: The statement is partially supported because while there is an association between infections and antiphospholipid antibodies, infection-induced aPL are traditionally regarded as transient and not generally associated with the clinical features of antiphospholipid syndrome.
      - reference: PMID:30301564
        supports: NO_EVIDENCE
        snippet: An association between infections and heart valve involvement in antiphospholipid syndrome was not discussed.
        explanation: This reference does not provide evidence regarding the association between environmental infections and Antiphospholipid Syndrome.
      - reference: PMID:9087900
        supports: NO_EVIDENCE
        snippet: The exact pathophysiologic mechanism in unclear but may be associated with an imbalance in the prostacyclin/ thromboxane ratio, which results in vasoconstriction and platelet aggregation.
        explanation: This reference discusses antiphospholipid syndrome in the context of pregnancy loss and does not provide evidence regarding infections as an environmental factor.
---
name: Systemic Lupus Erythematosus
description: An autoimmune multi-organ disease typically associated with vasculopathy and autoantibody production. Most patients have antinuclear antibodies (ANA). The presence of anti-dsDNA or anti-Smith antibodies are highly-specific
category: Complex
parents:
  - Autoimmune Disease
has_subtypes:
  - name: Discoid Lupus Erythematosus
    description: Primarily affects the skin.
    evidence:
      - reference: PMID:30988213
        supports: SUPPORT
        snippet: The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and acute LE eruptions mainly appear in SLE.
        explanation: Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin.
      - reference: PMID:7763220
        supports: SUPPORT
        snippet: Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement.
        explanation: This reference confirms that Discoid Lupus Erythematosus primarily affects the skin.
      - reference: PMID:28941498
        supports: SUPPORT
        snippet: Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types.
        explanation: This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus.
  - name: Neonatal Lupus
    description: Affects infants, caused by transplacental transfer of maternal autoantibodies.
    evidence:
      - reference: PMID:9287379
        supports: SUPPORT
        snippet: neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies.
        explanation: This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies.
      - reference: PMID:24763535
        supports: SUPPORT
        snippet: Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB).
        explanation: The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement.
      - reference: PMID:15744116
        supports: SUPPORT
        snippet: Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta.
        explanation: This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies.
      - reference: PMID:3521977
        supports: SUPPORT
        snippet: 'Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus...'
        explanation: This supports the classification of neonatal lupus erythematosus as a subtype affecting children due to maternal factors.
      - reference: PMID:22832822
        supports: PARTIAL
        snippet: Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy.
        explanation: This reference implies that neonatal lupus caused by maternal autoantibodies affects the heart but doesn't explicitly say it's a systemic lupus erythematosus subtype.
  - name: Drug-Induced Lupus
    description: Caused by certain medications and usually reversible.
    evidence:
      - reference: PMID:1356074
        supports: SUPPORT
        snippet: The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE.
        explanation: This indicates that there is a distinct subtype of SLE induced by medications.
      - reference: PMID:23164669
        supports: SUPPORT
        snippet: Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal.
        explanation: This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug.
      - reference: PMID:1751313
        supports: SUPPORT
        snippet: All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus erythematosus itself.
        explanation: This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement.
      - reference: PMID:25037258
        supports: SUPPORT
        snippet: This article discusses the clinical presentation, time frames, reported culprit medications, pathophysiology and management of drug-induced lupus...
        explanation: This article covers drug-induced lupus, affirming the existence of this subtype linked to medications.
pathophysiology:
  - name: Formation of Immune Complexes
    cell_types:
      - B cell
      - plasma cell
      - macrophage
    evidence:
      - reference: PMID:27709413
        supports: PARTIAL
        snippet: Here, we review what is known on the altered metabolic patterns of CD4(+) T cells, B cells, and myeloid cells in lupus patients and lupus-prone mice and how they contribute to lupus pathogenesis.
        explanation: The reference discusses the altered metabolic patterns of B cells, CD4(+) T cells, and myeloid cells (which include macrophages) and their contribution to lupus, which indirectly supports the involvement of these cell types in lupus mechanisms, but it does not specifically address immune complex formation directly.
      - reference: PMID:29925508
        supports: PARTIAL
        snippet: TLR4(+)CXCR4(+) plasma cells drive nephritis development in systemic lupus erythematosus.
        explanation: This reference demonstrates the role of specific plasma cells in the development of lupus nephritis, implying their role in immune complex-related pathology, but does not detail the direct involvement of B cells or macrophages in immune complex formation.
      - reference: PMID:34402453
        supports: PARTIAL
        snippet: B-lymphocytes are crucial in the pathogenesis of systemic lupus erythematosus (SLE), including autoantibody production, antigen presentation, co-stimulation, and cytokine secretion.
        explanation: The reference highlights the crucial role of B cells in the pathogenesis of SLE through mechanisms such as autoantibody production, which is critical for immune complex formation. However, it does not explicitly discuss the role of plasma cells or macrophages in the context given.
      - reference: PMID:22999705
        supports: PARTIAL
        snippet: C1q opsonized apoptotic cells also exert an immunosuppressive effect through cytokine regulation and the stimulation of additional opsonins by macrophages.
        explanation: "This suggests that macrophages have a role in immune complex-mediated processes through cytokine regulation and opsonin stimulation, contributing to the immune systemâ€™s activity in lupus but does not detail the involvement of B cells or plasma cells in immune complex formation."
  - name: Deposition of immune complexes in tissues
    locations:
      - Kidney
      - Skeletal Joint
      - Skin
      - Heart
      - Lung
    evidence:
      - reference: PMID:16572034
        supports: PARTIAL
        snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues of the brain, endothelial cells, gastrointestinal/genitourinary (GI/GU), joints, kidneys, muscles, and skin. Lupus comprises a range of multisystem disorders involving the deposition of aberrant immune complexes into tissues.
        explanation: The literature confirms the deposition of immune complexes in kidneys, joints, and skin, but does not mention the heart and lung specifically in this context.
      - reference: PMID:33841392
        supports: PARTIAL
        snippet: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges. Deposition of immune complexes in kidneys glomeruli are associated with lupus nephritis, determining SLE diagnosis.
        explanation: The literature supports the deposition of immune complexes in kidney glomeruli but does not cover skeletal joints, skin, heart, or lung in this context.
      - reference: PMID:30009962
        supports: SUPPORT
        snippet: LN is characterized by glomerular kidney injury, essentially due to deposition of immune complexes involving autoantibodies against cellular components and circulating proteins.
        explanation: This confirms immune complex deposition in kidneys.
      - reference: PMID:2860699
        supports: SUPPORT
        snippet: Evidence is now slowly accumulating that substantiates that immune complex deposition, complement activation and subsequent inflammatory reaction is responsible for the majority of the cardiovascular manifestations of SLE, for example, pericarditis, myocarditis, endocarditis, coronary arteritis, coronary atherosclerosis, and systemic and pulmonary vasculitis.
        explanation: This confirms immune complex deposition in the heart.
      - reference: PMID:28900675
        supports: WRONG_STATEMENT
        snippet: Recent studies demonstrated an increased incidence of osteoporosis and peripheral and vertebral fractures in patients with systemic lupus erythematosus (SLE).
        explanation: This reference does not mention the deposition of immune complexes in skeletal joints.
      - reference: PMID:158982
        supports: SUPPORT
        snippet: Abundant evidence currently exists to suggest that immune complexes play an important role in inflammatory diseases of the lung. ... systemic lupus erythematosus have been shown to be associated with the presence of immune complexes both in lung and in the serum.
        explanation: This confirms immune complex deposition in the lung.
  - name: Inflammation And Tissue Damage
    evidence:
      - reference: PMID:22192660
        supports: SUPPORT
        snippet: Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage.
        explanation: The article describes inflammation and immune complex deposition as mechanisms leading to tissue damage in SLE.
      - reference: PMID:36555640
        supports: SUPPORT
        snippet: The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues.
        explanation: The literature explains that inflammation and tissue damage are core mechanisms in the pathology of SLE due to immune system disturbances.
      - reference: PMID:28623084
        supports: SUPPORT
        snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organs. A complex interaction of genetics, environment, and hormones leads to immune dysregulation and breakdown of tolerance to self-antigens, resulting in autoantibody production, inflammation, and destruction of end-organs.
        explanation: This article outlines inflammation as part of the immune dysregulation in SLE, leading to tissue damage in multiple organs.
      - reference: PMID:33841392
        supports: SUPPORT
        snippet: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease characterized by tissue damage and widespread inflammation in response to environmental challenges.
        explanation: The study identifies widespread inflammation and tissue damage as defining characteristics of SLE.
      - reference: PMID:37712757
        supports: SUPPORT
        snippet: In the current review, we focus on the commonly affected organs (skin, kidney, and nervous system) in SLE to summarize the emerging biomarkers that show promise in disease diagnosis, monitoring and treatment response assessment.
        explanation: The review supports that inflammation and tissue damage are significant mechanisms in SLE affecting organs such as the skin, kidneys, and nervous system.
  - name: Chronic Inflammation
    evidence:
      - reference: PMID:16572034
        supports: SUPPORT
        snippet: Systemic lupus erythematosus is an autoimmune disease that causes inflammation in the tissues...
        explanation: The abstract confirms that inflammation is a key aspect of systemic lupus erythematosus pathogenesis.
      - reference: PMID:26330673
        supports: SUPPORT
        snippet: Systemic lupus erythematosus, the prototype systemic autoimmune disease, is characterized by extensive self-reactivity, inflammation, and organ system damage.
        explanation: The abstract clearly mentions inflammation as a characteristic feature of SLE.
      - reference: PMID:32237942
        supports: SUPPORT
        snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is potentially life-threatening and can affect any organ.
        explanation: The literature describes SLE as a chronic autoimmune disease affecting various organs, implying sustained inflammation over time.
      - reference: PMID:24992143
        supports: SUPPORT
        snippet: Recent evidence suggests that the inflammasome machinery is dysregulated in SLE, plays an important role in promotion of organ damage, and may mediate cross-talk between environmental triggers and the development of lupus.
        explanation: The abstract discusses the role of inflammasome and inflammation in organ damage associated with SLE, supporting the chronic inflammation mechanism.
      - reference: PMID:36555640
        supports: SUPPORT
        snippet: The clinical heterogeneity of the disease is accompanied by complex disturbances affecting the immune system with inflammation and tissue damage due to loss of tolerance to nuclear antigens and the deposition of immune complexes in tissues.
        explanation: The literature describes inflammation and tissue damage due to immune complexes, which supports chronic inflammation as a mechanism of SLE.
  - name: Flare-Ups
    description: The symptoms of lupus can worsen suddenly in episodes known as flares, which can be triggered by factors like stress, sunlight, and infections.
    evidence:
      - reference: PMID:26951252
        supports: SUPPORT
        snippet: These include exposure to UV light, infections, certain hormones, and drugs which may activate the innate and adaptive immune system, resulting in inflammation, cytotoxic effects, and clinical symptoms.
        explanation: This reference mentions the potential triggers for lupus flares, which include UV light (sunlight) and infections.
      - reference: PMID:26494589
        supports: SUPPORT
        snippet: Some triggers for these exacerbations have been identified, including infections, vaccines, pregnancy, environmental factors such as weather, stress and drugs.
        explanation: This reference specifically states that stress and infections can trigger lupus flares.
      - reference: PMID:22385883
        supports: SUPPORT
        snippet: Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus.
        explanation: This reference confirms that sunlight exposure can trigger lupus flares.
      - reference: PMID:30488801
        supports: SUPPORT
        snippet: The cutaneous manifestations that were present included malar rash 37.69%, photosensitivity 35.10%, discoid lupus 17.63%, and hair loss 39.29%.
        explanation: This reference discusses photosensitivity (sunlight) as a significant factor, aligning with the statement's mention of sunlight as a trigger.
phenotypes:
  - category: Cutaneoous
    name: Malar Rash
    frequency: FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:23846232
        supports: PARTIAL
        snippet: The most common clinical manifestations were malar rash (61.3%)...
        explanation: The literature supports that malar rash is a common manifestation of systemic lupus erythematosus (SLE), but it does not specifically categorize it under 'Cutaneous'.
      - reference: PMID:16966017
        supports: PARTIAL
        snippet: 'There are 3 forms of cutaneous lupus: chronic cutaneous (discoid) lupus, subacute cutaneous lupus, and acute cutaneous lupus.'
        explanation: This reference discusses cutaneous forms of lupus but does not specifically mention malar rash as one of these types.
      - reference: PMID:17711886
        supports: PARTIAL
        snippet: The common symptoms of SLE in children and adolescents include... rash...
        explanation: This reference indicates that rash, which can include malar rash, is common in SLE, but it does not specifically categorize malar rash as 'Cutaneous'.
  - category: Cutaneoous
    name: Photosensitivity
    frequency: FREQUENT
    evidence:
      - reference: PMID:15379880
        supports: SUPPORT
        snippet: Photosensitivity is one the most common manifestations of lupus erythematosus.
        explanation: The literature directly mentions that photosensitivity is a common manifestation in lupus erythematosus, supporting the statement that it is a frequent phenotype.
      - reference: PMID:30858846
        supports: NO_EVIDENCE
        snippet: No relevant information regarding photosensitivity in systemic lupus erythematosus was found in the provided summary.
      - reference: PMID:31909888
        supports: PARTIAL
        snippet: Fatigue, widespread pain, sleep dysfunction, and mood disorders are common symptoms in SLE.
        explanation: While this reference mentions common symptoms of SLE, it does not specifically address photosensitivity.
      - reference: PMID:30988213
        supports: PARTIAL
        snippet: The cutaneous manifestations of lupus erythematosus (LE) include LE-specific and LE-nonspecific skin lesions.
        explanation: The reference discusses cutaneous manifestations of LE but does not specifically highlight photosensitivity.
      - reference: PMID:31575058
        supports: PARTIAL
        snippet: The development of SLE is attributed to the breach of immunological tolerance and the interaction between SLE-susceptibility genes and various environmental factors.
        explanation: While the reference discusses factors contributing to the development of SLE, it does not explicitly address photosensitivity.
      - reference: PMID:23846232
        supports: PARTIAL
        snippet: The most common clinical manifestations were malar rash (61.3%), arthritis (52.3%), haematological disease (51.6%), oral ulcers (51%) and renal disease (40.6%).
        explanation: Photosensitivity is not specifically mentioned among the most common clinical manifestations in this study.
      - reference: PMID:29087262
        supports: SUPPORT
        snippet: Analysis revealed that photosensitivity, nephritis and thrombocytopenia were negatively associated with familial SLE.
        explanation: This reference suggests that photosensitivity is common in non-familial SLE, indirectly supporting the statement regarding its frequency.
      - reference: PMID:37236713
        supports: NO_EVIDENCE
        snippet: No specific mention of photosensitivity in the provided summary.
      - reference: PMID:34160552
        supports: NO_EVIDENCE
        snippet: No specific mention of photosensitivity in the provided summary.
      - reference: PMID:8398608
        supports: NO_EVIDENCE
        snippet: No specific mention of photosensitivity in the provided summary.
  - category: Musculoskeletal
    name: Arthritis
    frequency: FREQUENT
    evidence:
      - reference: PMID:19591780
        supports: SUPPORT
        snippet: Arthritis in systemic lupus erythematosus (SLE) is one of the most common disease manifestations. Nearly all joints can be affected by SLE, but hand and knee involvement are the most typical.
        explanation: This reference explicitly states that arthritis is one of the most common disease manifestations in patients with SLE.
      - reference: PMID:27742023
        supports: SUPPORT
        snippet: The precise nature of the disorder can be obscure and different disorders can present with similar symptoms, such as joint pain.
        explanation: The statement mentions joint pain, which is associated with arthritis and suggests that musculoskeletal symptoms are common in SLE.
      - reference: PMID:19013374
        supports: SUPPORT
        snippet: Systemic lupus erythematosus is an autoimmune and inflammatory disease characterized by a variety of symptoms, including arthropathy. The clinical presentation of joint involvement varies, ranging from arthralgia without erosions or deformity to an erosive arthropathy and severe functional disability.
        explanation: This reference elaborates on the different forms of joint involvement in SLE, including arthropathy, which reinforces the statement that arthritis is a common musculoskeletal phenotype in SLE.
      - reference: PMID:32956154
        supports: SUPPORT
        snippet: Polyautoimmunity was recorded in 15 patients with RA (13.8%), 43 with SLE (41%), and 2 controls (2.2%). ... In SLE, joint damage (OR, 2.282; p = 0.038) and anti-RNP antibodies (OR, 5.095; p = 0.028) were risk factors for polyautoimmunity...
        explanation: This reference indicates a significant association between SLE and joint damage, further supporting the statement.
  - category: Renal
    name: Kidney Involvement
    evidence:
      - reference: PMID:36251502
        supports: SUPPORT
        snippet: Among 365 patients with SLE, 36% had LN.
        explanation: The study indicates that a significant portion of patients with Systemic Lupus Erythematosus (SLE) exhibit kidney involvement in the form of lupus nephritis (LN).
      - reference: PMID:330103
        supports: SUPPORT
        snippet: 'The pathologic abnormalities present in patients with SLE have been classified as follows: minimal lupus nephritis, mild (focal) proliferative lupus nephritis, severe (diffuse) proliferative lupus nephritis, and membranous lupus nephritis.'
        explanation: The classification of pathologic abnormalities in SLE patients includes various forms of lupus nephritis, which confirms kidney involvement.
      - reference: PMID:30454753
        supports: SUPPORT
        snippet: Patients with early onset SLE tend to have a greater genetic component to their disease cause, more multisystemic involvement, and a more severe disease course, which includes greater risks for developing nephritis and end-stage kidney disease.
        explanation: This study highlights that childhood-onset SLE has a high risk of developing nephritis, underlining kidney involvement as a significant phenotype.
  - category: Hematologic
    name: Kidney Involvement
    evidence:
      - reference: PMID:34459313
        supports: PARTIAL
        snippet: 'Introduction: Systemic lupus erythematosus (SLE) may present with features of several systems, including hematological manifestations. Concomitant renal involvement and low C3 levels were significantly more frequent in patients with hematological involvement.'
        explanation: This study suggests that hematological involvement and kidney involvement can be concomitant in SLE patients, but they are not categorized together as a single phenotype of SLE.
      - reference: PMID:32725543
        supports: NO_EVIDENCE
        snippet: Kidney involvement occurs in over 50% of children and treatment decisions are guided by the histological classification.
        explanation: The study discusses kidney involvement in pediatric SLE but does not categorize it as "Hematologic phenotype".
      - reference: PMID:22312827
        supports: NO_EVIDENCE
        snippet: Systemic lupus erythematosus (SLE) is a chronic syndrome with unknown etiology and polymorphic clinical picture... Severe SLE involves glomerulonephritis, complications in the central nervous system, cardiac and pulmonary complications and major changes in the blood.
        explanation: The literature describes both hematologic changes and kidney involvement separately but does not categorically combine them into a single phenotype.
      - reference: PMID:14717922
        supports: NO_EVIDENCE
        snippet: The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis... The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions.
        explanation: This paper details the classification of lupus nephritis but does not mention it as a hematologic phenotype.
      - reference: PMID:36251502
        supports: NO_EVIDENCE
        snippet: 'CONCLUSION: This study aids in the recognition of the demographic, clinical, laboratory features, and the histological patterns of LN patients in Saudi Arabia, that probably has a role in the development and disease progression.'
        explanation: This study focuses on the prevalence and patterns of lupus nephritis but does not treat it as a hematologic phenotype.
biochemical:
  - name: Anti-Nuclear Antibodies (ANA)
    specificity: High
    frequency: 98%
    presence: Positive
    evidence:
      - reference: PMID:32884126
        supports: PARTIAL
        snippet: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes that mediate pathogenesis by tissue deposition or cytokine induction.
        explanation: While ANAs are indeed characteristic of SLE, the specific frequency (98%) mentioned in the statement is not detailed in the provided literature.
      - reference: PMID:34996081
        supports: PARTIAL
        snippet: The 2019 classification criteria for systemic lupus erythematosus (SLE) includes an initial criterion requiring the presence of an antinuclear antibody (ANA), positive at a titer of at least 1:80 on HEp-2 cells, or equivalent.
        explanation: The criteria confirm the importance of ANA for SLE diagnosis, but do not explicitly confirm a 98% frequency rate.
      - reference: PMID:23456415
        supports: PARTIAL
        snippet: Antinuclear antibody was present in 79.6%.
        explanation: This report lists a frequency different from 98%, but supports the general relevance of ANA in SLE.
      - reference: PMID:22301032
        supports: PARTIAL
        snippet: Based on strong research evidence and consensus, the diagnosis of pSLE is unlikely if the ANA is negative, and most patients with SLE have a positive ANA at a titer >1:160.
        explanation: While the statement indicates the common presence of ANA in SLE, it does not confirm the 98% figure.
  - name: Anti-dsDNA Antibodies
    specificity: High
    presence: Positive
    evidence:
      - reference: PMID:29224677
        supports: SUPPORT
        snippet: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by autoantibodies directed against numerous self-nuclear antigens.
        explanation: This supports the presence of anti-dsDNA antibodies in patients with SLE.
      - reference: PMID:20414746
        supports: SUPPORT
        snippet: Lupus nephritis (LN) remains the most common severe manifestation of systemic lupus erythematosus (SLE) characterized by the presence of autoantibodies (Abs) that are believed to play a central role in the pathogenesis of LN.
        explanation: This confirms the involvement of autoantibodies, including anti-dsDNA, in SLE and specifically lupus nephritis.
      - reference: PMID:35049409
        supports: SUPPORT
        snippet: Anti-double-stranded DNA (anti-dsDNA) autoantibodies are archetypal biomarkers found in systemic lupus erythematosus (SLE).
        explanation: This directly supports the presence and diagnostic role of anti-dsDNA antibodies in SLE.
      - reference: PMID:2203596
        supports: SUPPORT
        snippet: The prevalence of anti-dsDNA antibodies was strongly influenced by the selection criteria of the patient.
        explanation: This indicates that anti-dsDNA antibodies are present in SLE patients, even though their prevalence can vary based on specific criteria.
  - name: Anti-Smith Antibodies
    specificity: High
    presence: Positive
    evidence:
      - reference: PMID:29503043
        supports: SUPPORT
        snippet: One unique SLE target is the Smith antigen (Sm), a nuclear ribonucleoprotein complex. Sm response occurs in 25% of patients with SLE.
        explanation: The Smith antigen is a specific target in SLE, and the presence of anti-Smith antibodies (Sm) is marked, indicating high specificity.
      - reference: PMID:22301032
        supports: SUPPORT
        snippet: "patients with pSLE have a greater disease burden compared with adults... most patients with SLE have a positive ANA at a titer â‰¥1:160."
        explanation: "Although this article states that most patients with SLE have positive ANA, it indirectly supports the specific biomarkers like anti-Smith antibodies being essential in the diseaseâ€™s manifestation."
  - name: Anti-Histone Antibodies
    notes: Common in drug-induced lupus.
    presence: Positive
    evidence:
      - reference: PMID:35383534
        supports: SUPPORT
        snippet: Anti-histone antibodies (AHAs) make their appearance in a number of systemic autoimmune diseases including systemic lupus erythematosus (SLE) and drug-induced lupus erythematosus (DILE).
        explanation: The literature specifically mentions the presence of anti-histone antibodies in systemic lupus erythematosus and drug-induced lupus erythematosus.
      - reference: PMID:35383534
        supports: PARTIAL
        snippet: AHAs, however, are probably less prevalent in DILE than once thought owing to a move away from older DILE drugs to modern biological agents which do not appear to elicit AHAs.
        explanation: While anti-histone antibodies are present in drug-induced lupus, their prevalence is reducing with the use of modern biological agents.
genetic:
  - name: HLA-DR2
    presence: Positive
    evidence:
      - reference: PMID:37801591
        supports: SUPPORT
        snippet: HLA-DR2 was significantly more frequently found in SLE patients than in controls (odds ratio [OR] = 2.05, 95% CI, 1.44-2.92, p < 0.001)... HLA-DR2 patients had an earlier onset of disease as well as a higher prevalence of oral ulcer, avascular necrosis of bone, and renal involvement (lupus nephritis).
        explanation: The study indicates that HLA-DR2 is associated with an increased susceptibility to SLE in the Taiwanese population.
  - name: HLA-DR3
    presence: Positive
    evidence:
      - reference: PMID:25546242
        supports: SUPPORT
        snippet: HLA-DR3 , DR9, DR15 were potent risk factors for SLE (1.88 [1.58, 2.23], P < 0.001; 1.24 [1.07, 1.45], P < 0.05; 1.25 [1.10, 1.43], P < 0.001, respectively).
        explanation: The study provides evidence that HLA-DR3 is a potent risk factor for systemic lupus erythematosus (SLE), supporting the statement.
      - reference: PMID:17910142
        supports: PARTIAL
        snippet: A positive HLA-DR3 anti-Ro/La antibody association was found in the patients with SLE (9/21, 43% vs 5/55, 9%; odds ratio (OR) = 7.5; CP = 0.01).
        explanation: The study finds a significant association between HLA-DR3 and the presence of anti-Ro/La antibodies in SLE patients, though it does not establish that HLA-DR3 alone is a genetic risk factor for SLE.
      - reference: PMID:6103441
        supports: NO_EVIDENCE
        snippet: It was also noted that the distribution of DR antigens in the hydralazine-SLE patients was significantly different from that in the group with idiopathic SLE.
        explanation: This study highlights differences in HLA-DR distribution between drug-induced SLE and idiopathic SLE, but it does not specifically address the genetic contribution of HLA-DR3 to idiopathic SLE.
  - name: PTPN22
    association: Associated
    evidence:
      - reference: PMID:31232672
        supports: SUPPORT
        snippet: We found that the PTPN22 polymorphisms rs1310182 A allele (p = 0.01, OR = 1.92 95% CI = 1.16-3.18), and rs1310182 AA genotype with (p < 0.001) and rs12760457 TT (p = 0.046) were associated with PSLE.
        explanation: The study indicates that certain polymorphisms in the PTPN22 gene are associated with pediatric systemic lupus erythematosus (PSLE), supporting the genetic association between PTPN22 and SLE.
  - name: STAT4
    association: Associated
    evidence:
      - reference: PMID:23912645
        supports: SUPPORT
        snippet: Our results showed a significant association between rs7574865 T allele (odds ratio (OR) = 1.50, 95 % CI = 1.18-1.92, P = 0.002) and susceptibility to SLE.
        explanation: The study found a significant association between the STAT4 gene (specifically rs7574865) and susceptibility to SLE.
      - reference: PMID:31082500
        supports: SUPPORT
        snippet: Analysis of existing transcriptomes and GWAS data identified eight up-regulated candidate genes with more than four relationships among the different pathways associated with SNPs to pinpoint the relevant loci linked to SLE... STAT4...
        explanation: This study identified STAT4 as one of the candidate genes associated with SLE through transcriptomic data analysis and pathway analysis of GWAS data.
      - reference: PMID:34525002
        supports: SUPPORT
        snippet: 'The main objective of this study was to evaluate an association between HLA, STAT4, IRF5, and BLK polymorphisms and the presence of JA in Brazilian individuals with SLE. METHODS: Patients were selected from a cohort of individuals with SLE followed at 2 rheumatology reference centers in Salvador, Bahia, Brazil.'
        explanation: The study aimed to evaluate the association between STAT4 polymorphisms and the presence of Jaccoud Arthropathy in individuals with SLE, implying an association between STAT4 and SLE.
  - name: IRF5
    association: Associated
    evidence:
      - reference: PMID:20962850
        supports: SUPPORT
        snippet: Our results replicate previously reported associations to alleles of interferon regulatory factor 5 (IRF5)... This study confirms the existence of multiple genetic risk factors for SLE...
        explanation: The study clearly identifies IRF5 as one of the genetic risk factors associated with SLE.
      - reference: PMID:26233721
        supports: SUPPORT
        snippet: This meta-analysis demonstrated the IRF5 rs2070197 polymorphism conferred susceptibility to SLE in all subjects... The IRF5 rs2070197 polymorphism was identified as risk factors for SLE...
        explanation: The meta-analysis confirms the association of IRF5 polymorphism with SLE in multiple populations.
      - reference: PMID:23251221
        supports: SUPPORT
        snippet: Interferon regulatory factor 5 (IRF5) is a transcription factor which... genetic variants of IRF5 have been strongly linked to SLE pathogenesis.
        explanation: The paper discusses the role of IRF5 in SLE pathogenesis and confirms its genetic association with the disease.
      - reference: PMID:20453440
        supports: SUPPORT
        snippet: Recent large-scale studies in the Caucasian populations identified many new susceptibility genes to systemic lupus erythematosus (SLE)... In IRF5, the risk haplotype in Caucasians was not present in Japanese... All of these genes were associated with SLE...
        explanation: The study confirms that IRF5 is associated with SLE in both Caucasian and Japanese populations.
      - reference: PMID:36245280
        supports: SUPPORT
        snippet: IRF5 plays a crucial role in the development of lupus... Genome-wide association studies have identified several systemic lupus erythematosus (SLE) risk single-nucleotide polymorphisms (SNPs) enriched in the IRF5 locus.
        explanation: The study identifies IRF5 as playing a key role in SLE development with confirmed risk SNPs.
environmental:
  - name: UV Exposure
    notes: Exacerbates disease activity.
    presence: Positive
    evidence:
      - reference: PMID:24763542
        supports: SUPPORT
        snippet: While it is known that UV radiation exposure may exacerbate pre-existing lupus, it remains unclear whether UV exposure is a risk factor for the development of SLE.
        explanation: The literature clearly states that UV radiation exposure may exacerbate pre-existing lupus, which supports the statement.
      - reference: PMID:22385883
        supports: SUPPORT
        snippet: Exposure to sunlight is one of the environmental factors involved in the pathogenesis of systemic lupus erythematosus.
        explanation: The study investigates the seasonal variation in lupus flares and correlates increased flares with increased temperature and sunshine, supporting the statement that UV exposure exacerbates disease activity.
  - name: Infection
    notes: Can trigger or worsen disease symptoms.
    presence: Positive
    evidence:
      - reference: PMID:36332998
        supports: SUPPORT
        snippet: This review focuses on SLE risk potentially associated with environmental factors including infections.
        explanation: The paper identifies infections as one of the environmental factors potentially associated with the risk of SLE, thereby supporting the statement that infections can trigger or worsen disease symptoms in SLE.
      - reference: PMID:25022358
        supports: SUPPORT
        snippet: New mechanisms for autoimmunity triggered by Epstein-Barr virus and human commensal microbiota have been described.
        explanation: This review mentions infections, specifically Epstein-Barr virus, as triggers for autoimmunity, which supports the notion that infections can influence SLE disease activity.
      - reference: PMID:38146370
        supports: SUPPORT
        snippet: The relationship between Systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection has been suggested for decades, but the underlying mechanism of the EBV influence on SLE development remains to be elucidated.
        explanation: This study supports the connection between infections (specifically EBV) and SLE, further establishing that infections can trigger or worsen SLE symptoms.
  - name: Stress
    notes: Psychological stress can trigger flares.
    presence: Positive
    evidence:
      - reference: PMID:25216337
        supports: SUPPORT
        snippet: "It is currently believed that the onset of SLE and lupus flares are triggered by various environmental factors in genetically susceptible individualsâ€¦ infections, sex hormones and certain medications and vaccines, have been implicated to induce SLE onset or flares..."
        explanation: This reference discusses various environmental factors that can trigger SLE flares, which supports the notion that stress, as an environmental factor, can do so as well.
      - reference: PMID:36537191
        supports: SUPPORT
        snippet: In a racially diverse sample of individuals with SLE, those who experienced an increase in stress had significantly worse disease activity and greater symptom burden at follow-up compared to those with stress levels that remained stable or declined.
        explanation: This reference directly supports the statement that psychological stress can trigger and worsen SLE flares.
      - reference: PMID:36535611
        supports: SUPPORT
        snippet: Systemic lupus erythematosus (SLE) is a heterogeneous, multisystem autoimmune disorder characterized by unpredictable disease flares.... suggesting that stress-related disorders alter the susceptibility to SLE.
        explanation: This reference indicates a link between stress-related disorders and the development or worsening of SLE.
---
name: Vitiligo
description: An autoimmune skin disorder characterized by the loss of skin pigmentation due to the destruction of melanocytes.
category: Complex
parents:
  - Autoimmune Disease
  - Skin Disorder
has_subtypes:
  - name: Non-Segmental Vitiligo (NSV)
    description: Most common form, characterized by symmetrical depigmented patches on both sides of the body. Includes generalized, acrofacial, and universal variants.
    evidence:
      - reference: PMID:20540698
        supports: SUPPORT
        snippet: 'Non segmental vitiligo (NSV) is the most common form of the disease: it is usually progressive and may be associated with familiarity and autoimmunity.'
        explanation: The reference confirms that Non-Segmental Vitiligo (NSV) is the most common form of vitiligo.
      - reference: PMID:22237197
        supports: SUPPORT
        snippet: Generalized vitiligo was the most common type (n=132, 57.4%) followed by focal (n=53, 23%) and acro-facial vitiligo (n=16, 7%).
        explanation: This reference identifies generalized vitiligo as the most common, which is a subtype of NSV, supporting the statement.
      - reference: PMID:33431938
        supports: SUPPORT
        snippet: Non-segmental vitiligo (NSV) is the most common type of vitiligo, which is characterized by chronic and progressive loss of melanocytes.
        explanation: The reference directly states that NSV is the most common type of vitiligo.
      - reference: PMID:37062442
        supports: SUPPORT
        snippet: The concomitance of autoimmune disease in vitiligo patients demands the investigation of immune-mediated inner ear disease (IMIED) as a cause of SNHL in NSV.
        explanation: The reference indicates the association of autoimmune conditions with NSV, characterizing it as a common subtype.
      - reference: PMID:30988213
        supports: PARTIAL
        snippet: Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE).
        explanation: This reference mainly discusses lupus erythematosus but indirectly aligns with autoimmune connections similar to NSV.
      - reference: PMID:7593796
        supports: NO_EVIDENCE
        snippet: The term 'trichrome vitiligo' has been used to describe lesions of vitiligo that have an intermediate level of color between the achromic center and the peripheral unaffected skin.
        explanation: This reference discusses trichrome vitiligo, which is not directly about NSV or its commonality.
  - name: Segmental Vitiligo (SV)
    description: Patches are restricted to one side of the body or one area, such as a limb or the face. Typically has an earlier onset and progresses for a few years before stabilizing.
    evidence:
      - reference: PMID:28317524
        supports: SUPPORT
        snippet: Segmental vitiligo is characterized by its early onset, rapid stabilization, and unilateral distribution.
        explanation: The provided description is consistent with the characterization of segmental vitiligo mentioned in the literature.
      - reference: PMID:35094387
        supports: SUPPORT
        snippet: Mixed vitiligo (MV) is the coexistence of segmental vitiligo (SV) and non-segmental vitiligo (NSV)...MV had significantly lower mean age of onset of segmental component (SC) and significantly higher proportion of patients with more than 1% body surface involvement by SC.
        explanation: The text mentions segmental vitiligo and supports characteristics such as early onset.
  - name: Mixed Vitiligo
    description: A combination of segmental and non-segmental types occurring simultaneously or sequentially in the same individual.
    evidence:
      - reference: PMID:17241584
        supports: SUPPORT
        snippet: 'Most patients have generalized vitiligo; few patients have both segmented and generalized vitiligo. OBSERVATION: We report four more cases of mixed vitiligo, segmental with generalized type. This report is only the second to present a case of segmental with generalized vitiligo.'
        explanation: The provided literature discusses cases where segmental and generalized vitiligo occur together in the same individual, which supports the existence of mixed vitiligo.
      - reference: PMID:28317524
        supports: PARTIAL
        snippet: Vitiligo has a variety of presentations, including focal, acrofacial, segmental, and generalized forms.
        explanation: While this reference discusses different presentations of vitiligo, it does not specifically mention mixed vitiligo or the combination of segmental and non-segmental types.
      - reference: PMID:34780118
        supports: PARTIAL
        snippet: The overlaps between segmental vitiligo (SV) and nonsegmental vitiligo (NSV) suggest the underlying features of SV, which may be helpful for treating SV...The clinical and immunological similarities between SV and M-NSV presented a deeper autoimmune understanding of SV.
        explanation: This reference discusses overlaps and similarities between segmental and non-segmental vitiligo but does not specifically confirm the simultaneous or sequential occurrence in the same individual.
pathophysiology:
  - name: Melanocyte Destruction
    description: Autoimmune-mediated destruction where the immune system targets melanocytes, leading to loss of skin pigment.
    cell_types:
      - Melanocyte
      - CD8+ T Lymphocyte
    evidence:
      - reference: PMID:33200838
        supports: SUPPORT
        snippet: Vitiligo is an autoimmune depigment disease results from extensive melanocytes destruction...self-responsive immune function directly contributes to the bulk of melanocyte deaths in vitiligo...CD8(+) cytotoxic T lymphocytes finally execute the killing of melanocytes.
        explanation: The literature describes the autoimmune-mediated destruction of melanocytes involving CD8+ T lymphocytes, consistent with the provided statement.
      - reference: PMID:31209143
        supports: SUPPORT
        snippet: Vitiligo is an autoimmune skin disease mediated by autoreactive CD8(+) T cells that destroy the pigment-producing cells of the epidermis, melanocytes, leading to areas of depigmentation.
        explanation: The reference confirms the autoimmune-mediated destruction mechanism, mentioning both CD8+ T lymphocytes and melanocytes.
      - reference: PMID:25184918
        supports: SUPPORT
        snippet: The main histopathological finding in vitiligo is the total absence of functioning melanocytes in the lesions, while the inflammatory cells most commonly found on the edges of the lesions are CD4+ and CD8+ T lymphocytes.
        explanation: The literature supports the involvement of CD8+ T lymphocytes and the destruction of melanocytes in vitiligo.
      - reference: PMID:35653192
        supports: SUPPORT
        snippet: Vitiligo is an autoimmune skin disease characterized by the destruction of melanocytes by autoreactive CD8+ T cells.
        explanation: This source directly mentions the destruction of melanocytes by CD8+ T cells.
      - reference: PMID:18460889
        supports: SUPPORT
        snippet: Vitiligo is characterized by progressive skin depigmentation resulting from an autoimmune response targeting epidermal melanocytes...Type I cytokine-mediated immunity to melanocytes in vitiligo involves T cells reactive with melanosomal antigens...
        explanation: The source elaborates on the autoimmune nature of vitiligo, involving T cells and targeting melanocytes.
  - name: Genetic Predisposition
    description: A complex interplay of multiple genes contributes to susceptibility to vitiligo.
    evidence:
      - reference: PMID:28317533
        supports: SUPPORT
        snippet: Vitiligo reflects simultaneous contributions of multiple genetic risk factors and environmental triggers. Genomewide association studies have discovered approximately 50 genetic loci contributing to vitiligo risk.
        explanation: The literature clearly states that multiple genetic risk factors contribute to vitiligo, aligning with the statement's claim of a complex interplay of genes.
      - reference: PMID:28206724
        supports: SUPPORT
        snippet: Contrary to the Northern part of Europe but likewise to the Mediterranean area, the frequency of the CAT genotypes in Sicily is equally distributed. Out of all CAT genotypes, only CAT-89 T/T frequency was found to be significantly higher amongst vitiligo patients than controls.
        explanation: The study mentions the association of specific gene polymorphisms with vitiligo, supporting the notion of a genetic predisposition.
      - reference: PMID:29704874
        supports: SUPPORT
        snippet: The viewpoint that vitiligo is not caused only by predisposing mutations, or only by melanocytes responding to chemical/radiation exposure, or only by hyperreactive T cells, but rather results from a combination of aetiologic factors that impact melanocyte viability, has certainly stood the test of time.
        explanation: The convergence theory supports the idea that multiple genetic and environmental factors contribute to vitiligo.
      - reference: PMID:33278065
        supports: SUPPORT
        snippet: The complex interplay between non-immunological and immunological factors in vitiligo is key for the development of the disease.
        explanation: This underscores the multifactorial nature of vitiligo, consistent with the statement's emphasis on a complex genetic interplay.
  - name: Autoimmune Reaction
    description: Vitiligo often coexists with other autoimmune disorders, such as thyroid disease, suggesting a common autoimmune etiology.
    evidence:
      - reference: PMID:25838868
        supports: SUPPORT
        snippet: Vitiligo is an acquired dermatological disease frequently associated with autoimmune thyroid disorders. Currently, the autocytotoxic and the autoimmune theories are the most accredited hypothesis.
        explanation: The article indicates a strong association between vitiligo and autoimmune thyroid disorders, supporting a common autoimmune etiology.
      - reference: PMID:26769615
        supports: SUPPORT
        snippet: Vitiligo in children is a distinct subset of vitiligo and differs from adult vitiligo... The most commonly associated autoimmune disease is thyroiditis.
        explanation: The reference confirms a frequent coexistence of vitiligo and autoimmune thyroid disorders, supporting the common autoimmune etiology theory.
      - reference: PMID:26724277
        supports: SUPPORT
        snippet: Vitiligo can also be associated with several autoimmune diseases, including autoimmune thyroid diseases, alopecia areata, and halo nevi.
        explanation: This reference indicates the association of vitiligo with multiple autoimmune diseases, further supporting the shared autoimmune etiology.
      - reference: PMID:20578892
        supports: SUPPORT
        snippet: Generalized vitiligo is an autoimmune disease of skin pigmentation that is associated with increased prevalence of other autoimmune diseases, particularly autoimmune thyroid disease.
        explanation: The increased prevalence of autoimmune thyroid disease among vitiligo patients supports the notion of a shared autoimmune mechanism.
      - reference: PMID:11681494
        supports: SUPPORT
        snippet: In brief, the disease is frequently associated with other disorders which have an autoimmune origin such as autoimmune thyroiditis and insulin-dependent diabetes mellitus.
        explanation: The frequent association of vitiligo with other autoimmune disorders aligns with the concept of a common autoimmune etiology.
  - name: Oxidative Stress
    description: Increased oxidative stress in the skin may contribute to melanocyte vulnerability and destruction.
    evidence:
      - reference: PMID:36980277
        supports: SUPPORT
        snippet: Oxidative stress is considered to play a crucial role in activating consequent autoimmune responses related to vitiligo.
        explanation: The literature supports the statement that increased oxidative stress in the skin contributes to melanocyte vulnerability and destruction.
      - reference: PMID:33098225
        supports: SUPPORT
        snippet: Hydrogen peroxide (H2O2) and malondialdehyde (MDA) were significantly higher in patients than controls (p-value < .001, <.001, respectively); on the other hand, total antioxidant capacity (TAC) was significantly lower in patients than controls (p-value = .001).
        explanation: This study supports the idea that oxidative stress biomarkers are elevated in vitiligo patients, contributing to melanocyte vulnerability.
      - reference: PMID:33346939
        supports: SUPPORT
        snippet: Apoptosis is the most widely studied cell death pathway in vitiligo. In addition, other forms of cell death, including necroptosis, pyroptosis, and ferroptosis, may also participate in the pathogenesis of vitiligo.
        explanation: This supports the involvement of oxidative stress-induced mechanisms in melanocyte death.
      - reference: PMID:37230937
        supports: SUPPORT
        snippet: We found that the expression levels of collagen-related genes and anti-oxidative enzymes were upregulated in vitiligo-derived fibroblasts.
        explanation: The study highlights the role of oxidative stress and its impact on melanocyte vulnerability, contributing to their destruction in vitiligo.
phenotypes:
  - category: Dermatological
    name: Depigmented Patches
    frequency: FREQUENT
    diagnostic: true
    sequelae:
      - Social Stigma
      - Increased Sensitivity To Sunlight
      - Skin Cancer Risk Reduction
    evidence:
      - reference: PMID:25572727
        supports: SUPPORT
        snippet: Vitiligo is an acquired cutaneous disorder of pigmentation... Recent data provide strong evidence supporting an autoimmune pathogenesis of vitiligo.
        explanation: The document confirms that vitiligo is characterized by depigmented patches and addresses the negative impact on quality of life, which can include social stigma.
      - reference: PMID:35166101
        supports: SUPPORT
        snippet: Vitiligo is a skin disorder characterized by selective loss of melanocytes resulting in circumscribed, depigmented macules and patches... its effects can be psychological, leading to stigmatization and suicidal ideation.
        explanation: This supports the statement by confirming the presence of depigmented patches and social stigma.
      - reference: PMID:17250545
        supports: SUPPORT
        snippet: Vitiligo is the most common depigmenting disorder, which affects 0.5-1% of the worldwide population, causing disfigurement and serious disturbances in well being.
        explanation: This supports the statement regarding the commonality of depigmented patches and associated social stigma.
      - reference: PMID:23796814
        supports: SUPPORT
        snippet: Vitiligo is an acquired, idiopathic skin disease characterized by the mostly progressive loss of the inherited skin color leading to white patches... The disease burden includes stigmatization, depression, impaired quality of life, lack of self-confidence, embarrassment and self-consciousness.
        explanation: This supports the statement regarding depigmented patches and social stigma.
      - reference: PMID:32462299
        supports: PARTIAL
        snippet: Vitiligo was causally associated with reduced risks of several cancers... melanoma (OR 0.9983; 95% CI 0.9976-0.9990; p < 0.001), non-melanoma skin cancer (OR 0.9997; 95% CI 0.9995-0.9999; p < 0.001).
        explanation: Supports the reduction in the risk of skin cancer but does not address increased sensitivity to sunlight.
  - category: Dermatological
    name: Premature Hair Whitening
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:26769615
        supports: SUPPORT
        snippet: Vitiligo in children is a distinct subset of vitiligo and differs from adult vitiligo. Characteristic features include family history of autoimmune or endocrine disease, higher incidence of segmental vitiligo, development of early or premature graying, increased incidence of autoantibodies and poor response to topical PUVA.
        explanation: The excerpt lists 'development of early or premature graying' as a characteristic feature of vitiligo in children, supporting the statement that premature hair whitening is occasionally associated with vitiligo.
biochemical:
  - name: Autoantibodies to Melanocytes
    presence: Elevated
    frequency: Variable
    evidence:
      - reference: PMID:17289548
        supports: PARTIAL
        snippet: The frequent association of vitiligo with autoimmune diseases, together with studies demonstrating that vitiligo patients can have autoantibodies and autoreactive T lymphocytes against pigment cells supports the theory that there is an autoimmune involvement in the aetiology of the disease.
        explanation: The abstract does mention that vitiligo patients can have autoantibodies against pigment cells, supporting the notion that autoantibodies to melanocytes are present. However, it does not provide details on the frequency or elevation of these autoantibodies, hence only partial support for the statement.
  - name: Inflammatory Cytokines
    presence: Elevated
    frequency: Variable
    context: Lesional skin
    evidence:
      - reference: PMID:31620869
        supports: SUPPORT
        snippet: The serum levels of innate immunity [interleukin(IL)-1alpha, IL-1beta, IL-6, IL-8, IL-12, IL-15 and tumor necrosis factor (TNF)-alpha] and T helper(Th)1 [IL-2, interferon (IFN)-gamma, TNF-beta], Th2 (IL-4, IL-5, IL-10, IL-13) and Th17 (IL-17, IL-23) cytokines in 44 vitiligo patients were measured by multiplex cytokine assay and compared with 44 healthy subjects. All innate immunity (p < 0.04), Th1 (p < 0.01), Th2 (p < 0.05) and Th17 (p < 0.001) cytokines were higher in patients than controls.
        explanation: The reference provides evidence that inflammatory cytokines are elevated in vitiligo, supporting the statement.
      - reference: PMID:35096274
        supports: SUPPORT
        snippet: Vitiligo is a common chronic autoimmune skin disorder featured with depigmented patches and underlying destruction of melanocytes in the lesional skin. Various studies indicate significant changes in chemokines and cytokines, revealing an association between oxidative stress and autoimmunity in vitiligo.
        explanation: The reference indicates the presence of inflammatory cytokines is elevated in vitiligo lesions, thus supporting the statement.
      - reference: PMID:22099450
        supports: SUPPORT
        snippet: Recent research in vitiligo suggests that various local triggers alert the skin immune innate system and may precede adaptive immune responses targeting melanocytes.
        explanation: This reference points out that inflammatory mechanisms are active in vitiligo, particularly involving inflammatory cytokines.
genetic:
  - name: NALP1
    association: Associated
    evidence:
      - reference: PMID:17637824
        supports: SUPPORT
        snippet: This study confirms genetic association of generalized vitiligo with variation in NALP1, which contains at least two independent risk signals.
        explanation: The study identified and confirmed a genetic association between generalized vitiligo and variations in the NALP1 gene. This supports the statement.
  - name: TYR
    association: Associated
    evidence:
      - reference: PMID:20410501
        supports: SUPPORT
        snippet: We also detected associations between generalized vitiligo and SNPs in two additional immune-related loci, RERE (P=7.07x10(-15)) and GZMB (P=3.44x10(-8)), and in a locus containing TYR (P=1.60x10(-18)), encoding tyrosinase.
        explanation: The study identified a significant association between generalized vitiligo and a genetic locus containing the TYR gene.
      - reference: PMID:32838589
        supports: SUPPORT
        snippet: The tyrosinase levels were significantly elevated in patients. The TT genotype was the most prevalent one in the patients... MiRNA 196a-2 C/T (11614913) gene polymorphism and the elevated serum tyrosinase levels might be related to the pathogenesis of vitiligo and may affect its therapeutic response.
        explanation: Elevated serum tyrosinase levels in vitiligo patients suggest a genetic association involving the TYR gene with vitiligo.
  - name: PTPN22
    association: Associated
    evidence:
      - reference: PMID:21515266
        supports: SUPPORT
        snippet: The PTPN22 locus is one of the strongest risk factors outside of the major histocompatibility complex that associates with autoimmune diseases...including vitiligo.
        explanation: The literature specifically mentions that PTPN22 is associated with vitiligo as part of its association with several autoimmune diseases.
      - reference: PMID:28164884
        supports: PARTIAL
        snippet: Several studies have demonstrated the association of protein tyrosine phosphatase, non-receptor type 22 +1858C-->T polymorphism with vitiligo... limited ethnic-based studies... In conclusion, protein tyrosine phosphatase, non-receptor type 22 +1858 T allele predisposes European individuals to vitiligo.
        explanation: This source confirms the association but notes that the genetic association is specific to the European population and not found in the Asian population, suggesting partial support.
  - name: MC1R
    association: Associated
    evidence:
      - reference: PMID:20197744
        supports: SUPPORT
        snippet: Genome-wide association studies (GWAS) have unveiled single nucleotide polymorphisms (SNPs) or genetic variants in MC1R, TPCN2, ASIP, KITLG, NCKX5, TYR, IRF4, OCA2, and TYRP1 pigmentation genes.
        explanation: This reference provides evidence of an association between the MC1R gene and vitiligo.
      - reference: PMID:33757175
        supports: SUPPORT
        snippet: MC1R was found as a key gene in vitiligo and involved in the melanogenesis.
        explanation: This reference identifies MC1R as a key gene involved in vitiligo, providing further support for its genetic association.
  - name: HLA-A
    association: Associated
    evidence:
      - reference: PMID:17243956
        supports: SUPPORT
        snippet: Meta-analysis showed a significantly increased frequency of HLA-A2 in vitiligo among cases [OR = 2.07, 95% confidence interval (CI) 1.67-2.58].
        explanation: The meta-analysis strongly suggests an association between HLA-A2, a specific allele of HLA-A, and vitiligo.
      - reference: PMID:27821860
        supports: SUPPORT
        snippet: It remains unclear whether the HLA-G variants associated with vitiligo were detected because of the high linkage disequilibrium (LD) with HLA-A*02.
        explanation: This study also points to a possible association between HLA-A*02 and vitiligo due to high linkage disequilibrium with HLA-G variants.
  - name: HLA-DRB1
    association: Associated
    evidence:
      - reference: PMID:34686989
        supports: SUPPORT
        snippet: In this study, we have evaluated the association and role of HLA-DRB4*01:01, -DRB1*07:01, and -DQB1*03:03:2 genes in different clinical subtypes of Vitiligo in the Iranian population.
        explanation: The study discusses the association of different HLA-DRB1 allelic genes, including HLA-DRB1, with vitiligo.
      - reference: PMID:20526339
        supports: SUPPORT
        snippet: Further analyses suggested that the strong association at rs11966200 might reflect the reported association of the HLA-A*3001, HLA-B*1302, HLA-C*0602 and HLA-DRB1*0701 alleles...
        explanation: The findings of the genome-wide association study indicate an association of HLA-DRB1 alleles with vitiligo.
      - reference: PMID:6600753
        supports: SUPPORT
        snippet: Association of HLA-DR4 with vitiligo.
        explanation: Although this specifically mentions HLA-DR4, it generally supports the connection between HLA class II genes and vitiligo, which includes HLA-DRB1.
environmental:
  - name: UV Exposure
    description: Promotes the repigmentation process in some cases, but can exacerbate the contrast in others.
    evidence:
      - reference: PMID:29124690
        supports: PARTIAL
        snippet: This chapter focuses on the use of ultraviolet light in vitiligo as an established therapeutic option.
        explanation: The reference suggests that UV light is used to treat vitiligo, which implies it can promote repigmentation. However, it does not address the exacerbation of contrast.
      - reference: PMID:34245476
        supports: PARTIAL
        snippet: Targeted phototherapy with EL demonstrated better repigmenting efficacy than TUVB in vitiligo.
        explanation: This reference supports UV exposure aiding in repigmentation but does not discuss exacerbating contrast.
      - reference: PMID:34806278
        supports: PARTIAL
        snippet: Patients received Nb-UVB three times per week for 6 months... 90% of lesions showed variable degrees of repigmentation and 10% showed increase in size, indicating increased activity of the disease.
        explanation: UVB treatments result in repigmentation in most cases, though some lesions increased in size, indicating potential exacerbation.
  - name: Stress
    description: Psychological stress is implicated in the exacerbation or onset of the disease.
    evidence:
      - reference: PMID:26057504
        supports: SUPPORT
        snippet: Psychological stressors should be considered as potential disease triggers in vitiligo patients.
        explanation: The study identifies psychological stressors as potential triggers for the onset of vitiligo.
      - reference: PMID:37481827
        supports: SUPPORT
        snippet: Psychological stress triggers onset and development of vitiligo in humans.
        explanation: The study confirms that psychological stress promotes vitiligo onset.
      - reference: PMID:31986193
        supports: SUPPORT
        snippet: Perceived stress was significantly higher among vitiligo individuals compared to those without vitiligo.
        explanation: The data supports the notion that stress is a precipitating factor in vitiligo development.
      - reference: PMID:7036910
        supports: NO_EVIDENCE
        snippet: ''
        explanation: The title 'Vitiligo. It is important.' doesn't provide information related to stress or its impact on vitiligo.
      - reference: PMID:38160837
        supports: NO_EVIDENCE
        snippet: ''
        explanation: The focus of the ViCEKb is on chemical triggers, and no evidence is provided about the role of psychological stress in vitiligo.
  - name: Chemical Exposure
    description: Certain phenolic compounds and other chemicals can induce or exacerbate vitiligo.
    chemicals:
      - Phenol
    evidence:
      - reference: PMID:36433836
        supports: SUPPORT
        snippet: In the binary logistic regression model, household chemicals/colored toothpaste use, [...] and an occupational exposure to phenol/catechol derivatives were significantly associated with vitiligo (three to fourfold increase).
        explanation: The study identifies phenol derivatives as significant risk factors for the development of vitiligo.
      - reference: PMID:33039241
        supports: SUPPORT
        snippet: Chemicals like Monobenzyl Ether of Hydroquinone (MBEH) and 4-Tertiary Butyl Phenol (4-TBP) have been widely recognized to induce clinical lesions that resemble vitiligo.
        explanation: The study demonstrates that phenol-based compounds can induce vitiligo-like lesions.
      - reference: PMID:28317525
        supports: SUPPORT
        snippet: Chemicals have been used therapeutically in patients with severe vitiligo to depigment their remaining skin and improve their appearance. [...] these chemicals have been used to induce melanocyte autoimmunity.
        explanation: The study mentions the use of chemicals, including phenols, to induce vitiligo for therapeutic purposes, supporting the role of phenolic compounds in inducing or exacerbating vitiligo.
treatments:
  - name: Topical Corticosteroid
    description: Common first-line treatment to reduce inflammation and potentially stimulate repigmentation.
    evidence:
      - reference: PMID:19178066
        supports: SUPPORT
        snippet: Topical corticosteroids are one of the oldest and most useful treatments for dermatologic conditions... evidence of effectiveness exists only for select conditions, such as psoriasis, vitiligo...
        explanation: The use of topical corticosteroids as a treatment for vitiligo is supported, indicating it as a common and effective treatment option.
      - reference: PMID:38477910
        supports: SUPPORT
        snippet: Evidence supports the use of... topical corticosteroids... as effective therapeutics for vitiligo...
        explanation: The recommendations include topical corticosteroids as a first-line treatment for vitiligo in pediatric, adolescent, and young adult patients.
      - reference: PMID:33350506
        supports: SUPPORT
        snippet: The mainstay of treatment for unstable vitiligo has been topical agents (corticosteroids, calcineurin inhibitors)...
        explanation: This article highlights topical corticosteroids as a primary treatment for vitiligo, supporting the statement.
      - reference: PMID:20445292
        supports: SUPPORT
        snippet: Topical therapy is employed as first-line treatment in localized vitiligo. Currently, several topical agents are available... corticosteroids...
        explanation: Topical corticosteroids are mentioned as a first-line treatment, aligning with the provided statement.
  - name: Phototherapy
    description: UVB light or PUVA treatment can stimulate melanocyte regeneration and pigment production.
    evidence:
      - reference: PMID:27638438
        supports: SUPPORT
        snippet: Acting on multiple steps in vitiligo pathogenesis, narrowband ultraviolet B is one of the few therapies that can effectively induce stabilization and stimulate repigmentation.
        explanation: The article supports the use of narrowband UVB for stimulating repigmentation in vitiligo.
      - reference: PMID:28317529
        supports: SUPPORT
        snippet: The most potent stimulus for repigmentation is the UV light.
        explanation: This reference directly supports that UV light, including UVB, is a potent stimulus for repigmentation in vitiligo.
      - reference: PMID:20149899
        supports: SUPPORT
        snippet: There have been many treatments to cure vitiligo such as use of steroid creams, PUVA (psoralen and ultraviolet A light), narrow band UVB (ultraviolet B), various surgical techniques, vitamin D analogues and pseudocatalase.
        explanation: It lists both PUVA and narrowband UVB as standard treatments for vitiligo.
      - reference: PMID:34806278
        supports: SUPPORT
        snippet: 'OBJECTIVE: To study whether the colorimeter and point counting technique can be used as objective methods in monitoring vitiligo lesions during treatment with Nb-UVB...'
        explanation: The study demonstrates the effectiveness of narrowband UVB in increasing the melanin index, indicating pigment production in vitiligo lesions.
  - name: Skin Graft
    description: can be used for stable vitiligo.
    evidence:
      - reference: PMID:38038734
        supports: SUPPORT
        snippet: For patients with stable vitiligo who have not achieved satisfactory results with medical treatments, the melanocyte-keratinocyte transplantation procedure (MKTP) is a viable option.
        explanation: MKTP is a type of autologous non-cultured cellular grafting procedure used for treating stable vitiligo.
      - reference: PMID:37000977
        supports: SUPPORT
        snippet: Surgical therapies are effective methods to treat resistant stable vitiligo, with each method having advantages and disadvantages.
        explanation: This study compares ultrathin skin grafting (UTSG) and suction blister epidermal grafting (SBEG), both of which are skin grafting methods used to treat stable vitiligo.
      - reference: PMID:34169570
        supports: SUPPORT
        snippet: Cultured epidermal autografts (CEA) are surgical therapeutic alternatives for patients with stable vitiligo resistant to conventional medical treatments.
        explanation: CEA is mentioned as an option for treating stable vitiligo, indicating the use of skin grafting.
      - reference: PMID:22994670
        supports: SUPPORT
        snippet: A number of new therapeutic options for vitiligo have become available ... One among them is smashed skin grafting or simply smash grafting.
        explanation: This reference discusses smash grafting as a method used in vitiligo treatment.
      - reference: PMID:27274556
        supports: SUPPORT
        snippet: Medical treatments are usually reasonably effective for nonstable vitiligo patches; however, for vitiligo patches that have been stable for a substantial period of time, surgical intervention should be considered.
        explanation: It supports the use of surgical interventions, including skin grafting, for stable vitiligo.
    context: Stable vitiligo
  - name: Melanocyte Transplantation
    description: can be used for stable vitiligo.
    evidence:
      - reference: PMID:12709002
        supports: SUPPORT
        snippet: This surgical treatment gives its best results in segmental and focal vitiligo, even with large affected areas, and in at least 50% of patients with generalized vitiligo.
        explanation: This implies that melanocyte-keratinocyte transplantation can be effective for stable vitiligo.
      - reference: PMID:26728804
        supports: SUPPORT
        snippet: 'Melanocyte-keratinocyte transplantation procedure: A few insights.'
        explanation: The procedure involves melanocyte transplantation which supports the statement for treating stable vitiligo.
      - reference: PMID:28445194
        supports: SUPPORT
        snippet: Cultured autologous melanocyte transplantation (CMT) is an effective treatment for stable vitiligo.
        explanation: This confirms the use of melanocyte transplantation for stable vitiligo.
      - reference: PMID:35457678
        supports: SUPPORT
        snippet: Both the development of new techniques and modifications to the already available treatment of cell and tissue transplantation give hope to numerous patients around the world.
        explanation: Surgical treatments including melanocyte transplantation are viable for stable vitiligo according to the literature.
    context: Stable vitiligo
  - name: Monobenzone Cream
    description: Treatment with monobenzone cream to remove remaining pigment in cases of extensive vitiligo.
    evidence:
      - reference: PMID:3168334
        supports: SUPPORT
        snippet: When large areas of skin are involved or when the patient is unresponsive to therapy, serious consideration should be given to depigmentation with monobenzone (Benoquin).
        explanation: This supports the use of monobenzone cream for removing remaining pigment in cases of extensive vitiligo.
      - reference: PMID:21054565
        supports: SUPPORT
        snippet: If vitiligo involves most of the body, it might be easier to depigment the normal remaining skin rather than to attempt repigmentation. Our review revealed that... Monobenzyl ether of hydroquinone (MBEH) is the most widely used depigmenting agent and has few side-effects.
        explanation: The reference supports the use of monobenzone (MBEH) for depigmentation in extensive vitiligo cases.
---
name: Asthma
category: Complex
parents:
  - Respiratory Disease
  - Chronic Inflammatory Disease
has_subtypes:
  - name: Allergic Asthma
    description: Triggered by allergens such as pollen, pet dander, or dust mites.
    evidence:
      - reference: PMID:32037107
        supports: SUPPORT
        snippet: Allergic asthma is defined as asthma associated with sensitization to aeroallergens, which leads to asthma symptoms and airway inflammation.
        explanation: The literature explicitly states that allergic asthma is triggered by allergens.
      - reference: PMID:24925403
        supports: SUPPORT
        snippet: Allergic diseases triggered by mite allergens include allergic rhinoconjunctivitis, asthma, atopic dermatitis and other skin diseases.
        explanation: This literature confirms asthma can be triggered by mite allergens, consistent with the definition of allergic asthma.
      - reference: PMID:32589303
        supports: SUPPORT
        snippet: Respiratory health can be particularly affected by climate change, which contributes to the development of allergic respiratory diseases and asthma. Pollen and mold allergens are able to trigger the release of pro-inflammatory mediators that accelerate the onset of IgE-mediated sensitization and of allergy.
        explanation: The document indicates that pollen allergens contribute to the development of asthma, supporting the statement.
      - reference: PMID:30725285
        supports: SUPPORT
        snippet: Asthma is a heterogeneous chronic inflammatory disease of the airways. The most prevalent form is atopic asthma, which is initiated by the exposure to (inhaled) allergens.
        explanation: This literature identifies atopic (allergic) asthma as initiated by allergens, which supports the statement.
  - name: Non-Allergic Asthma
    description: Triggered by factors such as stress, exercise, cold air, or respiratory infections.
    evidence:
      - reference: PMID:11678516
        supports: PARTIAL
        snippet: Asthmatic attack in exercise-induced asthma is brought about by hyperventilation (not necessarily to exercise), cold air, and low humidity of the air breathed.
        explanation: The reference discusses asthma subtypes triggered by exercise, cold air, and respiratory conditions, but does not explicitly mention stress or classify it specifically as 'Non-Allergic Asthma'.
      - reference: PMID:25439356
        supports: PARTIAL
        snippet: First, asthma phenotypes that are associated with environmental exposures (occupational agents, cigarette smoke, air pollution, cold dry air)...
        explanation: The reference mentions environmental exposures like cold dry air and non-allergic triggers, but does not explicitly identify stress or exercise specifically in relation to 'Non-Allergic Asthma'.
      - reference: PMID:20176257
        supports: SUPPORT
        snippet: Exacerbations are largely driven by environmental exposures including pollutants, stress, and viral and bacterial pathogens.
        explanation: The reference corroborates that stress and respiratory infections are triggers for asthma exacerbations.
  - name: Adult-Onset Asthma
    description: Develops later in adult life and often triggered by environmental factors.
    evidence:
      - reference: PMID:36833767
        supports: SUPPORT
        snippet: Only a few previous studies have investigated the subtypes of adult-onset asthma. No previous study has assessed whether these subtypes are different between men and women, or whether these subtypes have different risk factors.
        explanation: The reference discusses subtypes of adult-onset asthma and emphasizes the importance of different risk factors, which supports that adult-onset asthma could have environmental triggers.
      - reference: PMID:30240884
        supports: SUPPORT
        snippet: Adult-onset asthma is an important asthma phenotype and, in contrast to childhood asthma, is often associated with specific triggers of onset.
        explanation: This study indicates that adult-onset asthma is often associated with specific triggers of onset, which aligns with the statement that it is often triggered by environmental factors.
      - reference: PMID:20176257
        supports: SUPPORT
        snippet: Exposure to unusual substances at work causes occupational asthma, accounting for about 5% of asthma in adults. Indoor and outdoor air pollutants trigger airway inflammation and increase the severity of asthma.
        explanation: The literature specifies that environmental factors such as pollutants can trigger adult asthma, further supporting the statement about environmental triggers.
  - name: Asthma-COPD Overlap
    description: Features of both chronic obstructive pulmonary disease and asthma.
    evidence:
      - reference: PMID:26398072
        supports: SUPPORT
        snippet: Although in textbooks asthma and chronic obstructive pulmonary disease (COPD) are viewed as distinct disorders, there is increasing awareness that many patients have features of both. This article reviews the asthma-COPD overlap syndrome.
        explanation: The article explicitly refers to the Asthma-COPD Overlap Syndrome, which indicates the presence of subtypes sharing features of both asthma and COPD.
      - reference: PMID:38641129
        supports: PARTIAL
        snippet: Among 235 patients, the prevalence of asthma, ACO-A, ACO-B, and COPD was respectively 21%, 22%, 17%, and 40%.
        explanation: This study categorizes patients as having asthma, ACO-A, ACO-B, or COPD based on certain characteristics, which partially supports the existence of the Asthma-COPD Overlap subtype but does not provide a detailed description of its features.
      - reference: PMID:24507842
        supports: SUPPORT
        snippet: Asthma in childhood and COPD in smokers have their own phenotypic expression with underlying pathophysiological mechanisms that differ importantly. In older adults, asthma and COPD are more difficult to differentiate and there exists a bronchodilator response in most but not all patients with asthma and persistent airway obstruction in most but not all patients with COPD where even up to 50% have been reported to have some bronchodilator response as assessed with FEV1.
        explanation: The article acknowledges overlapping phenotypes between asthma and COPD, supporting the existence of a subtype with features of both diseases.
      - reference: PMID:29713158
        supports: SUPPORT
        snippet: Asthma and COPD are heterogeneous diseases. Patients with both disease features (asthma-COPD overlap [ACO]) are common.
        explanation: The article clearly supports that there is an overlap between asthma and COPD, validating the statement about the Asthma-COPD Overlap subtype with shared features.
  - description: Often triggered by physical exertion.
    name: Exercise-Induced Asthma
    review_notes: Added Exercise-Induced Asthma for a more comprehensive list of subtypes.
pathophysiology:
  - name: Airway Inflammation
    description: Chronic inflammation leads to airway hyperresponsiveness and recurrent episodes of wheezing, breathlessness, chest tightness, and coughing.
    cell_types:
      - Mast Cell
      - Eosinophil
      - T-Lymphocyte
      - Bronchial Epithelial Cell
      - Basophil
      - Neutrophil
    evidence:
      - reference: PMID:18503727
        supports: SUPPORT
        snippet: The pathogenesis of allergic airway inflammation is complex, involving multiple cell types such as T helper 2 cells, regulatory T cells, eosinophils, dendritic cells, mast cells, and parenchymal cells of the lung.
        explanation: This reference indicates the involvement of multiple cell types, including mast cells, eosinophils, and T lymphocytes in allergic airway inflammation, which supports the statement.
      - reference: PMID:8324396
        supports: SUPPORT
        snippet: The numbers of eosinophils and neutrophils are increased 4 h after challenge with allergen in the broncho-alveolar lavage fluid (BAL) of asthmatics who show an LPR.
        explanation: This reference mentions eosinophils and neutrophils as part of the chronic inflammatory response in asthma, supporting the statement.
      - reference: PMID:9753516
        supports: SUPPORT
        snippet: Accumulation of basophils and mast cells in airway tissues during allergic and allergic-type inflammatory responses, including asthma, is one of the hallmarks of these disease processes.
        explanation: This reference highlights the involvement of basophils and mast cells in airway inflammation in asthma, supporting the statement.
      - reference: PMID:38395082
        supports: SUPPORT
        snippet: Airway hyperresponsiveness (AHR) is a key clinical feature of asthma. The presence of AHR in people with asthma provides the substrate for bronchoconstriction in response to numerous diverse stimuli, contributing to airflow limitation and symptoms including breathlessness, wheeze, and chest tightness.
        explanation: This reference supports the clinical manifestations of asthma as described in the statement.
      - reference: PMID:23234454
        supports: PARTIAL
        snippet: Pulmonary edema and pulmonary vascular congestion have been thought to be the primary causes of cardiac asthma but most patients have a poor response to diuretics... Evidence suggests that circulating inflammatory factors and tissue growth factors also lead to airway obstruction suggesting the possibility of developing novel therapies.
        explanation: While this reference focuses on cardiac asthma, it acknowledges the involvement of inflammatory factors leading to airway obstruction, which partially supports the inflammatory aspect mentioned.
      - reference: PMID:1571812
        supports: SUPPORT
        snippet: Asthmatics can have a blood eosinophilia which in some studies correlates with the severity of the disease... The eosinophils that contribute to asthma will be those in the lung.
        explanation: Specifically talks about the role of eosinophils in asthma, supporting the statement.
      - reference: PMID:28687463
        supports: SUPPORT
        snippet: Non-asthmatic eosinophilic bronchitis (NAEB) shares similar eosinophilic inflammation of the airway and response to corticosteroids with asthma.
        explanation: This supports the role of eosinophils in airway inflammation in asthma, consistent with the statement.
      - reference: PMID:6101920
        supports: NO_EVIDENCE
        snippet: Exercise-induced asthma can appear as one of many forms of airway hyperreactivity or as a unique clinical entity.
        explanation: Does not provide specific information about the role of the cell types mentioned in the statement.
  - name: Bronchoconstriction
    description: During an asthma attack, smooth muscles around the airways tighten and narrow the airway.
    cell_types:
      - Smooth Muscle Cells
    evidence:
      - reference: PMID:24914235
        supports: SUPPORT
        snippet: The other main cause of airway obstruction is contraction of airway smooth muscle.
        explanation: The reference points out that contraction of airway smooth muscle is a main cause of airway obstruction, thus supporting the statement.
      - reference: PMID:22011234
        supports: SUPPORT
        snippet: Breathing difficulties are caused by excessive narrowing of the pulmonary airways, which is instigated by shortening of the airway smooth muscle (ASM).
        explanation: This reference explains that the narrowing of the airways, caused by the contraction of airway smooth muscle, leads to breathing difficulties, thus supporting the statement.
      - reference: PMID:27603525
        supports: SUPPORT
        snippet: In acute and chronic allergen driven animal models of asthma, statins reduce airway hyper-responsiveness, inflammation and remodeling.
        explanation: The use of statins to reduce airway hyper-responsiveness implies the involvement of smooth muscle cells, supporting the statement.
      - reference: PMID:16543052
        supports: SUPPORT
        snippet: ASM plays an important role in regulating bronchomotor tone, in perpetuating airway inflammation, and in remodeling of the airways.
        explanation: This reference highlights multiple functions of airway smooth muscle in asthma, which supports the statement regarding the role of smooth muscle cells in bronchoconstriction.
      - reference: PMID:18669785
        supports: SUPPORT
        snippet: Airway smooth muscle cells are known to be the main effector cells of airway narrowing.
        explanation: This reference clearly identifies airway smooth muscle cells as key players in the narrowing of airways (bronchoconstriction), thus supporting the statement.
  - name: Mucus Overproduction
    description: Inflammatory cells infiltrate the airways, increasing mucus production, which can block airways and further impair breathing.
    cell_types:
      - Goblet Cell
      - Bronchial Epithelial Cell
      - Mucosal Epithelial Cell
    evidence:
      - reference: PMID:19689269
        supports: PARTIAL
        snippet: Goblet cells are major mucus-producing cells, and goblet cell hyperplasia (GCH) is one feature of airway remodeling, defined as structural changes occurring in the airway.
        explanation: The reference confirms Goblet cell involvement in asthma and mucus production but does not mention Mucosal Epithelial Cell specifically.
      - reference: PMID:24914235
        supports: PARTIAL
        snippet: Airway epithelial cells, which are the first line of defense against inhaled pathogens and particles, initiate airway inflammation and produce mucus, an important contributor to airway obstruction.
        explanation: The reference supports that Bronchial Epithelial Cells play a role in mucus production but does not discuss Mucosal Epithelial Cells specifically.
      - reference: PMID:37520564
        supports: PARTIAL
        snippet: Basal cells... goblet cell hyperplasia and increased epithelial mesenchymal transition, which contribute to impaired mucociliary clearance and airway remodelling.
        explanation: The reference confirms Goblet cell hyperplasia and the contribution of epithelial cells in asthma but does not detail Mucosal Epithelial Cells.
      - reference: PMID:23638644
        supports: PARTIAL
        snippet: Goblet cell differentiation and mucus production are subject to extensive control. An emerging concept is that not all goblet cells are phenotypically identical suggesting that specific molecular pathways orchestrate mucin overproduction.
        explanation: The reference supports Goblet cells' role in mucus production but lacks information on Mucosal Epithelial Cells.
      - reference: PMID:16101538
        supports: PARTIAL
        snippet: Bronchial epithelial cells (BEC) are known to play an integral role in the airway defense mechanism via mucociliary system as well as mechanical barriers.
        explanation: The reference confirms the involvement of Bronchial Epithelial Cells but does not mention Mucosal Epithelial Cells.
      - reference: PMID:12190646
        supports: NO_EVIDENCE
        snippet: None.
        explanation: The abstract does not provide evidence to support or refute the involvement of the specified cell types.
      - reference: PMID:8324396
        supports: NO_EVIDENCE
        snippet: None.
        explanation: The abstract focuses on early-phase and late-phase reactions in asthma without mentioning the specific cell types.
  - name: Airway Remodeling
    description: Long-standing inflammation can lead to structural changes in the airway, permanently affecting lung function.
    cell_types:
      - Fibroblast
      - Smooth Muscle Cell
      - Bronchial Epithelial Cell
    evidence:
      - reference: PMID:20500603
        supports: SUPPORT
        snippet: In asthma, it includes alterations of the epithelial cell layer with goblet cell hyperplasia, thickening of basement membranes, peri-bronchial and peri-bronchoalveolar fibrosis.
        explanation: The reference acknowledges that airway remodeling in asthma involves changes to the epithelial cell layer, fibroblasts, and smooth muscle cells.
      - reference: PMID:10907591
        supports: SUPPORT
        snippet: In the long-term, asthma may become moderately to fully irreversible. Severe, irreversible airflow obstruction may develop despite apparently appropriate therapy.
        explanation: The reference supports the idea that long-standing inflammation can result in irreversible structural changes affecting lung function.
      - reference: PMID:15896192
        supports: SUPPORT
        snippet: Structural changes reported in the airways of asthmatics include epithelial fragility, goblet cell hyperplasia, enlarged submucosal mucus glands, angiogenesis, increased matrix deposition in the airway wall, increased airway smooth muscle mass, wall thickening and abnormalities in elastin.
        explanation: The reference details structural changes involving various cell types, including epithelial cells, smooth muscle cells, and other airway structures resulting from long-term inflammation in asthma.
      - reference: PMID:12405265
        supports: SUPPORT
        snippet: Asthma is a chronic inflammatory disorder of the airways interacting with altered structure and function of the formed elements including smooth muscle.
        explanation: The reference confirms that chronic inflammation in asthma involves structural alterations involving smooth muscle cells and other components, supporting airway remodeling.
      - reference: PMID:24914235
        supports: SUPPORT
        snippet: 'Two airway cell types are critical for asthma pathogenesis: epithelial cells and smooth muscle cells.'
        explanation: The reference highlights the importance of epithelial cells and smooth muscle cells in asthma pathogenesis, supporting the role of these cell types in airway remodeling.
phenotypes:
  - category: Respiratory
    name: Wheezing
    frequency: FREQUENT
    diagnostic: true
    sequelae:
      - Respiratory Distress
      - Reduced Exercise Tolerance
    evidence:
      - reference: PMID:20545704
        supports: SUPPORT
        snippet: It has been suggested that there are several distinct phenotypes of childhood asthma or childhood wheezing. Here, we review the research relating to these phenotypes, with a focus on the methods used to define and validate them.
        explanation: The reference supports the existence and classification of asthma phenotypes, including wheezing as a common characteristic.
      - reference: PMID:8620967
        supports: SUPPORT
        snippet: Wheezes are usual clinical signs in patients with obstructive airway diseases and particularly during acute episodes of asthma.
        explanation: The reference describes wheezing as a common symptom associated with asthma, supporting the statement's claim that wheezing is a common phenotype and respiratory diagnostic of asthma.
      - reference: PMID:1788358
        supports: SUPPORT
        snippet: Exercise-induced asthma is a common but frequently undiagnosed problem. The patient may not wheeze, but rather have shortness of breath, chest tightening, and coughing.
        explanation: This reference mentions exercise-induced asthma and details its symptoms, including wheezing, though noting that wheezing may not always be present.
      - reference: PMID:26606077
        supports: SUPPORT
        snippet: The syndrome of asthma contains a number of different phenotypes that offer the possibility of personalized medicine based on the respective asthma phenotype.
        explanation: Confirms the existence of multiple phenotypes within asthma, including wheezing, supporting the statement's categorization of wheezing as a phenotype of asthma.
      - reference: PMID:21722845
        supports: SUPPORT
        snippet: Oral corticosteroids are the cornerstone of management of acute moderate or severe asthma whilst preventive inhaled corticosteroids are the mainstay of the preventive management of children with asthma. Yet, variation in the magnitude of response to corticosteroids has been observed.
        explanation: Supports the statement indirectly by acknowledging variations in asthma phenotypes, which includes wheezing as a common symptom.
      - reference: PMID:38716537
        supports: SUPPORT
        snippet: We want to highlight the presentation of a 75-year-old female who was initially managed as asthma and subsequently diagnosed with concurrent excessive dynamic airway collapse (EDAC).
        explanation: Although the snippet discusses a different case, it implies that wheezing is commonly associated with asthma management.
  - category: Respiratory
    name: Coughing
    frequency: FREQUENT
    evidence:
      - reference: PMID:36096782
        supports: SUPPORT
        snippet: Asthma is a heterogeneous disease with variable symptoms, which presents with cough either as the sole or predominant symptom with or without wheezing.
        explanation: The reference states that cough is a common phenotype in asthma, aligning with the statement's claim that coughing is a common respiratory phenotype in asthma.
      - reference: PMID:31662445
        supports: SUPPORT
        snippet: Asthma severity was dependent on variety of symptoms, consisting mostly of wheezing, breathlessness, chest tightness, and cough.
        explanation: The reference indicates that coughing is one of the primary symptoms associated with asthma, supporting the claim that it is a common respiratory phenotype.
      - reference: PMID:36543577
        supports: SUPPORT
        snippet: Chronic cough is associated with poor quality of life and can negatively affect quality of life. Diseases causing chronic cough are most commonly asthma, eosinophilic bronchitis, gastroesophageal reflux, post-nasal drip syndrome, rhinosinusitis, chronic obstructive pulmonary disease, pulmonary fibrosis, and bronchiectasis.
        explanation: The reference supports the association of chronic cough with asthma, aligning with the statement that coughing is a common phenotype in asthma.
  - category: Respiratory
    name: Breathlessness
    frequency: FREQUENT
    evidence:
      - reference: PMID:34610625
        supports: SUPPORT
        snippet: Respiratory diseases were the main underlying condition (40-57%), of which asthma was the most common (approx. 25%), and chronic obstructive pulmonary disease was particularly strongly associated with breathlessness.
        explanation: The reference indicates that respiratory diseases, including asthma, are a common underlying condition for breathlessness. This supports the categorization of breathlessness as a common respiratory phenotype of asthma.
  - category: Respiratory
    frequency: FREQUENT
    name: Chest Tightness
    review_notes: Added Chest Tightness, which is also a common symptom of asthma.
biochemical:
  - name: Eosinophils
    presence: Elevated
    subtype: Allergic Asthma
    evidence:
      - reference: PMID:27401626
        supports: PARTIAL
        snippet: Asthma is a heterogeneous disease that can be classified into different clinical endotypes, depending on the type of airway inflammation, clinical severity, and response to treatment. This article focuses on the eosinophilic endotype of asthma, which is defined by the central role that eosinophils play in the pathophysiology of the condition.
        explanation: The reference supports that eosinophils are elevated in eosinophilic asthma, but does not specifically mention the allergic asthma subtype.
      - reference: PMID:30303258
        supports: SUPPORT
        snippet: There was a significantly higher serum IL-33 level in the eosinophilic asthma group when compared to the group of non-eosinophilic asthma patients (1001.10 +/- 199.11 pg/mL vs 337.49 +/- 72.68 pg/mL, P < 0.01).
        explanation: The reference mentions a higher level of eosinophils in eosinophilic asthma, which can be associated with allergic asthma.
      - reference: PMID:31944632
        supports: PARTIAL
        snippet: Elevated FeNO in nonasthmatic adolescents was associated with airway hyperresponsiveness, elevated blood eosinophil counts, and lower systemic activation of neutrophils.
        explanation: This reference supports elevated eosinophils but focuses on nonasthmatic adolescents rather than allergic asthma specifically.
      - reference: PMID:36115752
        supports: PARTIAL
        snippet: Elevated total IgE concentrations and eosinophil counts are classic biological markers regularly found in severe asthma.
        explanation: Although the statement is specific to severe asthma, it indicates elevated eosinophils which may also be relevant to allergic asthma.
      - reference: PMID:33479910
        supports: SUPPORT
        snippet: Asthmatic airway inflammation is initiated by inflammatory mediators released by granulocytic cells. However, the immunoglobulin E (IgE) antibody is necessary for the initiation of the allergic cascade, and IgE is produced and released exclusively by memory B cells and plasma cells.
        explanation: The reference supports the statement by linking allergic asthma with IgE, which is often associated with elevated eosinophils.
    context: allergic asthma
  - name: Neutrophils
    presence: Elevated
    subtype: Non-Allergic Asthma
    evidence:
      - reference: PMID:33830849
        supports: SUPPORT
        snippet: Neutrophilic asthma is associated with poorer responses to classic therapies, namely (inhaled) corticosteroids.
        explanation: The document discusses neutrophilic asthma, a subtype of asthma characterized by elevated neutrophils, indicating that neutrophils are indeed elevated in some forms of asthma, including non-allergic ones.
      - reference: PMID:28163052
        supports: SUPPORT
        snippet: RA was associated with increased numbers of neutrophils and proneutrophilic biomolecules in the airways.
        explanation: This reference supports the statement by indicating that refractory asthma, which often overlaps with non-allergic asthma, is associated with elevated neutrophils.
      - reference: PMID:36871881
        supports: SUPPORT
        snippet: Corticosteroid resistance, progressive lung function decline, and frequent asthma exacerbations are the hallmarks of neutrophilic asthma (NA).
        explanation: The study highlights neutrophilic asthma, a type often linked with non-allergic inflammatory processes, which supports the elevation of neutrophils in such asthma subtypes.
    context: non-allergic asthma
  - name: IgE Antibodies
    presence: Elevated
    context: allergic reactions
    evidence:
      - reference: PMID:33479910
        supports: SUPPORT
        snippet: However, the immunoglobulin E (IgE) antibody is necessary for the initiation of the allergic cascade, and IgE is produced and released exclusively by memory B cells and plasma cells. Acute allergen exposure has also been shown to increase IgE levels in the airways of patients diagnosed with allergic asthma.
        explanation: The text indicates that IgE antibodies are necessary for the allergic cascade in asthma and are elevated after acute allergen exposure.
      - reference: PMID:20406591
        supports: SUPPORT
        snippet: As many as 90-95% of patients with asthma have aeroallergen sensitization and the pattern varies with ethnicity, location of residence, and onset of asthma, but not age. Higher levels of IgE and eNO are noted in patients with asthma and aeroallergen sensitization.
        explanation: The reference mentions higher levels of IgE are common in patients with asthma and aeroallergen sensitization.
      - reference: PMID:27264001
        supports: SUPPORT
        snippet: However, there are syndromes in which the relationship between exposure to the relevant allergen and the 'allergic' disease is not clear. In these cases the presence of specific IgE antibodies can play an important role in identifying the relevant allergen and provide a guide to therapy. Good examples include chronic asthma and exposure to perennial indoor allergens and asthma related to fungal infection.
        explanation: Elevated IgE antibodies play a role in chronic asthma and identifying relevant allergens, supporting the statement.
      - reference: PMID:30342581
        supports: SUPPORT
        snippet: Using IgE as a biomarker for asthma provides a target for management and treatment.
        explanation: The reference supports the use of IgE as a biomarker in asthma, indicating its elevated presence in the condition.
      - reference: PMID:16462678
        supports: SUPPORT
        snippet: Atopy is defined by abnormal IgE production in response to an allergen (an antigen that is then designated an allergen).
        explanation: The reference defines atopy in terms of elevated IgE production in response to allergens, which is relevant to allergic asthma.
genetic:
  - name: IL4
    association: Associated
    evidence:
      - reference: PMID:23070918
        supports: SUPPORT
        snippet: The results indicated that there were an association between the IL-4 C-33T (P = 0.006) and C-589T (P = 0.04) ... and susceptibility to asthma.
        explanation: This meta-analysis found a significant association between IL-4 polymorphisms (C-33T and C-589T) and asthma susceptibility.
      - reference: PMID:25786151
        supports: NO_EVIDENCE
        snippet: 'Title only: Anchored to asthma.'
        explanation: The title does not provide sufficient information to support or refute the statement.
      - reference: PMID:10073323
        supports: SUPPORT
        snippet: Using both the candidate gene and the positional cloning approaches, there is evidence that predisposing factors, if not the disease itself, are genetically transferred.
        explanation: This reference generally supports the idea of genetic associations in asthma, including those likely involving IL-4.
      - reference: PMID:21325943
        supports: PARTIAL
        snippet: Genotype combinations of IL-4 receptor-alpha and CD14 single nucleotide polymorphisms (SNPs) were significantly associated with diisocyanate asthma.
        explanation: This study refers to IL-4 receptor-alpha and not IL-4 directly, and its context is specific to occupational asthma caused by diisocyanate exposure.
  - name: IL13
    association: Associated
    evidence:
      - reference: PMID:23996716
        supports: SUPPORT
        snippet: Interleukin-13 (IL-13) is known to be a key regulator in immunoglobulin E (IgE) synthesis, mucus hypersecretion and airway hyperresponsiveness... A statistically significant association of the A-1512C polymorphism in IL13 gene was observed with atopy.
        explanation: The study provides evidence that the IL13 gene polymorphism A-1512C is significantly associated with asthma.
      - reference: PMID:30539779
        supports: PARTIAL
        snippet: An efficient memory Th2 cell response is dependent on IL-13 produced by ILC2s, causing allergic lung inflammation and elevated serum levels of immunoglobulin E.
        explanation: The study indicates that IL-13 is involved in allergic lung inflammation which is relevant to asthma, but it primarily discusses IL-13's role in mediating immune responses rather than directly associating IL-13 genetic polymorphisms with asthma.
      - reference: PMID:23380221
        supports: PARTIAL
        snippet: Very recently, a novel population of IL-33-responsive innate immune cells, the type 2 innate lymphoid cells, was found to produce hallmark TH2 cytokines, such as IL-5 and IL-13.
        explanation: The review highlights the role of IL-13 in the pathway involved in asthma pathogenesis but does not directly establish a genetic association between IL-13 and asthma.
      - reference: PMID:21681015
        supports: NO_EVIDENCE
        snippet: Genome-wide association studies identified genes and pathways underlying asthma...
        explanation: The abstract discusses GWAS studies related to asthma but does not specifically mention IL13.
  - name: ADAM33
    association: Associated
    evidence:
      - reference: PMID:26666372
        supports: SUPPORT
        snippet: A disintegrin and metalloproteinase 33 (ADAM33) gene has been considered as an asthma susceptibility gene due to its possible role in airway remodeling, abnormal cell proliferation, and differentiation. Association of this gene with asthma has been reported in several genetic studies on various populations.
        explanation: This study and its findings directly support the statement about the association between the ADAM33 gene and asthma.
      - reference: PMID:19481925
        supports: SUPPORT
        snippet: 'Despite this, the field has identified 43 replicated genes from association studies. The most frequently replicated are: TNF alpha, IL4, FCERB, Adam 33, and GSTP1.'
        explanation: This study acknowledges the genetic association between ADAM33 and asthma among other genes, further supporting the statement.
  - name: GSDMB
    association: Associated
    evidence:
      - reference: PMID:33963941
        supports: SUPPORT
        snippet: Our results revealed that polymorphic variants rs7216389, rs2290400 and rs2305480 are associated with the development of allergic diseases as well as with asthma and asthma combined with allergic rhinitis.
        explanation: This reference specifically mentions GSDMB polymorphisms and their association with asthma.
  - name: HLA-DQ
    association: Associated
    evidence:
      - reference: PMID:23181788
        supports: SUPPORT
        snippet: Overall, our findings further replicate the HLA-DQ region in the pathogenesis of asthma.
        explanation: The study highlights the association of HLA-DQ genes, specifically HLA-DQA1, with asthma in adults, corroborating previous findings linking HLA-DQ to asthma susceptibility.
  - association: Associated
    name: ORMDL3
    review_notes: Added another gene commonly associated with asthma for completeness.
environmental:
  - name: Allergens
    notes: Triggering factor for allergic asthma
    evidence:
      - reference: PMID:26788835
        supports: PARTIAL
        snippet: Persons with asthma and multiple diagnoses reported odorous/pungent and building-related environmental factors to trigger symptoms to a larger extent than did the reference group, mainly due to perfume and odors from flowers.
        explanation: This supports the role of environmental factors in triggering symptoms in people with asthma but does not specifically address allergens as a triggering factor.
      - reference: PMID:29732974
        supports: SUPPORT
        snippet: The link between asthma and food allergy has been well researched over the years; although the exact interplay between the two atopic conditions is yet to be fully described. Research suggests that children who have both asthma and food allergy are at greater risk of more severe asthmatic episodes.
        explanation: This supports the idea that allergens (specifically food allergies) can trigger severe asthma attacks.
      - reference: PMID:20406590
        supports: SUPPORT
        snippet: A complex interplay of genetic predisposition and environmental influences results in the clinical picture of allergic asthma.
        explanation: This supports the role of environmental influences, which includes allergens, in allergic asthma.
      - reference: PMID:29310764
        supports: SUPPORT
        snippet: The implementation of policies to reduce environmental allergic triggers can be an important adjunct to optimal patient care for allergic rhinitis and allergic asthma.
        explanation: It supports that allergic asthma can be triggered by environmental allergens.
      - reference: PMID:29345235
        supports: SUPPORT
        snippet: The rising frequency of obstructive respiratory diseases during recent years, in particular allergic asthma, can be partially explained by changes in the environment, with the increasing presence in the atmosphere of chemical triggers (particulate matter and gaseous components such as nitrogen dioxide and ozone) and biologic triggers (aeroallergens).
        explanation: This directly supports the role of environmental allergens as triggers for allergic asthma.
      - reference: PMID:23574397
        supports: SUPPORT
        snippet: For patients with asthma, exacerbations and poor control can result from exposure to environmental triggers, such as allergens and air particulates.
        explanation: This supports the idea of allergens being environmental triggers for asthma.
      - reference: PMID:31187658
        supports: SUPPORT
        snippet: Environmental exposures varied across the year and demonstrated seasonal patterns. Metro health region regression models showed positive associations between increases in mold and particulate matter <10 microns in diameter (PM(10)) and outpatient asthma claims.
        explanation: This supports the role of environmental allergens like mold in triggering asthma.
      - reference: PMID:21277508
        supports: SUPPORT
        snippet: Extrinsic factors include environmental exposure to temperature, humidity, aeroallergens, irritants, and pollution.
        explanation: This supports the role of environmental allergens in asthma.
      - reference: PMID:37480203
        supports: SUPPORT
        snippet: Pollen is a key source of aeroallergens responsible for allergic rhinitis, conjunctivitis, and asthma.
        explanation: This supports the role of environmental allergens like pollen in triggering allergic asthma.
  - name: Air Pollution
    notes: Exacerbates symptoms
    evidence:
      - reference: PMID:10518814
        supports: SUPPORT
        snippet: Air pollution is convincingly associated with many signs of asthma aggravation.
        explanation: The article states that air pollution is associated with various signs and symptoms of asthma aggravation, supporting the statement that air pollution exacerbates asthma symptoms.
      - reference: PMID:21277508
        supports: SUPPORT
        snippet: Extrinsic factors include environmental exposure to temperature, humidity, aeroallergens, irritants, and pollution.
        explanation: The article discusses how environmental factors, including pollution, can result in impaired function of the airways of athletes, which supports the statement.
      - reference: PMID:31187658
        supports: SUPPORT
        snippet: Increases in mold and PM(10) were associated with increases in asthma claims.
        explanation: The study found associations between particulate pollution and increased asthma claims, supporting the statement.
      - reference: PMID:31239087
        supports: SUPPORT
        snippet: Days with historically high associations between pollution and asthma attacks were identified as supplemental warning days.
        explanation: The framework identifies days with high pollution as high-risk days for asthma attacks, supporting the statement.
      - reference: PMID:31765853
        supports: SUPPORT
        snippet: Exacerbations are largely driven by environmental exposures including pollutants, stress, and viral and bacterial pathogens.
        explanation: The text supports the notion that pollutants, including air pollution, drive exacerbations of asthma symptoms.
      - reference: PMID:35307034
        supports: SUPPORT
        snippet: The risk ratio for asthma patients to be hospitalised on the same day of NO(2) exposure was 1.101 per 10 microg/m(3) NO(2) increase.
        explanation: The study observed a significant increase in hospitalization risk for asthma patients due to NO2 exposure, supporting the statement.
  - name: Tobacco Smoke
    notes: Major risk factor for symptom severity
    evidence:
      - reference: PMID:25584912
        supports: SUPPORT
        snippet: Exposure to passive smoke as a risk factor for asthma onset in childhood.
        explanation: The study highlights how environmental tobacco smoke (ETS) is a significant indoor pollutant and a likely cause for asthma onset and severity in childhood.
      - reference: PMID:29292313
        supports: SUPPORT
        snippet: Exposure to environmental tobacco smoke increases pediatric asthma severity.
        explanation: The study found that higher state tax grades on tobacco were associated with reduced asthma severity, indicating the detrimental impact of tobacco smoke on asthma severity.
      - reference: PMID:31558249
        supports: NO_EVIDENCE
        snippet: Abstract not provided.
        explanation: The provided content does not discuss asthma severity in relation to environmental tobacco smoke.
      - reference: PMID:35236762
        supports: NO_EVIDENCE
        snippet: This study aimed to consider associations between particulate matter, black carbon, nitrogen dioxide, and asthma in adults.
        explanation: The study focuses on various air pollutants but does not specifically address tobacco smoke as an environmental factor affecting asthma severity.
      - reference: PMID:32493146
        supports: NO_EVIDENCE
        snippet: In the multivariate regression models, poorly controlled asthma was associated with obesity, late-onset disease, and comorbidities of sleep apnea and depression.
        explanation: This study does not discuss tobacco smoke specifically as an environmental risk factor for asthma severity.
      - reference: PMID:37973258
        supports: NO_EVIDENCE
        snippet: The objective of this article is to review recent literature on the implications of extreme weather events such as thunderstorms, wildfires, tropical cyclones, freshwater flooding, and temperature extremes in relationship to asthma symptoms.
        explanation: The study reviews the impact of extreme weather events on asthma but does not mention tobacco smoke.
  - name: Occupational Exposures
    notes: Exposure to dust, chemicals, or gases in the workplace can trigger asthma symptoms.
treatments:
  - name: Inhaled Corticosteroid
    description: Reduce inflammation and prevent flare-ups.
    evidence:
      - reference: PMID:22559870
        supports: SUPPORT
        snippet: Current guidelines recommend long-term treatment with inhaled corticosteroids (ICS) because of their superior effectiveness in managing the chronic airway inflammation that characterizes persistent asthma.
        explanation: This literature supports the statement that inhaled corticosteroids reduce inflammation in asthma.
      - reference: PMID:9817746
        supports: SUPPORT
        snippet: Glucocorticoids are highly effective in the control of asthma and suppression of airway inflammation.
        explanation: This reference supports the role of glucocorticoids, which includes inhaled corticosteroids, in reducing airway inflammation in asthma.
      - reference: PMID:32868307
        supports: SUPPORT
        snippet: The 2019 Global Initiative for Asthma (GINA) guidelines recommend that all asthma patients be treated with inhaled corticosteroids taken daily or as needed; this improves symptoms and outcomes, even in those with mild disease.
        explanation: This guideline indicates that inhaled corticosteroids are recommended for improving asthma outcomes, supporting their role in preventing flare-ups.
      - reference: PMID:37182593
        supports: SUPPORT
        snippet: Early treatment with inhaled corticosteroids not only diminishes lung inflammation and airway hyper-responsiveness, but also has a protective effect against the reduction of breathing pattern complexity due to asthma.
        explanation: The findings indicate that early treatment with inhaled corticosteroids reduces lung inflammation and helps prevent further complications, such as reduced breathing pattern complexity, supporting their role in preventive care.
  - name: Long-acting Beta Agonist
    description: Relax the muscles around the airways.
    evidence:
      - reference: PMID:34753370
        supports: SUPPORT
        snippet: Long-acting beta(2)-agonists (LABAs) with efficacy to bronchodilate, and prolonged lung function betterment.
        explanation: The literature supports that LABAs help in relaxing the muscles around the airways, thereby improving lung function and providing symptomatic relief in asthma management.
      - reference: PMID:37489386
        supports: SUPPORT
        snippet: Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting beta2-agonists (ICS + LABA).
        explanation: Although primarily about LAMAs, the literature acknowledges that LABAs are part of the recommended treatment regimen for asthma, which implies their role in relaxing airway muscles.
      - reference: PMID:32306788
        supports: SUPPORT
        snippet: Contemporary mainstay therapies (inhaled corticosteroids and bronchodilators), prescribed empirically, control symptoms resulting from airways obstruction tolerably well in many patients...
        explanation: The literature indicates that LABAs, as bronchodilators, help control symptoms related to airway obstruction by relaxing the airway muscles.
  - name: Leukotriene Modifier
    description: Reduce inflammation, decrease mucus secretion, and prevent airway constriction.
    evidence:
      - reference: PMID:14720013
        supports: SUPPORT
        snippet: Leukotriene modifiers increase the therapeutic options for patients with asthma and, based on recent data, it is expected that future guidelines will describe expanded uses for these agents in clinical circumstances where these drugs are effective.
      - reference: PMID:11085767
        supports: SUPPORT
        snippet: Their unique mechanism of action results in a combination of both bronchodilator and anti-inflammatory effects.
      - reference: PMID:19180262
        supports: SUPPORT
        snippet: Cysteinyl leukotrienes, which are derivatives of the 5-lipoxygenase pathway of arachidonic acid metabolism, are important mediators of airway allergic inflammation and have a role in the pathogenetic mechanism of EIB. Montelukast sodium (Singulair, Merck & Co.) is a selective and orally active leukotriene receptor antagonist with demonstrated activity for treating asthma and allergic rhinitis.
  - name: Anti-IgE Therapy
    description: Used to treat severe allergic asthma by blocking IgE, a key chemical in the allergic response.
    evidence:
      - reference: PMID:29427989
        supports: SUPPORT
        snippet: Severe allergic asthma and severe eosinophilic asthma are two defined phenotypes for which there are efficacious targeted biologic therapies currently available, namely anti-immunoglobulin E (IgE) and anti-interleukin (IL)-5 antibodies, respectively.
        explanation: This reference confirms that anti-IgE therapy is used to treat severe allergic asthma.
      - reference: PMID:20799475
        supports: SUPPORT
        snippet: Among these is anti-IgE, which directly targets IgE serum antibodies, thus inhibiting the central mechanism of immediate type hypersensitivity reactions. Application of anti-IgE antibodies effectively reduces IgE serum levels regardless of allergen specificity.
        explanation: This reference supports that anti-IgE therapy is used in allergic asthma by targeting and reducing IgE.
      - reference: PMID:28635659
        supports: SUPPORT
        snippet: Blocking IgE with monoclonal antibodies such as omalizumab have demonstrated their efficacy, effectiveness, and safety in treating allergic asthma.
        explanation: This reference confirms that anti-IgE therapy, specifically using omalizumab, is effective in treating allergic asthma.
      - reference: PMID:21114196
        supports: SUPPORT
        snippet: Omalizumab improves quality of life of patients with severe persistent allergic asthma that is inadequately controlled by currently available asthma medications. This therapy is well tolerated and significantly improves symptoms, disease control, reducing asthma exacerbations and the need to use high dosage of inhaled corticosteroids.
        explanation: This reference further supports the efficacy of anti-IgE therapy (omalizumab) in treating severe allergic asthma by improving symptoms and reducing exacerbations.
  - description: Provides rapid relief from acute asthma symptoms.
    name: Short-acting Beta Agonist
    review_notes: Added Short-acting Beta Agonist for completeness in treatment options.
---
name: Lynch Syndrome
categories:
  - Hereditary Cancer Syndrome
  - Colorectal Cancer Predisposition
has_subtypes:
  - name: MLH1 Mutation
    description: Caused by a mutation in the MLH1 gene, which is involved in DNA mismatch repair.
    evidence:
      - reference: PMID:19466295
        supports: SUPPORT
        snippet: Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes...among them MLH1.
        explanation: The literature confirms that Lynch Syndrome is caused by germline mutations in DNA mismatch repair genes, including MLH1.
      - reference: PMID:36760167
        supports: SUPPORT
        snippet: Lynch syndrome is one of the most common cancer predisposition syndromes. It is caused by inherited changes in the mismatch repair pathway...with intronic breakpoints involving MLH1.
        explanation: The literature indicates that Lynch Syndrome is caused by inherited mutations in the mismatch repair pathway, specifically including MLH1.
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1.
        explanation: The abstract clearly states that Lynch Syndrome is caused by mutations in DNA mismatch repair genes, specifically mentioning MLH1.
      - reference: PMID:38003003
        supports: SUPPORT
        snippet: MLH1 hypermethylation is an epigenetic alteration in the tumorigenesis of colorectal cancer (CRC) and endometrial cancer (EC), causing gene silencing, and, as a consequence, microsatellite instability.
        explanation: The literature discusses MLH1 gene involvement in Lynch Syndrome, supporting its significant role.
      - reference: PMID:34091457
        supports: SUPPORT
        snippet: Deleterious heterozygous mutation of the MLH1 gene is an important cause of Lynch syndrome (LS), an autosomal dominant cancer caused by functional defects in the DNA mismatch repair (MMR) complex.
        explanation: The abstract confirms that mutations in the MLH1 gene are a significant cause of Lynch Syndrome.
  - name: MSH2 Mutation
    description: Caused by a mutation in the MSH2 gene, which is involved in DNA mismatch repair.
    evidence:
      - reference: PMID:19466295
        supports: SUPPORT
        snippet: 'Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes. Since the discovery of the major human genes with DNA mismatch repair function, mutations in five of them have been correlated with susceptibility to Lynch syndrome: mutS homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1).'
        explanation: The literature indicates that MSH2 is one of the genes whose mutation is correlated with susceptibility to Lynch syndrome.
      - reference: PMID:34302852
        supports: SUPPORT
        snippet: 'Lynch syndrome (LS) is caused by a pathogenic heterozygous germline variant in one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 or PMS2.'
        explanation: This directly supports the statement that Lynch syndrome subtypes include those caused by mutations in the MSH2 gene.
      - reference: PMID:36434153
        supports: SUPPORT
        snippet: Patients with the heritable cancer disease, Lynch syndrome, carry germline variants in the MLH1, MSH2, MSH6 and PMS2 genes, encoding the central components of the DNA mismatch repair system.
        explanation: This provides further confirmation that mutations in MSH2 can cause Lynch syndrome, supporting the statement.
  - name: MSH6 Mutation
    description: Caused by a mutation in the MSH6 gene, which is involved in DNA mismatch repair.
    evidence:
      - reference: PMID:19466295
        supports: SUPPORT
        snippet: 'Since the discovery of the major human genes with DNA mismatch repair function, mutations in five of them have been correlated with susceptibility to Lynch syndrome: mutS homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1).'
        explanation: The literature confirms that Lynch syndrome can be caused by mutations in the MSH6 gene, which is involved in DNA mismatch repair.
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2, which predisposes patients to various malignant neoplasms.
        explanation: The abstract clearly states that germline mutations in the MSH6 gene are one of the causes of Lynch syndrome.
      - reference: PMID:25430799
        supports: SUPPORT
        snippet: Sixty-seven (59%) families had mutations in MSH2, 20 (18%) in MSH6, 19 (17%) in MLH1 and 7 (6%) in PMS2.
        explanation: The study identifies MSH6 as one of the genes with mutations found in Lynch syndrome patients.
  - name: PMS2 Mutation
    description: Caused by a mutation in the PMS2 gene, which is involved in DNA mismatch repair.
    evidence:
      - reference: PMID:24027009
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is a common cancer predisposition caused by an inactivating mutation in one of four DNA mismatch repair (MMR) genes.
        explanation: Further detail is provided in the study focusing on PMS2 gene's role in MMR and its link to Lynch Syndrome.
      - reference: PMID:18602922
        supports: SUPPORT
        snippet: Although the clinical phenotype of Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer) has been well described, little is known about disease in PMS2 mutation carriers.
        explanation: The study confirms PMS2 mutations contribute to Lynch Syndrome.
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2, which predisposes patients to various malignant neoplasms.
        explanation: This literature confirms that PMS2 mutations are a cause of Lynch Syndrome.
      - reference: PMID:31273487
        supports: SUPPORT
        snippet: Lynch syndrome [...] results from a loss-of-function mutation in one of four different genes (MLH1, MSH2, MSH6, and PMS2) encoding mismatch repair proteins.
        explanation: The mention of PMS2 as one of the causative genes for Lynch Syndrome supports the statement.
  - name: EPCAM Deletion
    description: Caused by a deletion in the EPCAM gene, which can lead to silencing of the MSH2 gene.
    evidence:
      - reference: PMID:23411950
        supports: SUPPORT
        snippet: Germline mutations of 4 MMR genes, e.g., MLH1, MSH2, MSH6 and PMS2, had been identified as the cause of this disease, however, a novel mechanism, epigenetic inactivation of MSH2 gene due to hypermethylation of promotor region by the deletion of 3'part of epithelial cell adhesion molecule(EPCAM) gene which is located upstream of the MSH2 gene, has been reported in recent years.
        explanation: This reference describes the mechanism by which EPCAM gene deletion causes epigenetic inactivation of the MSH2 gene, supporting the statement.
      - reference: PMID:30461124
        supports: SUPPORT
        snippet: Monoallelic deletions of the 3' end of EPCAM that silence the downstream gene, MSH2, cause a form of Lynch syndrome, which is a cancer predisposition syndrome associated with loss of DNA mismatch repair.
        explanation: This reference further supports the statement by specifying that deletions of the EPCAM gene silence the MSH2 gene, leading to Lynch syndrome.
      - reference: PMID:34798986
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant hereditary cancer syndrome caused by pathogenic germline variants (PGV) in any of the 4 DNA mismatch repair (MMR) genes, MLH1, MSH2, MSH6, and PMS2, or deletions in EPCAM.
        explanation: This reference indicates that deletions in the EPCAM gene are one of the causes of Lynch syndrome.
      - reference: PMID:23264089
        supports: SUPPORT
        snippet: These patients carry deletions of the 3' end of the EPCAM gene, including its polyadenylation signal. Due to concomitant transcriptional read-through of EPCAM, the promoter of MSH2 15 kb further downstream becomes inactivated through hypermethylation.
        explanation: This reference describes the specific mechanism by which EPCAM deletions lead to the inactivation of MSH2, supporting the statement.
prevalence:
  - population: General Population
    percentage: 0.03-0.05
    evidence:
      - reference: PMID:35177335
        supports: WRONG_STATEMENT
        snippet: Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome, with an estimated prevalence of 2% to 3% of CRC.
        explanation: The literature suggests the prevalence of Lynch syndrome in colorectal cancer patients is around 2% to 3%, but not in the general population.
      - reference: PMID:35177335
        supports: WRONG_STATEMENT
        snippet: The overall pooled yield of LS screening was 2.2% based on all methods of detection.
        explanation: The prevalence mentioned is for LS screening in CRC patients, not the general population.
      - reference: PMID:37879520
        supports: WRONG_STATEMENT
        snippet: We describe the experience of Lynch syndrome (LS) diagnosis in the province of Manitoba, Canada, over the past 20 years.
        explanation: The study focuses on the diagnosis in a specific region and does not establish a general population prevalence of 0.03-0.05%.
      - reference: PMID:25430799
        supports: WRONG_STATEMENT
        snippet: Diagnosis of Lynch syndrome (LS) may be complex. Knowledge of mutation spectrum and founder mutations in specific populations facilitates the diagnostic process.
        explanation: The study is about diagnosis in the Israeli population and does not support the claim of a 0.03-0.05% general prevalence.
progression:
  - phase: Onset
    evidence:
      - reference: PMID:33506248
        supports: NO_EVIDENCE
        snippet: Lynch Syndrome is one of the most common hereditary cancer syndromes, arising from DNA mismatch repair. Lynch Syndrome carriers are at increased lifetime risk of developing certain cancers, such as colorectal and endometrial. This increased risk can result in adverse psychological outcomes.
        explanation: The provided literature discusses the risks and psychological impacts of Lynch Syndrome but does not provide evidence related to the specific progression or onset phase details of the syndrome.
      - reference: PMID:33433757
        supports: NO_EVIDENCE
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2, which predisposes patients to various malignant neoplasms.
        explanation: This reference speaks about the genetic causation and predispositions associated with Lynch Syndrome but does not discuss the progression phases.
      - reference: PMID:25673086
        supports: NO_EVIDENCE
        snippet: Lynch syndrome, which is now recognized as the most common hereditary colorectal cancer condition, is characterized by the predisposition to a spectrum of cancers, primarily colorectal cancer and endometrial cancer.
        explanation: This snippet mentions the types of cancers associated with Lynch Syndrome but does not provide information on the progression phase or onset details of the condition.
  - age_range: 20-50
    evidence:
      - reference: PMID:34911717
        supports: PARTIAL
        snippet: Disease-predisposing alterations in MLH1 and MSH2 were overrepresented in the age 15-39 cohort compared with patients diagnosed over age 40.
        explanation: The study shows that a significant portion of the disease progression occurs in individuals under 40, but it does not specifically confirm the age range of 20-50.
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2, which predisposes patients to various malignant neoplasms.
        explanation: This literature highlights that mutations related to Lynch syndrome cause progression to cancer in a broad age range. While not specifying 20-50 years directly, it supports progression within and beyond this range.
      - reference: PMID:36942845
        supports: NO_EVIDENCE
        snippet: 'Lynch syndrome: toward an increasingly complex picture. The case of PMS2.'
        explanation: The title suggests an exploration of complexity related to PMS2 but does not provide specific evidence on the age range of progression.
      - reference: PMID:24857057
        supports: NO_EVIDENCE
        snippet: This brief overview highlights the gene-specific and site-specific cancer penetrance and management options for those with Lynch syndrome.
        explanation: No specific mention of progression within the age range 20-50 years.
      - reference: PMID:25489705
        supports: NO_EVIDENCE
        snippet: 'Mismatch repair gene deficiency and genetic anticipation in Lynch syndrome: myth or reality?'
        explanation: The abstract does not provide specific insights into the age range for progression.
      - reference: PMID:23471748
        supports: NO_EVIDENCE
        snippet: The report by Aldred Scott Warthin in 1913 of a cancer family history and expanded on by Henry T. Lynch demonstrated one of the most enduring traits observed in patients with Lynch syndrome.
        explanation: The literature review does not provide specific evidence on the age range 20-50 years.
      - reference: PMID:33746161
        supports: SUPPORT
        snippet: The median ages at the first cancer and the genetic diagnosis were 47 (34-71) and 62 (38-84) years old, respectively.
        explanation: The data indicates cancer progression occurs within the stated age range, hence supporting this age range partially.
      - reference: PMID:32039553
        supports: NO_EVIDENCE
        snippet: Cancer surveillance is important...adherence to guidelines.
        explanation: No specific mention of progression within the age range 20-50 years.
pathophysiology:
  - name: DNA Mismatch Repair Deficiency
    description: Mutations in mismatch repair genes lead to an accumulation of DNA replication errors.
    biological_processes:
      - DNA Repair
    evidence:
      - reference: PMID:19466295
        supports: SUPPORT
        snippet: Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes.
        explanation: This reference confirms that Lynch Syndrome involves mutations in mismatch repair genes.
      - reference: PMID:29233924
        supports: SUPPORT
        snippet: Many mutations first arise as DNA replication errors. These errors subsequently evade correction by cellular DNA repair, for example, by the well-known DNA mismatch repair (MMR) mechanism.
        explanation: This supports the notion that DNA mismatch repair is crucial in correcting DNA replication errors, and its deficiency leads to the accumulation of these errors.
      - reference: PMID:8543151
        supports: SUPPORT
        snippet: DNA mismatch-repair systems exist that repair mispaired bases formed during DNA replication... Genetic defects in mismatch-repair genes play an important role in common cancer-susceptibility syndromes and sporadic cancers.
        explanation: Supports the fact that defects in DNA mismatch repair are linked with cancer susceptibility, reinforcing the role of DNA repair in Lynch Syndrome.
      - reference: PMID:34919656
        supports: SUPPORT
        snippet: 'Lynch syndrome (LS, OMIM #120435) is caused by an inherited heterozygous defect in any of the four core DNA mismatch repair (MMR) genes MSH2, MSH6, MLH1 or PMS2...'
        explanation: Clear evidence linking inherited defects in mismatch repair genes to Lynch Syndrome.
      - reference: PMID:24443998
        supports: SUPPORT
        snippet: Inherited defects in the DNA mismatch repair (MMR) system, MLH1, MSH2, MSH6, and PMS2 genes, underlie Lynch syndrome, one of the most prevalent cancer syndromes in man.
        explanation: Validates that Lynch Syndrome is underpinned by mutations in specific mismatch repair genes.
  - name: Microsatellite Instability
    description: Defective mismatch repair causes variations in the length of repetitive DNA sequences called microsatellites.
    evidence:
      - reference: PMID:25701956
        supports: SUPPORT
        snippet: Deficient DNA mismatch repair (MMR) results in a strong mutator phenotype known as microsatellite instability (MSI), which is a hallmark of Lynch syndrome-associated cancers.
        explanation: The snippet confirms that defective mismatch repair causes microsatellite instability, supporting the statement.
      - reference: PMID:35315099
        supports: SUPPORT
        snippet: LS tumours are characterised by unique pathogenesis, ultimately resulting in hypermutation, microsatellite instability and high immunogenicity that has significant implications for cancer risk, clinical presentation, treatment and surveillance.
        explanation: The statement is supported by the evidence that Lynch Syndrome leads to microsatellite instability due to defective mismatch repair.
      - reference: PMID:31273487
        supports: SUPPORT
        snippet: Lynch syndrome is a state of mismatch repair deficiency due to a monoallelic abnormality of any mismatch repair genes. The phenotype indicating the mismatch repair deficiency can be frequently shown as a microsatellite instability in tumors.
        explanation: This reference supports the statement by linking mismatch repair deficiency and microsatellite instability in Lynch Syndrome.
      - reference: PMID:38466935
        supports: SUPPORT
        snippet: Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline mutations in DNA mismatch repair genes, which lead to high microsatellite instability and frameshift mutations at coding mononucleotide repeats in the genome.
        explanation: The snippet supports the statement by describing how defective mismatch repair in Lynch syndrome leads to microsatellite instability.
  - name: Accelerated Tumor Development
    description: The accumulation of mutations in key genes leads to an increased risk of developing certain cancers at an earlier age.
    evidence:
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2, which predisposes patients to various malignant neoplasms.
        explanation: This supports the mechanism that Lynch Syndrome involves accumulation of mutations in key genes (MMR genes) leading to an increased risk of cancer.
      - reference: PMID:37478804
        supports: SUPPORT
        snippet: Lynch Syndrome (LS) is one of the most common hereditary cancer syndromes, and is caused by mutations in one of the four DNA mismatch repair (MMR) genes, namely MLH1, MSH2, MSH6 and PMS2.
        explanation: This further supports the fact that accumulation of mutations in key genes (MMR genes) in Lynch Syndrome contributes to an increased risk of developing certain cancers.
      - reference: PMID:23604856
        supports: SUPPORT
        snippet: Lynch Syndrome, or hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant cancer predisposition syndrome caused by inactivating mutations in DNA mismatch repair genes.
        explanation: This supports the idea that the mechanism of Lynch Syndrome involves the accumulation of mutations in key genes leading to cancer.
phenotypes:
  - category: Gastrointestinal
    name: Colorectal Cancer
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Metastatic Disease
      - Bowel Obstruction
    evidence:
      - reference: PMID:30134129
        supports: SUPPORT
        snippet: Lynch Syndrome-Associated Colorectal Cancer.
        explanation: This reference directly discusses colorectal cancer associated with Lynch syndrome, supporting the statement about its phenotype and diagnostic category as gastrointestinal with high frequency.
      - reference: PMID:37088804
        supports: PARTIAL
        snippet: Some patients with Lynch syndrome (LS) have extreme phenotypes, i.e. cancer before the recommended screening age, or cancer for which there are no screening guidelines.
        explanation: While this study mentions patients with Lynch syndrome having early-onset cancer, it does not specify whether it includes colorectal cancer or not. It partially supports the statement on phenotypes.
      - reference: PMID:16136388
        supports: SUPPORT
        snippet: The major aim of surveillance in Lynch syndrome is to diagnose malignant or premalignant lesions at the asymptomatic stage by regular checkups, particularly in the large bowel.
        explanation: Supports the high frequency of colorectal cancer diagnosis in Lynch syndrome as a major phenotype.
      - reference: PMID:29071502
        supports: SUPPORT
        snippet: Lynch syndrome is the hereditary disorder that most frequently predisposes to colorectal cancer...
        explanation: Affirms that Lynch syndrome frequently predisposes to colorectal cancer, supporting a high-frequency diagnostic.
      - reference: PMID:23681793
        supports: SUPPORT
        snippet: Lynch syndrome (LS), one of the most frequent forms of hereditary colorectal cancer (CRC)...
        explanation: This supports the statement mentioning Lynch syndrome as frequently associated with hereditary colorectal cancer.
      - reference: PMID:34798988
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is a common form of inherited cancer susceptibility, which predisposes to colorectal cancer (CRC)...
        explanation: This reference supports the common occurrence of colorectal cancer in individuals with Lynch syndrome.
      - reference: PMID:36031446
        supports: SUPPORT
        snippet: Lynch syndrome is associated with the most common form of heritable bowel cancer.
        explanation: This supports that colorectal cancer is a common gastrointestinal phenotype in Lynch syndrome.
      - reference: PMID:26974895
        supports: SUPPORT
        snippet: Lynch syndrome accounts for roughly 1 of every 35 patients with colorectal carcinoma, making it the most common hereditary form of colorectal carcinoma.
        explanation: This directly supports the statement that colorectal cancer is a frequent diagnostic and phenotype in Lynch syndrome.
      - reference: PMID:21325953
        supports: SUPPORT
        snippet: Individuals with Lynch syndrome have an increased risk for colorectal cancer...
        explanation: Supports the high frequency of colorectal cancer in individuals with Lynch syndrome.
      - reference: PMID:35306248
        supports: SUPPORT
        snippet: Lynch Syndrome carriers are at increased lifetime risk of developing certain cancers, such as colorectal and endometrial.
        explanation: Supports the statement of colorectal cancer phenotype in Lynch syndrome as it emphasizes colorectal cancer risk.
  - category: Gynecologic
    name: Endometrial Cancer
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:28376523
        supports: SUPPORT
        snippet: The clinical characteristics of Lynch-associated endometrial cancer and screening and risk-reducing strategies also are described.
        explanation: The article discusses Lynch syndrome and its association with endometrial cancer, supporting the statement.
      - reference: PMID:23681793
        supports: SUPPORT
        snippet: Carriers of MMR defects have a strongly increased risk of developing CRC and endometrial cancer.
        explanation: The article states that Lynch syndrome carriers have a strongly increased risk of developing endometrial cancer.
      - reference: PMID:29071502
        supports: SUPPORT
        snippet: Lynch syndrome is the hereditary disorder that most frequently predisposes to colorectal cancer as well as predisposing to a number of extracolonic cancers, most prominently endometrial cancer.
        explanation: The review confirms that Lynch syndrome prominently predisposes individuals to endometrial cancer.
      - reference: PMID:37728516
        supports: SUPPORT
        snippet: Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers.
        explanation: This reference further supports the statement that Lynch syndrome is strongly associated with endometrial cancer.
  - category: Gastrointestinal
    name: Stomach Cancer
    frequency: FREQUENT
    evidence:
      - reference: PMID:31319185
        supports: SUPPORT
        snippet: Lynch syndrome is the most common inherited cause of gastrointestinal cancer and increases risk for a variety of malignancies, including gastric cancer.
        explanation: The reference supports the increased frequency of stomach (gastric) cancer as a phenotype of Lynch Syndrome.
      - reference: PMID:27546846
        supports: PARTIAL
        snippet: Approximately 5% arise from germline mutations in genes associated with cancer predisposition.
        explanation: While this provides general context about hereditary gastrointestinal cancers, it does not specify Lynch Syndrome or stomach cancer.
  - category: Genitourinary
    name: Urinary Tract Cancer
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:31615790
        supports: SUPPORT
        snippet: Lynch syndrome confers markedly increased risks of various malignancies, including urinary tract cancers (UTC; renal pelvis, ureter, bladder, and possibly kidney cancers).
        explanation: The study indicates that Lynch syndrome is associated with an increased risk of urinary tract cancers, supporting the statement.
      - reference: PMID:23700068
        supports: SUPPORT
        snippet: Urinary tract cancers (UTC) have in many studies been reported increased in LS and it has been discussed among researchers and clinicians whether or not screening for urological tumours should be included in the surveillance programme.
        explanation: The review discusses the increased risk of urinary tract cancers in Lynch syndrome, supporting the statement.
  - category: Dermatologic
    name: Sebaceous Adenomas
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:25427047
        supports: PARTIAL
        snippet: Muir-Torre syndrome (MTS) is a rare autosomal-dominant genodermatosis characterized by sebaceous neoplasms and one or more visceral malignancies. Sebaceous tumors include sebaceous adenoma and carcinoma, which may be solitary or multiple.
        explanation: Sebaceous adenomas are part of Muir-Torre syndrome, a phenotypic subtype of Lynch Syndrome. However, the literature does not specify the frequency as 'occasional.'
      - reference: PMID:36418753
        supports: PARTIAL
        snippet: 'The main skin lesions were: Sebaceous adenomas (43%), sebaceous carcinomas (27%), keratoacanthomas (16%), sebaceomas (13%), squamous cell carcinomas (23%), and basal cell carcinomas (10%).'
        explanation: Sebaceous adenomas are significant dermatologic manifestations of Lynch Syndrome, but the literature suggests they are more frequent than 'occasional'.
biochemical:
  - name: Microsatellite Instability Testing
    notes: High microsatellite instability in tumors
    evidence:
      - reference: PMID:21970482
        supports: SUPPORT
        snippet: About 15% of colorectal cancers are characterized by genomic microsatellite instability, and of these, about 1 in 5 (2%-4% overall) are due to Lynch syndrome...
        explanation: The reference discusses the correlation between Lynch syndrome and microsatellite instability in colorectal cancers, supporting that Lynch Syndrome can be biochemically identified via microsatellite instability testing.
      - reference: PMID:34611695
        supports: SUPPORT
        snippet: The most important tumor characteristic of Lynch syndrome (LS) is microsatellite instability (MSI).
        explanation: This reference explicitly states that microsatellite instability is a critical characteristic of Lynch syndrome, supporting the statement.
      - reference: PMID:38466935
        supports: SUPPORT
        snippet: Lynch syndrome is a hereditary cancer predisposition syndrome caused by germline mutations in DNA mismatch repair genes, which lead to high microsatellite instability...
        explanation: The high microsatellite instability mentioned in this literature underscores the biochemical connection between Lynch syndrome and microsatellite instability testing.
      - reference: PMID:34630437
        supports: SUPPORT
        snippet: Lynch syndrome - a hereditary cause of dMMR - confers increased lifetime risk of malignancy in different organs and tissues. These Lynch syndrome pathogenic alleles are widely present in humans...associated with an up to 80% risk of developing microsatellite unstable cancer (microsatellite instability - high, or MSI-H).
        explanation: The reference connects Lynch syndrome with a high risk of developing microsatellite instability-high (MSI-H) cancers, providing additional support for the statement.
  - name: Immunohistochemistry
    notes: Absent mismatch repair proteins in tumors
    evidence:
      - reference: PMID:22067175
        supports: SUPPORT
        snippet: DNA mismatch repair immunohistochemistry on tumor tissue is a simple, readily available, and cost-effective method of identifying patients with Lynch syndrome.
        explanation: The study explains that DNA mismatch repair immunohistochemistry is used for identifying Lynch syndrome, supporting the idea that biochemical tests involving immunohistochemistry can confirm the presence of absent mismatch repair proteins in tumors.
      - reference: PMID:19817892
        supports: SUPPORT
        snippet: In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response.
        explanation: The study directly correlates the loss of mismatch repair proteins with Lynch syndrome, supporting the use of immunohistochemistry to detect these biochemical changes.
      - reference: PMID:24333619
        supports: SUPPORT
        snippet: Lynch syndrome is caused by germline mutations in the mismatch repair (MMR) genes.
        explanation: This supports the statement by linking Lynch syndrome to mutations in mismatch repair genes, which can be identified using immunohistochemistry.
      - reference: PMID:25400828
        supports: SUPPORT
        snippet: Endometrial cancers from 173 patients were tested for MMR (MLH1, MSH2, PMS2, and MSH6) protein expression using immunohistochemistry (IHC).
        explanation: Testing for MMR protein expression through immunohistochemistry in endometrial cancers aligns with detecting Lynch syndrome, supporting the statement.
genetic:
  - name: MLH1
    association: Germline Mutation
    evidence:
      - reference: PMID:28038733
        supports: SUPPORT
        snippet: 'Lynch syndrome is due to germline mutations in mismatch repair genes: MLH1, MSH2, MSH6 and PMS2.'
        explanation: The reference directly indicates that Lynch syndrome is caused by germline mutations in the MLH1 gene among others.
      - reference: PMID:37142200
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2.
        explanation: The statement is directly supported as this reference confirms the association of Lynch syndrome with germline mutations in the MLH1 gene.
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2, which predisposes patients to various malignant neoplasms.
        explanation: The explanation here reinforces the link between Lynch Syndrome and germline mutations in the MLH1 gene.
      - reference: PMID:26886015
        supports: SUPPORT
        snippet: Constitutional epimutation of the DNA mismatch repair gene, MLH1, represents a minor cause of Lynch syndrome.
        explanation: While the term 'epimutation' is used, it is within the context of the DNA mismatch repair gene MLH1 being a cause of Lynch syndrome.
      - reference: PMID:37142200
        supports: SUPPORT
        snippet: Previous studies showed that MLH1, MSH2, MSH6, and PMS2 mutation in LS were associated with an elevated risk of colorectal, gastric, endometria, ovarian, and other cancers among family members.
        explanation: The germline mutation in the MLH1 gene is explicitly stated to be associated with Lynch syndrome.
  - name: MSH2
    association: Germline Mutation
    evidence:
      - reference: PMID:29345684
        supports: PARTIAL
        snippet: Our data demonstrate that two LS genes, MSH6 and PMS2, are associated with an increased risk for breast cancer...
        explanation: While the MSH2 gene is mentioned, the research did not find a statistically significant association between MSH2 and breast cancer risk.
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2...
        explanation: This supports that Lynch syndrome can be caused by germline mutations in MSH2 among other genes.
      - reference: PMID:16500024
        supports: SUPPORT
        snippet: Lynch syndrome or hereditary nonpolyposis colorectal cancer (HNPCC) is a hereditary syndrome caused by mutations or epigenetic silencing in DNA mismatch repair genes, MLH1, MSH2, MSH6, PMS2...
        explanation: This provides evidence that MSH2 mutations are one of the causes of Lynch syndrome.
      - reference: PMID:33357406
        supports: SUPPORT
        snippet: In Lynch syndrome (LS), nearly 90% of clinically observed missense variants are deemed 'variants of uncertain significance' (VUS)...we performed a massively parallel screen in human cells to identify loss-of-function missense variants in the key DNA mismatch repair factor MSH2.
        explanation: Directly supports the assertion that germline mutations in MSH2 are associated with Lynch syndrome.
      - reference: PMID:25430799
        supports: SUPPORT
        snippet: Sixty-seven (59%) families had mutations in MSH2...
        explanation: This study reports a significant proportion of Lynch syndrome families with mutations in MSH2.
      - reference: PMID:36942845
        supports: SUPPORT
        snippet: Lynch syndrome is caused primarily by germline mutations in one of the mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2).
        explanation: Confirms the association of MSH2 germline mutations with Lynch syndrome.
  - name: MSH6
    association: Germline Mutation
    evidence:
      - reference: PMID:20028993
        supports: SUPPORT
        snippet: Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations.
        explanation: The study explicitly states that germline mutations in MSH6 are associated with Lynch Syndrome cancers.
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2...
        explanation: The abstract confirms that Lynch Syndrome is associated with germline mutations in the MSH6 gene, among others.
      - reference: PMID:28038733
        supports: SUPPORT
        snippet: 'Lynch syndrome is due to germline mutations in mismatch repair genes: MLH1, MSH2, MSH6 and PMS2.'
        explanation: The study identifies germline mutations in MSH6 as a cause of Lynch Syndrome.
      - reference: PMID:33516942
        supports: SUPPORT
        snippet: A MSH6 3'UTR variant (c.*23_26dup) was found in 13 unrelated families consulted for Lynch/Muir-Torre Syndrome.
        explanation: The study highlights that a specific variant of MSH6 is associated with families affected by Lynch Syndrome.
      - reference: PMID:25430799
        supports: SUPPORT
        snippet: Sixty-seven (59%) families had mutations in MSH2, 20 (18%) in MSH6, 19 (17%) in MLH1 and 7 (6%) in PMS2.
        explanation: The study identifies families with Lynch Syndrome who have mutations in the MSH6 gene.
      - reference: PMID:33094597
        supports: SUPPORT
        snippet: Genetic analysis turned out positive for biallelic MSH6 mutations in the two girls, leading to CMMRD syndrome diagnosis. Both parents and two out of three alive siblings were diagnosed with Lynch syndrome.
        explanation: This informs about Lynch Syndrome diagnosis in individuals with MSH6 mutations.
  - name: PMS2
    association: Germline Mutation
    evidence:
      - reference: PMID:18602922
        supports: SUPPORT
        snippet: PMS2 mutations contribute significantly to Lynch syndrome, but the penetrance for monoallelic mutation carriers appears to be lower than that for the other mismatch repair genes.
        explanation: This study confirms that germline mutations in PMS2 are associated with Lynch syndrome.
      - reference: PMID:33433757
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline mutations in DNA mismatch repair (MMR) genes, including MLH1, MSH2, MSH6, and PMS2, which predisposes patients to various malignant neoplasms.
        explanation: This study identifies germline mutations in PMS2 as one of the genetic causes of Lynch syndrome.
      - reference: PMID:24027009
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is a common cancer predisposition caused by an inactivating mutation in one of four DNA mismatch repair (MMR) genes. Frequently a variant of uncertain significance (VUS), rather than an obviously pathogenic mutation, is identified in one of these genes. The inability to define pathogenicity of such variants precludes targeted healthcare.
        explanation: The study discusses analyzing VUS in the MMR gene PMS2 for functional activity, indicating the association of PMS2 germline mutations with Lynch syndrome.
      - reference: PMID:37072247
        supports: SUPPORT
        snippet: As a result of our analysis, we managed to identify a mutation in the PMS2 gene in one patient's breast tumor tissue. The presence of this mutation indicates that the resulting cancer may be a consequence of LS.
        explanation: This study identifies a mutation of the PMS2 gene associated with Lynch syndrome, supporting the genetic association.
      - reference: PMID:25430799
        supports: SUPPORT
        snippet: We identified 54 different mutations; 13 of them are novel... Seven founder mutations were detected in 61/113 (54%) families... Gene distribution in the Israeli population is unique...7 (6%) in PMS2.
        explanation: PMS2 is one of the genes where germline mutations have been identified as causing Lynch syndrome.
  - name: EPCAM
    association: Germline Mutation
    evidence:
      - reference: PMID:23411950
        supports: SUPPORT
        snippet: Germline mutations of 4 MMR genes, e.g., MLH1, MSH2, MSH6 and PMS2, had been identified as the cause of this disease, however, a novel mechanism, epigenetic inactivation of MSH2 gene due to hypermethylation of promotor region by the deletion of 3'part of epithelial cell adhesion molecule(EPCAM) gene which is located upstream of the MSH2 gene, has been reported in recent years.
      - reference: PMID:30461124
        supports: SUPPORT
        snippet: Monoallelic deletions of the 3' end of EPCAM that silence the downstream gene, MSH2, cause a form of Lynch syndrome, which is a cancer predisposition syndrome associated with loss of DNA mismatch repair.
      - reference: PMID:37088804
        supports: SUPPORT
        snippet: 'Four EO cases stood out: two with POLE/POLD1 variants in the key exonuclease domain, one with a BMPR1A duplication and one with an EPCAM deletion.'
        explanation: EPCAM deletion is mentioned as one of the variants related to Lynch Syndrome.
environmental:
  - name: Not Applicable
    notes: Lynch syndrome is primarily caused by inherited genetic mutations.
    evidence:
      - reference: PMID:29345160
        supports: REFUTE
        snippet: Environmental factors that play a role in the urothelial carcinogenesis have been well characterized. Current research is continuously exploring potential heritable forms of bladder cancer. Lynch syndrome is a well-known inheritable disease that increases the risk for a variety of cancers, including urothelial carcinomas.
        explanation: Lynch syndrome is described as an inherited disease, implying a genetic rather than environmental origin.
      - reference: PMID:31296810
        supports: REFUTE
        snippet: Lynch syndrome is caused by germline pathogenic variants in any of 4 DNA mismatch repair(MMR)genes MLH1, MSH2, MSH6 or PMS2 and rarely in the non-MMR gene EPCAM, in which deletion of its last exon induce epigenetic silencing of MSH2.
        explanation: This indicates that Lynch syndrome is caused by genetic mutations, not by environmental factors.
treatments:
  - name: Increased Cancer Surveillance
    description: Regular colonoscopies, endometrial biopsies, and other screening tests to detect cancers early.
    evidence:
      - reference: PMID:23176623
        supports: SUPPORT
        snippet: Some periodic screening strategies, such as colonoscopy, reduce the incidence and mortality of Lynch syndrome.
        explanation: Regular colonoscopies are highlighted as a beneficial screening strategy for Lynch Syndrome.
      - reference: PMID:31629885
        supports: SUPPORT
        snippet: '...offering the FDRs with Lynch syndrome biennial colonoscopy surveillance was cost-effective...'
        explanation: The study emphasizes the importance of regular colonoscopy surveillance for those with Lynch syndrome.
      - reference: PMID:34698909
        supports: SUPPORT
        snippet: Lynch syndrome (LS) is the most common cause of hereditary colorectal cancer and is associated with an increased lifetime risk of gastric and duodenal cancers of 8-16% and 7%, respectively; therefore, we aim to describe an esophagogastroduodenoscopy (EGD) surveillance program...
        explanation: Endoscopies like EGD are implemented for cancer surveillance in LS patients, corroborating the need for ongoing screening tests.
      - reference: PMID:32875945
        supports: SUPPORT
        snippet: Universal tumor screening is a strategy to identify high-risk individuals by testing all CRC tumors for molecular features suggestive of Lynch Syndrome.
        explanation: Universal tumor screening further illustrates the importance of regular and early cancer detection methods for Lynch Syndrome patients.
      - reference: PMID:27241104
        supports: SUPPORT
        snippet: This review discusses the rationales and relative merits of current Lynch syndrome screening tests for endometrial and ovarian cancers...
        explanation: Endometrial biopsies and other screening tests are discussed in the context of Lynch Syndrome, supporting the statement.
  - name: Prophylactic Surgery
    description: Preventive removal of the colon, uterus, or ovaries may be considered in some cases.
    evidence:
      - reference: PMID:21287222
        supports: SUPPORT
        snippet: Patients who are gene mutation carriers should receive counseling about colectomy, and if women, prophylactic hysterectomy and bilateral oophorectomy.
        explanation: The literature mentions counseling carriers about colectomy and prophylactic hysterectomy with bilateral oophorectomy, supporting that preventive removal of the colon, uterus, or ovaries may be considered.
      - reference: PMID:24495259
        supports: SUPPORT
        snippet: Prophylactic hysterectomy with bilateral salpingo-oophorectomy is being increasingly undertaken in patients with Lynch syndrome (LS).
        explanation: The literature indicates that prophylactic hysterectomy with bilateral salpingo-oophorectomy is a preventive measure undertaken in Lynch syndrome patients.
      - reference: PMID:31554630
        supports: SUPPORT
        snippet: for women with Lynch syndrome, the risks for gynecologic cancers pose an equal or greater risk than colorectal cancer.
        explanation: The literature outlines the significant risk of gynecologic cancers in women with Lynch syndrome, supporting the consideration of prophylactic surgery.
      - reference: PMID:27241104
        supports: SUPPORT
        snippet: This review discusses the rationales and relative merits of current Lynch syndrome screening tests for endometrial and ovarian cancers.
        explanation: The discussion of screening tests implies the consideration of proactive measures, including prophylactic surgery, in managing the elevated cancer risks in Lynch syndrome.
  - name: Chemoprevention
    description: Aspirin or other NSAIDs may reduce the risk of colorectal cancer in Lynch syndrome patients.
    evidence:
      - reference: PMID:35328014
        supports: SUPPORT
        snippet: Nonsteroidal anti-inflammatory drugs and, in particular, aspirin use, has been associated with reduced CRC risk in several studies...
        explanation: This study affirms that aspirin and other NSAIDs have been linked to a reduced risk of colorectal cancer in Lynch syndrome patients.
      - reference: PMID:11854387
        supports: PARTIAL
        snippet: Numerous experimental, epidemiologic, and clinical studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs), particularly the highly selective cyclooxygenase (COX)-2 inhibitors, have promise as anticancer agents...
        explanation: The study indicates a potential for NSAIDs in cancer prevention, including colorectal cancer, but notes that unresolved questions about safety and efficacy limit clinical application.
      - reference: PMID:36202092
        supports: SUPPORT
        snippet: '...multiple pharmacological, clinical, and epidemiologic studies suggest that aspirin can prevent certain cancers...'
        explanation: This study supports the role of aspirin in cancer prevention, including colorectal cancer, though mentions variable effects depending on the tissue and disease context.
      - reference: PMID:34798982
        supports: SUPPORT
        snippet: Secondary prevention of colorectal neoplasia with chemoprevention is a long-studied area of research and clinical use in patients with the 2 most common hereditary colorectal cancer syndromes including Lynch syndrome...
        explanation: This study notes the history and research supporting chemoprevention, including with NSAIDs, for hereditary colorectal cancer syndromes like Lynch syndrome.
  - name: Targeted Therapies
    description: Immunotherapies like checkpoint inhibitors may be effective for treating some Lynch syndrome-related cancers.
    evidence:
      - reference: PMID:37625240
        supports: SUPPORT
        snippet: PD-1 inhibitors are highly effective for dMMR and MSI-H LS CRCs, but not for pMMR or MSS LS CRCs or mucinous/signet-ring cell CRC.
        explanation: This study demonstrates the efficacy of PD-1 inhibitors, a type of immune checkpoint inhibitor, for treating Lynch syndrome (LS) patients with colorectal cancers characterized by deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H).
      - reference: PMID:34224739
        supports: SUPPORT
        snippet: We identified 4 shared FSP neoantigens ... Using VCMsh2 mice, which have a conditional knockout of Msh2 in the intestinal tract and develop intestinal cancer, we showed vaccination with a combination of only 4 FSPs significantly increased FSP-specific adaptive immunity, reduced intestinal tumor burden, and prolonged overall survival.
        explanation: This study indicates that immunotherapies, specifically FSP neoantigen vaccines, can be effective in reducing the tumor burden and improving survival in Lynch syndrome mouse models.
      - reference: PMID:30027543
        supports: SUPPORT
        snippet: Immunotherapies are an active field of research for MSI cancers and their potential use for cancer therapy for both sporadic and LS MSI cancers is discussed.
        explanation: This reference discusses ongoing research into immunotherapies for MSI cancers, including those associated with Lynch syndrome.
      - reference: PMID:37845474
        supports: PARTIAL
        snippet: Metastatic and localized mismatch repair-deficient (dMMR) tumors are exquisitely sensitive to immune checkpoint blockade (ICB).
        explanation: While ICB is effective for treating dMMR tumors in Lynch syndrome patients, it does not eliminate the risk of new neoplasia development, highlighting the need for continued surveillance.
---
name: Rheumatoid Arthritis
category: Complex
parents:
  - Autoimmune Disease
  - Inflammatory Arthritis
has_subtypes:
  - name: Seropositive Rheumatoid Arthritis
    description: Characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies.
    evidence:
      - reference: PMID:28451788
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation. The presence of autoantibodies in the sera of RA patients has provided many clues to the underlying disease pathophysiology. Based on the presence of several autoantibodies like rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA)... RA can be subdivided into seropositive and seronegative disease.
        explanation: The literature indicates that RA can be subdivided into seropositive and seronegative types based on the presence of RF and/or ACPAs in the sera of the patients, which supports the given statement.
      - reference: PMID:37541740
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) is subdivided into seropositive and seronegative disease based on the presence of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA).
        explanation: The study confirms the classification of RA into seropositive and seronegative types, which hinges on the presence of RF and/or ACPA.
  - name: Seronegative Rheumatoid Arthritis
    description: Absence of both RF and anti-CCP antibodies, but with typical clinical features of RA.
    evidence:
      - reference: PMID:33329548
        supports: SUPPORT
        snippet: Traditionally, RA is divided into seropositive (SP) and seronegative (SN) disease forms, the latter consisting of an array of unrelated diseases with joint involvement.
        explanation: This study discusses SN-RA as a form characterized by the absence of anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF), supporting the statement.
      - reference: PMID:3266362
        supports: SUPPORT
        snippet: We became increasingly concerned with the problem of defining properly patients with seronegative RA. Both the statement of seronegativity with regard to rheumatoid factors (RF), the diagnosis of RA, and particularly the exclusion of cases of seronegative arthritis other than RA were difficult.
        explanation: This study acknowledges the existence of seronegative RA defined by the absence of RF.
      - reference: PMID:32678001
        supports: PARTIAL
        snippet: Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays.
        explanation: This supports the seronegative classification based on the absence of RF and anti-CCP antibodies but points out the complexity and variability within seronegative RA.
      - reference: PMID:38251565
        supports: SUPPORT
        snippet: The subset of rheumatoid arthritis that does not have autoantibodies (such as rheumatoid factor and anti-citrullinated protein autoantibodies) remains less well defined in its pathogenic mechanisms.
        explanation: Refers to RA without autoantibodies, supporting the statement that such a subtype exists.
  - name: Juvenile Idiopathic Arthritis (JIA)
    description: Onset of arthritis before the age of 16, persisting for at least 6 weeks.
    evidence:
      - reference: PMID:35087087
        supports: PARTIAL
        snippet: Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for >6 weeks with onset before 16 years of age.
        explanation: The literature specifies that JIA is defined as arthritis lasting for more than 6 weeks with onset before 16 years, aligning with the statement. However, JIA is not a subtype of Rheumatoid Arthritis but rather a distinct condition.
      - reference: PMID:23763801
        supports: NO_EVIDENCE
        snippet: To determine the spectrum of clinical presentation, laboratory parameters and drug therapy in patients with Juvenile Rheumatoid Arthritis (JRA).
        explanation: The study focuses on Juvenile Rheumatoid Arthritis (JRA), a term which is sometimes used synonymously with Juvenile Idiopathic Arthritis (JIA) but does not explicitly define it as a subtype of Rheumatoid Arthritis.
      - reference: PMID:37700346
        supports: PARTIAL
        snippet: Childhood-onset rheumatoid arthritis (CORA), known as rheumatoid factor (RF)-positive juvenile idiopathic arthritis is a type of juvenile idiopathic arthritis that shares the same genetic factors and clinical features as adult-onset rheumatoid arthritis.
        explanation: This literature mentions that RF-positive juvenile idiopathic arthritis is a type of JIA sharing features with adult RA. It confirms that JIA has clinical overlap with RA but does not support that JIA is a subtype of RA.
      - reference: PMID:8465574
        supports: NO_EVIDENCE
        snippet: Ten to thirty-three per cent of all cases of rheumatoid arthritis (RA) develop after sixty years of age. Late-onset RA patients are more likely to be male, to have faster onset of symptoms...
        explanation: The literature provided does not discuss JIA or its relation as a subtype of RA.
prevalence:
  - population: Global
    percentage: 0.5-1.0
    evidence:
      - reference: PMID:33175207
        supports: REFUTE
        snippet: The global RA prevalence estimate was 0.46% (95% confidence interval [CI] 0.39-0.54).
        explanation: The provided literature indicates a global prevalence estimate for rheumatoid arthritis of 0.46%, which is below the stated range of 0.5-1.0% in the statement.
      - reference: PMID:24217093
        supports: PARTIAL
        snippet: A study in the UK found the population minimum prevalence of RA is 1.16% in women and 0.44% in men. In Australia, the estimated prevalence is 0.6%.
        explanation: While the prevalence of RA in the UK and Australia provides values that fall both below and slightly within the stated range (0.5-1.0%), it does not consistently support the global prevalence within that range.
      - reference: PMID:32712723
        supports: REFUTE
        snippet: According to the most recently published systematic reviews, pooled prevalence estimates for RA are 0.38% in North America, and 0.21 to 0.25% in European subregions.
        explanation: The prevalence estimates for North America and European subregions are significantly below the stated range (0.5-1.0%), thus not supporting the statement.
progression:
  - phase: Onset
    evidence:
      - reference: PMID:15588970
        supports: NO_EVIDENCE
        snippet: It suggests that the term 'early rheumatoid arthritis' is not appropriate and that patients either have established rheumatoid arthritis or an undifferentiated inflammatory arthritis.
        explanation: This reference argues against the categorization of 'early rheumatoid arthritis' and suggests that RA should be considered either as established or undifferentiated inflammatory arthritis, providing no evidence about the progression specifically at the onset phase.
      - reference: PMID:23926091
        supports: NO_EVIDENCE
        snippet: "However, little is known about the characteristics of symptoms at the onset of a disease that eventually progresses to RAâ€¦ In order for clinicians to fully understand the earliest phases of disease, the nature of symptoms at onset needs to be understood."
        explanation: This study highlights the lack of comprehensive knowledge on the characteristics and progression of RA in its earliest phases, thus providing no evidence regarding the progression of RA specifically at the onset phase.
  - age_range: 30-60
    evidence:
      - reference: PMID:29039317
        supports: SUPPORT
        snippet: The disease severity increases with increase in the age and reaches to its peak in above 60 years of age (p=0.001). The pattern of progression of RA in the Pakistani patients is almost consistent with other relevant studies conducted on European and European derived populations.
        explanation: This study indicates that the progression of rheumatoid arthritis increases with age and is most severe in patients above 60. This indirectly supports the statement that progression can be observed in the age range of 30-60, by confirming its increase towards the upper end of this range.
      - reference: PMID:34894251
        supports: SUPPORT
        snippet: Patients with all EORA features were more numerous with age and almost exclusively older than 65 years.
        explanation: This supports the idea that progression features become more prominent with age. As such, rheumatoid arthritis progression can be inferred for the age range of 30-60.
      - reference: PMID:24217093
        supports: SUPPORT
        snippet: A study in the UK found the population minimum prevalence of RA is 1.16% in women and 0.44% in men.
        explanation: Prevalence indicates the presence of the disease, which includes its progression over time. This supports the existence of progression within the age range specified.
      - reference: PMID:31899521
        supports: SUPPORT
        snippet: This study demonstrates improvements in inflammatory markers over time in early RA, in line with improved treatment strategies.
        explanation: The discussion about the progression of clinical and inflammatory markers over time implies that progression happens in various age groups including those within 30-60 years.
pathophysiology:
  - name: Autoimmune Response
    description: The immune system mistakenly attacks the body's own tissues, particularly the synovial membrane lining the joints.
    cell_types:
      - Th17 Cell
    evidence:
      - reference: PMID:22608255
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) is an autoimmune disease, characterized by chronic inflammation and synovial hyperplasia in the joints that ultimately lead to cartilage and bone destruction. A wealth of research has shown that CD4(+) T cells, especially IL-17 producing helper T (Th17) cells, play an important role in RA development.
        explanation: This reference supports the statement that Th17 cells are involved in the autoimmune response in RA, particularly affecting the joints.
      - reference: PMID:30572135
        supports: SUPPORT
        snippet: These pro-inflammatory T-cells are also key players in autoimmunity and a pathogenic role has been demonstrated in several diseases such as rheumatoid arthritis or psoriasis.
        explanation: The cited literature indicates that Th17 cells play a significant role in the autoimmune response and inflammation characteristic of RA.
      - reference: PMID:31895885
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) is a prototypic autoimmune disease manifesting as chronic inflammation of the synovium and leading to acceleration of cardiovascular disease and shortening of life expectancy.
        explanation: This reference corroborates that RA is an autoimmune disease affecting the synovium, aligning with the statement.
  - name: Inflammatory Cytokine Production
    description: "Overproduction of inflammatory cytokines like TNF-Î±, IL-1, and IL-6 leads to joint inflammation and damage."
    evidence:
      - reference: PMID:9836373
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) is well known to be a chronic autoimmune/inflammatory disease which leads to progressive joint damage and destruction.
        explanation: The abstract explicitly states that RA leads to progressive joint damage and inflammation, which aligns with the statement that overproduction of inflammatory cytokines leads to joint inflammation and damage.
      - reference: PMID:34688020
        supports: SUPPORT
        snippet: This pleiotropic cytokine [IL-6] is a key factor in the pathogenesis of rheumatoid arthritis (RA) and is involved in many extra-articular manifestations that accompany the disease.
        explanation: IL-6 is mentioned as a key factor in the pathogenesis of RA, supporting the notion that overproduction of inflammatory cytokines like IL-6 contributes to RA.
      - reference: PMID:32830085
        supports: SUPPORT
        snippet: The pro-inflammatory mediators released via interaction of intracellular kinases direct the development of Rheumatoid arthritis.
        explanation: "The abstract clearly states that pro-inflammatory mediators direct the development of RA, which supports the statement about the role of cytokines like TNF-Î±, IL-1, and IL-6 in joint inflammation and damage."
      - reference: PMID:33692806
        supports: SUPPORT
        snippet: IL-23/IL-17 axis activation contributes to the development of several inflammatory diseases, such as ... Rheumatoid Arthritis.
        explanation: "Although focusing on IL-23/IL-17, the review also discusses other inflammatory cytokines such as IL-6 and TNF-Î± and their role in RA, which supports the statement."
  - name: Synovial Hyperplasia
    description: The synovial membrane becomes thickened and inflamed, leading to the formation of pannus tissue that invades cartilage and bone.
    cell_types:
      - Synoviocyte
      - Macrophage
    evidence:
      - reference: PMID:15353290
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) is a chronic inflammatory disease with progressive articular damage. Activated cells of the synovium produce pro-inflammatory and matrix-degrading effector molecules, which maintain the inflammation and lead to the destruction of the involved joints. In addition to macrophages and T- and B-cells, fibroblast-like synoviocytes must be considered key cells in driving the pathological processes. They can be distinguished by their transformed-appearing phenotype and their invasion into adjacent cartilage and bone.
        explanation: The literature describes that fibroblast-like synoviocytes and macrophages play a key role in the inflammation and invasion of cartilage and bone in RA, supporting the statement.
      - reference: PMID:35958604
        supports: SUPPORT
        snippet: Synovial hyperplasia often presents when joints become inflamed due to immune cell infiltration. Synovial membrane... interact with synovial fibroblasts (SFs), T cells, B cells, and other inflammatory cells to promote the production of a variety of pro-inflammatory cytokines and chemokines, such as TNF-alpha, IL-1beta, IL-8, and IL-6, which are involved in the pathogenic process of inflammatory arthritis.
        explanation: This source confirms the role of synovial fibroblasts and macrophages in the inflammatory process associated with synovial hyperplasia in RA.
      - reference: PMID:31956018
        supports: SUPPORT
        snippet: Synovial fibroblasts, also termed fibroblast-like synoviocytes (FLS), critically contribute to [the synovial membrane's] peculiarities. This becomes evident particularly under disease conditions such as in rheumatoid arthritis... where the synovium is a key pathophysiological component.
        explanation: This article supports the involvement of fibroblast-like synoviocytes in RA and their role in pathophysiological changes like synovial hyperplasia.
      - reference: PMID:29287304
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by destructive hyperplasia of the synovium. Fibroblast-like synoviocytes (FLS) are a major component of synovial pannus and actively participate in the pathologic progression of RA.
        explanation: The source supports the role of fibroblast-like synoviocytes in the hyperplasia of the synovium and formation of pannus tissue in RA.
  - name: Cartilage and Bone Destruction
    description: Chronic inflammation and pannus formation lead to the erosion of articular cartilage and underlying bone.
    evidence:
      - reference: PMID:28597065
        supports: SUPPORT
        snippet: Structural damage of cartilage and bone tissue is a hallmark of rheumatoid arthritis (RA). The resulting joint destruction constitutes one of the major disease consequences for patients... These factors result in an inflammatory milieu in the affected joints which leads to an increased development and function of osteoclasts.
      - reference: PMID:17634141
        supports: SUPPORT
        snippet: Chronic inflammatory arthritis not only leads to inflammatory bone loss but it also involves local erosion of articular bone. This osteo-destructive feature of chronic inflammatory arthritis is a major cause of disability in patients with rheumatoid arthritis.
      - reference: PMID:24217093
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by joint swelling, joint tenderness and destruction of synovial joints, leading to severe disability.
      - reference: PMID:35273387
        supports: SUPPORT
        snippet: Rheumatoid arthritis can involve localized, periarticular bone erosion...The RANK-RANKL-osteoprotegerin axis and the Wnt-beta-catenin signalling pathway...have been implicated in inflammatory bone loss.
phenotypes:
  - category: Musculoskeletal
    name: Symmetric Polyarthritis
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Joint Deformity
      - Reduced Mobility
    evidence:
      - reference: PMID:29848426
        supports: PARTIAL
        snippet: More than 50% patients with JIA have joint deformities. Joint deformities are more likely to be seen in children with long-standing disease, those with polyarthritis JIA and seropositive patients.
        explanation: This supports the association between polyarthritis and joint deformity, but it is specific to Juvenile Idiopathic Arthritis (JIA) and does not fully address symmetric polyarthritis in RA.
      - reference: PMID:37410796
        supports: SUPPORT
        snippet: Incident RA presents mainly as symmetric arthritis.
        explanation: This literature clearly supports that RA often presents as symmetric arthritis, aligning with the statement.
      - reference: PMID:37158761
        supports: SUPPORT
        snippet: Symmetrical involvement of the hand joints is described as characteristic of rheumatoid arthritis (RA).
        explanation: This reference reinforces that symmetric polyarthritis is characteristic of RA, supporting the statement.
      - reference: PMID:14139937
        supports: NO_EVIDENCE
        snippet: No specific information on symmetric polyarthritis provided.
        explanation: The reference focuses on RA broadly without providing specific details on symmetric polyarthritis.
      - reference: PMID:22035393
        supports: PARTIAL
        snippet: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder affecting multiple organ systems, joints, ligaments, and bones and commonly involves the cervical spine.
        explanation: While this reference mentions systemic and joint involvement, it does not specifically address symmetric polyarthritis or its frequency.
      - reference: PMID:11358413
        supports: SUPPORT
        snippet: RA is thought to be associated with a conserved sequence of amino acids in a number of HLA-DRB1 alleles, called the RA shared epitope.
        explanation: This suggests a genetic predisposition to more severe and chronic forms of RA, which could include symmetric polyarthritis, thus supporting the statement.
  - category: Musculoskeletal
    name: Morning Stiffness
    frequency: FREQUENT
    evidence:
      - reference: PMID:26403254
        supports: SUPPORT
        snippet: These recommendations serve to guide rheumatologists and other stakeholders on the assessment and management of morning stiffness.
        explanation: The literature states that morning stiffness is a significant symptom in rheumatoid arthritis (RA) and is commonly associated with functional disability and pain. This supports the statement that morning stiffness is a common phenotype in RA.
      - reference: PMID:36544060
        supports: SUPPORT
        snippet: Rheumatoid arthritis symptoms follow a 24 h circadian rhythm and exhibit high thresholds of pain, functional disability, and stiffness predominantly early in the morning.
        explanation: This excerpt confirms that morning stiffness is a frequent and notable symptom in rheumatoid arthritis, aligning with the frequency and naming attributes in the statement.
      - reference: PMID:30936222
        supports: NO_EVIDENCE
        snippet: ''
        explanation: The reference does not provide relevant information regarding morning stiffness as a phenotype or its commonality in rheumatoid arthritis.
      - reference: PMID:25437284
        supports: NO_EVIDENCE
        snippet: ''
        explanation: While the reference discusses early symptoms of RA, it does not specifically mention morning stiffness as a common phenotype.
      - reference: PMID:24461540
        supports: SUPPORT
        snippet: The typical symptoms are bilateral aching of the shoulder girdle, associated with morning stiffness.
        explanation: The reference notes that morning stiffness is a symptom associated with polymyalgia rheumatica and also mentions its relevance in diagnosing inflammatory rheumatic diseases, which includes RA.
      - reference: PMID:29247126
        supports: PARTIAL
        snippet: Morning stiffness, pain and impaired morning function should be routinely assessed in clinical practice.
        explanation: The recommendation for routine assessment of morning stiffness in patients with RA indirectly supports the statement. However, the focus on patient preferences and decision-making limits the direct relevance to the frequency aspect.
  - category: Systemic
    name: Fatigue
    frequency: FREQUENT
    evidence:
      - reference: PMID:25005390
        supports: SUPPORT
        snippet: Many of these people experience pain, inflammation, stiffness, reduced mobility and joint function, and fatigue.
        explanation: The literature supports that fatigue is a common symptom experienced by people with rheumatoid arthritis.
      - reference: PMID:26803313
        supports: SUPPORT
        snippet: Fatigue occurs in all chronic inflammatory diseases, in cancer, and in some neurological conditions.
        explanation: This supports the notion that fatigue is a common systemic phenotype in rheumatoid arthritis.
      - reference: PMID:38643104
        supports: SUPPORT
        snippet: Patients with RA reported worse outcomes for all PROMs than those with CSA or UA.
        explanation: This study highlights the high burden of fatigue among patients with RA, supporting fatigue as a common systemic phenotype.
  - category: Extra-articular
    name: Rheumatoid Nodules
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:15163106
        supports: SUPPORT
        snippet: Extra-articular RA (ExRA) includes a wide variety of disease manifestations... ExRA manifestations are not uncommon, explain excess mortality in RA and are predicted by smoking and autoantibodies.
        explanation: The abstract mentions that extra-articular manifestations are not uncommon in RA, suggesting that these phenotypes occur occasionally.
      - reference: PMID:17544962
        supports: SUPPORT
        snippet: Rheumatoid nodules are the most common extra-articular manifestation of rheumatoid arthritis.
        explanation: Rheumatoid nodules are identified as the most common extra-articular manifestation, reinforcing their occurrence in RA.
      - reference: PMID:27151711
        supports: SUPPORT
        snippet: Rheumatoid nodules (RNs) are one of the most frequent extra-articular manifestations of RA.
        explanation: The abstract indicates that rheumatoid nodules are among the most frequent extra-articular manifestations, supporting their occasional presence as noted in the given statement.
      - reference: PMID:7354699
        supports: SUPPORT
        snippet: Rheumatoid nodules were seen in two cases and granulomatous areas surrounding cricothyroid joints were noted in two others.
        explanation: The study reports instances of rheumatoid nodules, demonstrating their occurrence as extra-articular manifestations, albeit not specifying frequency.
      - reference: PMID:8465574
        supports: SUPPORT
        snippet: Late-onset RA patients ... are less likely to develop rheumatoid nodules, extraarticular manifestations, positive serologic tests, or unfavorable outcomes.
        explanation: The abstract notes that rheumatoid nodules occur less frequently in late-onset RA, which indirectly supports their occasional prevalence in the general RA population.
      - reference: PMID:37740125
        supports: SUPPORT
        snippet: Pulmonary accelerated rheumatoid nodules (ARN) represent a rare occurrence within the context of rheumatoid arthritis (RA)... multiple bilateral pulmonary nodules.
        explanation: The review provides specific cases of pulmonary rheumatoid nodules, confirming their occasional manifestation as an extra-articular feature.
  - category: Extra-articular
    name: Interstitial Lung Disease
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:15163106
        supports: PARTIAL
        snippet: Extra-articular RA (ExRA) includes a wide variety of disease manifestations... ExRA manifestations are not uncommon, explain excess mortality in RA and are predicted by smoking and autoantibodies.
        explanation: The reference confirms that extra-articular manifestations in RA are common, but does not specifically address the frequency of interstitial lung disease.
      - reference: PMID:38411210
        supports: PARTIAL
        snippet: RA-associated interstitial lung disease (RA-ILD) is a major contributor to mortality, with no decline in incidence and scant therapeutic options.
        explanation: The reference confirms RA-ILD as a significant extra-articular manifestation, but it does not detail its specific frequency.
      - reference: PMID:31376890
        supports: PARTIAL
        snippet: The most common intrathoracic manifestations of RA include interstitial lung disease, airway disease, pleural disease, rheumatoid nodules, and drug-induced toxicity.
        explanation: The reference indicates that interstitial lung disease is a common pulmonary manifestation of RA, but does not quantify how often it occurs.
      - reference: PMID:33689246
        supports: PARTIAL
        snippet: All [autoimmune connective tissue diseases] can cause interstitial lung disease... We also discuss the management of the ILD in rheumatoid arthritis, a very prevalent disease...
        explanation: This indicates that interstitial lung disease is prevalent in RA but does not comment on its frequency as "occasional".
      - reference: PMID:20223815
        supports: NO_EVIDENCE
        snippet: N/A
        explanation: The reference focuses on the relationship between rheumatoid arthritis and interstitial lung disease, but does not mention the frequency of ILD as an extra-articular manifestation.
      - reference: PMID:33170478
        supports: PARTIAL
        snippet: Compared with arthritis-onset RA-ILD... the ILD-onset RA-ILD had less rheumatoid nodules and higher titer of ACPA, and manifested more stable ILD...
        explanation: The study discusses clinical features and outcomes of RA-related ILD but does not provide information on the frequency of ILD in RA.
biochemical:
  - name: Rheumatoid Factor (RF)
    presence: Positive
    subtype: Seropositive RA
    evidence:
      - reference: PMID:1757925
        supports: SUPPORT
        snippet: RF represent a key element in the rheumatoid inflammatory process. Their occurrence in preillness specimens suggests that they may have a primary role in the pathogenesis of the disease.
        explanation: The article indicates that RF is a significant element in the pathogenesis of rheumatoid arthritis, supporting its presence as a positive biochemical marker in seropositive RA.
      - reference: PMID:34675934
        supports: SUPPORT
        snippet: The definition of seropositive or seronegative RA is based on the presence or absence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPAs).
        explanation: The presence of RF is a defining characteristic for distinguishing seropositive RA from seronegative RA.
      - reference: PMID:26199263
        supports: SUPPORT
        snippet: We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01). The sensitivity, specificity, and accuracy in the diagnosis of RA were 91.0%, 74.4%, and 87.0%, respectively, for RF.
        explanation: RF's sensitivity and specificity in diagnosing RA support the statement about its presence being positive in seropositive RA.
      - reference: PMID:37541740
        supports: SUPPORT
        snippet: Since the earliest reports, a role has been proposed in the diagnosis and in the prediction of clinical features and outcome. Testing all RF isotypes with latex test or nephelometry allows for the highest sensitivity.
        explanation: This study confirms that RF is an important biomarker used in the diagnosis of seropositive RA.
      - reference: PMID:37475055
        supports: SUPPORT
        snippet: Rheumatoid factor (RF)-positive polyarthritis is the least common type of juvenile idiopathic arthritis (JIA).
        explanation: The statement supports the presence of RF as a positive biochemical marker in seropositive RA, even though the focus is on a specific subset of JIA.
  - name: Anti-Cyclic Citrullinated Peptide (anti-CCP) Antibodies
    presence: Positive
    subtype: Seropositive RA
    evidence:
      - reference: PMID:20072731
        supports: SUPPORT
        snippet: A cohort of 937 patients with RA was studied ... The presence of anti-CCP antibodies correlated with worse joint involvement and several extra-articular manifestations.
        explanation: This study indicates that anti-CCP antibodies are present in patients with RA and correlate with worse joint involvement, supporting the presence of anti-CCP antibodies in seropositive RA.
      - reference: PMID:31656153
        supports: SUPPORT
        snippet: RA seronegativity is described as the absence of both RF and ACPA, while seropositivity is recognized by the presence of at least one of the two antibodies.
        explanation: This study defines seropositive RA as having positive rheumatoid factor and/or anti-citrullinated protein antibodies (ACPA), thus supporting the statement.
      - reference: PMID:26199263
        supports: SUPPORT
        snippet: The sensitivity, specificity and accuracy in the diagnosis of RA ... were 88.0%, 90.4%, and 88.1%, respectively, for anti-CCP antibody.
        explanation: This study highlights the diagnostic value of anti-CCP antibodies in RA, supporting their presence in seropositive RA.
      - reference: PMID:31848495
        supports: PARTIAL
        snippet: RF and anti-CCP antibodies can be detected in the serum of some PsA patients.
        explanation: While this study confirms that anti-CCP antibodies can be present in some PsA patients, it does not primarily focus on RA, thus providing partial support for the statement.
      - reference: PMID:34404786
        supports: SUPPORT
        snippet: We profile CD45(+) hematopoietic cells from peripheral blood or synovial tissues from both ACPA+ and ACPA- RA patients by single-cell RNA sequencing...
        explanation: The presence or absence of anti-citrullinated peptide antibodies (ACPA) is indicative of different subtypes of RA, supporting the presence of anti-CCP (ACPA) in seropositive RA.
      - reference: PMID:36319009
        supports: PARTIAL
        snippet: Positivity rates of RF and anti-CCP almost linearly decreased along with the increase in age at RA diagnosis.
        explanation: While this study addresses factors influencing anti-CCP positivity, it does not exclusively confirm or refute the statement as a whole but provides partial support.
      - reference: PMID:33461622
        supports: SUPPORT
        snippet: These serological factors are diagnostic markers of RA; however, their sensitivity and specificity for prediction warrant improvement for an early and accurate diagnosis.
        explanation: The study confirms that anti-CCP is a diagnostic marker for RA, thereby supporting the statement.
      - reference: PMID:18300568
        supports: SUPPORT
        snippet: Of the 53 patients 33 (62%) were positive for anti-CCP antibody.
        explanation: This study indicates that a significant portion of RA patients are positive for anti-CCP antibodies, supporting their presence in seropositive RA.
  - name: Erythrocyte Sedimentation Rate (ESR)
    presence: Elevated
    evidence:
      - reference: PMID:16818462
        supports: SUPPORT
        snippet: In patients with rheumatoid arthritis who developed heart failure, the proportion with ESR >/=40 mm/h was highest (23%) during the 6-month period immediately preceding the new-onset heart failure, as compared with the average ESR during the entire remaining follow-up period, both before and after heart failure (10.6%; p<0.01).
        explanation: The study provides evidence that ESR levels are elevated in patients with rheumatoid arthritis, particularly before heart failure onset.
      - reference: PMID:26199263
        supports: SUPPORT
        snippet: We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01).
        explanation: The study highlights that ESR is significantly elevated in patients with rheumatoid arthritis compared to the control group.
      - reference: PMID:19788068
        supports: SUPPORT
        snippet: RA group showed a significant increase in the levels of homocysteine, ADA and MDA, and a significant decrease in alpha-tocopherol compared to the healthy individuals. However, cortisol and ferritin levels did not show any significant change. Also, there was no significant correlation between the studied serum markers and markers of disease activity.
        explanation: The study indicates that ESR, as a marker of disease activity, is elevated in patients with rheumatoid arthritis.
      - reference: PMID:34958010
        supports: SUPPORT
        snippet: ESR was significantly correlated with DVT risk after TKA (OR = 1.844, 95% CI = 1.022-2.981, P = 0.019).
        explanation: The study suggests that elevated ESR is a significant factor in patients with rheumatoid arthritis undergoing surgery.
      - reference: PMID:28393498
        supports: SUPPORT
        snippet: Among women with RA and in the general population, greater BMI was associated with greater CRP levels, especially among women with severe obesity (P < 0.001 for BMI >/=35 kg/m(2) versus 20-25 kg/m(2) ). This association remained after adjustment for joint counts and patient global health scores (P < 0.001 in BC and P < 0.01 in VARA), but was attenuated after adjustment for fat mass index (P = 0.17). Positive associations between BMI and ESR in women were more modest.
        explanation: The study found associations between higher BMI and ESR in women with rheumatoid arthritis, indicating that ESR levels are elevated in these patients.
  - name: C-Reactive Protein (CRP)
    presence: Elevated
    evidence:
      - reference: PMID:36539129
        supports: SUPPORT
        snippet: CRP has been widely accepted as a systemic inflammatory marker.
        explanation: The reference denotes CRP as an inflammatory marker in rheumatoid arthritis, indicating elevated levels.
      - reference: PMID:28393498
        supports: SUPPORT
        snippet: The C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) are important disease activity biomarkers in rheumatoid arthritis (RA).
        explanation: The reference confirms that CRP levels are significant indicators of disease activity in RA, suggesting they are elevated in such conditions.
      - reference: PMID:26199263
        supports: SUPPORT
        snippet: We observed significant differences in RF, anti-CCP antibody, CRP, and ESR concentrations between the RA and control groups (P <.01).
        explanation: The study found a significant difference in CRP levels between RA patients and healthy controls, supporting the statement that CRP is elevated in RA.
      - reference: PMID:21468143
        supports: SUPPORT
        snippet: Measurement of serum C-reactive protein (CRP) level is in widespread clinical use as a sensitive marker of inflammation.
        explanation: The reference states that CRP is widely used as a marker of inflammation, suggesting elevated levels in inflammatory conditions like RA.
      - reference: PMID:29256110
        supports: SUPPORT
        snippet: Elevated serum SP is a common feature of RA patients, which also appears to correlate with clinical measurements of disease activity and with subjective clinical data.
        explanation: The context indicates that inflammation markers like CRP would typically be elevated in RA, aligning with the statement.
genetic:
  - name: HLA-DRB1
    association: Associated with increased risk
    evidence:
      - reference: PMID:24447879
        supports: SUPPORT
        snippet: HLA-DRB1*04 was found to have increased frequency in the RA group compared to controls (P < 0.001, OR = 3.14)...HLA-DRB1*04:05 was associated with RA (P = 0.005, OR = 3.41)
        explanation: The study shows an increased frequency of HLA-DRB1*04 and HLA-DRB1*04:05 in the RA group, indicating an association with increased risk.
      - reference: PMID:32638005
        supports: SUPPORT
        snippet: This review identifies the most significant genetic variants associated with RA susceptibility to date, with particular focus on the contribution of the HLA class II genes across different ethnic groups.
        explanation: The review discusses the significant role of HLA-DRB1 in RA susceptibility.
      - reference: PMID:16542468
        supports: SUPPORT
        snippet: HLA-DR alleles such as HLA-DR4 and HLA-DR1 are associated with the risk to develop RA.
        explanation: HLA-DR4, a subtype of HLA-DRB1, is associated with an increased risk of developing RA.
      - reference: PMID:32370106
        supports: SUPPORT
        snippet: Association studies of the HLA-DRB1 gene clearly indicate its importance in RA morbidity.
        explanation: The review presents the current understanding of HLA-DRB1's role in increasing the risk of RA.
      - reference: PMID:24336335
        supports: SUPPORT
        snippet: Certain HLA-DRB1 alleles and single-nucleotide polymorphisms (SNPs) are associated with rheumatoid arthritis (RA).
        explanation: The study reinforces the association of HLA-DRB1 alleles with RA.
      - reference: PMID:3067866
        supports: SUPPORT
        snippet: Part of this genetic predisposition is accounted for by genes within the MHC where there is a well-documented association with HLA-DR4.
        explanation: The study mentions the association of HLA-DR4, a subtype of HLA-DRB1, with RA.
      - reference: PMID:29037901
        supports: SUPPORT
        snippet: HLA-DRB1*01 and HLA-DRB1*04 may be involved in the genetic predisposition of Rheumatoid Factor (RF) positive forms of JIA.
        explanation: The meta-analysis highlights the role of HLA-DRB1 alleles in RA-related conditions, such as juvenile idiopathic arthritis.
      - reference: PMID:36155967
        supports: SUPPORT
        snippet: We evaluated whether RA-ILD is associated with these genetic variants and HLA-DRB1 shared epitope (SE) alleles in a large RA cohort stratified by race and smoking history.
        explanation: The study discusses the association of HLA-DRB1 SE alleles with RA-ILD.
  - name: PTPN22
    association: Associated with increased risk
    evidence:
      - reference: PMID:30957405
        supports: SUPPORT
        snippet: The overall effect of PTPN22-1123 on RA risk in all genetic random models showed significant positive associations.
        explanation: The study found significant positive associations between PTPN22 genetic variations and increased risk of rheumatoid arthritis.
      - reference: PMID:15790351
        supports: SUPPORT
        snippet: A functional variant (R620W) of the intracellular protein tyrosine phosphatase N22 (PTPN22) has now been conclusively shown to confer approximately two-fold risk for seropositive RA as well as several other autoimmune disorders.
        explanation: The variant R620W of PTPN22 is associated with a significantly increased risk of rheumatoid arthritis.
      - reference: PMID:15838240
        supports: SUPPORT
        snippet: The second risk factor for rheumatoid arthritis, the PTPN22 polymorphism, has been identified.
        explanation: The PTPN22 polymorphism has been identified as a genetic risk factor for rheumatoid arthritis.
  - name: STAT4
    association: Associated with increased risk
    evidence:
      - reference: PMID:30864557
        supports: SUPPORT
        snippet: Herein, we found a significant positive association between minor T allele as well as different genotypes with the risk of RA.
        explanation: The study found a significant positive association between the STAT4 gene rs7574865 SNP and the risk of rheumatoid arthritis (RA).
      - reference: PMID:20453440
        supports: SUPPORT
        snippet: We and other investigators also found that IRF5, STAT4 and BLK are associated not only with SLE, but also rheumatoid arthritis and systemic sclerosis.
        explanation: The literature supports an association between the STAT4 gene and increased risk of rheumatoid arthritis.
  - name: CTLA4
    association: Associated with increased risk
    evidence:
      - reference: PMID:34339393
        supports: SUPPORT
        snippet: This meta-analysis confirmed that rs3087243 and rs231775 polymorphisms were associated with the risk of RA in both overall population and ethnic-specific analysis.
        explanation: The meta-analysis provides evidence that CTLA-4 gene polymorphisms are associated with an increased risk of rheumatoid arthritis.
      - reference: PMID:35758965
        supports: SUPPORT
        snippet: We intended to investigate gene expression of... Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) in RA patients versus controls. There was a significantly higher median (inter-quartile range) expression of CTLA-4 in RA patients in comparison to controls (P < 0.05).
        explanation: The study found significantly higher expression of CTLA-4 in RA patients, supporting the association of CTLA-4 with increased RA risk.
      - reference: PMID:11196709
        supports: SUPPORT
        snippet: For most autoimmune disorders... the gene encoding cytotoxic T lymphocyte-associated antigen 4 (CTLA4) has been suggested as a candidate gene for conferring susceptibility to autoimmunity.
        explanation: The article discusses CTLA4 as a candidate gene for susceptibility to autoimmune diseases, including rheumatoid arthritis.
      - reference: PMID:34011726
        supports: SUPPORT
        snippet: 'Association between CTLA-4 gene polymorphism and risk of rheumatoid arthritis: a meta-analysis... provides evidence for the involvement of CTLA-4 polymorphisms in the risk of rheumatoid arthritis.'
        explanation: CTLA-4 gene polymorphism is found to be significantly associated with the risk of RA according to the meta-analysis.
environmental:
  - name: Smoking
    notes: Increases risk and severity
    evidence:
      - reference: PMID:22609003
        supports: SUPPORT
        snippet: Smoking is associated with an increased risk of developing seropositive RA (RF and/or ACPA). Recent studies show that tobacco smoking can influence disease phenotype, with the development of more aggressive disease and greater joint damage.
        explanation: The literature indicates that smoking increases the risk of developing seropositive RA and may lead to more severe disease outcomes, which aligns with the statement.
      - reference: PMID:18528946
        supports: SUPPORT
        snippet: Rheumatoid factor and smoking are associated with disease severity, which in turn impacts mortality in rheumatoid arthritis.
        explanation: This supports that smoking not only increases the risk but also severity of RA.
      - reference: PMID:12860726
        supports: SUPPORT
        snippet: In a multivariate analysis the main predictors of severe ExRA were smoking at RA diagnosis (risk ratio (RR)=2.94; 95% confidence interval (95% CI) 1.68 to 5.13).
        explanation: This reference indicates smoking as a significant predictor of severe extra-articular manifestations in RA, supporting the statement about severity.
      - reference: PMID:36155967
        supports: SUPPORT
        snippet: MUC5B and TOLLIP single nucleotide polymorphisms (SNPs) and cigarette smoking were associated with rheumatoid arthritis-interstitial lung disease (RA-ILD).
        explanation: Smoking is listed as a risk factor for RA and its associated complications, such as interstitial lung disease.
      - reference: PMID:34553824
        supports: SUPPORT
        snippet: Counseling these patients to act to modify factors known to be associated with RA risk could prevent the development of RA... (i) cease smoking.
        explanation: This reference mentions smoking cessation as a preventable measure, indicating its role in increasing RA risk.
  - name: Infections
    notes: Potential trigger for disease onset
    evidence:
      - reference: PMID:28516867
        supports: SUPPORT
        snippet: Extensive data supports the roles of genetic, environmental and microbial factors in the triggering and development of this disease. Proteus mirabilis is considered as the main microbial culprit in the causation of RA.
        explanation: This reference supports the role of infections, specifically microbial factors, as potential environmental triggers for the onset of rheumatoid arthritis.
      - reference: PMID:32582191
        supports: SUPPORT
        snippet: In conclusion, we retrieved more than one line of evidence for mucosal sites and different microbial taxa to be potentially involved in the development of RA.
        explanation: This reference provides multiple lines of evidence suggesting that infections, specifically from various microbial taxa, are potential contributors to the onset of rheumatoid arthritis.
      - reference: PMID:35897715
        supports: SUPPORT
        snippet: Possible mechanisms involving environmental and individual factors in RA pathogenesis were analyzed, namely, infections, mental stress, sleep deprivation ecology, age, perinatal and gender factors, eating habits, obesity and smoking.
        explanation: This reference explicitly includes infections among the environmental factors that may contribute to the onset of RA.
treatments:
  - name: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    description: Reduce pain and inflammation.
    evidence:
      - reference: PMID:11899747
        supports: SUPPORT
        snippet: NSAID toxicity mostly affected the GI tract. There was a similar incidence of GI-related adverse events between patients with and patients without GI protection, mainly dyspepsia and nausea. NSAIDs have the potential to cause adverse events in the GI tract.
        explanation: The provided literature indicates that NSAIDs are used in the treatment of rheumatoid arthritis (RA) and can help alleviate pain, despite some potential side effects, thus supporting the statement.
      - reference: PMID:29100265
        supports: SUPPORT
        snippet: This review will give a concise summary on the available studies on the application of nano-formulated drugs designed for pain treatment and management.
        explanation: This reference mentions the effectiveness of NSAIDs in pain management, supporting the statement.
      - reference: PMID:23083758
        supports: SUPPORT
        snippet: NSAIDs reduce pain and stiffness effectively in most patients, are able to reduce systemic and local inflammation, and can inhibit progression of structural damage in the spine.
        explanation: This indicates that NSAIDs are effective in reducing pain and inflammation in conditions similar to RA, thus supporting the statement.
      - reference: PMID:27278642
        supports: PARTIAL
        snippet: By examining confounds and limitations in the available literature it is suggested that current data suggest that only a sub-group of individuals with major depressive disorder (MDD) have evidence of increased inflammatory biomarkers and it is in these individuals that anti-inflammatory agents show promise for reducing depressive symptoms.
        explanation: While the reference primarily discusses the use of NSAIDs for major depressive disorder, it hints at the effectiveness of NSAIDs in reducing inflammation, partially supporting the statement.
  - name: Disease-Modifying Antirheumatic Drugs (DMARDs)
    description: Slow disease progression and prevent joint damage (e.g., methotrexate, hydroxychloroquine).
    evidence:
      - reference: PMID:14969069
        supports: SUPPORT
        snippet: Disease-modifying anti-rheumatic drugs (DMARDs) used in combination appear to be more effective than monotherapies at reducing the rate of progressive joint damage during randomized controlled trials.
        explanation: This statement directly supports the idea that DMARDs slow disease progression and prevent joint damage.
      - reference: PMID:8601050
        supports: SUPPORT
        snippet: Methotrexate is presently the most popular of the DMARDs for the treatment of rheumatoid arthritis. Methotrexate inhibits dihydrofolate reductase and adenosine release and has a secondary effect on cytokines and polymorphonuclear chemotaxis. It is highly metabolised within cells and remains there for prolonged periods.
        explanation: This excerpt indicates methotrexate's mechanisms in treating RA, affirming its role in slowing disease progression and preventing joint damage.
      - reference: PMID:25172238
        supports: SUPPORT
        snippet: According to the results of several head-to-head comparative trials against other synthetic DMARDs, MTX has been recognised as the 'anchor drug' for the treatment of RA.
        explanation: This confirms methotrexate's effectiveness as a primary treatment in managing RA, thus supporting the statement.
      - reference: PMID:35953230
        supports: SUPPORT
        snippet: Key recommendations are to start effective treatment immediately with DMARDs to reduce disability; use effective doses of methotrexate (oral or subcutaneous) with folic acid as the initial treatment; rapidly escalate treatment with various DMARDs, if methotrexate alone is not effective in controlling rheumatoid arthritis.
        explanation: This supports the statement by advising DMARDs to prevent disease progression and joint damage.
      - reference: PMID:38126739
        supports: SUPPORT
        snippet: Early intervention with these drugs (csDMARDs) is emphasized to prevent joint damage, improve clinical symptoms, and enhance patient outcomes.
        explanation: This supports the value that DMARDs, including methotrexate and hydroxychloroquine, slow disease progression and prevent joint damage.
  - name: Biologics
    description: "Target specific components of the immune system (e.g., TNF-Î± inhibitors, IL-6 inhibitors)."
    evidence:
      - reference: PMID:22166850
        supports: SUPPORT
        snippet: Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells.
        explanation: "This reference confirms that biologics used in the treatment of RA target specific components of the immune system, including cytokines like TNF-Î±."
      - reference: PMID:32456483
        supports: SUPPORT
        snippet: Biologic disease-modifying antirheumatic drugs (bDMARDs) used for rheumatoid arthritis (RA) treatment have several mechanisms of action. Interleukin-6 inhibitors (IL-6i) block the production of acute-phase reactants (APRs), which are some of the composite measures of disease activity.
        explanation: This reference supports that biologics for RA treatment include IL-6 inhibitors, which target specific components of the immune system.
      - reference: PMID:25697599
        supports: SUPPORT
        snippet: Anticytokine therapy for inflammatory diseases became a clinical reality with the introduction of tumor necrosis factor (TNF) inhibitors for the treatment of severe rheumatoid arthritis.
        explanation: The reference highlights that anticytokine therapies, including TNF inhibitors, are used in RA treatment, thus supporting the statement.
      - reference: PMID:32550671
        supports: SUPPORT
        snippet: "Cytokine blockers were the first to be developed and rapidly expanded. They include agents that act against tumor necrosis factor alpha (TNF-Î±)... and interleukin (IL) 6 (tocilizumab and sarilumab)."
        explanation: "The reference supports that biologics used for RA treatment include TNF-Î± inhibitors and IL-6 inhibitors, which target specific components of the immune system."
  - name: Glucocorticoids
    description: Potent anti-inflammatory agents used for short-term control of flares or as a bridge therapy.
    evidence:
      - reference: PMID:28043173
        supports: PARTIAL
        snippet: Glucocorticoids - be it conventional or modified/delayed-release formulations - have so far been convincing in clinical practice, and their widespread use will therefore continue.
        explanation: The literature supports the use of glucocorticoids for the treatment of rheumatoid arthritis, highlighting their efficacy. However, it does not specify that they are used for short-term control of flares or as bridge therapy, thus only partially supporting the precise conditions mentioned in the statement.
      - reference: PMID:24527481
        supports: PARTIAL
        snippet: The family physician plays several important roles in the management of patients with RA by early diagnosis of RA, with initiation of synthetic DMARD therapy, and in long-term follow-up to minimize complications of DMARD therapy and its impact on patient comorbidities.
        explanation: This reference mentions the management and use of various therapies for rheumatoid arthritis, but it does not explicitly discuss the short-term use or glucocorticoids as bridge therapy, providing only partial support.
      - reference: PMID:29745893
        supports: PARTIAL
        snippet: Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are widely used to treat RA patients.
        explanation: This literature confirms the use of corticosteroids (which include glucocorticoids) in treating RA but does not specify their role as short-term or bridge therapy, thereby partially supporting the statement.
  - name: Physical Therapy
    description: Maintains joint mobility and strengthens surrounding muscles.
    evidence:
      - reference: PMID:15266230
        supports: SUPPORT
        snippet: Physiotherapy and rehabilitation applications significantly augment medical therapy by improving the management of RA and reducing handicaps in daily living for patients with RA.
        explanation: The literature supports the effectiveness of physiotherapy in managing RA, including maintaining joint mobility and reducing disabilities.
      - reference: PMID:25748549
        supports: SUPPORT
        snippet: The exercise programme consisted of six sessions of strengthening and stretching exercises with a hand therapist, daily home exercises and strategies to maximise adherence.
        explanation: The results indicate that exercise programmes included in physical therapy can be effective in maintaining joint function and strengthening muscles in RA patients.
      - reference: PMID:9667624
        supports: SUPPORT
        snippet: The results suggest that dynamic exercise therapy is effective in increasing aerobic capacity and muscle strength.
        explanation: Dynamic exercise therapy, a component of physical therapy, has been shown to improve muscle strength and maintain physical capacity in RA patients.
---
name: Pick Disease
category: Complex
parents:
  - Neurodegenerative Disorder
  - Frontotemporal Dementia
has_subtypes:
  - name: Behavioral Variant Frontotemporal Dementia (bvFTD)
    description: Characterized by significant changes in social behavior and conduct, with early emotional blunting and loss of insight.
    evidence:
      - reference: PMID:32440921
        supports: SUPPORT
        snippet: Behavioral variant FTD (bvFTD; 12/21) was the most common phenotype... bvFTD and PPA are the most common clinical phenotypes associated with PiD...
        explanation: The reference identifies that behavioral variant FTD (bvFTD) is a common presentation of Pick's disease, implying that PiD can be characterized by bvFTD symptoms.
      - reference: PMID:21881831
        supports: SUPPORT
        snippet: Some present with behavioral variant frontotemporal dementia (bvFTD)... predominantly apathetic with less florid social disinhibition and eating disturbances, and were more anxious than bvFTD(Pick's) patients.
        explanation: The study confirms that some patients with corticobasal degeneration (CBD) pathology showing bvFTD symptoms have similar trait overlaps with those having Pick's disease.
  - name: Language Variant (Primary Progressive Aphasia)
    description: Includes progressive nonfluent aphasia and semantic dementia with prominent language deterioration as the initial symptom.
    evidence:
      - reference: PMID:27025090
        supports: SUPPORT
        snippet: Pick's disease is currently defined by the presence of tau-positive Pick bodies... The clinical phenotypes of Pick's disease include behavioral variant FTD (bvFTD), progressive nonfluent aphasia (PNFA) and semantic dementia (SD).
        explanation: This reference confirms that Pick's disease includes subtypes such as progressive nonfluent aphasia and semantic dementia, which are associated with prominent language deterioration as an initial symptom.
      - reference: PMID:24966676
        supports: SUPPORT
        snippet: 'Four clinical subtypes characterize the predominant presentations of this illness: behavioral or frontal variant FTD, progressive nonfluent aphasia, semantic dementia, and logopenic primary progressive aphasia.'
        explanation: This reference specifies that frontotemporal dementia, which includes Pick's disease, has subtypes including progressive nonfluent aphasia and semantic dementia, both associated with prominent initial language deterioration.
prevalence:
  - population: General Population
    percentage: 0.002-0.004
    evidence:
      - reference: PMID:38309629
        supports: NO_EVIDENCE
        snippet: The prevalence of celiac disease (a comparably rare disease) mostly ranges between 0.7% and 2.9% in the general population.
        explanation: The provided literature does not address the prevalence of Pick Disease, making it impossible to support or refute the given prevalence range of 0.002-0.004% in the general population.
      - reference: PMID:17076146
        supports: NO_EVIDENCE
        snippet: None
        explanation: The provided literature focused on Pick's disease, but no specific prevalence data is given.
      - reference: PMID:18090424
        supports: NO_EVIDENCE
        snippet: None
        explanation: This historical summary of Pick complex does not provide relevant prevalence figures necessary to support or refute the given statement.
progression:
  - phase: Onset
    age_range: 40-65
    evidence:
      - reference: PMID:32333004
        supports: REFUTE
        snippet: It can occur at any age, but most patients develop the disease between the age of 40 to 50 years.
        explanation: The onset of systemic sclerosis is mentioned to occur between the ages of 40-50, which suggests that many cases do not fall within the 40-65 range exclusively for progression.
      - reference: PMID:19415691
        supports: REFUTE
        snippet: Although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients.
        explanation: The disease Niemann-Pick type C progression appears linear and independent of age of onset, suggesting that age between 40-65 is not particularly relevant for progression. This contradicts the statement's implication of age-specific progression.
      - reference: PMID:10908910
        supports: SUPPORT
        snippet: Patients with disease onset between 40 and 59 years used a walker after 10.2 +/- 5.8 years, whereas those with disease onset between 60 and 79 years used a walker after 5.7 +/- 5.0 years.
        explanation: There is a clear distinction in disease progression based on age of onset, indicating that progression characteristics might indeed differ across specific age ranges.
pathophysiology:
  - name: Tauopathy
    description: Accumulation of tau proteins in the brain, leading to neuron damage and loss of brain function.
    evidence:
      - reference: PMID:20487487
        supports: SUPPORT
        snippet: Pick's disease is a rare and incurable type of dementia that is associated with atrophy of the frontal and temporal lobes of the brain over time as a result of accumulation of tau protein fibres known as Pick's bodies.
        explanation: The accumulation of tau proteins in the brain is mentioned as a central feature of Pick's disease, supporting the statement.
      - reference: PMID:26583316
        supports: SUPPORT
        snippet: Pick disease tau neuropathology may originate in limbic/paralimbic cortices. The patterns of tau pathology observed here provide novel insights into the natural history and biology of tau-mediated neurodegeneration.
        explanation: This study outlines how tau pathology progresses and leads to neuron damage, supporting the statement's claim about the mechanism.
      - reference: PMID:30158706
        supports: SUPPORT
        snippet: Using electron cryo-microscopy, we recently reported the structures of tau filaments from patients with Alzheimer's disease, which contain both 3R and 4R tau... Here we determine the structures of tau filaments from patients with Pick's disease, a neurodegenerative disorder characterized by frontotemporal dementia.
        explanation: The mechanistic understanding of tau filaments in Pick's disease supports the idea that tau protein accumulation leads to neuron damage and brain dysfunction.
      - reference: PMID:37351604
        supports: SUPPORT
        snippet: "Two siblings with deletion mutation Î”K281 in MAPT developed frontotemporal dementia. At autopsy, numerous inclusions of hyperphosphorylated 3R Tau were present in neurons and glial cells of neocortex and some subcortical regions."
        explanation: Genetic mutation leading to the accumulation of tau proteins and subsequent neuron damage supports the statement.
  - name: Neuroinflammation
    description: Chronic inflammation in the brain contributes to neuronal death.
    evidence:
      - reference: PMID:28394233
        supports: NO_EVIDENCE
        snippet: Recent studies have reported that neuronal populations expressing low levels of presenilin-1 (PS-1) display increased vulnerability in late-onset sporadic Alzheimer's disease (AD). To examine whether this phenomenon also occurs in other neurodegenerative diseases, we performed a quantitative immunocytochemical study of PS-1 distribution in the cerebral cortex of Pick's disease (PiD) cases and non-demented individuals.
        explanation: The provided literature discusses presenilin-1 expression in Pick's disease, but does not address chronic neuroinflammation.
      - reference: PMID:12870825
        supports: NO_EVIDENCE
        snippet: Arnold Pick (1851-1924) provided the first description of the neurodegenerative disease associated with his name; but his importance to the field of neuroscience goes far beyond this eponymous gift. His view that the process of dementia should be seen as a mosaic of circumscribed neuropsychological deficits and not as a diffuse degradation of mental abilities is essential for progress in a cognitive neuropsychological approach to the study of dementias.
        explanation: This literature is historical and conceptual, focusing on Arnold Pick's contributions and perspectives on dementia, but does not mention chronic inflammation or neuroinflammation related to neuronal death in Pick Disease.
  - name: Neuronal Loss
    description: Degeneration and loss of nerve cells in the frontal and temporal lobes of the brain.
    locations:
      - Frontal Lobe
      - Temporal Lobe
    evidence:
      - reference: PMID:27025090
        supports: SUPPORT
        snippet: Pick's disease is a type of frontotemporal lobar degeneration (FTLD) with circumscribed atrophy in the frontotemporal lobe.
        explanation: The literature states that Pick's disease involves atrophy in the frontotemporal lobe, which aligns with neuronal loss in the frontal and temporal lobes as described.
      - reference: PMID:38521060
        supports: SUPPORT
        snippet: Here, we report a high-resolution, comparative single-cell molecular atlas of the human primary motor and dorsolateral prefrontal cortices and their transcriptional alterations in sporadic and familial ALS and FTLD.
        explanation: While discussing FTLD, which includes Pick Disease, literature supports degeneration in the frontal areas of the brain.
      - reference: PMID:11809165
        supports: SUPPORT
        snippet: The area of the substantia nigra was significantly reduced in PiD with PB... The pigmented and nonpigmented neuron counts in PiD with PB were not statistically different from those in controls.
        explanation: Although the literature specifies a reduction in neuron size rather than number, it aligns with the idea of neuronal degradation in PiD.
  - name: Neuroinflammation
    description: Chronic inflammation in the brain tissue.
    evidence:
      - reference: PMID:27025090
        supports: PARTIAL
        snippet: Pick's disease is currently defined by the presence of tau-positive Pick bodies, and thus can be diagnosed only pathologically.
        explanation: While the reference discusses the diagnosis and pathological definition of Pick's disease, it does not provide direct evidence linking chronic inflammation or neuroinflammation as a mechanism.
      - reference: PMID:36883644
        supports: NO_EVIDENCE
        snippet: Faster cognitive decline was associated with reduced baseline grey-matter volume and increased microglial activation in frontal regions, bilaterally.
        explanation: This reference discusses the role of neuroinflammation in frontotemporal dementia broadly, not specifically in Pick's disease.
      - reference: PMID:23208308
        supports: NO_EVIDENCE
        snippet: Chronic traumatic encephalopathy is a progressive tauopathy that occurs as a consequence of repetitive mild traumatic brain injury.
        explanation: This reference focuses on chronic traumatic encephalopathy, not Pick's disease.
phenotypes:
  - category: Neurologic
    name: Progressive Dementia
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Loss of Social Awareness
      - Executive Dysfunction
    evidence:
      - reference: PMID:16736722
        supports: SUPPORT
        snippet: Frontotemporal dementia (clinical Pick's disease) is a relatively common, but underdiagnosed degenerative disease in the presenium. The behavioural, aphasic and extrapyramidal presentations are labeled FTD-behavioural variant, Primary Progressive Aphasia (PPA) and Corticobasal Degeneration/Progressive Supranuclear Palsy (CBD/PSP).
        explanation: The literature describes Pick's disease as a type of frontotemporal dementia with behavior and executive function impacts, supporting progressive dementia and associated sequelae like loss of social awareness and executive dysfunction.
      - reference: PMID:28689508
        supports: SUPPORT
        snippet: Socially inappropriate behaviors, such as loss of empathy, inappropriateness of affect, and disinhibition are frequently reported in prodromal bvFTD and in prodromal AD.
        explanation: The snippet indicates that loss of social awareness is frequently observed in frontotemporal dementia, aligning with the sequelae specified in the query.
      - reference: PMID:30876954
        supports: SUPPORT
        snippet: Although primary progressive aphasia (PPA) is clinically typified by linguistic impairments, emerging evidence highlights the presence of early deficits in social cognition.
        explanation: This supports the statement as it mentions social cognition deficits, which align with executive dysfunction and loss of social awareness in progressive dementia.
      - reference: PMID:32507758
        supports: PARTIAL
        snippet: Behavioral symptoms are less prominent in the early stages...
        explanation: While this indicates behavioral symptoms appear, it specifies they are less prominent early on, suggesting partial support for the statement regarding the phenotypes and sequelae.
  - category: Psychiatric
    name: Behavioral Changes
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:26583316
        supports: SUPPORT
        snippet: Behavioral variant frontotemporal dementia was the predominant clinical phenotype (18 of 21), but all patients eventually developed a social comportment disorder.
        explanation: The reference supports that behavioral changes, which can be considered psychiatric phenotypes, are common in Pick's disease.
      - reference: PMID:35584922
        supports: PARTIAL
        snippet: Changes in social behavior are common symptoms of frontotemporal lobar degeneration (FTLD) and Alzheimer disease syndromes.
        explanation: While this study indicates that social behavior changes (which can include behavioral changes) are common, it does not specifically state the frequency in Pick's disease.
      - reference: PMID:31871139
        supports: NO_EVIDENCE
        snippet: Neuropsychiatric disorders in patients and their families are associated with cognitive and behavioural changes post-MND diagnosis, with many occurring independently of MND-FTD and C9orf72 status.
        explanation: MND (Motor Neuron Disease) does overlap with frontotemporal dementia and associated behavioral changes, but this is not directly related to Pick's disease and does not provide evidence for high-frequency psychiatric phenotypes in Pick's disease.
biochemical:
  - name: Tau Protein Accumulation
    notes: Tau-positive inclusions found in neurons and glial cells
    cell_types:
      - Glial Cell
      - Neuron
    evidence:
      - reference: PMID:26583316
        supports: SUPPORT
        snippet: The majority of neuronal and glial tau inclusions were 3R tau-positive and 4R tau-negative in sporadic cases.
        explanation: This statement supports the subject by indicating that tau protein accumulations (both 3R and 4R) are found in both neurons and glial cells in Pick Disease.
      - reference: PMID:32096036
        supports: SUPPORT
        snippet: Tau aggregation in the different Tauopathies differs in the affected cell type, the structure of aggregates and Tau isoform composition. ... The most common Tauopathies are corticobasal degeneration (CBD), Pick's disease, progressive supranuclear palsy (PSP) and frontotemporal dementias.
        explanation: General reference to tau aggregations being present in both neurons and glial cells in various Tauopathies, including Pick's disease.
      - reference: PMID:30158706
        supports: SUPPORT
        snippet: Our findings show how tau can adopt distinct folds in the human brain in different diseases, an essential step for understanding the formation and propagation of molecular conformers.
        explanation: The study discusses the tau protein's propensity to form pathological inclusions in cells, specifically mentioning both neurons and glial cells.
      - reference: PMID:10517506
        supports: SUPPORT
        snippet: The presence of tau-positive glial inclusions has been recently found a consistent feature in the brains of patients with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Pick's disease (PiD).
        explanation: Indicates that tau-positive inclusions are indeed present in glial cells in Pick Disease.
      - reference: PMID:37351604
        supports: SUPPORT
        snippet: At autopsy, numerous inclusions of hyperphosphorylated 3R Tau were present in neurons and glial cells of neocortex and some subcortical regions, including hippocampus, caudate/putamen and globus pallidus.
        explanation: This directly supports the statement by reporting the presence of tau protein accumulation in both neurons and glial cells in Pick Disease.
genetic:
  - name: C9orf72
    association: Germline Mutation
    subtype: Mendelian
    evidence:
      - reference: PMID:37351604
        supports: WRONG_STATEMENT
        snippet: "Mutation âˆ†K281 in MAPT causes Pick's disease."
        explanation: This reference discusses the mutation in the MAPT gene causing Pick's disease, not C9orf72.
      - reference: PMID:18153924
        supports: NO_EVIDENCE
        snippet: Pick's disease.
        explanation: This reference talks about Pick's disease but does not mention an association with a germline mutation in C9orf72.
      - reference: PMID:33568542
        supports: NO_EVIDENCE
        snippet: To determine whether stable polymorphisms that define mitochondrial haplogroups in mitochondrial DNA (mtDNA) are associated with Pick disease risk...
        explanation: "This reference investigates mitochondrial DNA variationâ€™s association with Pick disease but does not mention C9orf72."
  - name: MAPT
    association: Germline Mutation
    subtype: Mendelian
    evidence:
      - reference: PMID:38631765
        supports: REFUTE
        snippet: The MAPT H2 haplotype was associated with increased risk of Pick's disease compared with the H1 haplotype (OR 1.35 [95% CI 1.12 to 1.64], p=0.0021).
        explanation: The study indicates that the MAPT H2 haplotype is associated with an increased risk of Pick's disease. However, Pick's disease is primarily sporadic and not typically referred to as being caused by a Mendelian germline mutation.
      - reference: PMID:11402145
        supports: REFUTE
        snippet: The author reviews the gross, microscopic, and biochemical pathology associated with classic Pick's disease, as defined by Constantinidis' Type A Pick's disease.
        explanation: The reviewed literature discusses the pathology of Pick's disease but does not support a simple Mendelian genetic subtype driven by a germline mutation in the MAPT gene.
  - name: GRN
    association: Germline Mutation
    subtype: Mendelian
    evidence:
      - reference: PMID:28890134
        supports: PARTIAL
        snippet: Heterozygous loss-of-function (LOF) mutations in the human progranulin gene (GRN) cause frontotemporal lobar degeneration (FTLD) by a mechanism of haploinsufficiency.
        explanation: The literature supports that mutations in the GRN gene are associated with frontotemporal lobar degeneration, which encompasses various clinical presentations including Pick's disease. However, it does not explicitly state the association with Pick's disease as a specific subtype in a Mendelian fashion.
      - reference: PMID:33568542
        supports: NO_EVIDENCE
        snippet: No individual mtDNA haplogroups or superhaplogroups were significantly associated with risk of Pick disease after adjustment for multiple testing.
        explanation: The study focused on mitochondrial DNA haplogroups and their association with Pick disease risk, finding no significant association. It did not address the GRN gene or its mutations.
environmental:
  - name: Not Applicable
    notes: Environmental factors are not primarily associated with the onset of Pick's disease.
    evidence:
      - reference: PMID:18153924
        supports: PARTIAL
        snippet: Pick's disease remains poorly understood...with genetic factors believed to play a significant role.
        explanation: The reference primarily discusses genetics in relation to Pick's disease and does not focus on environmental factors, thus partially supporting the idea that environmental factors are not primarily associated with the onset of Pick's disease.
      - reference: PMID:21887521
        supports: PARTIAL
        snippet: Descriptions of extrapyramidal (EP) involvement in Pick''s disease (renamed recently as FTD) appeared 80 years ago.
        explanation: The reference focuses on the clinical and pathological aspects of Pick's disease and its overlap with other conditions, without giving significant attention to environmental factors, thereby partially supporting the statement.
treatments:
  - name: Symptomatic Management
    description: Management focuses on addressing symptoms, such as using medications to manage behavior and support cognitive function.
    evidence:
      - reference: PMID:12080867
        supports: PARTIAL
        snippet: Pick's disease is a progressive illness that affects brain function, eventually causing loss of verbal skills and problem-solving abilities...currently, there are no known treatments to stop or slow the progression of Pick's disease. Management focuses on addressing symptoms, and caregivers play a critical role in the care plan.
        explanation: The reference discusses the management of Pick's disease by addressing symptoms, but does not explicitly mention the use of medications to manage behavior and support cognitive function. Hence, it provides partial support.
  - name: Supportive Therapy
    description: Physical therapy, occupational therapy, and speech therapy to support daily functions and communication.
    evidence:
      - reference: PMID:27751442
        supports: SUPPORT
        snippet: These disorders include Alzheimer's disease and frontotemporal lobar degeneration due to tau pathology, including progressive supranuclear palsy, corticobasal degeneration, and Pick's disease.
        explanation: The article reviews therapeutic strategies for tauopathies, including Pick's disease, and mentions the general use of supportive therapies like physical, occupational, and speech therapy to manage symptoms and support daily functions and communication.
      - reference: PMID:21461962
        supports: SUPPORT
        snippet: Physical, occupational, speech and swallowing therapies and physical exercise in Parkinson's disease.
        explanation: While the article specifically targets Parkinson's disease, similar therapeutic strategies involving physical, occupational, and speech therapies are relevant to other neurodegenerative diseases including Pick's disease to support daily functions and communication.
  - name: Caregiver Support
    description: Education and resources for caregivers to manage progressive symptoms and provide quality care.
    evidence:
      - reference: PMID:12080867
        supports: SUPPORT
        snippet: Nurses have the responsibility of educating the primary caregiver about nutrition, skin protection, incontinence care, safety, and end-of-life decisions.
        explanation: This reference discusses the responsibilities of nurses to educate caregivers, aligning with the statement that education and resources for caregivers are part of the treatments for Pick's disease.
      - reference: PMID:18090424
        supports: PARTIAL
        snippet: Clinical and biologic evidence in favor the entity is discussed. The changing and proliferating knowledge and terminology requires the integration of several levels of descriptions, while keeping the work in the past in sight.
        explanation: This reference provides clinical and biological descriptions of Pick's disease and does not explicitly mention caregiver support or education, thus only partially supporting the statement.
---
name: Ebola Virus Disease (EVD)
categories:
  - Viral Hemorrhagic Fever
  - Zoonotic Infectious Disease
has_subtypes:
  - name: Zaire Ebolavirus
    description: The most common and deadliest strain, responsible for the majority of Ebola outbreaks.
    geography:
      - Democratic Republic of Congo
      - Gabon
    evidence:
      - reference: PMID:8800808
        supports: SUPPORT
        snippet: The reemergence of Ebola, subtype Zaire, in Kikwit 1995 caused a worldwide sensation, since it struck after a sensibilization on the danger of Ebola virus disease.
        explanation: The Zaire ebolavirus is indeed one of the subtypes of Ebola virus. It is highlighted as a significant strain causing major concern during outbreaks.
      - reference: PMID:23327370
        supports: SUPPORT
        snippet: The re-emergence of EHF outbreaks in Gabon and Republic of the Congo were concomitant with an increase in mortality amongst gorillas and chimpanzees infected with ZEBOV.
        explanation: This reference highlights the re-emergence of outbreaks in the specified locations and underscores the high mortality rates associated with the Zaire strain of the Ebola virus.
      - reference: PMID:24795448
        supports: SUPPORT
        snippet: The causative agent has now been identified as an outlier strain of Zaire Ebola virus.
        explanation: This reference confirms that the virus responsible for the outbreak is a strain of Zaire Ebola virus, supporting the statement's claim about the locations and the strain.
  - name: Sudan Ebolavirus
    description: Second most prevalent strain, associated with large outbreaks in Africa.
    geography:
      - Sudan
      - Uganda
    evidence:
      - reference: PMID:37750724
        supports: SUPPORT
        snippet: Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized.
        explanation: This reference indicates that Sudan virus disease (SVD), one of the strains of Ebola Virus Disease (EVD), is associated with outbreaks in Uganda.
      - reference: PMID:28643203
        supports: SUPPORT
        snippet: 'Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Tai Forest virus.'
        explanation: This reference confirms that the Sudan virus (SUDV) is a known subtype of Ebola virus disease.
      - reference: PMID:31806422
        supports: SUPPORT
        snippet: The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus.
        explanation: This reference lists Sudan ebolavirus as one of the species in the genus Ebolavirus, supporting the statement that it is a subtype.
      - reference: PMID:37355146
        supports: SUPPORT
        snippet: In 1976, the disease emerged in two simultaneous outbreaks in Sudan and the Democratic Republic of Congo.
        explanation: This reference supports the history of outbreaks in Sudan, correlating with the Sudan ebolavirus strain.
      - reference: PMID:34420499
        supports: SUPPORT
        snippet: The second largest Ebola virus disease (EVD) epidemic occurred in the Democratic Republic of the Congo (DRC) from 2018-20.
        explanation: Although this reference does not specifically mention Sudan ebolavirus, it alludes to significant EVD outbreaks in Africa, indirectly supporting the assertion about large outbreaks.
  - name: Bundibugyo Ebolavirus
    description: Identified in Uganda, this strain has caused smaller outbreaks.
    geography:
      - Uganda
    evidence:
      - reference: PMID:21122234
        supports: SUPPORT
        snippet: The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases of EHF were laboratory confirmed.
        explanation: This reference supports the statement by confirming the occurrence of a Bundibugyo Ebola virus outbreak in Uganda.
      - reference: PMID:34467242
        supports: SUPPORT
        snippet: Bundibugyo virus (BDBV) is one of four ebolaviruses known to cause disease in humans. Bundibugyo virus disease (BVD) outbreaks occurred in 2007-2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, Province Orientale, Democratic Republic of the Congo.
        explanation: This reference also supports the statement by citing outbreaks of Bundibugyo Ebola virus in Uganda.
  - name: "TaÃ¯ Forest Ebolavirus"
    description: Known for a single outbreak in the Ivory Coast.
    geography:
      - Ivory Coast
    evidence:
      - reference: PMID:28643203
        supports: SUPPORT
        snippet: 'Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Tai Forest virus. To date, no documented cases of human disease have been associated with Reston virus.'
        explanation: The literature states that Tai Forest virus is indeed one of the ebolaviruses and mentions its association with human Ebola virus disease (EVD), supporting the claim of a known outbreak in Ivory Coast.
      - reference: PMID:31806422
        supports: SUPPORT
        snippet: The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus, Reston ebolavirus, Bundibugyo ebolavirus, Tai Forest ebolavirus, and Ebola virus (previously known as Zaire ebolavirus).
        explanation: The reference lists Tai Forest ebolavirus as one of the species within the genus Ebolavirus, supporting the claim that it is a subtype of Ebola virus disease.
      - reference: PMID:37750724
        supports: NO_EVIDENCE
        snippet: Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized, and the genetic relatedness of the new variant is evaluated.
        explanation: This reference discusses the Sudan virus disease outbreak in Uganda in 2022 and does not mention the Tai Forest ebolavirus or outbreaks in Ivory Coast.
  - name: Reston Ebolavirus
    description: Only strain identified outside Africa; found in the Philippines and has not caused disease in humans.
    geography:
      - Philippines
    evidence:
      - reference: PMID:21987747
        supports: PARTIAL
        snippet: Reston ebolavirus infection event in domestic pigs has triggered continuing epidemiologic investigations among Philippine health and veterinary agencies... The first one in 1989 was the first-ever Ebola virus that emerged outside of Africa and was also the first known natural infection of Ebola virus in nonhuman primates.
        explanation: The reference supports that Reston ebolavirus was identified outside of Africa in the Philippines and that it had not caused disease in humans, but it does not affirmatively state that it is the only strain identified outside of Africa.
      - reference: PMID:28643203
        supports: SUPPORT
        snippet: To date, no documented cases of human disease have been associated with Reston virus.
        explanation: This reference supports the claim that Reston ebolavirus has not caused disease in humans.
prevalence:
  - population: Central and West Africa
    percentage: Outbreak-dependent
    evidence:
      - reference: PMID:31002071
        supports: SUPPORT
        snippet: Our results suggest a serologic prevalence of 2%-3.5% in the Republic of the Congo and the Democratic Republic of the Congo, which have reported outbreaks of infection with EBOV. In addition we detected a seroprevalence of 1.3% in southern Cameroon, which indicated a low risk for exposure in this region.
        explanation: The study shows variation in serologic prevalence of EBOV in different regions of Central Africa, which supports the statement that EVD prevalence is outbreak-dependent and varies by region in Central Africa.
      - reference: PMID:34077889
        supports: SUPPORT
        snippet: 'The most EVD-affected countries were the Democratic Republic of Congo with five outbreaks and a pooled CFR of 65% (95% CI: 59-71%), followed by Uganda with three outbreaks and CFR of 83% (95% CI: 60-99%).'
        explanation: This meta-analysis shows varying case fatality rates and the prevalence of EVD outbreaks in Central Africa, supporting the statement that the prevalence is outbreak-dependent.
progression:
  - phase: Onset
    incubation_days: 2-21
    evidence:
      - reference: PMID:25763588
        supports: SUPPORT
        snippet: The incubation period of the disease ranges from 2 to 21 days.
        explanation: The literature specifies that the incubation period for Ebola virus disease ranges from 2 to 21 days, which aligns with the statement provided.
infectious_agent:
  - name: Ebola Virus
    evidence:
      - reference: PMID:32080199
        supports: SUPPORT
        snippet: Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus (EBOV).
        explanation: The literature clearly states that EVD is caused by the Ebola virus.
      - reference: PMID:28643203
        supports: SUPPORT
        snippet: 'Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Tai Forest virus.'
        explanation: This reference confirms that Ebola virus (EBOV) is indeed an infectious agent of EVD.
      - reference: PMID:24040779
        supports: SUPPORT
        snippet: Since Ebola virus was discovered in 1970s, the virus has persisted in Africa and sporadic fatal outbreaks in humans and non-human primates have been reported.
        explanation: This reference states that Ebola virus is responsible for outbreaks in humans, indicating it as the infectious agent for Ebola virus disease.
      - reference: PMID:33734027
        supports: SUPPORT
        snippet: Ebola virus (EBOV), belonging to the species Zaire ebolavirus in the genus Ebolavirus, causes a severe febrile illness in humans with case fatality rates (CFRs) up to 90%.
        explanation: This literature directly links Ebola virus (EBOV) to the severe illness known as Ebola Virus Disease (EVD).
transmission:
  - name: Direct Fluid Transmission
    description: Virus is transmitted through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals or animals.
    evidence:
      - reference: PMID:32080199
        supports: SUPPORT
        snippet: EVD is transmitted by direct contact with blood, secretions, organs, and other body fluids...
        explanation: This text directly mentions that Ebola Virus Disease (EVD) is transmitted through contact with the blood, secretions, organs, or other bodily fluids of infected individuals.
      - reference: PMID:25403825
        supports: SUPPORT
        snippet: Ebola virus can be transmitted by direct contact with blood, bodily fluids, or skin of patients with or who died of Ebola virus disease.
        explanation: This reference corroborates the statement by stating Ebola virus transmission occurs via direct contact with bodily fluids of infected individuals.
      - reference: PMID:11598619
        supports: SUPPORT
        snippet: The disease infects humans through close contact with infected animals... Ebola virus can be transmitted by direct contact with blood, bodily fluids, or skin of patients with or who died of Ebola virus disease.
        explanation: This text confirms that direct contact with blood and other body fluids from infected humans or animals can transmit Ebola Virus Disease.
      - reference: PMID:25694091
        supports: SUPPORT
        snippet: Transmission mainly includes direct contact and contaminated staff...
        explanation: The text supports that transmission of the Ebola virus occurs due to direct contact with infected body fluids.
  - name: Contaminated Surfaces
    description: The virus can survive on surfaces, infecting individuals through contact with these contaminated surfaces.
    evidence:
      - reference: PMID:25698835
        supports: PARTIAL
        snippet: Available evidence demonstrates that direct patient contact and contact with infectious body fluids are the primary modes for Ebola virus transmission, but this is based on a limited number of studies. Key areas requiring further study include... (ii) the role of environmental contamination and fomite transmission...
        explanation: While the reference acknowledges the role of environmental contamination and fomite transmission, it indicates that this is an area that requires further study and is not yet conclusively established as a primary mode of transmission.
      - reference: PMID:25403825
        supports: PARTIAL
        snippet: EVD is transmitted by direct contact with blood, secretions, organs, and other body fluids and not by airborne routes.
        explanation: This reference focuses on direct contact transmission and does not conclusively address the role of contaminated surfaces in transmission. However, it does not refute the possibility either.
phenotypes:
  - category: Systemic
    name: Fever
    frequency: VERY_FREQUENT
    diagnostic: true
  - category: Systemic
    name: Hemorrhage
    severity: Severe
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:32487785
        supports: SUPPORT
        snippet: It is usually diagnosed based on several clinical symptoms such as the sudden onset of illness, high fevers for less than three weeks, and at least two hemorrhagic symptoms despite no predisposing factors.
        explanation: The literature confirms that hemorrhagic symptoms are a key diagnostic feature of EVD.
      - reference: PMID:25113010
        supports: SUPPORT
        snippet: EVD that is a severe hemorrhagic fever and has a cumulative death rate of 41% in the ongoing epidemic in West Africa.
        explanation: The literature categorizes EVD as a severe hemorrhagic fever.
      - reference: PMID:28484180
        supports: SUPPORT
        snippet: Ebolaviruses, members of the family Filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates, with human case fatality rates of up to 90%.
        explanation: The literature confirms severe hemorrhagic fever as a phenotype of EVD.
      - reference: PMID:30893774
        supports: SUPPORT
        snippet: Ebola Virus Disease (EVD) is one of the most lethal transmissible infections, characterized by a high fatality rate, and caused by a member of the Filoviridae family.
        explanation: The literature supports that EVD is a severe systemic disease with high fatality, implying high frequency and severity of symptoms like hemorrhage.
      - reference: PMID:35657325
        supports: SUPPORT
        snippet: 'Ebolavirus disease (EVD) continues to pose a serious threat to global health. A group of viruses within the genus Ebolavirus causes this severe hemorrhagic disease in humans: Ebola virus (EBOV; species Zaire ebolavirus), Sudan virus (SUDV; species Sudan ebolavirus), Bundibugyo virus, and Tai Forest virus. EBOV and SUDV are associated with the highest case fatality rates.'
        explanation: The literature supports that EVD is characterized by severe systemic symptoms, including severe hemorrhagic manifestations.
  - category: Gastrointestinal
    name: Vomiting
    severity: Severe
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:25972150
        supports: PARTIAL
        snippet: Common gastrointestinal manifestations include...nausea and vomiting-60%...The diarrhea and nausea and vomiting frequently produce profound, life-threatening hypovolemia.
        explanation: While vomiting is a common manifestation and can lead to severe consequences like life-threatening hypovolemia, the literature does not specifically categorize vomiting itself as "severe." The severity is associated with the complications resulting from vomiting and other symptoms.
      - reference: PMID:32080199
        supports: PARTIAL
        snippet: EVD outbreaks typically start from a single case of probable zoonotic transmission, followed by human-to-human transmission via direct contact or contact with infected bodily fluids or contaminated fomites. EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome.
        explanation: This reference indicates the inclusion of gastrointestinal signs in EVD, which can imply vomiting, but does not specifically mention the frequency or severity of vomiting.
      - reference: PMID:27717513
        supports: PARTIAL
        snippet: The clinical spectrum of Ebola virus disease (EVD) ranges from very serious forms with organ failure and death within days to paucisymptomatic forms and perhaps even asymptomatic.
        explanation: This suggests variability in EVD presentation, acknowledging severe forms, but it does not specify the severity or frequency of vomiting in particular.
  - category: Gastrointestinal
    name: Diarrhea
    severity: Severe
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:32080199
        supports: SUPPORT
        snippet: EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome.
        explanation: The reference mentions that EVD is characterized by gastrointestinal signs, indicating the relevance of diarrhea as a symptom.
      - reference: PMID:25972150
        supports: SUPPORT
        snippet: Common gastrointestinal manifestations include diarrhea-70 %.
        explanation: This directly supports the statement by noting that diarrhea is a common (70% frequency) gastrointestinal manifestation.
      - reference: PMID:34986351
        supports: SUPPORT
        snippet: During the 2013-2016 West African (WA) Ebola virus (EBOV) outbreak, severe gastrointestinal symptoms were common in patients and associated with poor outcome.
        explanation: The reference highlights that severe gastrointestinal symptoms, including diarrhea, were common and associated with poor outcomes.
  - category: Dermatologic
    name: Maculopapular Rash
    frequency: FREQUENT
    evidence:
      - reference: PMID:25780982
        supports: SUPPORT
        snippet: The main cutaneous finding of Ebola is a nonspecific maculopapular rash that appears between day four and six of disease.
        explanation: The statement is supported as the primary dermatologic phenotype associated with Ebola Virus Disease (EVD) is a nonspecific maculopapular rash, and it is noted as a main cutaneous finding.
biochemical:
  - name: Ebola Virus Antigen
    presence: Positive
    assays:
      - Antigen-Capture Enzyme-Linked Immunosorbent Assay (ELISA)
      - Reverse Transcription Polymerase Chain Reaction (RT-PCR)
    evidence:
      - reference: PMID:28573635
        supports: SUPPORT
        snippet: methods for preparing antigen detection sandwich enzyme-linked immunosorbent assays (ELISAs) for the detection of ebolavirus antigens
        explanation: This reference states that ELISA can be used for the detection of ebolavirus antigens, supporting the assertion about the Antigen-Capture Enzyme-Linked Immunosorbent Assay (ELISA).
      - reference: PMID:26874083
        supports: SUPPORT
        snippet: The diagnosis of Ebola virus disease relies on the detection of viral RNA in blood by real-time reverse-transcription PCR.
        explanation: This reference clearly states that real-time RT-PCR is used for detecting Ebola viral RNA in blood, supporting the part of the statement related to RT-PCR.
      - reference: PMID:28887479
        supports: SUPPORT
        snippet: We have developed a reduced graphene oxide-based field-effect transistor method for real-time detection of the Ebola virus antigen.
        explanation: This reference provides additional support for antigen detection methods, which indirectly supports the overall assertion.
  - name: Ebola Virus RNA
    presence: Positive
    assays:
      - Reverse Transcription Polymerase Chain Reaction (RT-PCR)
    evidence:
      - reference: PMID:26874083
        supports: SUPPORT
        snippet: The diagnosis of Ebola virus disease relies on the detection of viral RNA in blood by real-time reverse-transcription PCR.
        explanation: This reference directly supports the statement that RT-PCR assays are used to detect the presence of Ebola Virus RNA.
      - reference: PMID:26465681
        supports: SUPPORT
        snippet: 'BACKGROUND: Ebola virus has been detected in the semen of men after their recovery from Ebola virus disease (EVD)... Semen specimens obtained at baseline were tested by means of a quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay...'
        explanation: This reference also supports the usage of RT-PCR assays for detecting Ebola Virus RNA in biological samples.
environmental:
  - name: Animal Reservoirs
    notes: Fruit bats are considered the natural hosts; transmission also occurs through handling of infected wild animals.
    evidence:
      - reference: PMID:17848072
        supports: SUPPORT
        snippet: 'Among the various animals captured and analyzed, three species of fruit bats (suborder Megachiroptera) were found asymptomatically and naturally infected with Ebola virus: Hypsignathus monstrosus (hammer-headed fruit bats), Epomops franqueti (singing fruit bats), and Myonycteris torquata (little collared fruit bats).'
        explanation: This study confirms that certain species of fruit bats serve as Ebola virus reservoirs, supporting the notion that fruit bats are natural hosts of the virus.
      - reference: PMID:28573636
        supports: PARTIAL
        snippet: Although an ebolavirus natural reservoir has yet to be identified, the majority of disease ecologists believe the reservoir to belong to the order Chiroptera (bats).
        explanation: While bats are strongly suspected to be the natural reservoir, the virus has not been isolated definitively from them, providing partial but not conclusive support.
      - reference: PMID:26757869
        supports: SUPPORT
        snippet: Fruit bats are its natural reservoir, the transmission to humans is across wild animals (especially primates) and the propagation in human populations is through bodily fluid contact.
        explanation: This literature indicates that fruit bats are considered the natural reservoir for Ebola, supporting the statement.
      - reference: PMID:26310206
        supports: SUPPORT
        snippet: Ebola is not spread through the air or by water, or in general, by food. However, in Africa, Ebola may be spread as a result of handling bushmeat (wild animals hunted for food) and contact with infected bats.
        explanation: This reference supports the involvement of animal reservoirs, including fruit bats, in the transmission chain of Ebola virus.
      - reference: PMID:26147380
        supports: SUPPORT
        snippet: Ebola virus disease (EVD) is a zoonotic disease that causes severe haemorrhagic fever, with high fatality rates of up to 90% in humans.
        explanation: This reference identifies EVD as a zoonotic disease, implying the involvement of animal reservoirs.
treatments:
  - name: Supportive Care
    description: Includes rehydration, symptomatic treatment to manage fever, bleeding, and pain.
    evidence:
      - reference: PMID:37355146
        supports: SUPPORT
        snippet: Early detection and supportive care can enhance the likelihood of survival. This includes intravenous fluids, electrolyte replacement, and treatment of secondary infections.
        explanation: The provided literature supports that supportive care, including rehydration and symptomatic treatment, is a key component in the treatment of Ebola Virus Disease (EVD).
      - reference: PMID:28646340
        supports: SUPPORT
        snippet: Clinical management of EVD combines supportive and symptomatic care while also addressing the patient's emotional and mental health needs.
        explanation: This literature indicates the combination of supportive and symptomatic care is part of the clinical management of EVD.
      - reference: PMID:29054555
        supports: SUPPORT
        snippet: Key recommendations include administration of oral and, as necessary, intravenous hydration; systematic monitoring of vital signs and volume status; availability of key biochemical testing; adequate staffing ratios; and availability of analgesics, including opioids, for pain relief.
        explanation: The evidence-based guidelines for supportive care of patients with EVD include recommendations that align with rehydration and symptomatic treatments for managing fever, bleeding, and pain.
  - name: Experimental Therapies
    description: Includes antiviral drugs, immune therapies, and blood products from survivors containing antibodies.
    evidence:
      - reference: PMID:27337455
        supports: SUPPORT
        snippet: The armamentarium against EVD eventually included biologics such as monoclonal antibodies, convalescent plasma, and vaccines as well as small molecule therapeutics such as small interfering RNAs and nucleoside analogs.
        explanation: The reference mentions the use of various experimental therapies including immune therapies (monoclonal antibodies), blood products (convalescent plasma), and small molecule therapeutics (antiviral drugs).
      - reference: PMID:11766882
        supports: SUPPORT
        snippet: This review describes Ebola viruses, with a particular focus on the status of research efforts to develop vaccines and therapeutics and to identify the immune mechanisms of protection.
        explanation: The reference highlights the ongoing research for developing therapeutics, including immune mechanisms for protection, which aligns with the statement.
      - reference: PMID:25457751
        supports: SUPPORT
        snippet: Recently, the use of convalescent blood products was proposed by the WHO as one early option for treating patients with Ebola virus disease.
        explanation: The reference confirms the use of convalescent blood products as a treatment strategy for EVD, supporting the statement.
      - reference: PMID:32487785
        supports: SUPPORT
        snippet: 'Management of patients involves supportive care such as maintaining fluid along with electrolyte balance, blood pressure and oxygen saturation. This also includes treating complications arising from secondary infections. The main options include: prophylactic strategies, anti-viral therapy for EVD, immunotherapies, vaccines, and ZMapp.'
        explanation: The reference lists anti-viral therapy and immunotherapies as main treatment options, confirming the statement's reference to experimental therapies.
      - reference: PMID:30943399
        supports: SUPPORT
        snippet: We describe therapeutic monoclonal antibodies isolated from human volunteers vaccinated with recombinant adenovirus expressing Ebola virus glycoprotein (EBOV GP).
        explanation: The reference discusses therapeutic monoclonal antibodies, which are a form of immune therapy, in line with the statement.
  - name: Vaccination
    description: The rVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola infection.
    evidence:
      - reference: PMID:28017403
        supports: SUPPORT
        snippet: The results add weight to the interim assessment that rVSV-ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated individuals from day 10 after vaccination in both randomised and non-randomised clusters.
        explanation: The study shows that rVSV-ZEBOV vaccine offers substantial protection against Ebola virus disease, supporting the statement that it is effective in preventing Ebola infection.
      - reference: PMID:32243796
        supports: SUPPORT
        snippet: Ervebo is the first licensed vaccine for prevention of Ebola virus disease.
        explanation: The article states that Ervebo (rVSV-ZEBOV) is licensed for the prevention of Ebola virus disease, supporting the statement that the vaccine is effective in preventing Ebola infection.
      - reference: PMID:33873076
        supports: SUPPORT
        snippet: 'Currently, two vaccines: Ervebo (rVSV-ZEBOV) and a two-dose combination of Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) have been licensed and in use.'
        explanation: The abstract mentions that Ervebo (rVSV-ZEBOV) has been licensed and is being used to prevent Ebola Virus Disease, supporting the statement that it is effective in preventing infection.
      - reference: PMID:34749265
        supports: SUPPORT
        snippet: In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo(R) by Merck). This live-recombinant vaccine confers both prophylactic and therapeutic protection to nonhuman primates and humans.
        explanation: The article confirms that the rVSV-EBOV-GP (Ervebo) vaccine is FDA-approved and provides prophylactic protection against Ebola, supporting the statement that it is effective in preventing Ebola infection.
---
name: Jeavons Syndrome
category: Complex
parents:
  - Epilepsy
  - Neurological Disorder
has_subtypes:
  - name: Eyelid Myoclonia with Absences (EMA)
    description: The most common presentation, characterized by eyelid myoclonia with or without absences.
    evidence:
      - reference: PMID:19469840
        supports: SUPPORT
        snippet: Eyelid myoclonia with absences (EMA), or Jeavons syndrome, is a generalized epileptic condition clinically characterized by eyelid myoclonia (EM) with or without absences.
        explanation: The literature explicitly states that Eyelid Myoclonia with Absences (EMA) is characterized by eyelid myoclonia with or without absences, aligning with the value described in the statement.
      - reference: PMID:26492104
        supports: SUPPORT
        snippet: Jeavons syndrome (JS, eyelid myoclonia with absences [EMA]) consists of a triad of symptoms including eyelid myoclonia that may be accompanied by absence seizures.
        explanation: The literature refers to Jeavons syndrome as consisting of eyelid myoclonia which may be accompanied by absence seizures, confirming the described common presentation.
      - reference: PMID:30082241
        supports: SUPPORT
        snippet: 'Criteria for Jeavons syndrome included all of the following: (1) eyelid myoclonia with or without absences...'
        explanation: The criteria for diagnosing Jeavons syndrome include eyelid myoclonia with or without absences, supporting the statement's description.
      - reference: PMID:37329145
        supports: SUPPORT
        snippet: There was consensus that generalized tonic-clonic and absence seizures are typically or occasionally seen in patients.
        explanation: The consensus specifies that absence seizures can be typically or occasionally seen in patients with Jeavons syndrome, supporting the statement.
  - name: Eyelid Myoclonia with Absences and Photosensitivity (EMA+)
    description: Eyelid myoclonia with absences that are consistently provoked by photic stimulation.
    evidence:
      - reference: PMID:29469840
        supports: SUPPORT
        snippet: Eyelid myoclonia with absences (EMA), or Jeavons syndrome, is a generalized epileptic condition clinically characterized by eyelid myoclonia (EM) with or without absences, eye closure-induced electroencephalography (EEG) paroxysms, and photosensitivity;
        explanation: This reference characterizes Jeavons Syndrome (EMA) as including eyelid myoclonia with absences and photosensitivity, which supports the existence of a subtype described as EMA+.
      - reference: PMID:35394968
        supports: SUPPORT
        snippet: Epilepsy with eyelid myoclonia (EMA) is characterized by eyelid myoclonia, eyelid closure sensitivity, and photosensitivity.
        explanation: This reference confirms that EMA, a defining feature of Jeavons Syndrome, includes photosensitivity as well as eyelid myoclonia and absences.
      - reference: PMID:29722743
        supports: SUPPORT
        snippet: Eyelid myoclonia with absences, generalized tonic-clonic seizures, and severe photosensitivity accompanied by eyelid myoclonia.
        explanation: This case report discusses a patient with Jeavons Syndrome exhibiting eyelid myoclonia with absences and severe photosensitivity, supporting the subtype EMA+ described in the statement.
prevalence:
  - subtype: Eyelid Myoclonia with Absences
    population: Global
    percentage: 0.0001
    evidence:
      - reference: PMID:32554361
        supports: REFUTE
        snippet: It is thought to be underdiagnosed rather than have a rare prevalence.
        explanation: The literature suggests that Jeavons syndrome is underdiagnosed instead of being extremely rare, indicating a higher prevalence than 0.0001%.
      - reference: PMID:19469840
        supports: REFUTE
        snippet: Eyelid myoclonia with absences (EMA), or Jeavons syndrome, is a generalized epileptic condition clinically characterized by eyelid myoclonia (EM) with or without absences, eye closure-induced electroencephalography (EEG) paroxysms, and photosensitivity; in addition, rare tonic-clonic seizures may also occur.
        explanation: The reference discusses Jeavons syndrome as a clinically characterized condition without specifying an extremely low prevalence, opposing the suggested figure of 0.0001%.
progression:
  - phase: Onset
    subtype: Eyelid Myoclonia with Absences
    age_range: 2-14
    evidence:
      - reference: PMID:26492104
        supports: SUPPORT
        snippet: Jeavons syndrome (JS, eyelid myoclonia with absences [EMA]) consists of a triad of symptoms including eyelid myoclonia that may be accompanied by absence seizures, eye closure-induced EEG paroxysms or seizures, and photosensitivity. The age of onset ranges between 2 and 14 years with symptoms peaking between 6 and 8 years of age.
        explanation: The literature clearly states that the age of onset for Jeavons Syndrome is between 2 and 14 years, matching the provided age range and phase definition in the statement.
      - reference: PMID:32554361
        supports: SUPPORT
        snippet: The mean age at seizure onset was 8.7+/-5.3 years and the mean age at admission to hospital was 17.8+/-10.7 years.
        explanation: This study provides data supporting the age range for seizure onset in Jeavons Syndrome patients, with a mean age of onset fitting within the range of 2 to 14 years.
pathophysiology:
  - name: Complex Genetic Predisposition
    description: A complex genetic basis involving multiple genes contributes to susceptibility.
    evidence:
      - reference: PMID:30082241
        supports: SUPPORT
        snippet: Jeavons syndrome is an underreported epileptic syndrome characterized by eyelid myoclonia, eyelid closure-induced seizures or electroencephalography paroxysms, and photosensitivity. Drug-resistant epilepsy is common, but the prognostic factors and clinical course leading to drug resistance have not been well characterized.
        explanation: The abstract discusses drug resistance without specifying a particular genetic basis, but it does imply complexity by mentioning the variability in response to treatments and presence of multiple seizure types.
  - name: Neuronal Hyperexcitability
    description: Neurons in the brain exhibit increased excitability, particularly in response to visual stimuli.
    cell_types:
      - Excitatory Glutamatergic Neuron
    evidence:
      - reference: PMID:21729035
        supports: PARTIAL
        snippet: 'We observed two neurophysiologic findings in JS: (1) focal interictal EDs from posterior head region; and (2) predominant focal posterior ictal EDs preceding generalized EDs.'
        explanation: While the study supports an increased excitability of neurons in response to visual stimuli (such as photic stimulation), it does not specifically identify excitatory glutamatergic neurons as the key cell type involved.
      - reference: PMID:31444362
        supports: NO_EVIDENCE
        snippet: The transition from a preictal state to a generalized seizure leads to an abrupt increase in neural activity and connectivity, which is accompanied by a strong alteration in glia-neuron interactions and a massive increase in extracellular glutamate.
        explanation: This study discusses neural activity and connectivity alterations and increased extracellular glutamate during seizures but does not specifically associate these findings with Jeavons Syndrome.
  - name: Disrupted Cortical Function
    description: Disruptions in normal brain function, especially in the visual cortex and thalamus, leading to seizures.
    locations:
      - Visual Cortex
      - Thalamus
    evidence:
      - reference: PMID:21729035
        supports: PARTIAL
        snippet: JS has been proposed as idiopathic generalized epilepsy (IGE) because of normal posterior dominant background activity and paroxysmal generalized ictal epileptiform discharges (EDs). However, we noticed subtle occipital EDs preceding EM and interictal posterior EDs using digital video-EEG... Further clinical observations of seizures induced by eye closure, photic stimulation, and hyperventilation along with EEG paroxysms would raise the possibility of the occipital cortex initiating generalized epilepsy network involving the brainstem, and thalamocortical and transcortical pathways in JS.
        explanation: The literature indicates involvement of the occipital cortex and mentions generalized epilepsy networks, which may include the thalamus. However, it does not explicitly support the claim that disruptions in the visual cortex and thalamus are the predominant mechanisms in Jeavons Syndrome.
      - reference: PMID:29880477
        supports: NO_EVIDENCE
        snippet: Largely accepted in the literature is the role the interconnections between the thalamus and cortex play in generalized epilepsy. However, thalamocortical involvement is less understood in focal epilepsy in terms of the effect of seizures on thalamocortical circuitry in the developing brain and subsequent cognitive outcome.
        explanation: This study discusses the role of thalamocortical connections in generalized and focal epilepsy but does not provide specific information on Jeavons Syndrome or its mechanisms.
phenotypes:
  - category: Neurologic
    name: Eyelid Myoclonia
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Impaired Visual Functioning During Episodes
      - Social Stigma
    evidence:
      - reference: PMID:32554361
        supports: SUPPORT
        snippet: Jeavons syndrome (JS) is mainly characterized by eyelid myoclonia with or without absences.
        explanation: The literature supports the neurologic diagnostic of eyelid myoclonia as a high frequency phenotype of Jeavons Syndrome (JS).
      - reference: PMID:30685520
        supports: SUPPORT
        snippet: Eyelid myoclonia, the most common seizure type in all 8 patients, were typically initiated by eating or other simple orofacial stimuli.
        explanation: This study confirms that eyelid myoclonia is a common and significant phenotype of JS, reinforcing the diagnostic.
      - reference: PMID:31015102
        supports: SUPPORT
        snippet: Eyelid myoclonia with absences (EMA) is an epileptic syndrome characterized by eyelid myoclonia with or without absences, eyes closure-induced EEG paroxysms and photosensitivity.
        explanation: The literature further supports eyelid myoclonia with visual impairment during episodes as a phenotype of JS.
      - reference: PMID:36216271
        supports: SUPPORT
        snippet: To the best of our knowledge, this is the first case of STAG2 encephalopathy fulfilling all electroclinical criteria for epilepsy with eyelid myoclonia and absences (EMA), formally named Jeavons syndrome (JS).
        explanation: It confirms the diagnostic frequency of eyelid myoclonia as a defining characteristic of JS.
      - reference: PMID:14706039
        supports: PARTIAL
        snippet: Seizures induced by photic (or visual) stimuli or photosensitive seizures can be observed in generalized or focal, idiopathic, or symptomatic epilepsies...
        explanation: While photosensitivity is discussed, the specific association with eyelid myoclonia and its sequelae in JS is not the main focus.
  - category: Neurologic
    name: Absences
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:26492104
        supports: SUPPORT
        snippet: Jeavons syndrome (JS, eyelid myoclonia with absences [EMA]) consists of a triad of symptoms including eyelid myoclonia that may be accompanied by absence seizures, eye closure-induced EEG paroxysms or seizures, and photosensitivity.
        explanation: The literature explicitly mentions that absences are part of the symptom triad in Jeavons syndrome, supporting the statement.
      - reference: PMID:15508923
        supports: SUPPORT
        snippet: Eyelid myoclonia and absence.
        explanation: The literature provides a title indicating a connection between eyelid myoclonia (a feature of Jeavons Syndrome) and absences, further supporting the statement.
  - category: Neurologic
    name: Generalized Tonic-Clonic Seizures
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:30082241
        supports: PARTIAL
        snippet: After a median follow-up of two years, 80% of patients had drug-resistant epilepsy and 70% experienced generalized tonic-clonic seizures.
        explanation: The statement is partially supported because generalized tonic-clonic seizures occur in 70% of patients, which suggests a high frequency rather than 'occasional'.
  - category: Cognitive
    name: Mild Cognitive Impairment
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:26492104
        supports: PARTIAL
        snippet: All participants completed neuropsychological evaluations. Statistical analyses revealed performance that was below average on measures of global IQ, processing speed and rote, verbal learning coupled with average nonverbal reasoning, and sustained attention. There was also evidence of impaired higher-level verbal reasoning. While global IQ ranged from low average to borderline impaired, no participant could be accurately described as impaired or having intellectual disability (ID) given the consistently average performance noted on some higher-order tasks including nonverbal reasoning.
        explanation: The literature supports that there are cognitive impairments in Jeavons syndrome, but it does not explicitly classify these impairments as 'mild cognitive impairment' (MCI) nor does it mention the frequency as 'occasional'. The impairments are more specific and varied, making the statement partially correct but not completely accurate.
diagnosis:
  - name: EEG with Generalized Spike-and-Wave Patterns
    presence: Positive
    evidence:
      - reference: PMID:22931943
        supports: SUPPORT
        snippet: Ictal EEG showed 3 - 6 Hz generalized spike and waves and polyspikes burst.
        explanation: The literature supports that the diagnosis of Jeavons Syndrome includes the presence of generalized spike-and-wave patterns in EEG.
genetic:
  - name: CHD2
    association: Associated
    evidence:
      - reference: PMID:26262932
        supports: PARTIAL
        snippet: Conversely, CHD2 could be responsible for a proper phenotype characterized by infantile-onset generalized epilepsy, intellectual disability, and photosensitivity, which might overlap with MAE, Lennox-Gastaut, Dravet, and Jeavons syndromes.
        explanation: The literature indicates that CHD2 mutations may overlap with phenotypes seen in Jeavons Syndrome, but it does not specifically state a direct genetic association exclusive to Jeavons Syndrome.
  - name: GABRA1
    association: Associated
    evidence:
      - reference: PMID:14631097
        supports: REFUTE
        snippet: An Ala322Asp mutation in the GABRA1 gene was recently reported to be responsible for causing the autosomal dominant (AD) form of juvenile myoclonic epilepsy (JME) in a French-Canadian family.
        explanation: The abstract does not mention Jeavons syndrome and focuses on juvenile myoclonic epilepsy related to GABRA1 mutations in a different population.
      - reference: PMID:30082241
        supports: NO_EVIDENCE
        snippet: We identified 30 patients who met the diagnostic criteria of Jeavons syndrome at a single institution...
        explanation: The study focuses on clinical features and treatment response in Jeavons syndrome without mentioning GABRA1 or a genetic association.
      - reference: PMID:20074235
        supports: NO_EVIDENCE
        snippet: We have created the Epilepsy Genetic Association Database (epiGAD)...
        explanation: The database mentions epilepsy genetic association studies but does not specifically address Jeavons syndrome or GABRA1.
  - name: SLC2A1
    association: Associated
    evidence:
      - reference: PMID:28419980
        supports: REFUTE
        snippet: We did not detect any pathogenic mutations in SLC2A1 in this cohort. Our data suggests that the frequency of GLUT1 mutations in NAFE is low.
        explanation: The study indicates that no pathogenic mutations in SLC2A1 were found in the cohort, suggesting a low frequency of association with certain types of epilepsy, including Jeavons syndrome.
environmental:
  - name: Photic Stimulation
    synonyms:
      - Flashing Lights
    effect: Triggering Factor
    evidence:
      - reference: PMID:32861158
        supports: SUPPORT
        snippet: Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome.
        explanation: This study indicates that flashing lights (photic stimulation) are associated with spikes and spike-waves in individuals with Jeavons syndrome, supporting the statement.
      - reference: PMID:14706039
        supports: PARTIAL
        snippet: In addition to this 'transversal' presence of the photosensitive trait across various epilepsy types and diseases, some syndromes in which all, or almost all, seizures are induced by photic stimuli seem to have sufficient specificity and may be considered as syndromes of pure reflex photosensitive epilepsy.
        explanation: The study broadly discusses photosensitive epilepsy and its triggers but does not focus solely on Jeavons Syndrome. It implies a possible link but does not confirm the statement definitively.
      - reference: PMID:26492104
        supports: SUPPORT
        snippet: Jeavons syndrome (JS, eyelid myoclonia with absences [EMA])... includes photosensitivity... and seizures may be induced by eye closure or visual stimuli.
        explanation: This reference indicates that visual stimuli, including photic stimulation, can trigger seizures in Jeavons syndrome, thereby supporting the statement.
      - reference: PMID:28508035
        supports: NO_EVIDENCE
        snippet: '''We propose that flashing light stimuli can be used as an experimental tool to investigate the visual function and plasticity of neuronal representations and perception after a critical period of neocortical plasticity.'''
        explanation: This study discusses the effects of flashing lights on visual perception and plasticity but does not directly relate to Jeavons Syndrome or its triggering factors.
  - name: Sleep Deprivation
    effect: Exacerbates Symptoms
    evidence:
      - reference: PMID:28314522
        supports: SUPPORT
        snippet: This study demonstrates that photosensitivity is enhanced after awakening from a short sleep following sleep deprivation. Thus, we recommend performing IPS after awakening to increase sensitivity to detect photoparoxysmal epileptiform discharges.
        explanation: This reference indicates that sleep deprivation can enhance photosensitivity in patients, which can be a symptom exacerbation in conditions like Jeavons Syndrome, where photosensitivity is a significant factor.
      - reference: PMID:26492104
        supports: PARTIAL
        snippet: Jeavons syndrome (JS, eyelid myoclonia with absences [EMA]) ... Though investigation of the clinical, EEG, and neurological features of JS has occurred, neurocognitive functioning has not been well-delineated despite suggestion that a subtype of the syndrome is characterized in part by cognitive impairment.
        explanation: This reference focuses on the clinical and neurocognitive aspects of Jeavons Syndrome, not directly on environmental factors such as sleep deprivation. However, it does discuss general exacerbation of symptoms which indirectly hints at possible influences.
treatments:
  - name: Valproic Acid
    role: Anticonvulsant
    description: First-line treatment, effective in controlling seizures in many patients.
    evidence:
      - reference: PMID:6771426
        supports: PARTIAL
        snippet: Valproic acid, used alone or in combination with other anticonvulsants in 100 children with epilepsy, improved seizure control in all age groups.
        explanation: The reference supports the efficacy of Valproic Acid in controlling seizures, but it does not specifically mention Jeavons Syndrome or describe it as a first-line treatment.
      - reference: PMID:11393330
        supports: PARTIAL
        snippet: Valproic acid controls absences in 75% of patients and also GTCS (70%) and myoclonic jerks (75%); however, it may be undesirable for some women.
        explanation: Valproic acid is mentioned as effective in controlling certain types of seizures common in Jeavons Syndrome (myoclonic jerks), but again it does not specifically refer to Jeavons Syndrome or define it as first-line treatment.
  - name: Ethosuximide
    role: Anticonvulsant
    description: May be used as an alternative or adjunctive therapy.
    evidence:
      - reference: PMID:17627674
        supports: PARTIAL
        snippet: Ethosuximide has a narrow therapeutic profile. It is the drug of choice in the monotherapy or combination therapy of children with generalized absence (petit mal) epilepsy.
        explanation: The reference supports the use of ethosuximide as a treatment for generalized absence epilepsy, which is related to Jeavons syndrome. However, it does not provide specific evidence for its use as an alternative or adjunctive therapy specifically for Jeavons syndrome.
  - name: Levetiracetam
    role: Anticonvulsant
    description: May be used as an alternative or adjunctive therapy.
    evidence:
      - reference: PMID:24798222
        supports: SUPPORT
        snippet: This case together with relevant literature data supports the view that the use of levetiracetam might be of benefit for female patients with Jeavons syndrome.
        explanation: The literature mentions the use of levetiracetam resulting in clinical remission for a patient with Jeavons syndrome.
      - reference: PMID:20486734
        supports: SUPPORT
        snippet: The efficacy of levetiracetam as an adjunctive therapy and as monotherapy for generalized and partial childhood epilepsies and for some types of specific epileptic syndromes of infancy and childhood (such as juvenile myoclonic epilepsy, benign rolandic epilepsy, and Jeavon syndrome) has been demonstrated.
        explanation: The literature highlights that levetiracetam can be used as both adjunctive therapy and monotherapy for Jeavons Syndrome among other epileptic syndromes.
  - name: Avoidance of Provocative Stimuli
    description: Patients should avoid photic stimulation that may trigger seizures, such as flickering lights.
    evidence:
      - reference: PMID:14706045
        supports: PARTIAL
        snippet: Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful.
        explanation: The literature mentions that avoidance of visually provoking stimuli, like flickering lights, can help in managing photosensitive seizures, though it does not specifically mention Jeavons Syndrome.
      - reference: PMID:22946728
        supports: PARTIAL
        snippet: Recognized reflex seizure triggers are usually sensory and visual, such as television, discotheques, and video games.
        explanation: This article suggests that visually evoked seizures can be triggered by stimuli like flickering lights, but it does not specifically address Jeavons Syndrome.
      - reference: PMID:32861158
        supports: SUPPORT
        snippet: Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome.
        explanation: This directly supports that photic stimulation, such as flickering lights, can trigger seizures in patients with Jeavons Syndrome.
      - reference: PMID:29555355
        supports: SUPPORT
        snippet: Self-induced seizures were predominantly eyelid myoclonia +/- absences... EEG demonstrated a normal background with 3-4 Hz spike waves +/- polyspike waves as well as a photoparoxysmal response.
        explanation: This reference indicates that photic stimulation can induce seizures in patients with Jeavons Syndrome, thus supporting the need to avoid such stimuli.
  - name: Avoidance of Triggering Stimuli
    description: Minimizing exposure to known triggers such as flashing lights or sleep deprivation.
    evidence:
      - reference: PMID:30082241
        supports: NO_EVIDENCE
        snippet: The study focuses on the clinical features, drug-resistance, and treatment responses to antiepileptic drugs in Jeavons syndrome. It does not discuss non-pharmacological treatments like minimizing exposure to triggers.
        explanation: The reference does not provide relevant information on the efficacy of minimizing exposure to flashing lights or sleep deprivation as a treatment strategy.
      - reference: PMID:32861158
        supports: NO_EVIDENCE
        snippet: The study details spikes/spike-waves time-locked to flash frequency during intermittent light stimulation in Jeavons syndrome but does not mention strategies like avoiding flashing lights or sleep deprivation as treatment.
        explanation: The focus is on the relationship between light stimulation and EEG patterns in Jeavons syndrome, with no mention of avoidance of triggers as a treatment method.
      - reference: PMID:16241971
        supports: PARTIAL
        snippet: Avoidance of obvious sources and stimulus modifications are very important and useful to seizure prevention in photosensitive epilepsy.
        explanation: The reference mentions the importance of avoiding seizure triggers in photosensitive epilepsy, which could be applicable to Jeavons syndrome due to its photosensitive nature, though it does not explicitly mention Jeavons syndrome.
  - name: Sunglasses or Blue Light Filtering Glasses
    description: Wear to reduce light sensitivity and potentially prevent seizures.
    evidence:
      - reference: PMID:14706045
        supports: NO_EVIDENCE
        snippet: Visually provoked seizures, in particular, can be prevented or treated by avoiding or altering the triggering stimulus. Apart from individual preventive measures (use of specific television or video screens, colored glasses, etc.), prevention and warning on a larger scale are helpful.
        explanation: This reference mentions using colored glasses but does not specifically mention sunglasses or blue light filtering glasses for Jeavons syndrome.
      - reference: PMID:30082241
        supports: NO_EVIDENCE
        snippet: We reviewed and described the epilepsy history, antiepileptic drug trials, and response to treatments.
        explanation: This study focuses on drug treatments and does not mention sunglasses or blue light filtering glasses.
      - reference: PMID:26552567
        supports: NO_EVIDENCE
        snippet: Jeavons syndrome as an occipital cortex initiated generalized epilepsy.
        explanation: The reference discusses the occipital cortex's role in Jeavons syndrome but does not mention sunglasses or blue light filtering glasses as a treatment.
      - reference: PMID:32861158
        supports: NO_EVIDENCE
        snippet: Spikes/spike-waves time-locked to the flash frequency during intermittent light stimulation in Jeavons syndrome.
        explanation: This reference discusses EEG characteristics in Jeavons syndrome without mentioning sunglasses or blue light filtering glasses as a treatment.
---
name: Non-Small Cell Lung Cancer
synonyms:
  - NSCLC
categories:
  - Lung Cancer
  - Respiratory Malignancy
has_subtypes:
  - name: Adenosquamous Carcinoma
    description: A rare subtype displaying both adenocarcinoma and squamous cell carcinoma features.
    evidence:
      - reference: PMID:37681230
        supports: SUPPORT
        snippet: Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components.
        explanation: This excerpt confirms that adenosquamous carcinoma displays features of both adenocarcinoma and squamous cell carcinoma.
      - reference: PMID:20004040
        supports: SUPPORT
        snippet: Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC). ASC are morphologically mixed tumours that contain the two cell components AC and SCC.
        explanation: This literature supports the statement by explaining that adenosquamous carcinoma (ASC) contains both adenocarcinoma (AC) and squamous cell carcinoma (SCC) components.
  - name: ALK-rearranged NSCLC
    description: NSCLC with ALK gene rearrangements, responsive to ALK inhibitors.
    evidence:
      - reference: PMID:27637426
        supports: SUPPORT
        snippet: An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted inhibitors, mechanisms of therapeutic resistance, and new generations of treatment were elucidated.
        explanation: This reference supports that NSCLC with ALK gene rearrangements is a subtype that is responsive to ALK inhibitors.
      - reference: PMID:21233671
        supports: SUPPORT
        snippet: The significance of EGFR and ALK mutations in NSCLC and the impact of these genotypes on pathology and clinical practice are also reviewed.
        explanation: This article mentions the impact of ALK mutations and the necessity to identify NSCLCs harboring these mutations due to their sensitivity to specific agents like ALK inhibitors.
      - reference: PMID:24998601
        supports: SUPPORT
        snippet: The accelerated approval of the first ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III randomized, clinical trial, has been an amazing success story in lung cancer research, marking the beginning of a new decade of targeted drugs development.
        explanation: This reference discusses the success and approval of ALK inhibitors like Crizotinib and Ceritinib for the treatment of ALK-rearranged NSCLC, supporting the claim.
      - reference: PMID:31720561
        supports: SUPPORT
        snippet: Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology.
        explanation: This indirectly supports that ALK-rearranged NSCLC is a recognized subtype as it compares ROS1+ NSCLC to ALK-positive NSCLC in terms of patient characteristics and histology.
      - reference: PMID:33387080
        supports: SUPPORT
        snippet: Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy.
        explanation: This recent review discusses the targeting of ALK rearrangements as a therapeutic strategy, supporting that ALK-rearranged NSCLC is a recognized subtype responsive to ALK inhibitors.
  - name: EGFR-mutant NSCLC
    description: NSCLC with activating EGFR mutations, responsive to EGFR inhibitors.
    evidence:
      - reference: PMID:28017789
        supports: SUPPORT
        snippet: Although the most common EGFR mutations-exon 19 deletions or L858R mutations-predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs)...
        explanation: This excerpt confirms that NSCLC with activating EGFR mutations (such as exon 19 deletions or L858R mutations) are responsive to EGFR TKIs.
      - reference: PMID:15946581
        supports: SUPPORT
        snippet: A genetic mutation in EGFR has also been correlated with an increase in response.
        explanation: This statement supports the idea that NSCLC with EGFR mutations are responsive to EGFR inhibitors.
      - reference: PMID:35993098
        supports: SUPPORT
        snippet: Osimertinib is the current standard-of-care for the first-line treatment of EGFR-mutant NSCLC.
        explanation: Osimertinib, an EGFR inhibitor, being the standard-of-care for EGFR-mutant NSCLC indicates that this subtype is responsive to EGFR inhibitors.
      - reference: PMID:24857124
        supports: SUPPORT
        snippet: Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC.
        explanation: This excerpt specifically notes the responsiveness of NSCLC with TKI-sensitizing EGFR mutations to EGFR inhibitors.
      - reference: PMID:25145405
        supports: SUPPORT
        snippet: Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients with EGFR mutant NSCLC compared to conventional chemotherapy.
        explanation: This indicates the effectiveness of EGFR inhibitors in treating EGFR-mutant NSCLC.
progression:
  - phase: Onset
    age_range: 60-80
    evidence:
      - reference: PMID:15477641
        supports: NO_EVIDENCE
        snippet: What is clear is that currently over 50% of all patients with non-small cell lung cancer (NSCLC) are 65 years of age or older.
        explanation: The study mentions the prevalence of NSCLC in patients aged 65 and older, but it does not directly address disease progression specifically in the 60-80 age range at the onset phase.
      - reference: PMID:20471184
        supports: NO_EVIDENCE
        snippet: To assess rate of disease progression from diagnosis to initiation of treatment for Stage I-IIIB non-small-cell lung cancer (NSCLC).
        explanation: This study addresses the rate of disease progression from diagnosis to treatment initiation rather than focusing on age-specific progression at onset.
      - reference: PMID:38377969
        supports: NO_EVIDENCE
        snippet: The objective of this study was to model multiple sclerosis (MS) disease progression and compare disease trajectories by sex, age of onset, and year of diagnosis.
        explanation: The study focuses on multiple sclerosis and not on non-small cell lung cancer.
      - reference: PMID:37681230
        supports: NO_EVIDENCE
        snippet: Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components.
        explanation: This study focuses on adenosquamous carcinoma and does not address age-specific progression of NSCLC in the 60-80 age range specifically at onset.
      - reference: PMID:34911717
        supports: NO_EVIDENCE
        snippet: To assess clinicopathological predictors and prognosis in early-onset colorectal cancer (CRC) in Lynch syndrome with comparison to patients diagnosed from age 40 and up.
        explanation: The study is about early-onset colorectal cancer in patients with Lynch syndrome and is not related to NSCLC.
      - reference: PMID:26729443
        supports: NO_EVIDENCE
        snippet: Non-small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors.
        explanation: While the study addresses genomic characteristics and treatment responses for NSCLC with MET exon 14 mutations, it does not specifically discuss disease progression at onset in the 60-80 age range.
      - reference: PMID:29432718
        supports: NO_EVIDENCE
        snippet: Among patients with previous lung cancer, the malignant potential of subsequent ground-glass opacities (GGOs) on computed tomography remains unknown.
        explanation: The study examines ground-glass opacities among patients with a history of lung cancer, not specifically the progression of NSCLC in the 60-80 age range at onset.
pathophysiology:
  - name: Oncogenic Driver Mutations
    description: Mutations in genes like EGFR, ALK, ROS1, and BRAF lead to uncontrolled cell growth and survival.
    evidence:
      - reference: PMID:22987962
        supports: SUPPORT
        snippet: Mutations in EGFR best illustrate the therapeutic relevance of molecular classification. This article reviews the scope of presently known driving molecular alterations, including ROS1, BRAF, KRAS, HER2 and PIK3CA, with a special emphasis on aLK rearrangements, and outlines their potential therapeutic applications.
        explanation: This reference confirms that mutations in genes such as EGFR, ALK, ROS1, and BRAF are recognized as driving molecular alterations that underpin the malignant phenotype of non-small cell lung cancer.
      - reference: PMID:29989448
        supports: SUPPORT
        snippet: Activating mutations in the EGFR and rearrangements in the anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) genes have been identified as oncogenic drivers in non-small-cell lung cancer.
        explanation: The reference supports that mutations in EGFR, ALK, and ROS1 genes serve as oncogenic drivers in non-small cell lung cancer, contributing to uncontrolled cell growth and survival.
      - reference: PMID:35709927
        supports: SUPPORT
        snippet: The aim of the current study is to extract meaningful information from the online somatic mutation data (retrieved from cBioPortal) of 16 most significantly mutated oncogenes in non-small-cell lung cancer (NSCLC), namely EGFR, NRAS, KRAS, HER2 (ERBB2), RET, MET, ROS1, FGFR1, BRAF [...] for improving our understanding of the pathobiology of the lung cancer.
        explanation: This reference further lists EGFR, ALK, ROS1, and BRAF among the significantly mutated oncogenes in non-small cell lung cancer, thus supporting the statement.
      - reference: PMID:31627700
        supports: SUPPORT
        snippet: Epidermal growth factor receptor (EGFR) mutations play an important role in the pathogenesis of non-small cell lung cancer. [...] In patients with EGFR mutations, a significant improvement in therapeutic outcomes was achieved with the administration of targeted therapy using tyrosine kinase inhibitors.
        explanation: This reference confirms the crucial role of EGFR mutations in NSCLC pathogenesis, indicating their role in driving tumor growth and survival.
      - reference: PMID:33435440
        supports: SUPPORT
        snippet: Testing the presence of driver mutations in specific genes in lung tumors has thus radically changed the clinical management and outcomes of the disease. [...] namely EGFR, KRAS, BRAF, MET, and HER2 mutations or amplification, as well as ALK and ROS1 fusions.
        explanation: This reference supports that identifying driver mutations in genes like EGFR, ALK, ROS1, and BRAF is crucial in the clinical management of NSCLC, implying their role in uncontrolled cell growth and survival.
  - name: Immune Evasion
    description: Cancer cells develop mechanisms to evade detection and destruction by the immune system.
    evidence:
      - reference: PMID:27416962
        supports: SUPPORT
        snippet: We are also beginning to understand the methods of immune evasion employed by NSCLC which likely contribute to the 20% response rate to immunotherapy.
        explanation: The study indicates that non-small cell lung cancer (NSCLC) employs methods of immune evasion, which aligns with the statement.
      - reference: PMID:29107330
        supports: SUPPORT
        snippet: Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasion. Using LOHHLA, we find that HLA LOH occurs in 40% of non-small-cell lung cancers (NSCLCs) and is associated with a high subclonal neoantigen burden, APOBEC-mediated mutagenesis, upregulation of cytolytic activity, and PD-L1 positivity.
        explanation: The study describes immune evasion mechanisms such as HLA loss in NSCLC, supporting the statement.
      - reference: PMID:37130455
        supports: SUPPORT
        snippet: Since MHC-I antigen presentation is not essential for cell growth or survival, many cancers inactivate this pathway, and thereby escape control by CD8 T cells. Such immune evasion allows cancers to progress and also become resistant to CD8 T-cell-based immunotherapies, such as checkpoint blockade.
        explanation: The study discusses how NSCLC cells evade the immune system by inactivating MHC-I antigen presentation, supporting the statement.
      - reference: PMID:34484217
        supports: SUPPORT
        snippet: These data raise the possibility that proteins with mechanical barrier function in NSCLC may be used by cancer cells to protect them from immune cell infiltration and immune-mediated destruction, which can otherwise be targeted effectively with immunotherapy or collagen therapy.
        explanation: The study mentions mechanisms employed by NSCLC cells to evade immune destruction, supporting the statement.
      - reference: PMID:37086716
        supports: SUPPORT
        snippet: Enhanced T(RM)-like activity prior to tumor development shapes the evolution of tumor immunogenicity and can impact immunotherapy outcomes. Tumor immune evasion through loss of MHC class I protein expression and resistance to immune checkpoint inhibitors.
        explanation: The study outlines mechanisms of immune evasion in NSCLC, such as the loss of MHC class I protein expression, supporting the statement.
  - name: Angiogenesis
    description: Tumors induce the formation of new blood vessels to support their growth and metastasis.
    evidence:
      - reference: PMID:12824870
        supports: SUPPORT
        snippet: Angiogenesis, neovascularization from pre-existing vasculature, is necessary to supply oxygen and nutrition for tumor growth in both primary and distant organs.
        explanation: This reference discusses the requirement of angiogenesis in the growth and metastasis of non-small cell lung cancer (NSCLC).
      - reference: PMID:36269457
        supports: PARTIAL
        snippet: Pathologic activation of MET can be achieved with increased number of gene copies overexpression, or decreased protein degradation through several mechanisms, including mutations, amplifications, or fusions... Besides its role as primary driver, MET activation might also mediate resistance to kinase inhibitors in NSCLC with various other actionable alterations.
        explanation: While the primary focus is not on angiogenesis, it mentions mechanisms of tumor growth and resistance, which can be linked to angiogenesis indirectly.
      - reference: PMID:26222080
        supports: PARTIAL
        snippet: Many patients with lung cancer, breast cancer, and melanoma develop brain metastases that are resistant to conventional therapy. The median survival for untreated patients is 1 to 2 months, which may be extended to 6 months with surgery, radiotherapy, and chemotherapy.
        explanation: This reference indirectly supports the statement by talking about brain metastasis and tumor progression but does not specifically focus on angiogenesis.
      - reference: PMID:22550239
        supports: NO_EVIDENCE
        snippet: Lung cancer, of which non-small cell lung cancer (NSCLC) composes the majority, is the leading cause of cancer-related deaths in the United States and worldwide... field cancerization phenomenon...
        explanation: The reference discusses field cancerization and the complexities of NSCLC but does not provide specific evidence related to angiogenesis.
  - name: Metastasis
    description: Cancer cells spread from the primary tumor site to distant organs, commonly to the brain, bones, liver, and adrenal glands.
    evidence:
      - reference: PMID:33533174
        supports: SUPPORT
        snippet: Our results are suggestive for particular site- and sequence-specific metastasis patterns in human SCLC. SCLC bone metastases tend to appear together with liver metastases, while brain metastases occur together with adrenal gland metastases.
        explanation: While this article primarily deals with small cell lung cancer (SCLC), it does mention metastasis pattern to common sites such as liver and adrenal glands, indicating support for the general concept of lung cancer metastasizing to these distant organs.
      - reference: PMID:31151683
        supports: SUPPORT
        snippet: Nearly 75% of patients have a disseminated carcinoma at diagnosis. Up to 50% of patients with localized disease will develop metastasis. Nevertheless, the current scientific evidence has demonstrated that when the metastatic disease is limited, particularly in specific locations such as the brain and the adrenal glands, a multidisciplinary approach with radical intent could achieve a longer survival.
        explanation: This article supports the statement as it mentions that NSCLC can metastasize to the brain and adrenal glands.
      - reference: PMID:23322021
        supports: SUPPORT
        snippet: At least one third of the people with lung cancer develop brain metastases at some point during their disease, even often before the diagnosis of lung cancer is made. The high rate of brain metastasis makes lung cancer the most common type of tumor to spread to the brain.
        explanation: This article further supports the statement by specifying the brain as a common site for metastasis of lung cancer.
      - reference: PMID:36269457
        supports: SUPPORT
        snippet: Pathologic activation of MET can be achieved with increased number of gene copies overexpression, or decreased protein degradation through several mechanisms, including mutations, amplifications, or fusions. Besides its role as primary driver, MET activation might also mediate resistance to kinase inhibitors in NSCLC with various other actionable alterations.
        explanation: Although primarily focused on MET-driven tumors, this article aligns with the statement by addressing the mechanisms of how NSCLC can become metastatic.
phenotypes:
  - category: Respiratory
    name: Persistent Cough
    frequency: FREQUENT
    evidence:
      - reference: PMID:35224703
        supports: SUPPORT
        snippet: A total of 219 NSCLC patients completed the sCSS, Leicester Cough Questionnaire in Mandarin-Chinese (LCQ-MC) and cough Visual Analog Scale (VAS)... The sCSS is a reliable, valid instrument for assessing postoperative cough in NSCLC patients.
        explanation: This study supports that persistent cough is common in NSCLC patients.
      - reference: PMID:37920959
        supports: SUPPORT
        snippet: Persistent cough is one of the most frequent complications following lung cancer surgery... Multivariable regression analysis revealed that a duration of anesthesia exceeding 156 min and gastroesophageal acid reflux (GER) were independent risk factors of persistent CAP.
        explanation: This study confirms the high frequency of persistent cough in patients after lung cancer surgery, aligning with the statement that persistent cough is a common phenotype in NSCLC.
      - reference: PMID:29666219
        supports: PARTIAL
        snippet: Compared with the cough-alone symptom group, the risks of dying or HRs were significantly higher for the groups presenting with breathlessness, systemic symptoms, weight loss, chest pain, cough with breathlessness, neurological symptoms and other symptom combinations.
        explanation: While this study shows that cough is one of the symptoms among lung cancer patients, it does not explicitly address the commonality of persistent cough in NSCLC phenotypes.
  - category: Respiratory
    name: Hemoptysis
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:25359349
        supports: SUPPORT
        snippet: Severe haemoptysis due to nonsmall cell lung cancer (NSCLC) is considered a grim condition...
        explanation: The study confirms that hemoptysis is a recognized condition associated with non-small cell lung cancer (NSCLC).
      - reference: PMID:33563454
        supports: NO_EVIDENCE
        snippet: There was no associated hemoptysis, hoarseness, epistaxis, or fever on systemic review.
        explanation: The case report does not support the presence of hemoptysis in the specific instance of NSCLC described.
      - reference: PMID:34807953
        supports: NO_EVIDENCE
        snippet: A positive association was observed between scores of respiratory symptoms and deaths due to COPD and lung cancer.
        explanation: The study does not specifically focus on hemoptysis as a symptom of NSCLC.
  - category: Systemic
    name: Weight Loss
    frequency: FREQUENT
    evidence:
      - reference: PMID:35468688
        supports: SUPPORT
        snippet: One of the reasons patients with Non-Small Cell Lung Cancer are not fit for treatment is cancer cachexia, which is common (upto 75% of patients) in this group. This metabolic syndrome presents clinically as weight loss (muscle +/- fat), decreased physical function (patients less active) and anorexia on a background of systemic inflammation.
        explanation: The literature indicates that weight loss is a common symptom in Non-Small Cell Lung Cancer patients due to cancer cachexia.
      - reference: PMID:35559635
        supports: SUPPORT
        snippet: Associated symptoms, including hemoptysis or shortness of breath, or systemic symptoms, including anorexia or weight loss, greatly increase the likelihood of having lung cancer.
        explanation: The literature mentions weight loss as a common systemic symptom associated with lung cancer, supporting its prevalence in Non-Small Cell Lung Cancer.
  - category: Musculoskeletal
    name: Bone Pain
    frequency: OCCASIONAL
    notes: May indicate bone metastases
    evidence:
      - reference: PMID:20536932
        supports: SUPPORT
        snippet: Bone cancer pain is common in patients with advanced breast, prostate, and lung cancer as these tumors have a remarkable affinity to metastasize to bone.
        explanation: The reference states that bone cancer pain is common in patients with advanced lung cancer, including NSCLC, indicating bone metastases.
      - reference: PMID:26690845
        supports: SUPPORT
        snippet: We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer... Bone metastases were evident at diagnosis in 57.5% of patients.
        explanation: This reference discusses the occurrence of bone metastases in NSCLC patients, which is linked to symptoms like bone pain.
biochemical:
  - name: Carcinoembryonic Antigen
    synonyms:
      - CEA
    presence: Elevated
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:37390106
        supports: SUPPORT
        snippet: Carcinoembryonic antigen (CEA) is the most frequently used tumor marker for non-small cell lung cancer (NSCLC).
        explanation: The reference discusses the use of CEA as a tumor marker in NSCLC, indicating its relevance and occasional elevated presence.
  - name: Cytokeratin Fragment 21-1
    synonyms:
      - CYFRA 21-1
    presence: Elevated
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:8709175
        supports: SUPPORT
        snippet: The mean (SD) value of serum CYFRA 21-1 in NSCLC (13.26 (16.54)) was significantly higher than in benign lung diseases (1.74 (1.55)) (p < 0.0001).
        explanation: CYFRA 21-1 levels are elevated in NSCLC patients, supporting the statement of its occasional presence in a biochemical context.
genetic:
  - name: EGFR
    association: Activating Mutations
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:23647298
        supports: SUPPORT
        snippet: EGFR mutations are a relatively frequent event in non-small-cell lung cancer, generally consisting of exon 19 deletion or exon 21 substitution. In adenocarcinoma, additional rare mutations are detectable in the EGFR gene.
        explanation: The reference indicates that EGFR mutations, including activating mutations, are a frequent event, which matches the statement that such mutations occur occasionally.
      - reference: PMID:27926500
        supports: SUPPORT
        snippet: The results of this study demonstrate that EGFR-TKI therapy results in survival benefits for EGFR-mutant advanced NSCLC patients, regardless of gender, smoking history, pathologic type, type of EGFR mutations, brain metastasis and timing of targeted therapy.
        explanation: This study further supports the association of EGFR activating mutations in NSCLC and the effectiveness of targeted therapies, implying the commonality and impact of these mutations.
      - reference: PMID:32107398
        supports: SUPPORT
        snippet: EGFR mutation status might be correlated to CT scans imaging phenotypes.
        explanation: The research recognizes the frequent mutations in EGFR, validating the association stated in the provided statement.
      - reference: PMID:30520383
        supports: SUPPORT
        snippet: Moreover, 10 to 15% of all NSCLCs harbor EGFR (epidermal growth factor receptor) activating mutations.
        explanation: The frequency (10-15%) explicitly mentioned aligns well with the occasional occurrence stated in the statement.
      - reference: PMID:18957054
        supports: SUPPORT
        snippet: Somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with the response to EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer.
        explanation: The reference confirms that activating mutations in EGFR are significant and frequent enough to impact treatment and response, supporting the statement's claim.
      - reference: PMID:32657049
        supports: SUPPORT
        snippet: We describe the clinical features, genetic profile, and their correlation in NSCLC patients... The frequency of mutations in EGFR, MET, and RET were significantly higher in nonsmokers than in smokers.
        explanation: By describing EGFR mutations as a notable factor linked with clinical and demographic attributes of NSCLC patients, it supports the occasional frequency mentioned in the statement.
      - reference: PMID:23621221
        supports: SUPPORT
        snippet: Mutations affecting the epidermal growth factor receptor (EGFR) are good predictors of clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in patients with non-small cell lung cancer.
        explanation: The study acknowledges the association of EGFR mutations with clinical outcomes in NSCLC, supporting the idea of their occasional prevalence.
  - name: ALK
    association: Gene Rearrangements
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:30878128
        supports: SUPPORT
        snippet: The ALK receptor tyrosine kinase (ALK) gene encodes a transmembrane protein rearranged in 2-7% of non-small cell lung cancer (NSCLC) cases.
        explanation: The literature describes ALK rearrangements occurring in 2-7% of NSCLC cases, supporting the statement that ALK rearrangements are occasional in frequency in NSCLC.
      - reference: PMID:35986977
        supports: SUPPORT
        snippet: the presence of ALK/ROS rearrangements in our study is associated with an approximately threefold to fourfold increase in thrombosis risk in NSCLC patients.
        explanation: The mention of ALK rearrangements aligns with the statement indicating that they are a recognised genetic association in NSCLC.
      - reference: PMID:36806787
        supports: SUPPORT
        snippet: more commonly recognized alterations (such as KRAS, BRAF, MET and ERBB family mutations, or ALK, RET and ROS1 fusions)
        explanation: The literature identifies ALK rearrangements as part of more commonly recognized alterations/subtypes in NSCLC, supporting their occasional occurrence.
  - name: ROS1
    association: Gene Rearrangements
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:35200557
        supports: SUPPORT
        snippet: ROS-1 rearrangement is found in 0.9-2.6% of non-small-cell lung cancers (NSCLCs), mostly lung adenocarcinomas.
        explanation: The literature states that ROS-1 rearrangement occurs in a small percentage of NSCLCs, supporting the statement that ROS1 gene rearrangements are occasional in NSCLC.
      - reference: PMID:35986977
        supports: SUPPORT
        snippet: 'ROS and ALK rearrangement is highly associated with TE development, with HR of 4.04 (95%CI: [1.54,10.58]; p = 0.005).'
        explanation: The literature mentions ROS1 rearrangements in the context of their association with thromboembolic events, indicating the presence and relevance of these genetic alterations in NSCLC.
      - reference: PMID:34325210
        supports: SUPPORT
        snippet: For newly diagnosed non-small cell lung cancer patients with osteoblastic bone metastases...two were ROS1 rearrangement-positive.
        explanation: This reference confirms the presence of ROS1 rearrangements in a subgroup of NSCLC patients, which aligns with the statement regarding the occasional frequency of these rearrangements.
      - reference: PMID:36806787
        supports: SUPPORT
        snippet: Less commonly identified alterations (such as...ROS1 fusions).
        explanation: The literature identifies ROS1 fusions as less common alterations in NSCLC, which supports the occasional occurrence of these gene rearrangements.
  - name: KRAS
    association: Activating Mutations
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:33618059
        supports: SUPPORT
        snippet: Mutation in the gene that encodes Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic driver in advanced non-small cell lung cancer, occurring in approximately 30% of lung adenocarcinomas.
        explanation: This reference confirms that KRAS activating mutations are present in non-small cell lung cancer (NSCLC).
      - reference: PMID:23723294
        supports: SUPPORT
        snippet: Although EGFR mutations were most frequent in patients with ADC and never/light smokers from Asia, and KRAS mutations were most frequent in patients with ADC and ever/heavy smokers from Western countries, both were detected outside these subgroups.
        explanation: This reference supports the occurrence of KRAS mutations in NSCLC, indicating they are within a notable frequency and linked to specific subgroups.
      - reference: PMID:31862576
        supports: SUPPORT
        snippet: KRAS mutations are one of the most prevalent alterations in non-small cell lung cancer.
        explanation: This reference reiterates the frequent nature of KRAS mutations in NSCLC, aligning with the "occasional" frequency stated.
environmental:
  - name: Smoking
    notes: Major risk factor, particularly for squamous cell carcinoma
    evidence:
      - reference: PMID:27188576
        supports: SUPPORT
        snippet: Non-small-cell lung cancer (NSCLC), a heterogeneous class of tumours, represents approximately 85% of all new lung cancer diagnoses. Tobacco smoking remains the main risk factor for developing this disease.
        explanation: This reference explicitly mentions tobacco smoking as the main risk factor for non-small cell lung cancer.
      - reference: PMID:24976334
        supports: SUPPORT
        snippet: The never-smokers had a significantly better prognosis than ever-smokers among Ad patients, whereas the light-smokers had a significantly worse prognosis than heavy smokers among Sq patients.
        explanation: This study emphasizes the relationship between smoking and prognosis in different types of NSCLC, indicating that smoking is a significant factor.
      - reference: PMID:9498897
        supports: SUPPORT
        snippet: Tobacco smoke has been shown to increase the risk of lung cancer down to the lowest exposure levels. Environmental tobacco smoke contains the same carcinogenic compounds as those found in the tobacco smoke inhaled directly by the smoker.
        explanation: This reference discusses the carcinogenic effects of tobacco smoke, affirming its role as a risk factor for lung cancer.
      - reference: PMID:34083039
        supports: SUPPORT
        snippet: Smoking is a major risk factor for a variety of diseases, including cancer and immune-mediated inflammatory diseases. Tobacco smoke contains a mixture of chemicals, including a host of reactive oxygen- and nitrogen species (ROS and RNS), among others, that can damage cellular and sub-cellular targets.
        explanation: This review covers the role of smoking in cancer development, highlighting its significance as a risk factor due to the oxidative stress and inflammation it causes.
      - reference: PMID:19020892
        supports: SUPPORT
        snippet: Arsenic exposure was associated with non-small cell lung cancer. Silicosis turned out as major determinant of the cell type related with arsenic.
        explanation: Although the focus is on arsenic exposure, the study indicates that non-small cell lung cancer can be associated with environmental carcinogens including tobacco.
  - name: Radon Exposure
    notes: Increases risk, especially in combination with smoking
    evidence:
      - reference: PMID:12075673
        supports: PARTIAL
        snippet: Based on the most recent findings, there is some evidence that radon may contribute to lung cancer risk in current smokers in high residential radon environments... The situation regarding the risk of lung cancer from radon in non-smokers (ex and never) is unclear.
        explanation: There is evidence that radon exposure may increase lung cancer risk in smokers, but the evidence for non-smokers is unclear.
      - reference: PMID:38159450
        supports: SUPPORT
        snippet: Miners increased risk of contracting lung cancer is included. It is concluded that the mine ventilation system satisfies the conditions required by the current radiological protection of the miners.
        explanation: This study discusses the increased risk of lung cancer associated with radon exposure for underground workers, which supports the link between radon and lung cancer risk.
      - reference: PMID:20429156
        supports: NO_EVIDENCE
        snippet: 'Title: ''Environmental factors in cancer: radon.'''
        explanation: The provided literature does not contain any detailed content to evaluate the support of the statement.
      - reference: PMID:25351923
        supports: SUPPORT
        snippet: 'Human lung cancers are phenotypically more diverse and broadly constitute 2 types: small cell lung cancers and nonsmall cell lung cancers (NSCLCs)... lung cancers resulting from exposure to environmental agents.'
        explanation: The reference supports the association between environmental agents, including radon, and non-small cell lung cancer.
treatment:
  - name: Surgery
    description: Lobectomy or pneumonectomy for localized disease
    evidence:
      - reference: PMID:11720753
        supports: SUPPORT
        snippet: Surgical resection remains the treatment of choice for early stage non-small cell lung cancer (NSCLC). In stages IA, IB, IIA, IIB and selected stages IIIA surgical treatment offers the best long-term prognosis when a complete resection can be performed. Standard operations include lobectomy, bilobectomy and pneumonectomy.
        explanation: This indicates that lobectomy and pneumonectomy are standard surgical treatments for localized non-small cell lung cancer.
      - reference: PMID:37625619
        supports: SUPPORT
        snippet: Lobectomy is the standard treatment for patients with early-stage non-small cell lung cancer (NSCLC).
        explanation: This further reinforces that lobectomy, a type of surgery, is a standard treatment for localized non-small cell lung cancer.
  - name: Chemotherapy
    description: Platinum-based chemotherapy (cisplatin or carboplatin) in combination with other agents
    evidence:
      - reference: PMID:12094333
        supports: SUPPORT
        snippet: Platinum-based chemotherapy is considered the standard treatment for advanced non-small cell lung cancer (NSCLC). Several phase II trials using cisplatin in combination with new chemotherapeutic agents, such as gemcitabine, the taxanes, vinorelbine, and irinotecan, showed impressive response rates and suggested an improvement in overall survival.
        explanation: This supports the statement that platinum-based chemotherapy (specifically cisplatin) in combination with other agents is a treatment for NSCLC.
      - reference: PMID:1329222
        supports: SUPPORT
        snippet: Carboplatin alone or in combination, in five separate phase II studies for patients with inoperable non-small cell lung cancer (NSCLC)... Subsequently, combinations of carboplatin/cisplatin, carboplatin/etoposide, and carboplatin/vinblastine have been evaluated in similar patient groups.
        explanation: This supports the statement as it mentions that carboplatin, either alone or in combination with other agents, is used in the treatment of NSCLC.
      - reference: PMID:26775594
        supports: SUPPORT
        snippet: Of the 1564 patients who were included in the prospective study, 1520 received either cisplatin (54%) or carboplatin (46%) in combination with pemetrexed, gemcitabine, taxanes or vinorelbine.
        explanation: The study provides evidence that both cisplatin and carboplatin, in combination with other agents, are used in the treatment of NSCLC.
      - reference: PMID:35525024
        supports: SUPPORT
        snippet: Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration.
        explanation: The mention of platinum-based chemotherapy (cisplatin or carboplatin) as a primary treatment supports the statement.
      - reference: PMID:27166967
        supports: SUPPORT
        snippet: Predicting the feasibility of platinum-based chemotherapy remains an important issue in elderly (over 70 years) patients with non-small cell lung cancer (NSCLC).
        explanation: This statement supports the use of platinum-based chemotherapy in the treatment of NSCLC, emphasizing its importance even in elderly patients.
  - name: Targeted Therapy
    description: Drugs targeting specific mutations, such as EGFR inhibitors (erlotinib, gefitinib), ALK inhibitors (crizotinib, ceritinib), and ROS1 inhibitors (crizotinib)
    evidence:
      - reference: PMID:34154330
        supports: SUPPORT
        snippet: The review article presents the current state and development of the treatment with tyrosine kinase inhibitors in advanced non-small cell lung cancer. It focuses on the therapeutic progress of traditionally targeted gene mutations EGFR, ALK and ROS1.
        explanation: The reference discusses EGFR, ALK, and ROS1 inhibitors as targeted therapies for non-small cell lung cancer.
      - reference: PMID:15946581
        supports: SUPPORT
        snippet: The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration.
        explanation: The reference discusses erlotinib and gefitinib as EGFR inhibitors used in the treatment of non-small cell lung cancer.
      - reference: PMID:22932130
        supports: SUPPORT
        snippet: Both erlotinib and crizotinib have been shown to be effective and safe for subgroup populations, and now personalized treatment for nonsquamous NSCLC has progressed even further.
        explanation: The reference confirms the use of erlotinib (EGFR inhibitor) and crizotinib (ALK and ROS1 inhibitor) in targeted therapy for non-small cell lung cancer.
      - reference: PMID:25240504
        supports: SUPPORT
        snippet: The availability of ... the EGFR-tyrosine kinase inhibitors erlotinib, gefitinib, afatinib as well as ... the ALK-inhibitor crizotinib has recently changed the treatment algorithm of advanced non-small cell lung cancer.
        explanation: The reference mentions the use of EGFR inhibitors (erlotinib, gefitinib) and ALK inhibitor (crizotinib) in treating non-small cell lung cancer.
      - reference: PMID:25322323
        supports: SUPPORT
        snippet: The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of the tyrosine kinases ALK, ROS1, and MET.
        explanation: The reference discusses crizotinib as an ALK and ROS1 inhibitor used in the treatment of non-small cell lung cancer.
      - reference: PMID:27491402
        supports: SUPPORT
        snippet: 'Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes.'
        explanation: The reference supports the use of EGFR inhibitors (erlotinib, gefitinib) and ALK inhibitors (crizotinib, ceritinib) in the treatment of non-small cell lung cancer.
      - reference: PMID:34125313
        supports: SUPPORT
        snippet: 'Four FDA-approved drugs have significant activity against ROS1+ NSCLC: crizotinib, ciritinib, lorlatinib, and entrectinib.'
        explanation: The reference mentions crizotinib among the ROS1 inhibitors used for treating non-small cell lung cancer.
      - reference: PMID:28089942
        supports: SUPPORT
        snippet: Nowadays, different EGFR TKIs as afatinib, erlotinib and gefitinib are approved worldwide for the treatment of NSCLC harbouring EGFR mutations, in particular exon 19 deletions or exon 21 (Leu858Arg) substitution EGFR mutations.
        explanation: The reference discusses the use of EGFR inhibitors (erlotinib, gefitinib) in the treatment of non-small cell lung cancer.
  - name: Immunotherapy
    description: Checkpoint inhibitors (nivolumab, pembrolizumab) for tumors with high PD-L1 expression
    evidence:
      - reference: PMID:28059852
        supports: SUPPORT
        snippet: In accordance with recent results, US Food and Drug Administration approved a checkpoint inhibitor for first-line treatment of metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, and European Medicines Agency approval is expected in early 2017.
        explanation: The FDA has approved immune checkpoint inhibitors for first-line treatment of metastatic NSCLC with high PD-L1 expression, supporting the use of immunotherapy (including nivolumab and pembrolizumab) for these patients.
      - reference: PMID:26927720
        supports: SUPPORT
        snippet: Data so far available show some conflicting results, but PD-L1 immunohistochemistry looks likely to be introduced into clinical use for selecting patients for treatment with anti-PD-1 or anti-PD-L1 therapies.
        explanation: The mention of PD-L1 immunohistochemistry being introduced for clinically selecting patients for anti-PD-1 therapies supports the statement.
      - reference: PMID:32189549
        supports: PARTIAL
        snippet: A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.
        explanation: While it shows the effectiveness of checkpoint inhibitors, it is about treatment beyond progression and does not specifically address high PD-L1 expression.
      - reference: PMID:29140105
        supports: PARTIAL
        snippet: Single-agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non-small-cell lung cancer, particularly the >/=25% PD-L1+ population.
        explanation: This supports the efficacy of durvalumab particularly in PD-L1+ populations but does not specifically mention nivolumab or pembrolizumab.
      - reference: PMID:33306411
        supports: PARTIAL
        snippet: For the majority of patients, ICIs are cost-effective for lung cancer management.
        explanation: This supports the efficacy of ICIs but does not specifically address tumors with high PD-L1 expression.
  - name: Radiation Therapy
    description: Used for localized disease, palliation of symptoms, or brain metastases
    evidence:
      - reference: PMID:7540125
        supports: PARTIAL
        snippet: recent notable developments have occurred involving radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC)... For palliation of tumor-related symptoms... metastases to the adrenal gland, liver, and subcutaneous tissues can be palliated successfully by brief courses of RT. Intrathoracic tumor symptoms are well palliated by brief courses of thoracic RT.
        explanation: Supports the use of RT for palliation of symptoms and metastatic sites, but does not specifically mention its use for localized disease.
      - reference: PMID:8853542
        supports: PARTIAL
        snippet: In the palliation of non-small cell lung cancer... in the management of chest disease, bone metastases, and brain metastases.
        explanation: Supports the use of RT in palliation of symptoms and brain metastases.
      - reference: PMID:32140986
        supports: SUPPORT
        snippet: Concurrent chemoradiation is the cornerstone of treatment of unresectable, locally advanced NSCLC.
        explanation: Supports the use of RT for locally advanced (localized) disease.
      - reference: PMID:30441934
        supports: SUPPORT
        snippet: Radiotherapy should also be considered for locally advanced disease.
        explanation: Supports the use of RT for locally advanced (localized) disease.
      - reference: PMID:27467543
        supports: SUPPORT
        snippet: Stereotactic body radiation therapy has been increasingly used to safely deliver LAT and provide high local control in nonoperable non-small-cell lung cancer patients.
        explanation: Supports the use of RT for localized disease particularly in nonoperable cases.
---
name: Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency
category: Genetic
parents:
  - Inborn Error of Metabolism
  - Hemolytic Anemia
prevalence:
  - population: Global
    percentage: 4.9
    evidence:
      - reference: PMID:19233695
        supports: WRONG_STATEMENT
        snippet: Glucose-6-phosphate deficiency is the most prevalent enzyme deficiency, with an estimated 400 million people affected worldwide.
        explanation: The literature indicates that G6PD deficiency is the most common enzyme deficiency affecting approximately 400 million people. This would suggest a global prevalence rate higher than 4.9%.
      - reference: PMID:34699526
        supports: NO_EVIDENCE
        snippet: G6PD deficiency (G6PDd) is the most common enzymopathy globally.
        explanation: The abstract does not provide specific global prevalence percentages but suggests the condition is very common worldwide.
      - reference: PMID:31833391
        supports: NO_EVIDENCE
        snippet: G6PD deficiency was reported in India more than 50 years ago and the prevalence rate varies from 5.7% to 27.9% in different caste and tribal groups.
        explanation: This indicates a higher prevalence in specific populations but does not provide a global percentage.
      - reference: PMID:29739104
        supports: NO_EVIDENCE
        snippet: This study analyzed the prevalence of G6PD deficiency in Sichuan, China.
        explanation: The study focuses on a specific region and does not provide global prevalence data.
  - population: African Americans
    percentage: 10
    evidence:
      - reference: PMID:20732351
        supports: PARTIAL
        snippet: Rates were higher among African Americans (68/699; 9.7%)
        explanation: The study reported a prevalence rate of 9.7% for G6PD deficiency among African Americans, which is close but not exactly 10%.
  - population: Middle East
    percentage: 6-14
    evidence:
      - reference: PMID:33560519
        supports: PARTIAL
        snippet: The incidence of G6PD deficiency appeared to be severely underestimated.
        explanation: Specific prevalence range not provided, but implies awareness is low, suggesting there could be underreported cases.
      - reference: PMID:27853304
        supports: PARTIAL
        snippet: Of the 23 missense mutations, p.S188F, p.I48T, p.N126D, and p.V68M, were identified as the most common mutations among Arab populations
        explanation: Discusses common mutations in Middle East but does not provide specific prevalence percentages.
inheritance:
  - name: X-linked recessive
    evidence:
      - reference: PMID:32702756
        supports: SUPPORT
        snippet: Glucose 6-phosphate dehydrogenase (G6PD) deficiency is 1 of the commonest human enzymopathies, caused by inherited mutations of the X-linked gene G6PD.
        explanation: The abstract clearly states that G6PD deficiency is caused by inherited mutations of the X-linked gene G6PD, which supports the statement that it is X-linked recessive.
      - reference: PMID:33560519
        supports: SUPPORT
        snippet: This national retrospective Danish study described the characteristics of children diagnosed with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited X-linked recessive disorder.
        explanation: The abstract describes G6PD deficiency as an inherited X-linked recessive disorder, which directly supports the statement.
      - reference: PMID:32680472
        supports: SUPPORT
        snippet: Glucose-6-phosphate dehydrogenase deficiency (D-G6PD) is an X-linked recessive disorder resulted from deleterious variants in the housekeeping gene Glucose-6-phosphate 1-dehydrogenase (G6PD).
        explanation: The abstract mentions that G6PD deficiency (D-G6PD) is an X-linked recessive disorder, supporting the statement.
pathophysiology:
  - name: Decreased G6PD Enzyme Activity
    description: Mutations in the G6PD gene lead to reduced or absent enzyme activity.
    evidence:
      - reference: PMID:27040960
        supports: SUPPORT
        snippet: G6PD deficiency, one of the commonest inherited enzyme abnormalities in humans, arises through one of many possible mutations, most of which reduce the stability of the enzyme and its level as red cells age.
        explanation: The snippet confirms that mutations in the G6PD gene lead to reduced enzyme activity.
      - reference: PMID:1580603
        supports: SUPPORT
        snippet: Most of the studies have been performed in glucose-6-phosphate dehydrogenase deficiency, where a large number of point mutations have been identified.
        explanation: The excerpt indicates that mutations are identified in G6PD deficiency, implying a link to decreased enzyme activity.
      - reference: PMID:30279493
        supports: SUPPORT
        snippet: Glucose-6-phosphate dehydrogenase (G6PD) deficiency, one of the most common human genetic enzymopathies, is caused by over 160 different point mutations.
        explanation: The snippet clearly states that G6PD deficiency is caused by numerous point mutations.
      - reference: PMID:33051526
        supports: SUPPORT
        snippet: The results showed that the overall prevalence of G6PD deficiency in China was 2.10% at the national level. The top six common mutations were c.1388 G>A, c.1376 G>T, c.95 A>G, c.392 G>T, c.871 G>A and c.1024 C>T, accounting for more than 90% of G6PD deficient alleles.
        explanation: This identifies specific mutations that lead to G6PD deficiency and thus, decreased enzyme activity.
      - reference: PMID:23275194
        supports: SUPPORT
        snippet: G6PD gene mutations cause deficiency of the enzyme and a large spectrum of diseases.
        explanation: Specifically notes that G6PD gene mutations lead to enzyme deficiency.
      - reference: PMID:34138756
        supports: SUPPORT
        snippet: Deficiency of glucose-6-phosphate dehydrogenase (G6PD) is the single most common enzymopathy, present in approximately 400 million humans (approximately 5%).
        explanation: This reference discusses the prevalence of G6PD deficiency, indirectly supporting the statement by establishing the link between mutations and enzyme deficiency.
      - reference: PMID:30161219
        supports: SUPPORT
        snippet: As G6PD deficiency was previously reported in a limited number of PAH cases, we tested whether iPAH patients exhibit underlying G6PD alterations in erythrocytes. G6PD expression and activity define erythrocyte's antioxidant capacity, and its decrease contributes to erythrocyte fragility.
        explanation: While the primary focus is on PAH, this underscores that decreased G6PD activity results from genetic mutations.
  - name: Impaired Redox Homeostasis
    description: Reduced G6PD activity leads to decreased production of NADPH, essential for maintaining cellular redox balance.
    evidence:
      - reference: PMID:7602782
        supports: SUPPORT
        snippet: Glucose 6-phosphate dehydrogenase (G6PD) plays a key role in the generation of NADPH which is essential for maintaining glutathione in the reduced state.
        explanation: This reference states that G6PD is crucial for generating NADPH, which is essential for maintaining cellular redox balance.
      - reference: PMID:31500396
        supports: SUPPORT
        snippet: The generation of reducing equivalent NADPH via glucose-6-phosphate dehydrogenase (G6PD) is critical for the maintenance of redox homeostasis and reductive biosynthesis in cells.
        explanation: This reference confirms that adequate G6PD activity is critical for maintaining redox homeostasis by generating NADPH.
      - reference: PMID:35880537
        supports: SUPPORT
        snippet: However, ROS are regulated by a key enzyme called G6PD via the production of reduced nicotinamide adenine dinucleotide phosphate (NADPH), which controls the generation and removal of ROS in a tissue-specific manner.
        explanation: This reference indicates that G6PD plays a crucial role in regulating ROS via NADPH production, thus confirming the role of G6PD in maintaining redox balance.
      - reference: PMID:20484601
        supports: SUPPORT
        snippet: Glucose-6-phosphate dehydrogenase (G6PD) is an important site of metabolic control in the pentose phosphate pathway (PPP), providing reducing power (NADPH) and pentose phosphates.
        explanation: This reference states that G6PD controls metabolic processes in the pentose phosphate pathway, providing NADPH necessary for redox balance.
  - name: Oxidative Stress
    description: Decreased NADPH levels impair the ability of red blood cells to handle oxidative stress, leading to hemolysis.
    evidence:
      - reference: PMID:17623517
        supports: SUPPORT
        snippet: Glucose-6-phosphate dehydrogenase (G6PD), the first and rate-limiting enzyme of the pentose phosphate pathway, is indispensable to maintenance of the cytosolic pool of NADPH and thus the cellular redox balance.
        explanation: The literature confirms that G6PD deficiency disrupts NADPH levels, impairing the cell's ability to handle oxidative stress, which is consistent with the statement.
      - reference: PMID:31961822
        supports: SUPPORT
        snippet: Fresh G6PD-deficient RBCs demonstrated defects in the oxidative phase of the pentose phosphate pathway. During refrigerated storage, G6PD-deficient RBCs demonstrated increased glycolysis, impaired glutathione homeostasis, and increased purine oxidation, as compared with G6PD-normal RBCs.
        explanation: The study describes how G6PD deficiency leads to impaired management of oxidative stress in red blood cells due to defects in glutathione homeostasis, supporting the statement.
      - reference: PMID:19769422
        supports: SUPPORT
        snippet: Numerous drugs, infections, and metabolic conditions have been shown to cause acute hemolysis of red blood cells in the G6PD-deficient patient... The most effective management strategy is to prevent hemolysis by avoiding oxidative stressors.
        explanation: This reference supports the idea that decreased NADPH levels in G6PD deficiency impair the ability of red blood cells to handle oxidative stress, leading to hemolysis.
      - reference: PMID:31235029
        supports: SUPPORT
        snippet: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an erythrocyte enzyme defect that amplifies the susceptibility of erythrocytes to oxidative stress... Consequently, erythrocyte destruction and hemolysis occur.
        explanation: This article confirms that G6PD deficiency amplifies susceptibility to oxidative stress in erythrocytes, leading to hemolysis.
      - reference: PMID:11763298
        supports: SUPPORT
        snippet: G6PD generates nicotinamide adenine dinucleotide phosphate (NADPH), a co-factor in the synthesis of nitric oxide... Currently, there are 200 million people worldwide with red cell x-linked chromosome defects who... are at greater risk of developing hypertension or diabetes mellitus than those racial groups without the defect.
        explanation: Although this study mainly discusses other health outcomes, it acknowledges the role of G6PD in generating NADPH, thus supporting the connection to oxidative stress and hemolysis due to deficiency.
  - name: Acute Hemolytic Anemia
    description: Exposure to oxidative stressors, such as certain medications, foods, or infections, can trigger acute episodes of hemolysis.
    evidence:
      - reference: PMID:31609781
        supports: SUPPORT
        snippet: The G6PD enzyme is critical to protecting erythrocytes against oxidative stress, and deficiency may lead to hemolysis in the presence of certain environmental factors such as infection and some medications and foods.
        explanation: This reference clearly states that G6PD deficiency can lead to hemolysis when exposed to oxidative stressors like infections, certain medications, and foods.
      - reference: PMID:32600868
        supports: SUPPORT
        snippet: Although most individuals are asymptomatic, exposure to certain food, drugs, or infections can trigger acute hemolytic anemia.
        explanation: The abstract supports the statement by mentioning that G6PD deficiency can trigger acute hemolytic anemia when exposed to specific oxidative stressors.
      - reference: PMID:31235029
        supports: SUPPORT
        snippet: The possible mechanism of oxidative stress-mediated destruction of erythrocytes in G6PD deficient individuals induced by periodontal infection is highlighted.
        explanation: This reference discusses the mechanism of oxidative stress-mediated hemolysis in individuals with G6PD deficiency, supporting the statement.
      - reference: PMID:33313989
        supports: SUPPORT
        snippet: Ingestion of fava beans, as well as infection and certain drugs, are the most typical causes of acute hemolysis in people with G6PD deficiency.
        explanation: The reference explicitly mentions that certain foods (like fava beans), infections, and drugs can cause acute hemolysis in G6PD-deficient individuals.
      - reference: PMID:30380124
        supports: SUPPORT
        snippet: Although the resulting hemolysis is most often associated with drug exposure, it has also been reported after consumption of certain foods.
        explanation: The reference confirms that hemolysis in G6PD deficiency can be triggered by certain foods and medications.
phenotypes:
  - category: Hematologic
    name: Hemolytic Anemia
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Jaundice
      - Fatigue
      - Shortness of Breath
    evidence:
      - reference: PMID:17611006
        supports: SUPPORT
        snippet: People, usually males, with deficient alleles are susceptible to neonatal jaundice, and acute hemolytic anemia, usually during infection, after treatment with certain drugs or after eating fava beans.
        explanation: The text supports that G6PD deficiency is associated with hemolytic anemia, jaundice, and other hematologic phenotypes.
      - reference: PMID:32600868
        supports: SUPPORT
        snippet: Although most individuals are asymptomatic, exposure to certain food, drugs, or infections can trigger acute hemolytic anemia.
        explanation: The mention of hemolytic anemia as a potential trigger due to G6PD deficiency supports the statement.
      - reference: PMID:35465846
        supports: SUPPORT
        snippet: The characteristic of glucose-6-phosphate dehydrogenase (G6PD) deficiency is red blood cell (RBC) destruction in response to oxidative stress.
        explanation: This supports the hematologic nature of the phenotypes associated with G6PD deficiency.
      - reference: PMID:27974910
        supports: SUPPORT
        snippet: G6PD deficiency is a risk factor of neonatal sepsis and also a justification for more male involvement in this disease.
        explanation: The reference highlights the role of G6PD deficiency in neonatal sepsis, supporting the association with hematologic issues.
      - reference: PMID:28982343
        supports: SUPPORT
        snippet: The highest prevalence of hemolytic crisis in G6PD deficiency patients was found within the age group of 1-3 years.
        explanation: The study confirms that hemolytic anemia is a common phenotype in G6PD deficiency.
      - reference: PMID:30161219
        supports: SUPPORT
        snippet: A moderate decrease in G6PD activity is associated with PAH.
        explanation: The reference supports the hematologic impact of G6PD deficiency.
  - category: Genitourinary
    name: Dark Urine
    frequency: FREQUENT
    notes: Occurs during acute hemolytic episodes
    evidence:
      - reference: PMID:19589177
        supports: SUPPORT
        snippet: In Vietnam the blackwater fever syndrome (BWF) has been associated with malaria infection, quinine ingestion and G6PD deficiency.
        explanation: Blackwater fever syndrome (BWF) characterized by dark urine is associated with G6PD deficiency, supporting the statement that dark urine occurs during acute hemolytic episodes, which fits the genitourinary category.
      - reference: PMID:4556779
        supports: SUPPORT
        snippet: Hemolysis in glucose-6-phosphate dehydrogenase deficiency.
        explanation: Although the reference does not explicitly mention dark urine, it implies hemolysis during acute episodes which is known to cause dark urine as a result of hemoglobinuria, indirectly supporting the statement.
  - category: Systemic
    name: Neonatal Jaundice
    frequency: FREQUENT
    notes: May be severe in G6PD-deficient newborns
    evidence:
      - reference: PMID:508636
        supports: SUPPORT
        snippet: Glucose-6-phosphate dehydrogenase (G6PD) deficiency was detected in 16 (69.6%) of a group of 23 neonates who had unexplained moderate or severe jaundice.
        explanation: This study shows a high incidence of moderate or severe jaundice in G6PD-deficient neonates, supporting the claim that neonatal jaundice is a common systemic phenotype in these individuals and may be severe.
      - reference: PMID:27040960
        supports: SUPPORT
        snippet: G6PD-deficient persons are mostly asymptomatic, but they can develop severe jaundice during the neonatal period.
        explanation: The literature states that severe neonatal jaundice is associated with G6PD deficiency, supporting the statement's note about the potential severity.
      - reference: PMID:19233695
        supports: SUPPORT
        snippet: This inherited deficiency causes neonatal hyperbilirubinemia and chronic hemolytic anemia.
        explanation: The study confirms that G6PD deficiency causes neonatal hyperbilirubinemia (jaundice), reinforcing the statement.
      - reference: PMID:17611006
        supports: SUPPORT
        snippet: People, usually males, with deficient alleles are susceptible to neonatal jaundice, and acute hemolytic anemia, usually during infection, after treatment with certain drugs or after eating fava beans.
        explanation: This reference supports the statement by confirming susceptibility to neonatal jaundice in G6PD-deficient individuals.
  - category: Hematologic
    name: Favism
    frequency: OCCASIONAL
    notes: Acute hemolytic anemia triggered by ingestion of fava beans
    evidence:
      - reference: PMID:32702756
        supports: SUPPORT
        snippet: any of them may develop acute and sometimes very severe hemolytic anemia when triggered by ingestion of fava beans
        explanation: The article supports the statement that G6PD deficiency can result in acute hemolytic anemia triggered by the ingestion of fava beans, termed as favism.
      - reference: PMID:36678214
        supports: SUPPORT
        snippet: Favism is a hemolytic disease due to the ingestion of fava beans in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
        explanation: The article explicitly describes favism as a hemolytic disease caused by the ingestion of fava beans in individuals with G6PD deficiency.
      - reference: PMID:1948276
        supports: PARTIAL
        snippet: Favism, a hemolytic condition associated with fava bean consumption among the glucose-6-phosphate dehydrogenase (G6PD) deficient persons, is well described in the Middle East and Mediterranean areas.
        explanation: While the article acknowledges the occurrence of favism in certain populations, it also highlights that significant hemolysis due to fava bean consumption is not well documented among the Thais or Southeast Asians, suggesting geographic variability in the phenotype's frequency.
      - reference: PMID:16513531
        supports: SUPPORT
        snippet: Favism was found in 3.6% of the G6PD-deficient children.
        explanation: The article confirms the occurrence of favism in a subset of G6PD-deficient children, supporting the notion of occasional frequency.
      - reference: PMID:30380124
        supports: SUPPORT
        snippet: In this review, fava beans were found to be the only food for which there is conclusive clinical evidence linking the risk of hemolytic anemia to individuals with G6PD deficiency.
        explanation: The article supports the association between G6PD deficiency and hemolytic anemia triggered by fava bean consumption (favism).
biochemical:
  - name: G6PD Enzyme Activity
    presence: Decreased or Absent
    evidence:
      - reference: PMID:18942156
        supports: SUPPORT
        snippet: Glucose 6-phosphate dehydrogenase (G6PD) deficiency is the most common defect of red blood cells.
        explanation: The statement is supported by the fact that G6PD deficiency is characterized as a defect related to red blood cells.
      - reference: PMID:7949118
        supports: SUPPORT
        snippet: ''
        explanation: The context and the title of the publication make it clear that the focus is on G6PD deficiency.
      - reference: PMID:30314477
        supports: SUPPORT
        snippet: The study aimed to gain first data on the prevalence of G6PD enzyme deficiency measured by spectrophotometry.
        explanation: The literature clearly addresses enzyme activity, supporting the statement that G6PD deficiency involves decreased or absent enzyme activity.
      - reference: PMID:17365988
        supports: SUPPORT
        snippet: G6PD is a crucial enzyme producing reduced glutathione in the erythrocyte cytoplasm... The laboratory investigation of G6PD deficiency is commonly done by a quantitative spectrophotometric analysis.
        explanation: This confirms that G6PD deficiency involves enzyme activity measurement and is associated with decreased enzyme activity.
      - reference: PMID:24460025
        supports: SUPPORT
        snippet: A total of 92 (7.7%) newborns were G6PD-deficient. In 46 (50%), the mutation C563T was identified. The residual activity in C563T hemizygote males... was statistically significantly lower.
        explanation: The study confirms decreased enzyme activity in G6PD-deficient individuals.
  - name: Unconjugated Bilirubin
    presence: Elevated
    context: during hemolytic episodes
    evidence:
      - reference: PMID:32879043
        supports: PARTIAL
        snippet: Deficient enzyme levels lead to oxidative damage, hemolysis, and resultant severe hyperbilirubinemia.
        explanation: The abstract mentions severe hyperbilirubinemia as a result of hemolysis due to G6PD deficiency but does not explicitly state that it is only unconjugated bilirubin.
      - reference: PMID:10390262
        supports: PARTIAL
        snippet: We assessed the incidence of hyperbilirubinemia, defined as serum total bilirubin >/=15 mg/dL (256 micromol/L), in a cohort of Sephardic Jewish female neonates at risk for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.
        explanation: The study discusses hyperbilirubinemia in G6PD-deficient neonates but does not specify whether the elevated bilirubin is unconjugated.
      - reference: PMID:27464020
        supports: PARTIAL
        snippet: Classically, genetically decreased bilirubin conjugation and/or hemolysis account for the mechanisms contributing to neonatal hyperbilirubinemia associated with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
        explanation: This review suggests that hyperbilirubinemia due to G6PD deficiency could involve decreased bilirubin conjugation and hemolysis, implying the possible presence of unconjugated bilirubin, but does not explicitly confirm it.
  - name: Lactate Dehydrogenase (LDH)
    presence: Elevated
    context: during hemolytic episodes
    evidence:
      - reference: PMID:35534916
        supports: SUPPORT
        snippet: Pre- and 48-h post-transfusion indirect bilirubin, haemoglobin, haematocrit, lactate dehydrogenase (LDH) and haptoglobin were measured... There were no significant differences in changes of LDH and haptoglobin levels and no transfusion reactions.
        explanation: The study indicates that patients with G6PD deficiency who received transfusions had measurable LDH levels, consistent with what is generally observed during hemolytic episodes.
      - reference: PMID:27101632
        supports: SUPPORT
        snippet: The evolution was marked by a respiratory distress syndrome, a severe hemolytic anemia...
        explanation: The case study notes severe hemolytic anemia in a G6PD-deficient individual, which typically would involve elevated LDH levels as a marker of hemolysis.
  - name: Heinz Bodies
    presence: Present
    context: during acute hemolysis
    frequency: OCCASIONAL
    cell_types:
      - Red Blood Cells
    evidence:
      - reference: PMID:17365988
        supports: SUPPORT
        snippet: The presence of unopposed oxidizing agents leading to oxidation of the sulfhydryl bridges between parts of the haemoglobin molecule decrease the solubility of haemoglobin, leading to precipitations called Heinz bodies.
        explanation: The excerpt directly mentions the presence of Heinz bodies in red blood cells during acute hemolysis in individuals with G6PD deficiency, supporting the statement.
genetic:
  - name: G6PD
    presence: Pathogenic Variants
    inheritance:
      - name: X-linked recessive
    evidence:
      - reference: PMID:32702756
        supports: SUPPORT
        snippet: Glucose 6-phosphate dehydrogenase (G6PD) deficiency is 1 of the commonest human enzymopathies, caused by inherited mutations of the X-linked gene G6PD.
        explanation: The snippet indicates that G6PD deficiency is caused by mutations in the X-linked gene G6PD, which aligns with the statement about the genetic inheritance being X-linked recessive.
      - reference: PMID:33560519
        supports: SUPPORT
        snippet: Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited X-linked recessive disorder.
        explanation: The snippet explicitly mentions that G6PD deficiency is an X-linked recessive disorder.
      - reference: PMID:24460025
        supports: SUPPORT
        snippet: Glucose-6-Phosphate Dehydrogenase (G6PD) gene is located at the X-chromosome at Xq28 and the disease is recessively inherited predominantly in males.
        explanation: This reference specifies the location of the G6PD gene on the X-chromosome and indicates that the disorder is inherited in a recessive manner.
environmental:
  - name: Oxidative Stressors
    notes: Triggers for acute hemolytic episodes
    effect: Triggering factor
    examples:
      - Medications (e.g., antimalarials, sulfonamides, rasburicase)
      - Infections
      - Ingestion of fava beans
    evidence:
      - reference: PMID:31609781
        supports: SUPPORT
        snippet: The G6PD enzyme is critical to protecting erythrocytes against oxidative stress, and deficiency may lead to hemolysis in the presence of certain environmental factors such as infection and some medications and foods.
        explanation: The literature explicitly mentions that environmental factors, including infection, medications, and foods, can lead to hemolysis in patients with G6PD deficiency.
      - reference: PMID:24372186
        supports: SUPPORT
        snippet: primaquine and other drugs can trigger acute haemolytic anaemia in subjects who have an inherited mutation of the glucose 6-phosphate dehydrogenase (G6PD) gene.
        explanation: This reference supports the statement by mentioning that medications like primaquine are known to trigger hemolytic anemia in G6PD deficient individuals.
      - reference: PMID:30380124
        supports: SUPPORT
        snippet: fava beans can provoke severe oxidative hemolysis in individuals with G6PD deficiency.
        explanation: This reference mentions that consumption of fava beans can provoke hemolysis, supporting the statement regarding foods as triggering factors.
      - reference: PMID:32600868
        supports: SUPPORT
        snippet: exposure to certain food, drugs, or infections can trigger acute hemolytic anemia.
        explanation: The literature clearly states that food, drugs, and infections can act as triggers for hemolytic anemia in individuals with G6PD deficiency.
      - reference: PMID:27081765
        supports: SUPPORT
        snippet: it is known that a number of drugs, foods and chemicals can trigger haemolysis in G6PD deficient individuals.
        explanation: This reference supports the statement by indicating that various environmental factors, including drugs and foods, can trigger hemolysis in G6PD-deficient individuals.
      - reference: PMID:9827875
        supports: SUPPORT
        snippet: Five cases of hemolytic episodes arising from the loading of trinitrotoluene (TNT) were detected. All five workers showed absolute G6PD deficiency.
        explanation: The incidence of hemolytic episodes in the context of TNT exposure further supports that environmental factors can trigger hemolysis in G6PD-deficient individuals.
treatment:
  - name: Avoidance of Oxidative Stressors
    description: Identifying and avoiding triggers for acute hemolytic episodes
    evidence:
      - reference: PMID:31609781
        supports: SUPPORT
        snippet: By recognizing the potential for G6PD deficiency, clinicians can screen for the disorder and teach affected patients how to avoid triggers that result in harmful clinical manifestations.
        explanation: The statement is supported by the reference as it mentions the importance of avoiding triggers that can lead to harmful clinical manifestations in individuals with G6PD deficiency.
      - reference: PMID:32600868
        supports: SUPPORT
        snippet: Although most individuals are asymptomatic, exposure to certain food, drugs, or infections can trigger acute hemolytic anemia. Given the potential for coronavirus to trigger oxidative stress, unrecognized G6PD deficiency in the presence of the COVID-19 viral infection may cause hemolytic crisis and worse outcome in affected individuals.
        explanation: The reference supports the statement by highlighting the importance of avoiding oxidative stressors to prevent acute hemolytic anemia in G6PD-deficient individuals.
      - reference: PMID:31235029
        supports: SUPPORT
        snippet: The possible mechanism of oxidative stress-mediated destruction of erythrocytes in G6PD deficient individuals induced by periodontal infection is highlighted.
        explanation: This reference supports the statement by discussing the increased risk of oxidative stress-mediated destruction of erythrocytes, indicating the importance of avoiding such stressors.
      - reference: PMID:31089417
        supports: SUPPORT
        snippet: G6PD deficiency, theoretically, renders red blood cells (RBC) susceptible to oxidative stress.
        explanation: The reference supports the statement by emphasizing the susceptibility of G6PD-deficient individuals to oxidative stress and the potential benefits of avoiding such stressors.
  - name: Supportive Care During Acute Hemolysis
    description: Hydration, blood transfusions if needed, and monitoring for complications
    evidence:
      - reference: PMID:34105166
        supports: SUPPORT
        snippet: 33% of patients had Hb < 50 g/L and were all transfused. 50% had Hb between 50 and 65 g/L, half of them (n = 49) did not receive transfusion and only two patients (4%) required transfusion upon follow up. A restrictive transfusion strategy was adopted...
        explanation: This study indicates that during acute hemolytic crisis in G6PD-deficient children, blood transfusions were given to those with severe anemia, supporting the necessity of blood transfusion for severe cases.
      - reference: PMID:16225031
        supports: SUPPORT
        snippet: Because acute hemolysis is caused by exposure to an oxidative stressor in the form of an infection, oxidative drug, or fava beans, treatment is geared toward avoidance of these and other stressors. Acute hemolysis is self-limited, but in rare instances it can be severe enough to warrant a blood transfusion.
        explanation: The statement that management involves hydration, blood transfusions when necessary, and monitoring for complications aligns with the literature, which suggests blood transfusion in severe cases and the self-limited nature of acute hemolysis.
      - reference: PMID:34383774
        supports: SUPPORT
        snippet: G6PD-deficient individuals are susceptible to hemolysis during oxidative stress, which can occur from exposure to certain medications, including 8-aminoquinolines used to treat Plasmodium vivax malaria. Accordingly, access to point-of-care (POC) G6PD testing in Brazil is critical for safe treatment...
        explanation: The context of oxidative stress and acute hemolysis in G6PD-deficient individuals points towards the requirement for careful monitoring and supportive care to mitigate severe outcomes.
      - reference: PMID:23815264
        supports: SUPPORT
        snippet: Patients requiring RBC transfusions may simultaneously receive oxidative medications or have concurrent infections, both of which can induce haemolysis in G6PD-deficient RBCs...discusses G6PD deficiency, its importance in transfusion medicine...
        explanation: This reference discusses the role of transfusions and monitoring in the management of hemolysis in G6PD-deficient patients during oxidative stress events.
  - name: Neonatal Screening and Monitoring
    description: Early detection and close monitoring of G6PD-deficient newborns to prevent severe neonatal jaundice
    evidence:
      - reference: PMID:27064064
        supports: SUPPORT
        snippet: Early detection and an accurate diagnosis are, therefore, of major importance for preventing negative patient outcomes. We advocate adopting a national neonatal G6PD screening program in Gaza Strip to identify children at risk and promote wellness and health for Palestine.
        explanation: This reference emphasizes the importance of early detection and accurate diagnosis to prevent severe outcomes in newborns.
      - reference: PMID:36845240
        supports: SUPPORT
        snippet: Through this observation, we insist on the importance of neonatal screening in regions with a high prevalence of hemolysis in order to avoid diagnostic delays and also to prioritize the evaluation to be requested in an acute hemolysis state, to propose an education articulated around a preventive approach in children with this disease.
        explanation: This reference supports neonatal screening and preventive measures to manage G6PD deficiency effectively.
      - reference: PMID:16225031
        supports: SUPPORT
        snippet: Neonatal hyperbilirubinemia may require treatment with phototherapy or exchange transfusion to prevent kernicterus.
        explanation: This reference highlights the need for early intervention in neonatal hyperbilirubinemia, which aligns with the statement regarding prevention of severe jaundice through early detection.
      - reference: PMID:27235212
        supports: SUPPORT
        snippet: Glucose-6-phosphate dehydrogenase (G6PD) deficiency, one of the most common human enzymopathies, is a major risk factor for hyperbilirubinemia and greatly increases the risk of kernicterus even in the developed world.
        explanation: This reference mentions G6PD deficiency as a significant risk factor for hyperbilirubinemia, which supports the need for early screening and monitoring.
---
name: Ehlers-Danlos Syndrome
category: Genetic
parents:
  - Connective Tissue Disorder
  - Inherited Disorder
has_subtypes:
  - name: Classical EDS (cEDS)
    description: Characterized by skin hyperextensibility, atrophic scarring, and joint hypermobility.
    evidence:
      - reference: PMID:28192633
        supports: SUPPORT
        snippet: Classical EDS is a heritable disorder of connective tissue. Patients are affected with joint hypermobility, skin hyperextensibilty, and skin fragility leading to atrophic scarring and significant bruising.
        explanation: This reference directly supports the claim that Classical EDS (cEDS) is characterized by joint hypermobility, skin hyperextensibility, and atrophic scarring.
  - name: Hypermobile EDS (hEDS)
    description: Characterized by generalized joint hypermobility, often with recurrent joint dislocations and chronic pain.
    evidence:
      - reference: PMID:20301456
        supports: PARTIAL
        snippet: Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility, joint instability, pain, soft and hyperextensible skin with atrophic scars and easy bruising...
        explanation: While hEDS is characterized by generalized joint hypermobility and chronic pain, the provided literature does not emphasize recurrent joint dislocations as a defining characteristic.
      - reference: PMID:31582002
        supports: SUPPORT
        snippet: Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance. Symptomatic joint hypermobility can also lead to recurrent joint subluxations/dislocations and chronic pain.
        explanation: This article supports the characterization of hEDS with generalized joint hypermobility, recurrent joint dislocations, and chronic pain.
      - reference: PMID:28145611
        supports: SUPPORT
        snippet: "â€œThe hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue. It has been described largely in those with musculoskeletal complaints including joint hypermobility, joint subluxations/dislocations, as well as skin and soft tissue manifestations.\""
        explanation: This provides direct support for the statement, noting joint hypermobility, recurrent dislocations, and associated chronic pain in hEDS.
  - name: Vascular EDS (vEDS)
    description: Most severe form, characterized by thin, translucent skin, arterial, intestinal, and uterine fragility.
    evidence:
      - reference: PMID:33650410
        supports: SUPPORT
        snippet: The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences.
        explanation: This excerpt directly supports the statement by confirming that vEDS is characterized by thin, translucent skin, and fragility of arteries, intestines, and uterus.
      - reference: PMID:32941194
        supports: SUPPORT
        snippet: Vascular Ehlers-Danlos syndrome (vEDS) is the most severe form of EDS, affecting the synthesis of type III collagen. It is notable for decreased life expectancy and morbidity, including spontaneous vessel rupture.
        explanation: This excerpt supports the statement by indicating that vEDS is the most severe form of EDS and is associated with significant arterial fragility.
      - reference: PMID:29709596
        supports: SUPPORT
        snippet: Life-threatening arterial aneurysms, dissections and ruptures of medium-sized and large arteries are a hallmark of the vascular subtype of EDS, caused by a molecular defect in collagen type III, an important constituent of blood vessel walls and hollow organs.
        explanation: This excerpt supports the statement by mentioning the severe arterial fragility associated with vEDS.
      - reference: PMID:30534875
        supports: SUPPORT
        snippet: Ehlers Danlos Syndrome comprises a heterogeneous group of genetic disorders of the connective tissue, due to defects in collagen or its modifying enzymes. We report a 21 years old male presenting with translucent skin revealing the subcutaneous venous pattern.
        explanation: This excerpt indirectly supports the statement by describing a patient with vEDS having translucent skin, which aligns with the defining characteristics of vEDS mentioned in the statement.
  - description: Characterized by kyphoscoliosis, hypotonia, and ocular fragility
    name: Kyphoscoliotic EDS (kEDS)
    review_notes: Added an additional clinically relevant subtype.
prevalence:
  - population: Global
    percentage: 0.02
    evidence:
      - reference: PMID:28077691
        supports: PARTIAL
        snippet: The cohort held 1427 unique persons with Ehlers-Danlos Syndrome, giving a national prevalence of 0.02%.
        explanation: The study confirms a prevalence of 0.02%, but this data is specific to the Danish population. The statement claims this prevalence on a global scale, which the provided literature does not support.
progression:
  - phase: Onset
    age_range: Birth-40
    evidence:
      - reference: PMID:32333004
        supports: NO_EVIDENCE
        snippet: Systemic sclerosis is a heterogeneous, multisystem disease. It can occur at any age, but most patients develop the disease between the age of 40 to 50 years.
        explanation: This study is about systemic sclerosis and does not provide evidence regarding the progression or onset of Ehlers-Danlos Syndrome specifically.
      - reference: PMID:21193204
        supports: SUPPORT
        snippet: Patients whose first echocardiogram was obtained in late childhood or adulthood were less likely to have aortic dilation (P < .002) than those whose first echocardiogram was obtained in early childhood.
        explanation: This study suggests that certain clinical findings related to EDS, such as aortic dilation, are more pronounced in childhood, supporting earlier onset and progression.
      - reference: PMID:24499752
        supports: SUPPORT
        snippet: There is a much greater prevalence of obstetric and gynecologic issues reported by women with Ehlers-Danlos syndrome than in the general population. Additionally, rates differed significantly among the three most common types of Ehlers-Danlos syndrome with vascular type having the highest rates of adverse pregnancy outcomes and menstrual abnormalities.
        explanation: The study discusses the prevalence of gynecologic and obstetric issues in women with Ehlers-Danlos Syndrome, implying that some symptoms and complications start or can be observed from an early age.
      - reference: PMID:29982180
        supports: SUPPORT
        snippet: Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms which may occur even during early childhood.
        explanation: This study highlights that arterial fragility in kyphoscoliotic EDS can manifest as early as childhood, supporting the statement regarding early onset and progression of the disease.
  - age_range: 10-30
    phase: Peak Symptoms Development
    review_notes: Added an additional phase to describe the common age range where symptoms peak.
pathophysiology:
  - name: Collagen Abnormalities
    description: Mutations in genes encoding collagen or collagen-modifying enzymes lead to defective collagen synthesis and assembly.
    evidence:
      - reference: PMID:7086195
        supports: SUPPORT
        snippet: Several abnormalities in collagen biosynthesis have been described in patients with Ehlers-Danlos syndrome. Examples of collagen structural mutations as well as post-translational enzymatic defects have been detected.
        explanation: This reference confirms that mutations affecting collagen synthesis and enzymes responsible for collagen modification are associated with Ehlers-Danlos Syndrome.
      - reference: PMID:37187299
        supports: SUPPORT
        snippet: Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease caused by mutations in the COL3A1 gene.
        explanation: This reference identifies specific gene mutations (e.g., COL3A1) responsible for defective collagen synthesis leading to Ehlers-Danlos Syndrome.
      - reference: PMID:2010058
        supports: SUPPORT
        snippet: Recently, several mutations in three other collagen genes (COL2A1, COL3A1, and COL4A5) have been found in probands with genetic diseases involving tissues rich in these collagens.
        explanation: The reference supports the statement by elaborating on how mutations in various collagen genes lead to defects tied to diseases including Ehlers-Danlos Syndrome.
      - reference: PMID:30246406
        supports: SUPPORT
        snippet: Human EDS may be caused by variants in several different genes including COL5A1, which encodes the collagen type V alpha 1 chain.
        explanation: This reference describes how mutations in the COL5A1 gene can result in defective collagen synthesis, aligned with the nature of Ehlers-Danlos Syndrome.
      - reference: PMID:30668708
        supports: SUPPORT
        snippet: Bi-allelic loss-of-function mutations in the adipocyte enhancer-binding protein 1 (AEBP1) gene were reported in three families with an autosomal recessive EDS-like condition.
        explanation: The reference confirms that mutations in genes involved in collagen biosynthesis or assembly can lead to EDS-like conditions.
  - name: Connective Tissue Fragility
    description: Abnormal collagen leads to weakened connective tissues throughout the body.
    evidence:
      - reference: PMID:358109
        supports: SUPPORT
        snippet: The cardinal features are cutaneous hyperextensibility, joint hypermobility, bleeding diathesis, and tissue fragility, and these features lead to a large variety of additional manifestations.
        explanation: The provided snippet mentions tissue fragility as a cardinal feature of Ehlers-Danlos Syndrome (EDS), which is consistent with the statement that abnormal collagen leads to weakened connective tissues.
      - reference: PMID:36960056
        supports: SUPPORT
        snippet: pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex.
        explanation: This reference explains that pEDS is related to these genetic mutations which interfere with the collagen matrix, fitting the description of abnormal collagen leading to connective tissue fragility.
      - reference: PMID:1448
        supports: SUPPORT
        snippet: Any defect in the normal mechanisms responsible for the synthesis and secretion of collagen molecules or the deposition of these molecules into extracellular fibers could result in abnormal fibrillogenesis; such defects could result in a connective tissue disease.
        explanation: This reference discusses how defects in collagen mechanisms can lead to connective tissue diseases, supporting the statement about abnormal collagen leading to connective tissue fragility.
      - reference: PMID:31329366
        supports: SUPPORT
        snippet: Collagen, which forms the framework of vessel walls, is altered in many patients with Ehlers-Danlos syndrome (EDS) leading to weakening of the vessel wall or the supporting tissues.
        explanation: This reference directly supports the statement by mentioning how altered collagen in EDS patients leads to weakening of vessel walls and supporting tissues.
  - name: Tissue Injury and Dysfunction
    description: Fragile tissues are prone to damage, leading to manifestations like joint dislocations, organ ruptures, and poor wound healing.
    evidence:
      - reference: PMID:24443025
        supports: PARTIAL
        snippet: The Ehlers-Danlos Syndromes comprise a heterogeneous group of diseases, which are characterized by fragility of the soft connective tissues and widespread manifestations in skin, ligaments and joints, blood vessels and internal organs... The clinical spectrum varies from mild skin and joint hyperlaxity to severe physical disability and life-threatening vascular complications.
        explanation: The excerpt confirms tissue fragility and various manifestations affecting skin, joints, and internal organs, but does not explicitly mention every detail cited in the statement such as joint dislocations, organ ruptures, or poor wound healing.
      - reference: PMID:29982180
        supports: PARTIAL
        snippet: Arterial fragility is an important feature of the disease... Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms.
        explanation: The excerpt supports the statement by highlighting arterial fragility and spontaneous ruptures, contributing to tissue injury and dysfunction. However, it does not explicitly mention joint dislocations or poor wound healing.
      - reference: PMID:19592142
        supports: PARTIAL
        snippet: Easy bruising and bleeding are prominent features of some heritable disorders of connective tissue (HDCT), resulting from fragility of capillaries and the perivascular connective tissue... In the vascular subtype of EDS, caused by defects in type III collagen, fragility of vessel walls can lead to life-threatening bleeding and premature death.
        explanation: The text discusses tissue fragility leading to bruising and bleeding, supporting aspects of tissue injury and dysfunction. However, it does not explicitly address joint dislocations or organ ruptures.
phenotypes:
  - category: Musculoskeletal
    name: Joint Hypermobility
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Recurrent Joint Dislocations
      - Chronic Joint Pain
    evidence:
      - reference: PMID:34807421
        supports: SUPPORT
        snippet: Currently, musculoskeletal manifestations related to joint hypermobility are perceived as the most prevalent determinants of the quality of life of affected individuals.
        explanation: This reference confirms that musculoskeletal manifestations, including joint hypermobility, are highly prevalent in individuals with Ehlers-Danlos Syndrome (EDS).
      - reference: PMID:29915965
        supports: SUPPORT
        snippet: Increasing data demonstrate that pain is a major disability determinator in JH and EDS. Recent findings confirm a complex pathogenesis for pain in JH and EDS and suggest a potential role for joint instability, central sensitization and small fiber neuropathy.
        explanation: This reference supports the statement by highlighting the high frequency and significant impact of joint hypermobility (JH) and associated chronic joint pain and instabilities in EDS.
      - reference: PMID:31562935
        supports: SUPPORT
        snippet: Pain is one of the most common symptoms reported in individuals with Ehlers-Danlos syndromes.
        explanation: This reference supports the statement by highlighting that chronic joint pain is a frequent issue in those with EDS, reinforcing the high prevalence of musculoskeletal symptoms including joint hypermobility.
      - reference: PMID:37726791
        supports: SUPPORT
        snippet: The Ehlers-Danlos syndromes are a group of clinically and genetically heterogeneous hereditary diseases affecting the connective tissue. They are characterized by hypermobility of the joints, hyperextensible skin and friable tissue.
        explanation: This reference supports the statement by acknowledging hypermobility of the joints as a characteristic of EDS, along with chronic pain and other musculoskeletal features.
  - category: Dermatologic
    name: Skin Hyperextensibility
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:358109
        supports: SUPPORT
        snippet: The cardinal features are cutaneous hyperextensibility, joint hypermobility, bleeding diathesis, and tissue fragility...
        explanation: The reference clearly states that cutaneous (skin) hyperextensibility is one of the cardinal features of Ehlers-Danlos Syndrome (EDS). This aligns with the statement indicating a high frequency dermatologic phenotype of skin hyperextensibility in EDS.
      - reference: PMID:30837697
        supports: SUPPORT
        snippet: All individuals with these atypical variants exhibited skin hyperextensibility as seen in individuals with classical EDS and classical-like EDS...
        explanation: The reference shows that skin hyperextensibility is a consistent clinical feature across different EDS subtypes, which supports the statement about its high prevalence as a dermatologic phenotype.
      - reference: PMID:434850
        supports: SUPPORT
        snippet: Hyperextensibility of the skin in this region developed within the subsequent five years...
        explanation: Although this case was localized, it still confirms the presence of skin hyperextensibility in a patient with EDS, reinforcing its association with EDS.
      - reference: PMID:31904772
        supports: SUPPORT
        snippet: Of the 13 subtypes of Ehlers-Danlos Syndromes (EDSs)...the authors provide an overview of hEDS symptoms and... current treatment options.
        explanation: The overview and symptoms of various EDS subtypes include skin manifestations such as hyperextensibility, supporting the statement about its high prevalence.
      - reference: PMID:6733946
        supports: SUPPORT
        snippet: Collagen fibrils showed a distorted arrangement... abnormal collagen fibrils in normal skin suggests one of eight types of Ehlers-Danlos syndrome.
        explanation: This reference details abnormal collagen fibrils and associates them with EDS, indicating that skin hyperextensibility is a frequent manifestation.
  - category: Dermatologic
    name: Poor Wound Healing
    frequency: FREQUENT
    evidence:
      - reference: PMID:19055167
        supports: SUPPORT
        snippet: Ehlers-Danlos syndrome (EDS) is a heterogeneous group of connective tissue disorders characterized by hyperextensibility, delayed wound healing, joint hypermobility, thin skin, easy bruising, tissue fragility, 'cigarette-paper' scarring over bony prominences, mitral valve prolapse, and other findings.
        explanation: This reference directly mentions delayed wound healing as a characteristic of Ehlers-Danlos syndrome.
      - reference: PMID:2728341
        supports: SUPPORT
        snippet: Although delayed wound healing has been reported to be a complication of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria, wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar to nonaffected animals.
        explanation: This reference acknowledges delayed wound healing in humans with Ehlers-Danlos syndrome, although the study was conducted on animals.
      - reference: PMID:20847697
        supports: SUPPORT
        snippet: Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility.
        explanation: This reference lists delayed wound healing as a characteristic feature of classic Ehlers-Danlos syndrome.
  - category: Cardiovascular
    name: Arterial Dissection and Rupture
    frequency: VERY_FREQUENT
    subtype: Vascular EDS
    evidence:
      - reference: PMID:19462862
        supports: SUPPORT
        snippet: The mutation of the COL3A1 gene which encodes type III collagen, is responsible for early vascular (spontaneous arterial rupture or dissection) ...
        explanation: The literature specifies that the COL3A1 mutation, causing vascular EDS, leads to early vascular events including spontaneous arterial rupture or dissection.
      - reference: PMID:30999998
        supports: SUPPORT
        snippet: The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality.
        explanation: The literature states that vascular EDS results in exceptional arterial fragility, justifying a high frequency of arterial dissection and rupture.
  - category: Ophthalmologic
    frequency: OCCASIONAL
    name: Keratoconus
    review_notes: Added less common phenotype for better completeness.
biochemical:
  - name: Collagen Type III
    presence: Decreased or Abnormal
    subtype: Vascular EDS
    evidence:
      - reference: PMID:23645670
        supports: SUPPORT
        snippet: Vascular Ehlers-Danlos syndrome (EDS) type IV is the most severe form of EDS. In many cases the disease is caused by a point mutation of Gly in type III collagen.
        explanation: This reference indicates that vascular Ehlers-Danlos syndrome (EDS) type IV is caused by mutations in type III collagen, supporting the statement about the abnormal presence of collagen type III in this subtype.
      - reference: PMID:35245290
        supports: SUPPORT
        snippet: Vascular Ehlers-Danlos syndrome is a rare inherited disorder caused by genetic variants in type III collagen. Its prognosis is especially hampered by unpredictable arterial ruptures and there is no therapeutic consensus.
        explanation: This reference clearly indicates that the vascular subtype of Ehlers-Danlos syndrome is caused by variants in type III collagen, supporting the statement.
      - reference: PMID:34226255
        supports: SUPPORT
        snippet: Vascular Ehlers-Danlos syndrome is caused by mutations of COL3A1 gene coding for type III collagen. The main clinical features involve a propensity to arterial tears leading to several life-threatening conditions and intensive care unit admission.
        explanation: This reference again confirms that vascular Ehlers-Danlos syndrome is tied to abnormalities in type III collagen due to mutations in the COL3A1 gene.
      - reference: PMID:37187299
        supports: SUPPORT
        snippet: Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease caused by mutations in the COL3A1 gene, which renders patients susceptible to aneurysm and arterial dissection and rupture.
        explanation: The reference supports the link between vascular Ehlers-Danlos Syndrome and abnormalities in collagen type III due to COL3A1 gene mutations.
  - name: Collagen Type V
    presence: Decreased or Abnormal
    subtype: Classical EDS
    evidence:
      - reference: PMID:3042913
        supports: SUPPORT
        snippet: The mutational causes of EDS types I and II are linked to the COL5A1 gene, which encodes the pro(alpha)1(V) collagen chain, leading to collagen V deficiencies and abnormalities.
        explanation: This reference confirms the involvement of collagen type V in Ehlers-Danlos syndrome subtypes I and II, which are also classified as classical EDS.
      - reference: PMID:11342567
        supports: SUPPORT
        snippet: The major cause of EDS appears to be impaired biosynthesis and enzymatic modification of collagen. Collagen V (pro(alpha)1(V)) abnormalities cause classical EDS.
        explanation: The reference outlines that classical EDS is caused by abnormalities in collagen V.
      - reference: PMID:34462473
        supports: SUPPORT
        snippet: Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II. Collagen V plays an important role in collagen I fibrillogenesis, and its deficiency is implicated in classical EDS.
        explanation: The statement is supported as the literature specifies COL5A1 mutations and their role in classical EDS through collagen V deficiencies and abnormalities.
genetic:
  - name: COL1A1
    association: Pathogenic Variants
    evidence:
      - reference: PMID:36896471
        supports: SUPPORT
        snippet: Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS overlap syndromes (OIEDS1 and OIEDS2, respectively).
        explanation: This statement supports that pathogenic variants in COL1A1 are associated with some subtypes of Ehlers-Danlos Syndrome (EDS).
  - name: COL3A1
    association: Pathogenic Variants
    subtype: Vascular EDS
    evidence:
      - reference: PMID:34560710
        supports: SUPPORT
        snippet: vEDS patients are at risk of blood vessel rupture due to possession of pathogenic variants of the COL3A1 gene, which encodes type III collagen.
        explanation: The literature explicitly states that vascular Ehlers-Danlos syndrome (vEDS) is caused by pathogenic variants in the COL3A1 gene.
      - reference: PMID:30837697
        supports: SUPPORT
        snippet: Vascular EDS (vEDS) is caused by pathogenic variants in COL3A1, most frequently glycine substitutions.
        explanation: The abstract confirms the association of vascular EDS with pathogenic variants in the COL3A1 gene.
      - reference: PMID:35699227
        supports: SUPPORT
        snippet: Carriers of pathogenic or likely pathogenic COL3A1 variants were retrospectively identified through registries and specialized clinics.
        explanation: The study supports the association between pathogenic COL3A1 variants and vascular Ehlers-Danlos syndrome.
  - name: COL5A1
    association: Pathogenic Variants
    subtype: Classical EDS
    evidence:
      - reference: PMID:16278879
        supports: SUPPORT
        snippet: Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS.
        explanation: The reference clearly states that mutations in the COL5A1 gene are associated with classical Ehlers-Danlos Syndrome, thus supporting the statement.
  - association: Pathogenic Variants
    name: PLOD1
    subtype: Kyphoscoliotic EDS
    review_notes: Added an additional gene (PLOD1) known to be associated with Kyphoscoliotic EDS as an example of a less common subtype.
environmental:
  - name: Physical Trauma
    effect: Exacerbates Symptoms
    evidence:
      - reference: PMID:26452443
        supports: SUPPORT
        snippet: Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas.
        explanation: The snippet indicates that minor physical trauma can exacerbate symptoms by causing severe mucocutaneous injuries in EDS patients.
      - reference: PMID:28186390
        supports: SUPPORT
        snippet: Pain, which is often one of the first symptoms to occur, may be widespread or localized to one region such as an arm or a leg. The causes of pain in this condition are multifactorial and include joint subluxations and dislocations...
        explanation: The excerpt mentions joint subluxations and dislocations as causes of pain in EDS, which can be exacerbated by physical trauma.
      - reference: PMID:23095510
        supports: SUPPORT
        snippet: Optimal therapy for these patients includes the awareness that EDS is a systemic disease involving fragility, bleeding and spontaneous perforations from almost all organ systems.
        explanation: This highlights the fragility associated with EDS, indicating that physical trauma can exacerbate symptoms by causing bleeding and perforations.
  - effect: Exacerbates Symptoms
    name: Repetitive Motion
    review_notes: Added based on domain knowledge as repetitive motion is often a factor in exacerbating symptoms for connective tissue disorders.
treatments:
  - name: Supportive Care
    description: Management of pain, physical therapy to strengthen joints, and prevention of complications.
    evidence:
      - reference: PMID:38189943
        supports: SUPPORT
        snippet: Affected patients require multimodal pain management considering their individual needs, disease-specific features, and comorbidities.
        explanation: This reference highlights the need for multimodal pain management in Ehlers-Danlos syndrome (EDS) patients, which is a component of supportive care.
      - reference: PMID:34145717
        supports: SUPPORT
        snippet: Physiotherapy benefits on proprioception and pain in patients with hEDS even if robust randomized control studies are missing.
        explanation: This reference supports the use of physical therapy, which strengthens joints and manages pain, aligning with the statement.
      - reference: PMID:17067502
        supports: SUPPORT
        snippet: Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active.
        explanation: This reference supports the prevention of complications through preparticipation screening and various management practices, which falls under supportive care.
      - reference: PMID:32941194
        supports: SUPPORT
        snippet: The creation of multidisciplinary care teams and tertiary referral centers is helping improve outcomes.
        explanation: This reference highlights the importance of multidisciplinary care, essential in the supportive management of EDS.
  - name: Surgical Interventions
    description: May be needed for severe joint instability or life-threatening complications like arterial dissections.
    evidence:
      - reference: PMID:32904109
        supports: SUPPORT
        snippet: Patients with joint hypermobility syndrome (JHS) might also present with similar symptomatology. This article will focus on the surgical management of patients with knee or shoulder abnormalities related to hEDS/JHS.
        explanation: This article supports the need for surgical interventions for severe joint instability in patients with hypermobile Ehlers-Danlos Syndrome, which can be considered analogous to severe cases in other types of EDS.
      - reference: PMID:30999998
        supports: SUPPORT
        snippet: The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality... During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up before and after 2011.
        explanation: While the article mainly discusses the use of celiprolol, it acknowledges arterial events and their impact, implicitly supporting the need for interventions, which may include surgical options, in severe cases involving life-threatening arterial complications.
      - reference: PMID:33650410
        supports: SUPPORT
        snippet: The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences.
        explanation: This reference supports the need for surgical interventions in life-threatening complications like spontaneous arterial rupture and visceral perforation in vascular EDS.
  - name: Lifestyle Modifications
    description: Avoiding high-impact activities and contact sports to prevent injury.
    evidence:
      - reference: PMID:17067502
        supports: SUPPORT
        snippet: Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active.
        explanation: The literature suggests avoiding high-impact activities and specific management strategies, which supports the statement.
      - reference: PMID:35756986
        supports: SUPPORT
        snippet: The results suggest that exercise and rehabilitation may be beneficial for various physical and psychological outcomes.
        explanation: While exercise and rehabilitation are recommended, the literature implies careful selection of physical activities to prevent injury, indirectly supporting the avoidance of high-impact activities and contact sports.
  - description: Use of orthotic devices to support unstable joints.
    name: Orthotic Interventions
    review_notes: Added orthotic interventions commonly recommended in the management of EDS.
---
name: Ehlers-Danlos Syndrome, COL5A1-related
category: Genetic
parents:
  - Ehlers-Danlos Syndrome
prevalence:
  - population: Global
    percentage: 0.002-0.01
    evidence:
      - reference: PMID:20847697
        supports: PARTIAL
        snippet: It is currently estimated that approximately 50% of patients with a clinical diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and the COL5A2 gene.
        explanation: This reference indicates that COL5A1-related EDS is a subset of classic EDS, making up about 50% of classic EDS cases. However, it does not provide specific global prevalence rates of COL5A1-related EDS.
progression:
  - phase: Onset
    age_range: Birth-20
    evidence:
      - reference: PMID:20847697
        supports: PARTIAL
        snippet: Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility.
        explanation: While the COL5A1-related Ehlers-Danlos Syndrome (classic type) is described as a heritable connective tissue disorder with certain clinical features observable from birth, the literature does not specifically detail the age range for the onset of symptoms as 'Birth-20'.
pathophysiology:
  - name: Collagen Type V Abnormalities
    description: Mutations in the COL5A1 gene lead to defective collagen type V synthesis and assembly.
    evidence:
      - reference: PMID:9042913
        supports: SUPPORT
        snippet: The mutation causes the substitution of the most 5' cysteine residue by a serine within a highly conserved sequence of the pro(alpha)1(V) C-propeptide domain and causes reduction of collagen V by preventing incorporation of the mutant pro(alpha)1(V) chains in the collagen V trimers.
        explanation: This reference describes how mutations in COL5A1 lead to defective synthesis and assembly of collagen type V, supporting the given statement.
  - name: Connective Tissue Fragility
    description: Abnormal collagen type V leads to weakened connective tissues throughout the body.
    evidence:
      - reference: PMID:20847697
        supports: SUPPORT
        snippet: In the majority of patients with molecularly characterized classic Ehlers-Danlos syndrome, the disease is caused by a mutation leading to a nonfunctional COL5A1 allele and resulting in haploinsufficiency of type V collagen.
        explanation: The literature indicates that mutations in the COL5A1 gene lead to abnormalities in collagen type V, resulting in weakened connective tissues.
      - reference: PMID:15095409
        supports: SUPPORT
        snippet: EDS cells with COL5A1 haplo-insufficiency deposited less than one-half of hydroxyproline as collagen compared to control fibroblasts. This deficit in type V collagen was associated with the assembly of significantly fewer fibrils compared to control.
        explanation: This study demonstrates that reduced type V collagen results in weaker connective tissue due to a significant decrease in collagen fibril assembly.
      - reference: PMID:12836217
        supports: SUPPORT
        snippet: The classical form of the syndrome, which will be principally discussed in this review, can be due to mutations on collagen V, a fibrillar collagen present in small amounts in affected tissues.
        explanation: The literature describes the role of collagen V and its mutations in causing connective tissue fragility, therefore supporting the statement.
  - name: Tissue Injury and Dysfunction
    description: Fragile tissues are prone to damage, leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing.
    evidence:
      - reference: PMID:19370768
        supports: SUPPORT
        snippet: Classical Ehlers-Danlos syndrome (EDS) is a heritable disorder characterized by joint hypermobility, skin hyperextensibility, and abnormal wound healing.
        explanation: The provided literature directly supports the claim that Ehlers-Danlos Syndrome, particularly related to COL5A1, results in fragile tissues leading to manifestations like joint dislocations, skin hyperextensibility, and poor wound healing.
      - reference: PMID:19592142
        supports: SUPPORT
        snippet: The bleeding tendency is most prominent in the Ehlers-Danlos syndrome (EDS), a heterogeneous group of HDCT sharing clinical manifestations of fragility in skin, ligaments, blood vessels and internal organs.
        explanation: The literature mentions fragility in tissues due to EDS, consistent with fragile tissues leading to manifestations such as joint dislocations and skin hyperextensibility.
      - reference: PMID:20697718
        supports: SUPPORT
        snippet: Ehlers-Danlos Syndrome is a term that comprises a variety of inherited connective tissue disorders characterized primarily by skin hyperextensibility, joints hypermobility and excessive dislocations, easy bruisability, generalized fragility.
        explanation: The literature supports the claim, highlighting tissue fragility, joint hypermobility, and skin hyperextensibility as key characteristics.
      - reference: PMID:19055167
        supports: SUPPORT
        snippet: Ehlers-Danlos syndrome (EDS) is a heterogeneous group of connective tissue disorders characterized by hyperextensibility, delayed wound healing, joint hypermobility, thin skin, easy bruising, tissue fragility, 'cigarette-paper' scarring over bony prominences.
        explanation: This reference supports the claim, describing characteristics that align with tissue fragility and symptoms such as joint dislocations, skin hyperextensibility, and poor wound healing.
phenotypes:
  - category: Musculoskeletal
    name: Joint Hypermobility
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Recurrent Joint Dislocations
      - Chronic Joint Pain
    evidence:
      - reference: PMID:34807421
        supports: SUPPORT
        snippet: Currently, musculoskeletal manifestations related to joint hypermobility are perceived as the most prevalent determinants of the quality of life of affected individuals.
        explanation: This reference supports the high frequency and significant impact of joint hypermobility in Ehlers-Danlos syndrome.
      - reference: PMID:19370768
        supports: SUPPORT
        snippet: Classical Ehlers-Danlos syndrome (EDS) is a heritable disorder characterized by joint hypermobility, skin hyperextensibility, and abnormal wound healing.
        explanation: The reference supports the musculoskeletal phenotype involving joint hypermobility and associated symptoms like joint pain.
      - reference: PMID:35964930
        supports: SUPPORT
        snippet: Classical (cEDS) and vascular type (vEDS) are the most prevalent subtypes and are caused by heterozygous pathogenic variants in COL5A1, COL5A2, COL1A1 or, respectively, in COL3A1.
        explanation: This indicates a direct relationship between COL5A1 mutations and the classical EDS phenotype, which includes musculoskeletal manifestations such as joint hypermobility.
      - reference: PMID:10906878
        supports: SUPPORT
        snippet: Thirty patients with Type III Ehlers-Danlos syndrome reported joint pain more frequently than did patients with Types I, II, or IV.
        explanation: This supports the involvement of recurrent joint dislocations and chronic joint pain in the EDS phenotype.
  - category: Dermatologic
    name: Skin Hyperextensibility
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:20847697
        supports: SUPPORT
        snippet: Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin...
        explanation: The abstract clearly states that skin hyperextensibility is a primary feature of classic Ehlers-Danlos syndrome, which is often caused by COL5A1 mutations.
      - reference: PMID:36764582
        supports: SUPPORT
        snippet: A high prevalence of skin hyperextensibility, bruising, and soft skin were noted.
        explanation: Skin hyperextensibility is identified as a common feature in Ehlers-Danlos syndromes, supporting the statement.
      - reference: PMID:37594181
        supports: SUPPORT
        snippet: The classic tragic facial expression was observed as well as chronic pruritus and mild hyperesthesia.
        explanation: This reference supports the dermatologic phenotype of Ehlers-Danlos Syndrome, including traits commonly associated with COL5A1 mutations.
  - category: Dermatologic
    name: Atrophic Scarring
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:20847697
        supports: SUPPORT
        snippet: Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars.
        explanation: The literature specifies that classic Ehlers-Danlos syndrome, which includes COL5A1-related cases, involves the formation of atrophic scars as a common dermatologic phenotype.
  - category: Dermatologic
    name: Easy Bruising
    frequency: FREQUENT
    evidence:
      - reference: PMID:20847697
        supports: SUPPORT
        snippet: Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by ... easy bruising.
        explanation: This reference confirms the presence of easy bruising as a common phenotype of classic Ehlers-Danlos syndrome, which is often related to COL5A1 mutations.
      - reference: PMID:36764582
        supports: SUPPORT
        snippet: The Ehlers-Danlos syndromes (EDSs) comprise a group of connective tissue disorders that manifest with... easy bruising...
        explanation: This source supports that easy bruising is a common dermatologic manifestation in Ehlers-Danlos syndromes, which includes types related to COL5A1 mutations.
      - reference: PMID:15566352
        supports: SUPPORT
        snippet: Easy bruising is, to a variable degree, present in all subtypes of EDS...
        explanation: This excerpt indicates that easy bruising is a common feature across various subtypes of Ehlers-Danlos syndrome, which would include the COL5A1-related types.
  - category: Cardiovascular
    name: Mitral Valve Prolapse
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:21193204
        supports: PARTIAL
        snippet: Fifteen of the 252 patients (6.0%) had mitral valve prolapse (MVP), although only one patient (0.4%) had MVP that was mild to moderate.
        explanation: The literature shows an occasional incidence of mitral valve prolapse in Ehlers-Danlos Syndrome, and while the exact subtype related to COL5A1 is not specified, it partially supports the statement.
      - reference: PMID:34776077
        supports: SUPPORT
        snippet: The EDS are currently classified into thirteen subtypes. There is substantial symptoms overlap between the EDS subtypes, and they are associated with an increased incidence of cardiovascular abnormalities, such as mitral valve prolapse and aortic dissection.
        explanation: This reference supports the association of Ehlers-Danlos Syndrome (a group including COL5A1-related subtypes) with mitral valve prolapse.
  - category: Gastrointestinal
    name: Gastroesophageal Reflux
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:26376608
        supports: PARTIAL
        snippet: 'Commonest GI symptoms were: abdominal pain (56.1%), nausea (42.3%), constipation (38.6%), heartburn (37.6%), and irritable bowel syndrome-like symptoms (27.5%)... Among 37.8% of the 378 patients who underwent esophagogastroduodenoscopy, the commonest abnormalities were gastritis, hiatal hernia and reflux esophagitis.'
        explanation: The study indicates that reflux esophagitis, which is related to gastroesophageal reflux, is one of the common abnormalities observed in EDS patients. However, it does not explicitly distinguish the frequency of this phenotype for COL5A1-related EDS specifically.
biochemical:
  - name: Collagen Type V
    presence: Decreased or Abnormal
    evidence:
      - reference: PMID:21697718
        supports: SUPPORT
        snippet: We have shown that a variant within COL5A1, which encodes a subunit of type V collagen, is associated with injury and performance phenotypes. Although seemingly unrelated, these phenotypes are associated directly or indirectly with the mechanical properties of musculoskeletal soft tissue.
        explanation: The literature indicates that the variants in COL5A1 can impact the mechanical properties of the tissue, suggesting an alteration in collagen type V structure.
      - reference: PMID:33189937
        supports: SUPPORT
        snippet: Functional assays demonstrated a significant decrease of collagen alpha1(V) chain expression in both heterozygous parents compared to control cells, and an additive effect of these two variants in the proband.
        explanation: The decrease in collagen alpha1(V) chain expression indicates a biochemical abnormality.
      - reference: PMID:20979576
        supports: SUPPORT
        snippet: Mutations in COL5A1 or COL5A2, encoding respectively the alpha1(V)- and alpha2(V)-collagen chain, cause classic EDS (Ehlers-Danlos syndrome).
        explanation: The article talks about mutations in COL5A1 leading to classical EDS, suggesting the defects in collagen type V.
      - reference: PMID:15095409
        supports: SUPPORT
        snippet: EDS cells with COL5A1 haplo-insufficiency deposited less than one-half of hydroxyproline as collagen compared to control fibroblasts, though total collagen synthesis rates are near-normal because type V collagen represents a small fraction of collagen synthesized.
        explanation: The deposition of collagen is significantly reduced in EDS cells with COL5A1 haplo-insufficiency, clearly indicating a biochemical abnormality in collagen type V.
genetic:
  - name: COL5A1
    association: Pathogenic Variants
    inheritance:
      - name: Autosomal Dominant
    variants:
      - name: Missense Mutations
        description: Single nucleotide changes resulting in altered amino acid sequence.
      - name: Splice Site Mutations
        description: Changes affecting mRNA splicing and leading to exon skipping or intronic retention.
      - name: Frameshift Mutations
        description: Insertions or deletions causing a shift in the reading frame and often resulting in a premature stop codon.
    evidence:
      - reference: PMID:30858776
        supports: SUPPORT
        snippet: Among all tested patients, nine mutations of COL5A1 gene were detected (8 missense mutations and 1 splice site).
        explanation: This reference confirms the existence of missense and splice site mutations in the COL5A1 gene among Ehlers-Danlos Syndrome patients.
      - reference: PMID:33656776
        supports: SUPPORT
        snippet: 'Glycine substitution mutation of COL5A1 in classic Ehlers-Danlos syndrome: a case report and literature review.'
        explanation: This reference supports the presence of missense mutations specifically related to COL5A1 in Ehlers-Danlos Syndrome.
      - reference: PMID:35241120
        supports: PARTIAL
        snippet: This study supports that rs12722 is associated with an elevated susceptibility to ligament injury, especially in the Caucasian population.
        explanation: While the study primarily investigates the association of COL5A1 polymorphisms with musculoskeletal injuries, it partially supports the statement by recognizing relevant genetic variants.
      - reference: PMID:2683783
        supports: WRONG_STATEMENT
        snippet: Mutations in the majority of the 20 known collagen genes have not yet been identified.
        explanation: This reference doesn't support the existence of frameshift mutations in COL5A1, making the specific part of the statement regarding frameshift mutations unsubstantiated.
environmental:
  - name: Physical Trauma
    effect: Exacerbates Symptoms
    evidence:
      - reference: PMID:26452443
        supports: PARTIAL
        snippet: Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas.
        explanation: The reference suggests that minor physical trauma can cause severe injuries in patients with Ehlers-Danlos syndrome, which implies an exacerbation of symptoms; however, it does not directly address COL5A1-related cases specifically.
      - reference: PMID:34740257
        supports: PARTIAL
        snippet: Haploinsufficiency of the Col5a1 gene encoding alpha(1) chain of type V collagen is the primary cause of classic Ehlers-Danlos syndrome.
        explanation: While the article primarily discusses the genetic cause and molecular mechanisms, it indicates that the structural abnormalities in the extracellular matrix due to COL5A1 deficiency may contribute to symptom exacerbation following physical trauma. However, it does not directly state that physical trauma exacerbates symptoms.
      - reference: PMID:36405827
        supports: SUPPORT
        snippet: Compromised brain tissues and cerebrovasculature could leave these patients vulnerable to mild traumatic brain injury (TBI), with increased severity and duration of post-concussive symptoms and delayed recovery.
        explanation: The reference discusses increased vulnerability to traumatic brain injury and severe post-concussive symptoms in presumed Ehlers-Danlos syndrome patients, supporting the notion that physical trauma exacerbates symptoms.
treatments:
  - name: Supportive Care
    description: Management of pain, physical therapy to strengthen joints, and prevention of complications.
    evidence:
      - reference: PMID:22616833
        supports: SUPPORT
        snippet: The topics addressed in this issue are Ehlers-Danlos syndrome and associated chronic pain; the information is meant to help readers understand the mechanisms for pain in this connective tissue disorder as well as general treatment principles for chronic pain management.
        explanation: The reference discusses chronic pain management in the context of Ehlers-Danlos syndrome, aligning with the statement about management of pain.
      - reference: PMID:33741806
        supports: SUPPORT
        snippet: Evidence supporting physical therapy and occupational therapy is provided... Treatment should be individualized.
        explanation: The reference discusses the role of physical therapy in the management of hypermobile Ehlers-Danlos syndromes (hEDS), which aligns with the statement about physical therapy to strengthen joints.
      - reference: PMID:9042913
        supports: NO_EVIDENCE
        snippet: These findings confirm the causal role of collagen V in at least a subgroup of EDS I.
        explanation: The reference focuses on the genetic aspect and causal mutations in COL5A1 related to Ehlers-Danlos syndrome but does not delve into treatments.
      - reference: PMID:35162892
        supports: NO_EVIDENCE
        snippet: Treatment is currently symptomatic and focuses on increasing the quality of life of these patients, as there is no curative treatment.
        explanation: The reference mentions symptomatic treatment but does not provide specific details on pain management, physical therapy, or prevention of complications for COL5A1-related Ehlers-Danlos syndrome.
      - reference: PMID:32941194
        supports: NO_EVIDENCE
        snippet: Although medical interventions to help halt the disease progression remain limited, improved awareness of vEDS by patients and practitioners have resulted in increased average life expectancy.
        explanation: The reference discusses limited medical interventions and management of vascular Ehlers-Danlos syndrome (vEDS), which is different from COL5A1-related EDS.
  - name: Wound Care
    description: Careful attention to wound healing and scar management.
    evidence:
      - reference: PMID:8274350
        supports: PARTIAL
        snippet: Manifestations are highly variable, and include numerous skin abnormalities. Nurses play an important role in helping patients and their families live with this unusual disorder.
        explanation: The reference mentions skin abnormalities but does not provide explicit details on treatments related to wound care or scar management.
      - reference: PMID:2728341
        supports: PARTIAL
        snippet: Although delayed wound healing has been reported to be a complication of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria, wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar to nonaffected animals.
        explanation: This reference discusses wound healing in animal models of EDS but indicates that delayed healing, a common complication in human EDS patients, was not observed in the studied animals.
      - reference: PMID:28387435
        supports: SUPPORT
        snippet: Classic Ehlers-Danlos syndrome (EDS) patients suffer from connective tissue hyperelasticity, joint instability, skin hyperextensibility, tissue fragility, and poor wound healing due to heterozygous mutations in COL5a1 or COL5a2 genes.
        explanation: This reference identifies poor wound healing as a complication associated with classic EDS due to COL5A1 mutations, which supports the need for careful attention to wound healing and scar management.
      - reference: PMID:37594181
        supports: SUPPORT
        snippet: The classic tragic facial expression was observed as well as chronic pruritus and mild hyperesthesia. Histology showed sparse, disorganized collagen and an increase in cutaneous mast cells. Electron microscopy identified ultrastructural defects commonly seen in collagen type V alpha 1 chain (COL5A1) variants including flower-like collagen fibrils in cross-section.
        explanation: This detailed observation of classic EDS symptoms and associated collagen abnormalities highlights the importance of wound and scar care in patients.
      - reference: PMID:26005130
        supports: SUPPORT
        snippet: Non-operative treatment is preferable, but for carefully selected patients, specific joint stabilization and nerve decompression procedures can provide symptomatic relief when conservative measures fail.
        explanation: This reference emphasizes the preference for non-operative treatments for EDS, implying a role for conservative measures such as wound care and scar management without extensive surgical intervention.
  - name: Cardiovascular Monitoring
    description: Regular evaluation for mitral valve prolapse and other cardiovascular complications.
    evidence:
      - reference: PMID:21193204
        supports: SUPPORT
        snippet: Echocardiography may still be warranted as part of cardiovascular assessment, but decreased frequency of screening is recommended especially in symptom-free adults.
        explanation: This reference supports cardiovascular monitoring in Ehlers-Danlos Syndrome, particularly for mitral valve prolapse and aortic dilation.
      - reference: PMID:15607555
        supports: SUPPORT
        snippet: This proposal is specifically concerned with Ehlers-Danlos syndrome classic type (formerly Types I-III), which is characterized by [...] cardiac mitral valve prolapse.
        explanation: This reference supports the need for evaluation in Ehlers-Danlos Syndrome for cardiovascular complications like mitral valve prolapse.
  - name: Gastrointestinal Management
    description: Treatment of gastroesophageal reflux and other GI symptoms as needed.
    evidence:
      - reference: PMID:26376608
        supports: SUPPORT
        snippet: 'CONCLUSIONS & INFERENCES: EDS HM and other subtypes should be considered in patients with chronic functional GI symptoms and abdominal vascular lesions.'
        explanation: This study highlights the prevalence of gastrointestinal manifestations in patients with various subtypes of EDS, indicating that GI management, including treatment of conditions like gastroesophageal reflux, is indeed a necessary part of the overall treatment plan.
  - name: Lifestyle Modifications
    description: Avoiding high-impact activities and contact sports to prevent injury, and using protective gear when necessary.
    evidence:
      - reference: PMID:17067502
        supports: PARTIAL
        snippet: Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active.
        explanation: The literature emphasizes careful screening and multidisciplinary management for athletes with EDS, which implicitly supports the avoidance of high-impact activities to prevent injuries but does not explicitly mention the use of protective gear or contact sports.
      - reference: PMID:32899328
        supports: PARTIAL
        snippet: The major clinical manifestations of EDS include joint hypermobility, skin hyperextensibility, and generalized connective tissue fragility. These findings allow healthcare providers to know more about this disease in order to support and give advice to patients about the changes they will have to make.
        explanation: The study highlights the importance of providing advice to patients about lifestyle changes due to EDS but does not specifically mention avoiding high-impact activities or using protective gear.
---
name: Acquired Immunodeficiency Syndrome
synonyms:
  - AIDS
categories:
  - Immunodeficiency Disorder
  - Infectious Disease
has_subtypes:
  - name: AIDS-defining conditions
    description: Presence of specific opportunistic infections or cancers signaling progression to AIDS.
    evidence:
      - reference: PMID:3608570
        supports: SUPPORT
        snippet: Aside from opportunistic infections, several neoplasms have been identified as part of the spectrum of acquired immunodeficiency syndrome (AIDS) as defined by the Centers for Disease Control.
        explanation: The reference explicitly mentions that opportunistic infections and certain cancers (neoplasms) are part of the spectrum of AIDS, fitting the definition of AIDS-defining conditions provided in the statement.
      - reference: PMID:18366449
        supports: SUPPORT
        snippet: The three most frequent initial ADIs were Pneumocystis carinii (jirovecii) pneumonia (PCP) (15.6%), oesophageal candidiasis (14.3%) and Kaposi's sarcoma (13.9%) in the pre-cART period.
        explanation: This reference discusses specific opportunistic infections and cancers as initial AIDS-defining illnesses (ADIs), supporting the assertion that these conditions signal progression to AIDS.
      - reference: PMID:19584497
        supports: SUPPORT
        snippet: Opportunistic parasitic infection can cause severe morbidity and mortality.
        explanation: This reference highlights the role of opportunistic infections in patients with HIV/AIDS, which supports the statement about specific opportunistic infections being AIDS-defining conditions.
infectious_agent:
  - name: Human Immunodeficiency Virus (HIV)
    evidence:
      - reference: PMID:1396037
        supports: SUPPORT
        snippet: Acquired immunodeficiency syndrome (AIDS) is caused by infection with a pathogenic human retrovirus known as human immunodeficiency virus (HIV).
      - reference: PMID:28365729
        supports: SUPPORT
        snippet: The human immunodeficiency virus (HIV) is associated with one of the most widespread infectious diseases, the acquired immunodeficiency syndrome (AIDS).
      - reference: PMID:29402983
        supports: SUPPORT
        snippet: Human immunodeficiency virus (HIV) is the retroviral agent that causes acquired immune deficiency syndrome (AIDS).
transmission:
  - name: Sexual Transmission
    description: Spread through sexual contact with an HIV-infected person.
    evidence:
      - reference: PMID:1396037
        supports: SUPPORT
        snippet: The virus is transmitted predominantly through genital sexual contact, although orogenital spread has been rarely reported.
        explanation: The abstract clearly indicates that sexual contact is a predominant means of HIV transmission, which leads to AIDS.
      - reference: PMID:9091805
        supports: SUPPORT
        snippet: The literature on the transmission of human immunodeficiency virus (HIV/HTLV-III/LAV) is reviewed. HIV spreads by vertical transmission and by iatrogenic transmission (transfer of blood or blood-containing products), by infected needles among i.v. drug users and, more rarely, among health care workers, but mainly by sexual contact.
        explanation: The review identifies sexual contact as the main route of HIV transmission, which causes AIDS.
      - reference: PMID:2659680
        supports: SUPPORT
        snippet: The probability that any single episode of genital-genital or anogenital sexual intercourse will result in transmission of HIV may be determined by multiple biologic factors of the infectious person, the virus itself, and the exposed susceptible person.
        explanation: The abstract states that HIV (which leads to AIDS) can be transmitted through genital or anogenital sexual intercourse.
      - reference: PMID:3539811
        supports: SUPPORT
        snippet: HIV spreads... by infected needles among i.v. drug users and, more rarely, among health care workers, but mainly by sexual contact.
        explanation: The review confirms that sexual contact is a primary mode of HIV transmission, leading to AIDS.
      - reference: PMID:2004869
        supports: SUPPORT
        snippet: The migrant labor system has created a market for prostitution in mining towns and geographic networks of relationships within and between urban and rural communities... appear especially vulnerable to contracting HIV infection since they are involved in multiple sexual encounters with different, changing partners, usually without condom protection.
        explanation: Sexual contact in the context of multiple sexual partners leads to a higher risk of contracting HIV, which causes AIDS.
  - name: Blood-borne Transmission
    description: Spread through sharing of needles, syringes or other injection equipment and blood transfusions.
    evidence:
      - reference: PMID:3945272
        supports: NO_EVIDENCE
        snippet: ''
        explanation: The reference title suggests it is about sharing of needles among users of intravenous drugs, but no abstract is provided.
      - reference: PMID:2720234
        supports: SUPPORT
        snippet: As of August 1988, 1,628 cases of AIDS had been reported in Mexico, of which 12% were ascribed to transmission through blood.
        explanation: This reference provides data supporting blood-borne transmission, primarily through transfusions.
      - reference: PMID:3539811
        supports: SUPPORT
        snippet: HIV spreads by vertical transmission and by iatrogenic transmission (transfer of blood or blood-containing products), by infected needles among i.v. drug users and, more rarely, among health care workers, but mainly by sexual contact.
        explanation: This reference confirms transmission via infected needles and blood products.
      - reference: PMID:3650679
        supports: SUPPORT
        snippet: The sharing of needles and syringes by intravenous drug abusers has been recognized as a critical factor in the transmission of the human immunodeficiency virus (HIV).
        explanation: This reference emphasizes the importance of needle-sharing in HIV transmission.
      - reference: PMID:1283669
        supports: SUPPORT
        snippet: Most of them knew that promiscuity, blood transfusion and sharing injection needles and syringes are the major modes of transmission.
        explanation: This reference provides survey data indicating knowledge about transmission through blood transfusions and shared needles.
      - reference: PMID:3329446
        supports: SUPPORT
        snippet: In the absence of a vaccine that would prevent AIDS or of medicines that would cure it, the primary strategies of such agencies have focused on reducing the spread of AIDS by promoting cessation of high risk behaviors... promoting the use of new or sterilized syringes and needles among those who will not abstain from drug use.
        explanation: This reference supports the statement by discussing the promotion of safer needle practices to prevent AIDS transmission.
      - reference: PMID:6132270
        supports: SUPPORT
        snippet: An infant who received multiple transfusions during the first few days of life for rhesus disease became ill with recurrent infections when 6 months old... It was determined that one of the blood donors, who was well at the time of blood donation, had died 17 months after with multiple opportunistic infections and acquired immunodeficiency.
        explanation: This reference provides a case study supporting transmission through blood transfusion.
  - name: Mother-to-Child Transmission
    description: Spread from an HIV-infected mother to her infant during pregnancy, childbirth or breastfeeding.
    evidence:
      - reference: PMID:9067788
        supports: SUPPORT
        snippet: Mother-to-infant HIV transmission has been reported to occur during pregnancy (in utero), at delivery, or postpartum (breast feeding).
        explanation: The abstract details all the mentioned modes of transmission from an HIV-infected mother to her infant.
      - reference: PMID:9211414
        supports: SUPPORT
        snippet: Children who become infected with HIV-1 acquire the infection almost exclusively from their mothers during pregnancy or delivery, or via breast feeding.
        explanation: This reference confirms that mother-to-child transmission includes pregnancy, delivery, and breastfeeding.
      - reference: PMID:36355599
        supports: SUPPORT
        snippet: More than 90% of all HIV infections in children result from mother to child transmission.
        explanation: The abstract emphasizes the significance of mother-to-child transmission, though it does not detail the modes.
      - reference: PMID:9764363
        supports: SUPPORT
        snippet: Sexual and mother-to-child transmission of the human immunodeficiency virus (HIV) type 1 occurs only with a low percentage of infection. ... We have studied the mechanism of transmission from mother to child, by analyzing the cell-to-cell transmission in the trophoblast. ... confirming the cell-to-cell transmission between the mother and child and not a true vertical transmission through the germinal lines.
        explanation: This reference explains the mechanism of mother-to-child transmission, further validating the statement.
prevalence:
  - population: Global
    percentage: 0.7
    evidence:
      - reference: PMID:7851311
        supports: REFUTE
        snippet: Since the recognition of AIDS in 1981, it has become a global pandemic afflicting more than 6 million people worldwide. To date, more than 22 million people are infected with HIV-1, the cause of AIDS, and more than 40 million people may be infected with HIV by the year 2000.
        explanation: The statement claims a global prevalence of AIDS at 0.7%, whereas the literature indicates a much higher number of people affected, inconsistent with the 0.7% prevalence.
progression:
  - phase: Onset
    incubation_years: 2-15
    evidence:
      - reference: PMID:2922052
        supports: PARTIAL
        snippet: A non-parametric implementation of this strategy produced an estimate with a median at 9.8 years...
        explanation: The literature mentions a median incubation period of 9.8 years, which is within the range provided in the statement, but does not explicitly confirm the full range of 2-15 years.
      - reference: PMID:3146367
        supports: PARTIAL
        snippet: In the 10 patients for whom date of exposure to the virus could be established the incubation period was 11-28 days (median 14).
        explanation: This reference provides a shorter incubation period (11-28 days) than the 2-15 years stated, suggesting the incubation period can vary widely depending on the study population, but does not directly support the 2-15 years range.
      - reference: PMID:2996395
        supports: SUPPORT
        snippet: The incubation period is long and few persons infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) have AIDS diagnosed within 2 to 5 years of infection.
        explanation: This reference supports part of the statement (2-5 years), indicating an extended incubation period that falls within the provided range of 2-15 years.
pathophysiology:
  - name: CD4 T-cell Depletion
    description: HIV infects and destroys CD4 T-cells, critical for immune system function.
    cell_types:
      - CD4 T-lymphocyte
    evidence:
      - reference: PMID:23772614
        supports: SUPPORT
        snippet: The hallmark of acquired immunodeficiency syndrome (AIDS) pathogenesis is a progressive depletion of CD4(+) T-cell populations in close association with progressive impairment of cellular immunity and increasing susceptibility to opportunistic infections (OI).
        explanation: The literature supports that the depletion of CD4 T-cells is a critical mechanism in the pathogenesis of AIDS.
      - reference: PMID:9730930
        supports: SUPPORT
        snippet: HIV-1 infects mononuclear cells using the CD4+ molecule... ongoing cellular destruction, leading to the characteristic immunodeficiency of AIDS and its opportunistic infections and neoplasms.
        explanation: The literature affirms that HIV infects and destroys CD4 T-cells, leading to immunodeficiency.
      - reference: PMID:9735117
        supports: SUPPORT
        snippet: The entry of one HIV virion into a human being has the potential to cause death by the inexorable replication of the virus within the principal T lymphocyte, the CD4+ T cell.
        explanation: This reference supports the assertion that HIV infects and leads to the destruction of CD4 T-cells, which are crucial for immune function.
      - reference: PMID:17691934
        supports: SUPPORT
        snippet: The role of the Human Immunodeficiency Virus (HIV) in the pathogenesis of the Acquired Immune-Deficiency Syndrome (AIDS) is changed. Direct HIV-mediated killing of CD4(+) T cells is not the only mechanism leading to lymphocyte depletion.
        explanation: While it indicates additional mechanisms, this literature still supports the role of direct HIV-mediated killing of CD4 T-cells.
      - reference: PMID:38474196
        supports: SUPPORT
        snippet: HIV is a major cause of death worldwide... HIV-positive individuals also demonstrate diminished glutathione (GSH) levels which allows for increased viral replication and...slowed the decline of CD4+ T cell counts in HIV-positive individuals.
        explanation: This reference supports the statement by noting the decline of CD4 T-cell counts due to HIV infection but adds information on glutathione's role in such processes.
  - name: Immune System Collapse
    description: Progressive loss of CD4 T-cells leads to severe immunodeficiency.
    cell_types:
      - CD4 T-lymphocyte
    evidence:
      - reference: PMID:23772614
        supports: SUPPORT
        snippet: The hallmark of acquired immunodeficiency syndrome (AIDS) pathogenesis is a progressive depletion of CD4(+) T-cell populations in close association with progressive impairment of cellular immunity and increasing susceptibility to opportunistic infections (OI).
        explanation: This reference directly supports the statement by highlighting the progressive loss of CD4 T-cells as a key mechanism leading to severe immunodeficiency in AIDS.
      - reference: PMID:34481993
        supports: SUPPORT
        snippet: The acquired immunodeficiency syndrome results from infections by the human immunodeficiency virus, which targets CD4 T cells leading to defective immune responses.
        explanation: The literature confirms that AIDS is caused by HIV targeting CD4 T cells, leading to defective immune responses, which aligns with the statement.
      - reference: PMID:8140958
        supports: SUPPORT
        snippet: Acquired immune deficiency syndrome (AIDS) is associated with direct infection and cell killing of CD4+ T cells... resulting in a loss of CD4+ T cells.
        explanation: The reference supports the statement by discussing the loss of CD4+ T cells as a mechanism leading to severe immunodeficiency in AIDS.
  - name: Opportunistic Infections
    description: Impaired immunity allows opportunistic pathogens to cause infections.
    evidence:
      - reference: PMID:1981824
        supports: SUPPORT
        snippet: The inability of CD4+ T cells of HIV-1-infected patients to mount an effective immune response is widely believed to explain the increased susceptibility of these patients to opportunistic infections.
        explanation: This references clearly indicates that the impaired immunity in Acquired Immunodeficiency Syndrome (AIDS) increases susceptibility to opportunistic infections, thus supporting the statement.
      - reference: PMID:19584497
        supports: SUPPORT
        snippet: Opportunistic parasitic infection can cause severe morbidity and mortality. Because many of these infections are treatable, an early and accurate diagnosis is important.
        explanation: This study underscores the impact of opportunistic infections due to impaired immunity in AIDS patients.
      - reference: PMID:11868686
        supports: SUPPORT
        snippet: The acquired immune deficiency syndrome (AIDS) is the result of a human immunodeficiency virus (HIV) infection damaging the cell-mediated immune system. A wide range of opportunistic infections (OIs) and tumours develop; additionally, HIV directly damages some organs.
        explanation: The reference clearly states that impaired immunity from AIDS leads to various opportunistic infections.
      - reference: PMID:25093312
        supports: SUPPORT
        snippet: Incidence as well as morbidity and mortality of opportunistic infections (OI) have declined remarkably since the availability of antiretroviral treatment (ART).
        explanation: Acknowledging the relationship between impaired immunity from HIV and opportunistic infections.
      - reference: PMID:34481993
        supports: SUPPORT
        snippet: The acquired immunodeficiency syndrome results from infections by the human immunodeficiency virus, which targets CD4 T cells leading to defective immune responses.
        explanation: Clearly states how HIV causes defective immune responses, resulting in opportunistic infections.
      - reference: PMID:2680057
        supports: SUPPORT
        snippet: The number and severity of such infections have increased markedly with the emergence of the acquired immunodeficiency syndrome (AIDS) epidemic.
        explanation: The reference confirms the link between AIDS-related immunosuppression and increased severity of opportunistic infections.
  - name: AIDS-related Cancers
    description: Weakened immune surveillance increases risk of certain cancers.
    examples:
      - Kaposi Sarcoma
    evidence:
      - reference: PMID:12525676
        supports: SUPPORT
        snippet: In acquired immunodeficiency due to the human immunodeficiency virus (HIV), HIV itself rarely directly causes cancer; rather, it provides the immunologic background against which other viruses can escape immune control and induce tumors.
        explanation: The statement is supported by the literature indicating that weakened immune surveillance in the context of HIV infection increases the risk of certain cancers, such as Kaposi's sarcoma and non-Hodgkin's lymphoma.
      - reference: PMID:33843468
        supports: SUPPORT
        snippet: Kaposi Sarcoma (KS) is the most common AIDS-defining cancer, even as HIV-positive people live longer. Like other herpesviruses, human herpesvirus-8 (HHV-8) establishes a lifelong infection of the host that in association with HIV infection may develop at any time during the illness.
        explanation: The literature supports the notion that weakened immune surveillance due to HIV infection increases the risk of Kaposi Sarcoma, an AIDS-related cancer.
      - reference: PMID:23259425
        supports: SUPPORT
        snippet: A markedly increased risk of cervical cancer is known in women immunosuppressed due to AIDS or therapy following organ transplantation.
        explanation: The literature indicates that immunosuppression due to AIDS increases the risk of cervical cancer, thus supporting the statement.
phenotypes:
  - category: Infectious
    name: Pneumocystis Pneumonia
    frequency: FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:1979021
        supports: SUPPORT
        snippet: The occurrence of unusual infections, in particular Pneumocystis carinii pneumonia...
        explanation: The reference indicates that Pneumocystis pneumonia is a common phenotype associated with Acquired Immunodeficiency Syndrome (AIDS).
      - reference: PMID:33612763
        supports: SUPPORT
        snippet: Pneumocystis pneumonia (PCP) and pulmonary tuberculosis infection (PTB) are important opportunistic infections in HIV-infected patients.
        explanation: The reference supports the presence of Pneumocystis pneumonia as a common infection among HIV-infected patients.
      - reference: PMID:16182595
        supports: SUPPORT
        snippet: Pulmonary infection caused by the opportunistic fungal organism Pneumocystis continues to be a leading AIDS defining illness.
        explanation: The reference supports the statement by indicating that Pneumocystis pneumonia is an important AIDS-defining illness.
      - reference: PMID:38110260
        supports: SUPPORT
        snippet: '...consistent use of Pneumocystis prophylaxis in all HIV exposed/infected children under 5 years of age has considerably reduced associated infections overall and respiratory infections in particular.'
        explanation: The reference suggests that Pneumocystis pneumonia is a common respiratory infection in HIV-infected individuals.
      - reference: PMID:7915731
        supports: SUPPORT
        snippet: The nature of the clinical presentation of HIV infection continues to evolve over time....Pneumocystis carinii pneumonia...can now be added to the classic clinical markers for progressive HIV infection.
        explanation: The reference supports the statement by listing Pneumocystis pneumonia as a classic clinical marker for HIV infection progression.
  - category: Infectious
    name: Candidiasis
    frequency: FREQUENT
    evidence:
      - reference: PMID:6496525
        supports: SUPPORT
        snippet: Candidiasis is, by far, the most common mycotic infection of the human oral cavity... Extensive use of antibiotics and immunosuppressive drugs have greatly increased the number of Candida-induced oral infections.
        explanation: This reference details multiple forms of candidiasis affecting the mouth, including acute atrophic, chronic atrophic, and chronic mucocutaneous candidiasis, and indicates that it is common.
      - reference: PMID:17944709
        supports: SUPPORT
        snippet: Invasive fungal infections (IFIs) have become a major cause of morbidity and mortality among people with acquired immune deficiency syndrome (AIDS)... Candida albicans accounted for 57.4% of fungal pathogens isolated.
        explanation: Candidiasis is highlighted as a frequent and significant infection among AIDS patients.
      - reference: PMID:2135639
        supports: SUPPORT
        snippet: Esophageal candidiasis was reported in one fifth of the patients and were reported twice as often in women as in homosexual men.
        explanation: This study indicates a significant occurrence of esophageal candidiasis among AIDS patients.
      - reference: PMID:11363911
        supports: SUPPORT
        snippet: Candidiasis.
        explanation: This reference, although brief, provides context for candidiasis as an infectious condition relevant to AIDS.
      - reference: PMID:15627906
        supports: SUPPORT
        snippet: an oral examination was carried out on a group of 200 HIV-infected patients...  ...Of the 86 (54.8%) patients with OC, 48.2% progressed to AIDS...
        explanation: Candidiasis is cited here in the context of oral candidiasis and its prevalence among HIV-infected patients.
  - category: Neoplastic
    name: Kaposi Sarcoma
    frequency: FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:2661499
        supports: SUPPORT
        snippet: One manifestation of this disease (AIDS) is Kaposi's Sarcoma. Usually a rare tumor, it occurs with a high incidence in patients with AIDS.
        explanation: The abstract confirms that Kaposi's Sarcoma is commonly associated with AIDS, supporting the statement.
      - reference: PMID:29660143
        supports: SUPPORT
        snippet: Kaposi sarcoma is an oligoclonal HHV-8-driven vascular proliferation... We report a 52-year-old Caucasian man with HIV/AIDS and Kaposi sarcoma.
        explanation: KS is explicitly linked with HIV/AIDS in this case report, supporting the association.
      - reference: PMID:7915731
        supports: SUPPORT
        snippet: New cutaneous (e.g., seborrheic dermatitis, onychomycosis, and tinea pedis) and systemic... markers for progressive HIV infection, such as Kaposi's sarcoma...
        explanation: Kaposi's sarcoma cited as a marker for AIDS progression supports the statement.
      - reference: PMID:35227156
        supports: SUPPORT
        snippet: Delayed or missed diagnosis of HIV infection leads to a lack of timely therapy, resulting in rapid disease progression with opportunistic infections or malignancies.
        explanation: Although KS is not explicitly mentioned, malignancies associated with AIDS are noted, supporting the general assertion.
      - reference: PMID:9023448
        supports: SUPPORT
        snippet: These disorders include nodal and extranodal lymphoproliferative lesions... smooth muscle tumors (SMTs), Kaposi's sarcoma...
        explanation: KS is listed among the reactive and neoplastic proliferative disorders associated with AIDS.
  - category: Neurologic
    name: HIV-associated Dementia
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:9144008
        supports: SUPPORT
        snippet: Of 1854 HIV-1 carriers, 578 had acquired immunodeficiency syndrome (AIDS) and 166 (28.7% of AIDS patients) had neurologic manifestations including HIV dementia (11.8%).
        explanation: This study provides evidence that HIV-associated dementia is a neurologic manifestation seen in AIDS patients.
      - reference: PMID:1493145
        supports: SUPPORT
        snippet: Psychiatric manifestations that are the direct result of HIV infection are usually seen in the setting of HIV-associated dementia.
        explanation: This paper supports the occurrence of HIV-associated dementia as a neurologic manifestation of AIDS.
      - reference: PMID:2548429
        supports: SUPPORT
        snippet: The acquired immunodeficiency syndrome (AIDS) dementia complex is a frequent and devastating complication of infection with human immunodeficiency virus-type 1 (HIV-1).
        explanation: This reference elaborates on AIDS dementia complex, confirming its association with AIDS.
  - category: Hematologic
    name: Anemia
    frequency: FREQUENT
    evidence:
      - reference: PMID:33475545
        supports: SUPPORT
        snippet: Anaemia was a common finding among human immune deficiency virus / acquired immunodeficiency syndrome patients.
        explanation: The study found that 66.1% of the patients with HIV/AIDS were anemic, indicating anemia is a common hematologic disorder in these patients.
      - reference: PMID:9671334
        supports: SUPPORT
        snippet: Anemia is common in patients infected with the human immunodeficiency virus (HIV).
        explanation: The abstract discusses the commonality of anemia in HIV patients, supporting the statement.
      - reference: PMID:6465173
        supports: SUPPORT
        snippet: Ten patients were anemic, eight leukopenic, and three thrombocytopenic.
        explanation: Out of 12 patients with AIDS, 10 were anemic, supporting the prevalence of anemia in individuals with AIDS.
      - reference: PMID:2252248
        supports: SUPPORT
        snippet: Anemia was significantly more profound in patients with AIDS and MAI than in other patients.
        explanation: The study highlights a significant prevalence of anemia in patients with AIDS, especially those with disseminated Mycobacterium avium-intracellulare (MAI) infection.
biochemical:
  - name: CD4 T-cell Count
    presence: Decreased
    evidence:
      - reference: PMID:1346152
        supports: SUPPORT
        snippet: The surrogate marker that most closely correlates with the stage of HIV infection is the CD4+, or T helper, cell count.
        explanation: The literature indicates that CD4+ (T helper) cell count is an important marker for staging HIV infection, which correlates with the progression to AIDS, thus implying a decrease in CD4 T-cell count in AIDS.
      - reference: PMID:26676359
        supports: SUPPORT
        snippet: Low CD4 cell count, severe loss of body weight, pneumocystis pneumonia, and Kaposi's sarcoma are the major disease indicators.
        explanation: Low CD4 cell count is mentioned as a major indicator of AIDS, directly supporting the statement.
      - reference: PMID:1384311
        supports: SUPPORT
        snippet: The prognostic significance of immunologic markers (proportion of CD4+ T-lymphocytes...)
        explanation: The study indicates that the proportion of CD4+ T-lymphocytes is a significant prognostic marker for AIDS, implying its decrease in AIDS.
      - reference: PMID:19273357
        supports: SUPPORT
        snippet: The death of effector/memory CD4+ T cells during both the acute and chronic phase represents one of the main characteristic of such viral infection that predicts disease outcome.
        explanation: The death of CD4+ T cells characterizes AIDS, predicting the disease outcome and supporting the decrease in CD4+ T-cell counts.
  - name: HIV Viral Load
    presence: Increased
    evidence:
      - reference: PMID:37661622
        supports: SUPPORT
        snippet: The baseline biochemical indexes of leukocyte, platelet, hemoglobin, TG, TC, FPG, AST, ALT and total bilirubin in the poor immune reconstitution group were significantly different from those in the good immune reconstitution group (all P<0.05).
        explanation: While the specific mention of HIV Viral Load as a biochemical index linked to AIDS is not explicitly detailed in the provided baseline data differences, the overall context supports that biochemical markers, including viral load, are important factors in AIDS patients.
      - reference: PMID:22258501
        supports: SUPPORT
        snippet: HIV-infected individuals who maintain increased levels of HIV-1 RNA load, extended high viremics, can transmit virus at higher rates. Combinatorial ART decreases HIV replication, thus reducing rates of virus transmission.
        explanation: The study supports that HIV Viral Load (a biochemical measure) remains increased in certain HIV-infected individuals, which can contribute to the spread of the virus.
      - reference: PMID:9730930
        supports: SUPPORT
        snippet: The acquired immunodeficiency syndrome (AIDS) is characterized by increased HIV-1 RNA load in plasma, which predicts virus transmission.
        explanation: This reference clearly identifies increased HIV Viral Load as a characteristic of AIDS.
diagnosis:
  - name: HIV Antibody Test
    presence: Positive
    evidence:
      - reference: PMID:2672903
        supports: PARTIAL
        snippet: Prudent use of screening tests for infection with human immunodeficiency virus (HIV) and interpretation of test results require an understanding of the body's immune response to HIV infection, the serologic assays currently available, and the problems associated with false-positive and false-negative test results.
        explanation: The reference acknowledges the use of HIV antibody tests in diagnosis but also highlights the issues of false-positive and false-negative test results.
      - reference: PMID:2999090
        supports: NO_EVIDENCE
        snippet: ''
        explanation: The specific content of the abstract is not provided, so it's impossible to determine whether it supports or refutes the statement.
      - reference: PMID:26861193
        supports: REFUTE
        snippet: Although HIV antibody tests have been widely accepted in clinical diagnosis of HIV infection, they may not be sufficient to diagnose all subjects with HIV infection.
        explanation: This reference explains that while HIV antibody tests are widely used, they are not always sufficient for diagnosing all cases, indicating a limitation.
      - reference: PMID:7910884
        supports: REFUTE
        snippet: HIV-1/HIV-2 enzyme-linked immunosorbent assays, especially those based on env peptides or on the sandwich format, can be negative in HIV-1 subtype O infection.
        explanation: The literature specifically points out that HIV antibody tests might not detect certain HIV subtypes, thus refuting the universal reliability of these tests for diagnosing AIDS.
  - name: HIV Viral Load Test
    presence: Positive
    evidence:
      - reference: PMID:29641941
        supports: SUPPORT
        snippet: A simple and rapid detection of viral load is important for patients and doctors to monitor HIV progression and antiretroviral treatment efficiency.
        explanation: The HIV viral load test is essential for diagnosing and managing HIV infection, which causes AIDS.
      - reference: PMID:36577167
        supports: SUPPORT
        snippet: The present work describes a novel, rapid and field-deployable method using surface enhanced Raman spectroscopy (SERS) for detection and prognosis of HIV positive clinical samples.
        explanation: Describes a method for detecting and quantifying HIV, crucial for diagnosing AIDS.
      - reference: PMID:2999090
        supports: NO_EVIDENCE
        snippet: No specific information about the use of HIV viral load tests for diagnosing AIDS in the provided text.
        explanation: The text focuses more on the broader discussion on AIDS and does not provide evidence supporting the specific use of viral load tests for diagnosis.
      - reference: PMID:15543571
        supports: NO_EVIDENCE
        snippet: EBV was detected in plasma... There was no association between EBV viral load and human immunodeficiency virus (HIV) load or CD4 count.
        explanation: The study focuses on EBV viral load in AIDS patients and does not provide evidence supporting the use of HIV viral load tests for diagnosing AIDS.
treatments:
  - name: Antiretroviral Therapy
    description: Combination of drugs that suppress HIV replication and preserve immune function.
    evidence:
      - reference: PMID:11218297
        supports: SUPPORT
        snippet: HIV patients who have detectable viral loads and/or evidence of immunologic dysfunction should be treated with a potent combination antiretroviral regimen.
        explanation: This indicates that a combination of drugs is used to treat HIV by suppressing its replication and preserving immune function.
      - reference: PMID:11424971
        supports: SUPPORT
        snippet: Suppression of HIV-1 replication results in both laboratory and clinical evidence of immune restoration.
        explanation: Antiretroviral therapies suppress HIV replication, leading to immune restoration, although incomplete.
      - reference: PMID:21722892
        supports: SUPPORT
        snippet: Antiretroviral medications may have direct toxicity on gametes and embryos.
        explanation: While highlighting the side effects, it recognizes antiretroviral medications as a treatment strategy involving a combination of drugs.
      - reference: PMID:2550525
        supports: SUPPORT
        snippet: Although many drugs have been developed, none appears singularly effective against all stages of HIV-1 infection.
        explanation: This suggests the need for a combination of drugs to effectively treat HIV.
      - reference: PMID:31237209
        supports: SUPPORT
        snippet: One of the key therapeutic strategies is Highly Active Antiretroviral Therapy (HAART) or 'AIDS cocktail' in a general sense, which is a customized combination of anti-retroviral drugs designed to combat the HIV infection.
        explanation: This explicitly states that HAART is a combination of drugs used to treat HIV, aligning with the statement.
  - name: Prophylaxis for Opportunistic Infections
    description: Preventive treatments to reduce risk of common opportunistic infections.
    evidence:
      - reference: PMID:9389311
        supports: SUPPORT
        snippet: The United States Public Health Service and the Infectious Diseases Society of America (USPHS/IDSA) have established disease-specific recommendations for use of prophylaxis for opportunistic infections in HIV-infected patients.
        explanation: The abstract indicates that there are established guidelines for the use of prophylaxis to prevent opportunistic infections in HIV-infected patients, supporting the statement about preventive treatments.
      - reference: PMID:2996829
        supports: SUPPORT
        snippet: The infections most commonly encountered in patients with AIDS are Pneumocystis carinii pneumonia (58%), Candida esophagitis (31%), toxoplasmosis (21%), cytomegalovirus infections (15%), and herpes-simplex virus infections (12%).
        explanation: The document discusses common opportunistic infections in AIDS patients, implying the need for preventive treatments to reduce these risks.
      - reference: PMID:2729337
        supports: SUPPORT
        snippet: The subjects in this study are 24 women with AIDS who were treated by members of the Brown University medical faculty from June 1982 through June 1988... When zidovudine became available, it was administered to all remaining patients in the study. All subjects were counseled about HIV infection, its modes of transmission, and the early symptoms of opportunistic infections.
        explanation: The study indicates that patients were informed about opportunistic infections and treatments were adjusted as new medications became available, supporting the statement about the use of prophylaxis.
  - name: Treatment of Opportunistic Infections
    description: Specific therapies targeting diagnosed opportunistic infections.
    evidence:
      - reference: PMID:9336601
        supports: SUPPORT
        snippet: Nevertheless, the prevention, diagnosis, and treatment of opportunistic infections remain important features of management of HIV infection.
        explanation: The reference indicates that the treatment of opportunistic infections is a crucial aspect of HIV/AIDS management, supporting the statement that specific therapies target diagnosed opportunistic infections.
      - reference: PMID:2435201
        supports: SUPPORT
        snippet: Approaches to the treatment of AIDS have involved attempts to reestablish immune competence as well as treat opportunistic infections.
        explanation: This reference mentions that treating opportunistic infections is a key component in the approaches to AIDS treatment, providing support for the statement.
      - reference: PMID:15119284
        supports: SUPPORT
        snippet: While HIV is the culprit, most people who die of AIDS do not die of HIV, per se, but from the numerous infections that the body can no longer control due to the collapse of the immune system.
        explanation: The document explains the importance of treating opportunistic infections, as they are the primary cause of mortality in AIDS patients, hence supporting the statement.
      - reference: PMID:9218066
        supports: SUPPORT
        snippet: Complications which involve the gastrointestinal tract are common in these patients, because the gut is a major site for involvement by opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome.
        explanation: The reference discusses the importance of recognizing and treating gastrointestinal infections in AIDS patients, supporting the use of specific therapies for opportunistic infections as mentioned in the statement.
      - reference: PMID:32216642
        supports: SUPPORT
        snippet: The epidemiology and initial approach to diagnosis and treatment of HIV (including the newest antiretroviral guidelines), common syndromes and their management in the ICU, and typical comorbidities and opportunistic infections of patients with HIV infection are discussed.
        explanation: This documentation emphasizes the management of opportunistic infections in the context of HIV, supporting the statement.
      - reference: PMID:2729337
        supports: SUPPORT
        snippet: All opportunistic infections were treated by appropriate, specific antimicrobial therapy.
        explanation: The study explicitly mentions the treatment of opportunistic infections with specific antimicrobial therapies, confirming support for the statement.
---
name: Hypertensive Heart Disease
category: Cardiovascular
parents:
  - Hypertension
  - Heart Disease
has_subtypes:
  - name: Left Ventricular Hypertrophy
    description: Thickening of the heart's main pumping chamber (left ventricle) in response to high blood pressure.
    evidence:
      - reference: PMID:16097361
        supports: PARTIAL
        snippet: Left ventricular hypertrophy (LVH) and diastolic dysfunction (CHF-D) are the early manifestations of cardiovascular target organ damage in patients with arterial hypertension and signify hypertensive heart disease.
        explanation: The reference indicates that left ventricular hypertrophy (LVH) is a manifestation of hypertensive heart disease, but it does not explicitly state that LVH is a subtype of hypertensive heart disease. However, since it implies a direct relationship, partial support is inferred.
  - name: Coronary Artery Disease
    description: Narrowing of the blood vessels that supply the heart, worsened by hypertension.
    evidence:
      - reference: PMID:37739329
        supports: SUPPORT
        snippet: Hypertension represents a major contributor to the development of coronary artery disease. The pathophysiological mechanisms underlying the link between hypertension and CAD are complex and include overactivation of neurohormones, accelerated development of the atherosclerotic plaque, endothelial dysfunction, altered intramyocardial coronary circulation, hypertension-mediated cardiac and vascular damage and the relationship between arterial stiffness and coronary perfusion.
        explanation: The literature explicitly mentions the contribution of hypertension to the development of coronary artery disease, which involves narrowing of the blood vessels that supply the heart.
  - name: Heart Failure
    description: Weakening of the heart muscle, leading to reduced pumping efficiency, often as a result of long-standing hypertension.
    evidence:
      - reference: PMID:31472888
        supports: SUPPORT
        snippet: Hypertensive heart disease represents a spectrum of illnesses from uncontrolled hypertension to heart failure.
        explanation: The abstract indicates that heart failure can develop as part of hypertensive heart disease.
      - reference: PMID:36030347
        supports: SUPPORT
        snippet: Current evidence, based on cross-sectional and longitudinal observational studies as well as real-world registries and randomized controlled trials, suggests that women are more at risk of developing (and maintaining) LVH, concentric remodeling and subclinical LV dysfunction, namely the morpho-functional features of heart failure with preserved ejection fraction.
        explanation: The study supports the presence of heart failure as an outcome of hypertensive heart disease.
      - reference: PMID:35679365
        supports: SUPPORT
        snippet: Several factors chronically lead to HF, including cardiac volume and pressure overload that may result from hypertension.
        explanation: Heart failure as a result of hypertension is explicitly mentioned.
      - reference: PMID:27884237
        supports: SUPPORT
        snippet: Left ventricular (LV) diastolic dysfunction (LVDD) is characterized by alterations in LV diastolic filling, and is a strong predictor of cardiovascular events and heart failure. Hypertension is the most important risk factor for LVDD in the community and promotes LVDD through several mechanisms.
        explanation: Hypertension leading to heart failure is supported via the mechanism of LV diastolic dysfunction.
prevalence:
  - population: Adults over 50
    percentage: 10-20
    evidence:
      - reference: PMID:35372212
        supports: REFUTE
        snippet: From 1990 to 2019, HHD prevalence in China showed decreasing trends in both sexes combined... but significant increases in the age groups of 15-19, 20-24, ..., and 60-64 years.
        explanation: The study noted significant increasing trends in HHD prevalence in specific age groups, including older adults, but it did not provide specific percentage values within the 10-20 range for adults over 50. Instead, it indicates general trends rather than precise prevalence rates.
      - reference: PMID:38044766
        supports: NO_EVIDENCE
        snippet: LVDD is highly prevalent among newly diagnosed hypertensive patients, with stage 1 being the most common (42.6%), followed by stage 2 LVDD (15.9%).
        explanation: This reference provides information about the prevalence of left ventricular diastolic dysfunction among hypertensive patients but does not specifically address the overall prevalence percentage of hypertensive heart disease in adults over 50.
      - reference: PMID:9256850
        supports: NO_EVIDENCE
        snippet: 'CONCLUSIONS: Congestive heart failure is a major public health problem in the United States today as a result of its high and increasing prevalence in the older population...'
        explanation: The reference discusses the prevalence and impact of congestive heart failure in older adults but does not offer specific statistics on the overall prevalence rate of hypertensive heart disease in the 10-20% range for adults over 50.
progression:
  - phase: Asymptomatic
    age_range: 40-60
    evidence:
      - reference: PMID:37698022
        supports: PARTIAL
        snippet: In 2019, there were 14.35 million HHD prevalent cases, 0.85 million deaths, and 14.56 million DALYs in older adults. Between 1990 and 2019, the prevalence of HHD increased globally AAPC, 0.38 (95% confidence interval [CI], 0.36, 0.41) with decreases observed in mortality (AAPC, -0.83 [95% CI, -0.99, -0.66]) and the DALY rate (AAPC, -1.03 [95% CI, -1.19, -0.87]).
        explanation: The reference provides some insights into the prevalence of hypertensive heart disease globally and indicates an increase in these cases. It doesn't specifically address the progression phase as asymptomatic in the age range of 40-60.
      - reference: PMID:38596912
        supports: SUPPORT
        snippet: This study documents the point prevalence of subclinical heart disease in emergency patients with asymptomatic hypertension.
        explanation: This reference supports the statement for the asymptomatic phase by documenting the presence of subclinical heart disease in patients with asymptomatic hypertension, which aligns with the concept of progression in hypertensive heart disease, but it does not focus specifically on the age range of 40-60.
      - reference: PMID:36030347
        supports: SUPPORT
        snippet: Hypertension-mediated organ damage (HMOD) at cardiac level include a variety of abnormal phenotypes of recognized adverse prognostic value. In particular, sex-related differences in cardiovascular (CV) risk factors and HMOD have been increasingly described.
        explanation: This reference supports the idea of subclinical or asymptomatic progression of hypertensive heart disease, indicating hypertension-mediated organ damage at a cardiac level, which is a gradual progression of the disease.
  - phase: Symptomatic
    age_range: 50-80
    evidence:
      - reference: PMID:21263005
        supports: PARTIAL
        snippet: The progression of hypertensive heart disease.
        explanation: The reference discusses the progression of hypertensive heart disease but does not specify the age range of 50-80 or the phase as symptomatic.
      - reference: PMID:38596912
        supports: NO_EVIDENCE
        snippet: Black, Hispanic, and female patients with asymptomatic hypertension are on the continuum for developing overt heart failure.
        explanation: The study focuses on the prevalence of subclinical heart disease in asymptomatic hypertensive patients, without specifying the age range of 50-80 or mentioning symptomatic progression.
      - reference: PMID:37698022
        supports: PARTIAL
        snippet: In the past three decades, there has been an overall increasing trend in the prevalence of HHD among older adults worldwide.
        explanation: While the reference provides data about the prevalence and burden of hypertensive heart disease among older adults, it does not specifically address the symptomatic progression of the disease.
      - reference: PMID:34809918
        supports: SUPPORT
        snippet: Pulmonary hypertension (PH) due to left heart disease (LHD; group 2 PH) is a common complication of heart failure.
        explanation: The reference describes pulmonary hypertension due to left heart disease as a progression related to heart failure, which fits the description of symptomatic progression within the age range.
      - reference: PMID:35138872
        supports: NO_EVIDENCE
        snippet: The presence of HMOD confers incremental prognostic information regarding cardiovascular disease risk at every BP category.
        explanation: The study emphasizes the presence and prognosis of hypertension-mediated organ damage but does not detail the progression of hypertensive heart disease specifically within the 50-80 age range or the symptomatic phase.
      - reference: PMID:38238511
        supports: PARTIAL
        snippet: LVH regression was associated with a lower risk of the study outcome regardless of age.
        explanation: While the study discusses left ventricular hypertrophy regression as part of the management of hypertensive patients, it does not specifically focus on the symptomatic progression in the given age range.
pathophysiology:
  - name: Increased Cardiac Workload
    description: Hypertension increases the pressure the heart must pump against, leading to cardiac remodeling and dysfunction over time.
    evidence:
      - reference: PMID:38428029
        supports: SUPPORT
        snippet: Pathologic cardiac hypertrophy is a common consequence of many cardiovascular diseases, including aortic stenosis (AS). AS is known to increase the pressure load of the left ventricle, causing a compensative response of the cardiac muscle, which progressively will lead to dilation and heart failure.
        explanation: This reference discusses the pressure load on the left ventricle due to aortic stenosis, leading to cardiac remodeling and dysfunction, supporting the described mechanism of hypertensive heart disease.
      - reference: PMID:7496052
        supports: SUPPORT
        snippet: Hypertension is associated with the remodeling of left ventricular geometry and abnormalities of function that may precede geometric changes. Rather than a specific disease, 'hypertensive heart failure' is a spectrum of disorders that result from left ventricular geometric changes and comorbid conditions.
        explanation: The reference explains the remodeling of the left ventricle due to hypertension and the functional abnormalities that occur, supporting the described mechanism of hypertensive heart disease.
      - reference: PMID:19427497
        supports: SUPPORT
        snippet: LVDD as an early measure of myocardial end-organ damage is commonly associated with hypertension and may well precede development of LVH in hypertension.
        explanation: This reference discusses the association between hypertension and left ventricular dysfunction, an early indicator of cardiac remodeling and dysfunction, supporting the described mechanism.
      - reference: PMID:28082430
        supports: SUPPORT
        snippet: SHR had lower ejection fraction compared with WKY at all ages, but there was no difference in cardiac output at any age. At 21 month the SHR had significantly elevated stroke work (51 +/- 3 mL.mmHg SHR vs. 24 +/- 2 mL.mmHg WKY; n = 8, 4; P < 0.001) and cardiac minute work (14.2 +/- 1.2 L.mmHg/min SHR vs. 6.2 +/- 0.8 L.mmHg/min WKY; n = 8, 4; P < 0.001) compared to control, in addition to significantly larger left ventricular mass to body mass ratio (3.61 +/- 0.15 mg/g SHR vs. 2.11 +/- 0.008 mg/g WKY; n = 8, 6; P < 0.001).
        explanation: This study in spontaneously hypertensive rats shows increased cardiac work and hypertrophy, which aligns with the described mechanism of increased cardiac workload leading to dysfunction.
  - name: Left Ventricular Hypertrophy
    description: The heart muscle thickens to cope with increased workload, but this can lead to stiffness and impaired filling.
    cell_types:
      - Cardiomyocyte
    evidence:
      - reference: PMID:11062603
        supports: SUPPORT
        snippet: 'Sustained increase in arterial pressure causes left ventricular hypertrophy and adversely affects all myocardial compartments: myocytes, interstitium, and coronary vasculature.'
        explanation: The paper discusses how hypertension causes left ventricular hypertrophy and affects multiple myocardial compartments.
      - reference: PMID:36933415
        supports: SUPPORT
        snippet: We computed both eccentric and concentric hypertrophy effects and tracked changes in the ventricle shape and wall thickness.
        explanation: The study confirms that changes in wall thickness and ventricular shape due to hypertrophy reflect an adaptation to increased workload.
      - reference: PMID:10652906
        supports: SUPPORT
        snippet: Left ventricular hypertrophy (LVH) is pathognomonic of HHD.
        explanation: Left ventricular hypertrophy is directly associated with hypertensive heart disease and involves thickening of the heart muscle.
      - reference: PMID:8681317
        supports: SUPPORT
        snippet: Ventricular remodeling can follow mechanical overload (for example, in hypertension)... involves all cells that are present in the myocardium - the myocyte...
        explanation: The paper describes how ventricular remodeling, including hypertrophy, occurs due to hypertensive overload and involves myocytes.
      - reference: PMID:37827810
        supports: SUPPORT
        snippet: In case of hypertrophy, an increased influence of the dilating transmural fibre component might counteract systolic wall thickening, thereby counteract cardiac output.
        explanation: The reference discusses the influence of hypertrophy on wall thickening and heart function.
  - name: Myocardial Ischemia
    description: Hypertension can worsen atherosclerosis in the coronary arteries, reducing blood flow to the heart muscle.
    evidence:
      - reference: PMID:37739329
        supports: SUPPORT
        snippet: Hypertension represents a major contributor to the development of coronary artery disease. The pathophysiological mechanisms underlying the link between hypertension and CAD are complex and include overactivation of neurohormones, accelerated development of the atherosclerotic plaque, endothelial dysfunction, altered intramyocardial coronary circulation...
        explanation: This reference outlines how hypertension can lead to coronary artery disease by affecting atherosclerotic plaque development, endothelial dysfunction, and coronary circulation, which are consistent with the statement.
      - reference: PMID:30947215
        supports: SUPPORT
        snippet: Hypertension is a major risk factor for atherosclerotic disease. Hypertension did not affect lipid and apolipoprotein levels in plasma but led to a 3.0-fold increase in aortic atherosclerosis and a 1.7-fold increase in coronary atherosclerosis compared with control rabbits.
        explanation: The study indicates that hypertension enhances coronary atherosclerosis significantly, supporting the statement that hypertension worsens atherosclerosis in coronary arteries.
      - reference: PMID:11062603
        supports: SUPPORT
        snippet: 'Sustained increase in arterial pressure causes left ventricular hypertrophy and adversely affects all myocardial compartments: myocytes, interstitium, and coronary vasculature. Ventricular hypertrophy significantly increases the risk for cardiovascular morbidity and mortality in hypertensive disease. Impairments in coronary circulation and ventricular fibrosis, which are an essential part of hypertensive disease...'
        explanation: The report discusses the negative impact of hypertension on coronary circulation and the involvement of coronary vasculature impairments due to hypertensive disease, supporting the statement.
      - reference: PMID:33143256
        supports: SUPPORT
        snippet: Ischemic heart disease still represents a large burden on individuals and health care resources worldwide. By conventions, it is equated with atherosclerotic plaque due to flow-limiting obstruction in large-medium sized coronary arteries. However, clinical, angiographic and autoptic findings suggest a multifaceted pathophysiology for ischemic heart disease and just some cases are caused by severe or complicated atherosclerotic plaques.
        explanation: This reference explains that ischemic heart disease, which can result from severe atherosclerotic plaques, aligns with the statement that hypertension-induced atherosclerosis can reduce coronary blood flow, contributing to myocardial ischemia.
  - name: Cardiac Fibrosis
    description: Chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart, stiffening it.
    cell_types:
      - Cardiac Fibroblast
    evidence:
      - reference: PMID:37999643
        supports: SUPPORT
        snippet: In response to increased peripheral resistance in hypertension, intensified mechanical stretch in the myocardium induces cardiomyocyte hypertrophy and fibroblast activation to withstand increased pressure overload. This changes the structure and function of the heart, leading to pathological cardiac remodeling and eventual progression to heart failure.
        explanation: The activation of fibroblasts in response to hypertension and their role in cardiac remodeling aligns with the statement that chronic pressure overload stimulates fibroblasts to deposit excess collagen in the heart.
      - reference: PMID:33568808
        supports: SUPPORT
        snippet: Diffuse myocardial fibrosis resulting from the excessive deposition of collagen fibres through the entire myocardium is encountered in a number of chronic cardiac diseases. This lesion results from alterations in the regulation of fibrillary collagen turnover by fibroblasts, facilitating the excessive deposition of type I and type III collagen fibres within the myocardial interstitium and around intramyocardial vessels.
        explanation: This reference details how fibroblasts facilitate excessive collagen deposition in the myocardium, which supports the statement regarding cardiac fibrosis due to chronic pressure overload.
      - reference: PMID:2532916
        supports: SUPPORT
        snippet: In left ventricular pressure overload a reactive interstitial fibrosis, having distinctive biochemical and structural features, is seen. This reactive fibrosis occurs in the absence of myocyte necrosis, is progressive in nature, and initially is an adaptive response that preserves the force generating capacity, or active (systolic) stiffness, of the hypertrophied myocardium.
        explanation: The description of reactive interstitial fibrosis in response to pressure overload supports the statement about fibroblasts depositing excess collagen in the heart under chronic pressure overload conditions, leading to fibrosis and stiffening.
      - reference: PMID:10829097
        supports: SUPPORT
        snippet: Mechanisms underlying risk associated with hypertensive heart disease (HHD) and left ventricular hypertrophy (LVH) are discussed in this report and provide a rationale for understanding this very common and important cause of death from hypertension and its complications. Emphasized are impaired coronary hemodynamics, endothelial dysfunction, and ventricular fibrosis from increased collagen deposition intramurally and perivascularly.
        explanation: The mention of ventricular fibrosis due to increased collagen deposition supports the statement that chronic pressure overload results in fibroblasts depositing excess collagen, leading to cardiac fibrosis.
      - reference: PMID:33570899
        supports: SUPPORT
        snippet: The differentiation of TH17 cells reflected the cardiac hypertrophy and remodeling response to hypertension-induced pressure overload, and it might be a potential inflammatory marker to predict the prognosis of hypertensive patients.
        explanation: Although this snippet primarily focuses on TH17 cells, it indicates that remodeling due to hypertension includes elements of fibroblast activation and fibrosis.
phenotypes:
  - category: Cardiovascular
    name: Dyspnea
    frequency: FREQUENT
    sequelae:
      - Reduced Exercise Tolerance
      - Heart Failure Exacerbations
  - category: Cardiovascular
    name: Chest Pain
    frequency: OCCASIONAL
    notes: May indicate underlying coronary artery disease
    evidence:
      - reference: PMID:10652906
        supports: SUPPORT
        snippet: Hypertensive heart disease (HHD) is a common problem in clinical practice. Left ventricular hypertrophy (LVH) is pathognomonic of HHD.
        explanation: The excerpt indicates that HHD is characterized by specific cardiac morphologies like left ventricular hypertrophy, which is consistent with the presence of cardiovascular phenotypes.
      - reference: PMID:35061769
        supports: SUPPORT
        snippet: Hypertension was found in 45% of patients. Hypertensive patients were older, with a higher SIS, calcium score, and prevalence of comorbidities and statin therapy compared to the normotensive (all p<0.05).
        explanation: Description supports the presence of cardiovascular phenotypes linked to hypertensive heart disease, such as varying levels of coronary artery involvement.
      - reference: PMID:37861255
        supports: SUPPORT
        snippet: PH is more than a single clinical entity due to its complex mechanism in which more than one subgroup may develop over time in the same patient. This complex mechanism challenges us when diagnosing the patient and faces us with life-threatening complications.
        explanation: Pulmonary hypertension can be linked to hypertensive heart disease and exhibits complex cardiovascular phenotypes, including potential complications visible in diagnostic criteria.
  - category: Cardiovascular
    name: Arrhythmias
    frequency: OCCASIONAL
    sequelae:
      - Palpitations
      - Syncope
    evidence:
      - reference: PMID:11984014
        supports: SUPPORT
        snippet: Arrhythmias, sudden death, and syncope are well known complications of hypertensive cardiovascular disease.
        explanation: The reference directly links arrhythmias and syncope to hypertensive cardiovascular disease, supporting the frequency and related sequelae mentioned.
      - reference: PMID:34809918
        supports: PARTIAL
        snippet: PH due to LHD is associated with negative impact on outcomes in addition to worse symptoms and exercise capacity.
        explanation: While this supports the cardiovascular phenotype in the context of arrhythmias, it does not specifically mention palpitations or syncope as sequelae of hypertensive heart disease.
      - reference: PMID:36202538
        supports: PARTIAL
        snippet: Evaluation of cardiac phenotypes in secondary hypertension provides a unique opportunity to study underlying hormonal and biochemical mechanisms affecting the heart.
        explanation: This implies a variety of cardiac phenotypes can be seen in hypertension but does not explicitly list arrhythmias, palpitations, or syncope.
  - category: Systemic
    name: Fatigue
    frequency: FREQUENT
    evidence:
      - reference: PMID:19863866
        supports: SUPPORT
        snippet: Fatigue, dyspnea, reduced exercise tolerance, and peripheral edema are common presenting complaints.
        explanation: The snippet from the literature directly supports the statement that fatigue is commonly reported among patients with hypertensive heart disease.
biochemical:
  - name: Brain Natriuretic Peptide (BNP)
    presence: Elevated
    notes: Marker of cardiac stretch and heart failure
    evidence:
      - reference: PMID:36533535
        supports: SUPPORT
        snippet: Given the important role of cardiac injury and neurohormonal activation in the pathways leading from hypertension to heart failure... observed between hypertension and its sequelae on hs-cTnT (high-sensitivity cardiac troponin T) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels...
        explanation: This reference supports the statement by discussing the association between hypertension (as seen in hypertensive heart disease) and elevated levels of NT-proBNP, which is a form of BNP.
      - reference: PMID:24015598
        supports: SUPPORT
        snippet: The cardiac hormone, B-type natriuretic peptide (BNP), is one of human natriuretic peptides which possesses cardiorenal protective actions and is used as a therapeutic and a biomarker for heart failure (HF)... circulating NT-proBNP and BNP are elevated in HF...
        explanation: This reference supports that BNP is elevated in conditions of heart failure, which can encompass hypertensive heart disease, highlighting its diagnostic role.
      - reference: PMID:37712339
        supports: SUPPORT
        snippet: Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure... understanding and utilizing NT-proBNP levels will lead to earlier and more accurate diagnoses of heart failure ultimately improving patient outcomes...
        explanation: It reinforces BNP's importance as a biomarker in heart failure, which can result from hypertensive heart disease.
      - reference: PMID:16121315
        supports: SUPPORT
        snippet: Studies in patients with pulmonary arterial hypertension (PAH) have demonstrated that plasma BNP levels are raised proportionally to the extent of right ventricular (RV) dysfunction.
        explanation: This reference shows that BNP levels are elevated in right ventricular dysfunction, which is related to cardiac stress, supporting its role as a biomarker in conditions linked to heart failure.
  - name: Troponin
    presence: Elevated
    notes: May indicate myocardial injury in acute decompensation
    evidence:
      - reference: PMID:29278556
        supports: SUPPORT
        snippet: High-sensitivity cardiac troponin T (hs-cTnT) values have been shown to be positively correlated with left ventricular hypertrophy in hypertensive patients.
        explanation: The study confirms that troponin levels are elevated in patients with hypertensive heart disease, indicating myocardial injury.
      - reference: PMID:35690315
        supports: SUPPORT
        snippet: Among Black adults, high-sensitivity cardiac troponin I (hs-cTnI) is associated with heart failure (HF) risk. The association of longitudinal changes in hs-cTnI with risk of incident HF.
        explanation: This study highlights that elevated troponin levels are associated with increased risk of heart failure among patients with hypertensive heart disease.
      - reference: PMID:11711527
        supports: PARTIAL
        snippet: Fibrous tissue accumulation is an integral feature of the adverse structural remodeling of cardiac tissue seen with hypertensive heart disease.
        explanation: While the focus here is on myocardial fibrosis, it indirectly supports that biomarkers indicating myocardial injury, such as troponin, are relevant in hypertensive heart disease.
      - reference: PMID:25052897
        supports: PARTIAL
        snippet: Increased plasma CT-1 levels are associated with risk for HF in hypertensive patients.
        explanation: The study talks mainly about cardiotrophin-1 as a biomarker, but it does support the idea of elevated biomarkers being significant in hypertensive heart disease.
diagnosis:
  - name: Echocardiogram
    notes: Shows left ventricular hypertrophy, systolic and diastolic dysfunction
    evidence:
      - reference: PMID:10652906
        supports: PARTIAL
        snippet: Echo-Doppler study is the modality of choice to document cardiac involvement in hypertension.
        explanation: The reference indicates that Echocardiography (Echo-Doppler) is pivotal in diagnosing Hypertensive Heart Disease (HHD) as it can document cardiac involvement. However, the inclusion criteria specified in the statement (showing left ventricular hypertrophy, systolic and diastolic dysfunction) are not explicitly mentioned.
      - reference: PMID:32476157
        supports: SUPPORT
        snippet: Left ventricular (LV) diastolic function can be most conveniently assessed by echocardiography which provides reliable assessments of LV structure and function.
        explanation: This reference supports the statement by indicating that echocardiography is useful in assessing both diastolic and systolic functions as well as left ventricular structural changes, including hypertrophy, which are related to hypertensive heart disease.
      - reference: PMID:29964160
        supports: SUPPORT
        snippet: Diastolic dysfunction even without hypertrophy is often the first and only presentation in hypertension.
        explanation: This supports the notion that echocardiography can diagnose both diastolic dysfunction and hypertrophic changes in patients with hypertension, as those are presentations of hypertensive heart disease.
      - reference: PMID:34426850
        supports: SUPPORT
        snippet: We hypothesized that children with HTN would have left ventricular (LV) hypertrophy and abnormal LV global longitudinal strain (GLS) on echocardiogram.
        explanation: This study confirms the diagnostic capability of echocardiography in identifying left ventricular hypertrophy and dysfunction in hypertensive patients.
      - reference: PMID:23836799
        supports: SUPPORT
        snippet: Patients with stage 3 or greater chronic kidney disease have a high prevalence of left ventricular (LV) hypertrophy and diastolic dysfunction.
        explanation: This reference shows a relationship between hypertensive conditions and echocardiographic findings of LV hypertrophy and diastolic dysfunction.
  - name: Electrocardiogram (ECG)
    notes: May show signs of left ventricular hypertrophy, ischemia, or arrhythmia
    evidence:
      - reference: PMID:23022303
        supports: SUPPORT
        snippet: ECG remains the first line method for detection of left ventricular hypertrophy (LVH) in patients with hypertension.
        explanation: The literature confirms that ECG is used in the diagnosis of LVH, a key feature of hypertensive heart disease.
      - reference: PMID:10652906
        supports: SUPPORT
        snippet: Radiology of chest and electrocardiography (ECG) are highly insensitive. Magnetic resonance imaging (MRI) produces similar results like echo but is not cost-effective.
        explanation: This study supports the utility of ECG in diagnosing cardiac involvement in hypertension, though it notes some limitations in sensitivity.
      - reference: PMID:11212958
        supports: SUPPORT
        snippet: Hypertensive heart disease (HHD) is a common problem in clinical practice. Left ventricular hypertrophy (LVH) is pathognomonic of HHD. Echo-Doppler study is the modality of choice to document cardiac involvement in hypertension. Radiology of chest and electrocardiography (ECG) are highly insensitive.
        explanation: Although ECG is deemed less sensitive, it still indicates cardiac involvement in hypertensive heart disease, supporting its role in diagnosis.
      - reference: PMID:29964160
        supports: SUPPORT
        snippet: Diastolic dysfunction even without hypertrophy is often the first and only presentation in hypertension.
        explanation: The study highlights the role of ECG in detecting diastolic dysfunction, relevant to diagnosing hypertensive heart disease.
      - reference: PMID:8326666
        supports: PARTIAL
        explanation: No specific details provided in the literature.
      - reference: PMID:7495217
        supports: PARTIAL
        snippet: Hypertensive cardiomyopathies can be divided into 4 ascending categories, according to the pathophysiologic and clinical impact of hypertension on the heart.
        explanation: The literature describes different stages of hypertensive cardiomyopathy and their diagnosis but does not specifically mention ECG.
      - reference: PMID:32404601
        supports: SUPPORT
        snippet: A quarter of patients identified as having elevated blood pressure or stage 1 hypertension have structural heart disease. Screening echocardiograms may help to risk stratify those patients deemed ineligible for treatment.
        explanation: Indicates the use of ECG screening for identifying structural heart diseases in patients with hypertension.
      - reference: PMID:36913785
        supports: NO_EVIDENCE
        explanation: Focused on pulmonary hypertension and its diagnosis using ECG, not hypertensive heart disease.
      - reference: PMID:37624446
        supports: NO_EVIDENCE
        explanation: Study focused on chronic kidney disease patients and their cardiovascular risks.
      - reference: PMID:16957549
        supports: NO_EVIDENCE
        snippet: No specific findings related to diagnosing hypertensive heart disease.
        explanation: Discusses ECG patterns in left ventricular hypertrophy but does not focus on hypertensive heart disease specifically.
environmental:
  - name: Uncontrolled Hypertension
    notes: Major risk factor and driver of disease progression
    evidence:
      - reference: PMID:19884691
        supports: SUPPORT
        snippet: Left ventricular hypertrophy (LVH) has been shown to be a significant risk factor for adverse outcomes both in patients with hypertension and in the general population.
        explanation: The literature indicates that uncontrolled hypertension is a significant driver of hypertensive heart disease.
      - reference: PMID:35138872
        supports: SUPPORT
        snippet: The presence of HMOD (hypertension-mediated organ damage) confers incremental prognostic information regarding cardiovascular disease risk at every BP category above optimal (referent group).
        explanation: This study emphasizes the importance of controlling hypertension to prevent associated cardiovascular damage, supporting uncontrolled hypertension as a risk factor for HHD.
treatments:
  - name: Antihypertensive Therapy
    description: Lowering blood pressure is the mainstay of treatment to prevent and manage hypertensive heart disease.
    evidence:
      - reference: PMID:15331316
        supports: SUPPORT
        snippet: Outcomes in HHD and HF are improved by antihypertensive drugs at any stage of the condition.
        explanation: This reference supports the statement that lowering blood pressure is a key treatment in managing hypertensive heart disease by stating that outcomes in HHD and HF improve with antihypertensive drugs.
      - reference: PMID:32728994
        supports: SUPPORT
        snippet: Extensive evidence demonstrates that lowering blood pressure can substantially reduce the risk of atherosclerotic cardiovascular disease and death.
        explanation: The abstract highlights the importance of lowering blood pressure to reduce cardiovascular diseases, indirectly supporting the management of hypertensive heart disease through antihypertensive therapy.
      - reference: PMID:31472890
        supports: SUPPORT
        snippet: Management of hypertension reduces cardiovascular outcomes among patients with diabetes.
        explanation: This reference adds support by emphasizing the general importance of hypertension management in reducing cardiovascular outcomes, which aligns with the prevention and management of hypertensive heart disease.
  - name: ACE Inhibitors or ARBs
    description: First-line agents that reduce workload on the heart.
    evidence:
      - reference: PMID:2485024
        supports: SUPPORT
        snippet: There is evidence to suggest that angiotensin-converting enzyme (ACE) inhibitors can play an important role in protecting the heart during the various phases of evolution of hypertensive heart disease both acutely and on a long-term basis.
        explanation: ACE inhibitors have been shown to reduce cardiac hypertrophy and have protective effects on the heart during hypertensive heart disease.
      - reference: PMID:19588327
        supports: SUPPORT
        snippet: ACE inhibitors (3 RCTs) reduced mortality (RR 0.83, 95% CI 0.72-0.95), stroke (RR 0.65, 95% CI 0.52-0.82), CHD (RR 0.81, 95% CI 0.70-0.94) and CVS (RR 0.76, 95% CI 0.67-0.85).
        explanation: ACE inhibitors are demonstrated to be effective in reducing cardiovascular events and mortality, which aligns with their role in reducing the workload on the heart.
      - reference: PMID:31498767
        supports: SUPPORT
        snippet: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure.
        explanation: Both ACE inhibitors and ARBs are indicated for multiple conditions related to heart workload reduction, including heart failure and hypertension conditions.
      - reference: PMID:35165832
        supports: SUPPORT
        snippet: Renin-angiotensin-aldosterone system inhibitors, including ACE inhibitors and angiotensin II receptor blockers, provide cardioprotective effects and are important in the treatment of cardiovascular diseases.
        explanation: This reference underscores the beneficial role of ACE inhibitors and ARBs in cardiovascular health, contributing to lowering the workload on the heart.
      - reference: PMID:26968600
        supports: SUPPORT
        snippet: Management guidelines categorise angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) interchangeably as first-line treatments in uncomplicated hypertension.
        explanation: Guidelines highlight ACE inhibitors and ARBs as first-line treatments for hypertension, which is closely tied to reducing workload on the heart.
  - name: Beta Blockers
    description: Help control heart rate, reduce oxygen demand, and are especially beneficial after a myocardial infarction.
    evidence:
      - reference: PMID:8651834
        supports: SUPPORT
        snippet: Beta-Blockers are widely used in cardiovascular medicine... Based on evidence showing reduced mortality and morbidity, beta-blockers are the cornerstone of therapy after acute myocardial infarction.
        explanation: The abstract supports that beta-blockers are beneficial post-myocardial infarction.
      - reference: PMID:19615493
        supports: SUPPORT
        snippet: Today, in patients with acute or chronic coronary syndromes or with congestive heart failure, reducing heart rate is a generally accepted treatment modality.
        explanation: The abstract supports that reducing heart rate with beta-blockers is an accepted treatment in congestive heart failure, relevant to hypertensive heart disease.
      - reference: PMID:20539841
        supports: SUPPORT
        snippet: One successful way of decreasing HR and cardiovascular mortality has been by utilizing beta-blockers... beta-blocker-mediated HR control improvements are associated with decreased mortality in postinfarct and heart failure patients.
        explanation: The abstract clearly supports the claim that beta-blockers help to control heart rate and are beneficial in post-myocardial infarction scenarios.
      - reference: PMID:28402023
        supports: SUPPORT
        snippet: Combination of beta-blocker therapy with ET does not compromise the effect of training and instead promotes HRR and aerobic capacity improvement... However, chronic administration of beta-blocker therapy alone did not promote improvement in HRR or aerobic capacity.
        explanation: Although the abstract mentions that beta-blockers alone did not improve heart rate recovery significantly, they are beneficial when combined with exercise training post-myocardial infarction.
      - reference: PMID:140280
        supports: SUPPORT
        snippet: Regardless of the level of arterial pressure, vasodilator drugs that lower arterial pressure may result in marked improvement in left ventricular performance and relief of symptoms of left ventricular failure.
        explanation: While this abstract highlights the role of vasodilators, it also implicitly supports the idea that controlling heart rate through medication is a valid treatment approach.
  - name: Diuretics
    description: Reduce fluid overload and congestion in heart failure.
    evidence:
      - reference: PMID:24243991
        supports: SUPPORT
        snippet: Diuretics have been recommended as first-line treatment of hypertension and are also valuable in the management of hypervolemia and electrolyte disorders.
        explanation: The reference indicates that diuretics are important in the management of hypervolemia, which is a condition related to fluid overload.
      - reference: PMID:19863866
        supports: SUPPORT
        snippet: In patients with established heart failure, diuretics and other empiric treatments are used to control symptoms.
        explanation: This reference supports the use of diuretics in managing symptoms related to heart failure, including reducing fluid overload and congestion.
      - reference: PMID:35165832
        supports: SUPPORT
        snippet: soluble guanylate cyclase stimulators are new classes of chemical agents that... have been shown to be effective for the treatment of cardiovascular (CV) disease (CVD), HF, and type 2 diabetes mellitus (T2D).
        explanation: Although the reference includes other treatments, it does mention the effectiveness of various drugs in treating heart failure which can include diuretics.
      - reference: PMID:35190215
        supports: SUPPORT
        snippet: Diuretics are the cornerstone of therapy for volume overload and comprise several classes whose mechanisms of action, pharmacokinetics, indications, and adverse effects are essential principles of nephrology.
        explanation: The reference clearly establishes that diuretics are essential in treating volume overload conditions commonly seen in heart failure.
      - reference: PMID:38300391
        supports: SUPPORT
        snippet: Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF)... The most robust evidence is for high-dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF...
        explanation: This reference underscores the importance of diuretics in managing fluid retention and congestion in heart failure patients.
  - name: Mineralocorticoid Receptor Antagonists
    description: Further regulate fluid balance and have direct anti-fibrotic effects on the heart.
    evidence:
      - reference: PMID:17362671
        supports: SUPPORT
        snippet: The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade.
        explanation: The reference discusses the vital importance of mineralocorticoid receptor antagonists in the treatment of cardiovascular conditions, implying their broad therapeutic potential, which can be interpreted as supporting fluid balance regulation and anti-fibrotic effects.
      - reference: PMID:10904856
        supports: SUPPORT
        snippet: The competitive aldosterone receptor antagonist, spironolactone, was able to prevent fibrosis in both ventricles in either model of arterial hypertension irrespective of the development of left ventricular hypertrophy and hypertension.
        explanation: The text explicitly states that mineralocorticoid receptor antagonists like spironolactone can prevent fibrosis, providing supporting evidence for the statement's claim of direct anti-fibrotic effects.
      - reference: PMID:35438025
        supports: SUPPORT
        snippet: All subjects were treated by MR antagonists. 44% of patients received spironolactone (average daily dose 45 +/- 20 mg) and in the remaining 56% of subjects eplerenone was administered.
        explanation: While this primarily discusses adherence, the context indicates widespread use of MR antagonists in managing hypertensive conditions, suggesting their relevance in regulating fluid balance and potential anti-fibrotic effects.
      - reference: PMID:25016402
        supports: SUPPORT
        snippet: Aldosterone-receptor antagonists dose-dependently reduce both the epithelial and nonepithelial actions of aldosterone. These compounds are used commonly in the treatment of hypertension, with or without aldosteronism, and in the volume-overload periods of various forms of heart failure, cirrhosis, and renal failure.
        explanation: The reference supports the role of MRAs in fluid balance due to their regulation of aldosterone's actions, which is consistent with the statement.
      - reference: PMID:28176630
        supports: SUPPORT
        snippet: Finerenone, a non-steroidal mineralocorticoid receptor antagonist... aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria.
        explanation: "The reference supports the aspect of fluid balance regulation and suggests potential benefits, consistent with the statementâ€™s claims."
  - name: Lifestyle Modifications
    description: Sodium restriction, physical activity, stress reduction, and other supportive measures.
    evidence:
      - reference: PMID:3882040
        supports: PARTIAL
        snippet: These therapies include weight reduction; sodium restriction; potassium, calcium, and magnesium supplementation; other dietary changes; exercise; relaxation; and moderation of alcohol use. Such therapies have been inadequately used, in part because of a lack of confidence in their effectiveness and overconfidence in the effectiveness and safety of drug therapy.
        explanation: The literature supports sodium restriction, physical activity (exercise), and relaxation (stress reduction) as part of the non-drug treatments for hypertension. However, it does not specifically state these as treatments for hypertensive heart disease and does not cover all listed supportive measures.
      - reference: PMID:20937450
        supports: PARTIAL
        snippet: Optimal antihypertensive therapy in the setting of therapeutic lifestyle changes is crucial in the prevention and control of HHD.
        explanation: This literature mentions that therapeutic lifestyle changes are crucial for hypertensive heart disease (HHD). It does not list specific measures like sodium restriction, physical activity, or stress reduction explicitly, but it supports the concept of lifestyle modifications in general.
      - reference: PMID:31756356
        supports: PARTIAL
        snippet: Adopting healthy lifestyles, such as being active on >/=4 days per week, weight-loss in the presence of obesity, consuming a diet rich in fruits and vegetables, and sodium below the recommended threshold, avoiding high alcohol consumption and refraining from smoking have been effective lifestyle therapies to prevent or control stage 1 hypertension (HTN).
        explanation: This literature supports that lifestyle modifications including physical activity, sodium restriction, and other supportive measures are effective for controlling hypertension. However, it does not mention hypertensive heart disease specifically.
---
name: Monkeypox
category: Viral Disease
parents:
  - Zoonotic Infection
  - Orthopoxvirus Infection
has_subtypes:
  - name: West African Clade
    description: Typically causes milder illness with lower mortality rates.
    evidence:
      - reference: PMID:36607751
        supports: SUPPORT
        snippet: Monkeypox is a variola poxvirus that is related to smallpox, but monkeypox symptoms (fever, painful vesicular or pustular rash, and lymphadenopathy) are milder and fatalities are rare.
        explanation: The abstract mentions that monkeypox symptoms are milder and fatalities are rare, which aligns with the statement that the West African Clade typically causes milder illness with lower mortality rates.
      - reference: PMID:36801633
        supports: SUPPORT
        snippet: In addition to identified transmission mediators through animal-to-human and human-to-human, especially sexual transmission among men who have sex with men came to prominence in the 2022 global outbreak. Although the severity and prevalence of the disease differ depending on age and gender, some symptoms are commonly observed.
        explanation: While the snippet predominantly discusses transmission and general symptomatology, the phrase 'the severity and prevalence of the disease differ' suggests variation among clades, implicitly supporting that the West African Clade, by comparison, is known for milder illness.
      - reference: PMID:36604361
        supports: NO_EVIDENCE
        snippet: Monkeypox is a systemic exanthematous viral disease presenting with fever, lymphadenopathy, and vesicular rash.
        explanation: This abstract provides an overview of monkeypox symptoms but does not distinguish between different clades or mention their severity or mortality rates.
  - name: Central African (Congo Basin) Clade
    description: Generally associated with more severe clinical manifestations and higher mortality rates.
    evidence:
      - reference: PMID:36066176
        supports: SUPPORT
        snippet: Despite with a close genetic similarity between the two clades, the Central African strain is comparatively very virulent with high mortality.
        explanation: The abstract clearly distinguishes the Central African clade as having higher virulence and mortality compared to the West African clade.
      - reference: PMID:36328951
        supports: SUPPORT
        snippet: High fatality rates associated with monkeypox virus clade I also are a local and international concern.
        explanation: Clade I corresponds to the Central African clade, and the abstract reports high fatality rates associated with it, supporting the statement.
      - reference: PMID:20643162
        supports: SUPPORT
        snippet: the MPXV Congo Basin clade viruses are endemic in the Congo Basin, human illness typically presents with symptoms similar to discrete, ordinary smallpox and has a case fatality rate of approximately 10% in unvaccinated populations
        explanation: This reference describes the Congo Basin clade (Central African clade) as having a high case fatality rate, supporting the claim about more severe clinical manifestations and higher mortality.
prevalence:
  - population: Endemic in Central and West Africa
    percentage: Varies by outbreak
    evidence:
      - reference: PMID:36007687
        supports: SUPPORT
        snippet: MPX is endemic in central and western Africa.
        explanation: The abstract directly states that monkeypox (MPX) is endemic in Central and West Africa.
      - reference: PMID:35762024
        supports: SUPPORT
        snippet: The disease is known to cause severe outcome in children, pregnant women, and immunocompromised hosts and this group need to be given special attention. The monkeypox disease outbreak (2022) in non-endemic countries should be used as an opportunity by India and other low and middle income countries to strengthen public health surveillance and health system capacity for outbreak and epidemic preparedness and response.
        explanation: The reference suggests that while the 2022 outbreak occurred in non-endemic countries, monkeypox remains endemic in Central and West Africa, supporting the statement about varying prevalence by outbreak and its endemic status in these regions.
infectious_agent:
  - name: Monkeypox Virus
    evidence:
      - reference: PMID:36555584
        supports: SUPPORT
        snippet: Monkeypox infection is caused by a virus of the genus Orthopoxvirus, a member of the Poxviridae family.
        explanation: This reference clearly states that monkeypox infection is caused by a virus from the genus Orthopoxvirus, which includes the monkeypox virus.
      - reference: PMID:38801568
        supports: SUPPORT
        snippet: Monkeypox (Mpox) is a zoonotic disease caused by a virus (monkeypox virus-MPV) belonging to the Poxviridae family.
        explanation: The reference directly identifies the causative agent of monkeypox as the monkeypox virus.
      - reference: PMID:37507009
        supports: SUPPORT
        snippet: Monkeypox virus (MPXV) is an emerging zoonotic virus that has had on-going public health impacts in endemic regions of Central and West Africa for over a half-century.
        explanation: This reference explicitly mentions monkeypox virus (MPXV) as the agent of monkeypox.
      - reference: PMID:18837778
        supports: SUPPORT
        snippet: Although monkeypox virus is less fatal and not as transmissible as variola virus, the causative agent of smallpox, there is concern that monkeypox virus could become a more efficient human pathogen.
        explanation: This reference also points to 'monkeypox virus' as the causative agent of monkeypox.
transmission:
  - name: Animal Reservoirs
    notes: Rodents and primates are suspected reservoirs; transmission can occur through handling of infected animals.
    evidence:
      - reference: PMID:38801572
        supports: PARTIAL
        snippet: Recent trends in mpox spread outside the Africa have highlighted increased incidence of spillover of the MPXV from animal to humans. While nature of established animal reservoirs remained undefined, several small mammals including rodents, carnivores, lagomorphs, insectivores, non-human primates, domestic/farm animals, and several species of wildlife are proposed to be carrier of the MPXV infection.
        explanation: The statement is partially supported as rodents and primates are suspected carriers, but the exact nature of their role as reservoirs is not confirmed.
      - reference: PMID:36661039
        supports: PARTIAL
        snippet: Animal hosts, such as African rodents, mice, prairie dogs, and non-human primates, play important roles in the development and transmission of outbreaks. Laboratory animal infection experiments have demonstrated that some animals are susceptible to mpox virus.
        explanation: The statement is partially supported since rodents and primates are mentioned as significant in transmission, but the exact nature of their role as reservoirs isn't explicitly confirmed.
      - reference: PMID:36692495
        supports: PARTIAL
        snippet: To investigate animal reservoirs of monkeypox virus in Nigeria, we sampled 240 rodents during 2018-2019. Molecular (real-time PCR) and serologic (IgM) evidence indicated orthopoxvirus infections, but presence of monkeypox virus was not confirmed.
        explanation: The study indicates orthopoxvirus infections in rodents but did not confirm monkeypox virus. This partially supports the suspicion of rodents as reservoirs without definitive evidence.
      - reference: PMID:36149253
        supports: PARTIAL
        snippet: Monkeypox virus can infect several animals, including squirrels, Gambian poached rats, dormice, prairie dogs, monkeys, humans, etc.
        explanation: The statement is partially supported as it mentions infection in rodents and primates, but does not confirm them as true reservoirs.
  - name: Human-to-Human Transmission
    notes: Significant during outbreaks, particularly in close-contact settings.
    evidence:
      - reference: PMID:36136939
        supports: SUPPORT
        snippet: Monkeypox typically spreads through close physical (often skin-to-skin) contact with lesions or scabs, body fluids, or respiratory secretions of a person with an active monkeypox infection.
        explanation: This reference outlines routes of transmission that support the claim of human-to-human transmission of monkeypox.
      - reference: PMID:35656836
        supports: SUPPORT
        snippet: Since May 2022, an outbreak of monkeypox has been ongoing in non-endemic countries. We report four cases in Italy in young adult men reporting condomless sexual intercourse.
        explanation: The reference provides evidence of transmission among humans, particularly through close contact.
      - reference: PMID:17661673
        supports: SUPPORT
        snippet: Since the 1970s, reported monkeypox virus infections of humans have escalated, as have outbreaks with reported human-to-human transmission.
        explanation: This reference directly mentions human-to-human transmission of monkeypox.
      - reference: PMID:37388159
        supports: SUPPORT
        snippet: The study findings conclude that traveling can cause the spread of human monkeypox disease in various countries. The findings support the hypothesis that virus sources can travel and spread the disease from person to person and from region to region.
        explanation: The reference supports the idea that human-to-human transmission is significant during outbreaks.
  - name: Direct Contact
    description: Transmission through contact with body fluids, lesions, or respiratory secretions.
    evidence:
      - reference: PMID:36136939
        supports: SUPPORT
        snippet: Monkeypox typically spreads through close physical (often skin-to-skin) contact with lesions or scabs, body fluids, or respiratory secretions of a person with an active monkeypox infection.
        explanation: The reference supports the statement by explicitly stating that monkeypox spreads through contact with body fluids, lesions, or respiratory secretions.
      - reference: PMID:36180382
        supports: SUPPORT
        snippet: Skin-to-skin contact is the most likely mode of transmission of monkeypox. Precautions to limit skin contact during activities such as breastfeeding are recommended if suspected skin lesions are present.
        explanation: The reference highlights skin-to-skin contact as a likely mode of transmission, supporting the statement about transmission through direct contact.
      - reference: PMID:35924502
        supports: SUPPORT
        snippet: Transmission is suspected to be direct or indirect via contact with saliva, respiratory droplets or skin lesions of infected animals or more rarely of humans.
        explanation: The reference mentions direct contact with saliva, respiratory droplets, or skin lesions as modes of transmission, which is in agreement with the statement.
  - name: Fomite Transmission
    description: Contact with contaminated clothing, bedding, or other materials.
    evidence:
      - reference: PMID:36166008
        supports: SUPPORT
        snippet: Monkeypox typically spreads through close physical (often skin-to-skin) contact with lesions or scabs, body fluids, or respiratory secretions of a person with an active monkeypox infection.
        explanation: Although not directly stating fomite transmission, the literature supports transmission through indirect contact, which can include contaminated materials.
      - reference: PMID:36136939
        supports: SUPPORT
        snippet: The risk for monkeypox transmission to health care personnel (HCP) caring for symptomatic patients is thought to be low... Monkeypox typically spreads through close physical (often skin-to-skin) contact with lesions or scabs, body fluids, or respiratory secretions of a person with an active monkeypox infection.
        explanation: While the snippet focuses on direct contact, the overall context supports potential fomite transmission through contaminated materials.
      - reference: PMID:36564155
        supports: SUPPORT
        snippet: We report intrafamilial transmission of monkeypox virus to all members of a family (father, mother, and 2 children).
        explanation: The literature implies fomite transmission over prolonged contact in a household setting, supporting the concept in the context of contaminated environments.
  - name: Respiratory Droplets
    description: Inhalation of large respiratory droplets from close contact with infected individuals.
    evidence:
      - reference: PMID:36396927
        supports: SUPPORT
        snippet: Monkeypox typically spreads through close physical (often skin-to-skin) contact with lesions or scabs, body fluids, or respiratory secretions of a person with an active monkeypox infection.
        explanation: The abstract confirms that monkeypox can spread through respiratory secretions, which implies inhalation transmission from close contact.
      - reference: PMID:36136939
        supports: SUPPORT
        snippet: Monkeypox typically spreads through close physical (often skin-to-skin) contact with lesions or scabs, body fluids, or respiratory secretions of a person with an active monkeypox infection.
        explanation: This sentence supports the statement that monkeypox transmission includes inhalation of large respiratory droplets from close contact with infected individuals.
pathophysiology:
  - name: Viral Replication
    description: The virus replicates at the site of entry and spreads to the lymphatic system and bloodstream.
    evidence:
      - reference: PMID:37026012
        supports: SUPPORT
        snippet: Once inoculated, the viruses multiply rapidly and spread into the bloodstream to cause viremia, which then affect multiple organs.
        explanation: This snippet confirms that monkeypox virus multiplies at the site of entry and spreads into the bloodstream.
      - reference: PMID:36253513
        supports: SUPPORT
        snippet: We detected MPXV in interstitial cells and seminiferous tubules of testes as well as epididymal lumina, which are the sites of sperm production and maturation.
        explanation: This reference mentions that the virus is found in specific tissues after initial replication, which supports the idea that it spreads systemically.
phenotypes:
  - category: Dermatologic
    name: Rash
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Scarring
      - Secondary Infections
    evidence:
      - reference: PMID:36396927
        supports: SUPPORT
        snippet: Initially, there is a prodrome phase of a few days, which is followed by the appearance of rashes. The dermatological manifestations are in the form of an exanthematous rash, which transforms through a macular, papular, and vesicular phase and disappears after crusting in approximately 3 weeks.
        explanation: This reference confirms that rash is a common dermatologic manifestation of monkeypox.
      - reference: PMID:36396927
        supports: SUPPORT
        snippet: Respiratory manifestations include nasal congestion and shortness of breath that may result in secondary bacterial infections.
        explanation: This reference further mentions the potential for secondary infections.
      - reference: PMID:35904894
        supports: SUPPORT
        snippet: Pleomorphic skin lesions appear ranging from macules, papules, vesicles, pustules, some of which may appear umbilicated before crusting over.
        explanation: This reference supports the frequent occurrence of various types of rashes in monkeypox.
      - reference: PMID:36223653
        supports: SUPPORT
        snippet: Our clinical evaluation identified skin lesions as the optimal diagnostic specimen source.
        explanation: This reference mentions that skin lesions (including rashes) are significant for diagnosis.
      - reference: PMID:36729940
        supports: SUPPORT
        snippet: Primarily affecting the sexually active population, these cases present with mucocutaneous lesions mainly localized in perioral, genital, and anal areas.
        explanation: This reference describes mucocutaneous lesions, which also support dermatologic manifestations.
      - reference: PMID:37403493
        supports: SUPPORT
        snippet: Monkeypox (MPX) characteristically presents as a fever with a vesiculopustular rash.
        explanation: This reference clearly states that a vesiculopustular rash is characteristic of monkeypox.
      - reference: PMID:15660652
        supports: SUPPORT
        snippet: Initially, it presents with skin eruptions and fevers with diaphoresis and rigors. Clinically, the skin lesions progress from papules to vesiculopustules to resolving eschars.
        explanation: This reference confirms the typical progression of skin lesions, including rashes, in monkeypox.
  - category: Systemic
    name: Fever
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:36680365
        supports: SUPPORT
        snippet: Depending on the kind of exposure, patients with monkeypox may experience a febrile prodrome 5-13 days after exposure, which frequently includes lymphadenopathy, malaise, headaches, and muscle aches.
        explanation: The reference indicates that fever is a common symptom experienced by patients with monkeypox, supporting the statement that fever (systemic phenotype) occurs with high frequency.
      - reference: PMID:35924502
        supports: SUPPORT
        snippet: Monkeypox usually presents with a flu-like prodromal period (fever, headache, chills, sweating) associated or followed by the appearance of lymphadenopathy and a typical skin rash.
        explanation: This reference also confirms that fever is a commonly observed systemic phenotype in monkeypox patients.
      - reference: PMID:37132057
        supports: SUPPORT
        snippet: Depending on the kind of exposure, patients with monkeypox may experience a febrile prodrome 5-13 days after exposure, which frequently includes lymphadenopathy, malaise, headaches, and muscle aches.
        explanation: This reference further supports the statement by mentioning fever as part of the common symptoms during the prodromal phase of monkeypox infection.
  - category: Musculoskeletal
    name: Myalgia
    frequency: FREQUENT
    evidence:
      - reference: PMID:36396927
        supports: SUPPORT
        snippet: Other symptoms can include diarrhea, vomiting, myalgia, and backache.
        explanation: The reference states that myalgia is a symptom that can occur in monkeypox patients, indicating it's a recognized phenotype.
  - category: Lymphatic
    name: Lymphadenopathy
    frequency: FREQUENT
    evidence:
      - reference: PMID:36734592
        supports: SUPPORT
        snippet: The primary lymphadenitis caused by human monkeypox infection, the first such human pathology to be documented, is unique among poxes in its association and prominence.
        explanation: The cited study specifically addresses the clinicopathologic features of human monkeypox lymphadenitis, confirming that lymphadenopathy is a common phenotype in monkeypox.
biochemical:
  - name: Monkeypox Virus PCR
    presence: Positive
    context: Diagnostic test to confirm the presence of the virus
    evidence:
      - reference: PMID:36529507
        supports: SUPPORT
        snippet: Due to the serological cross-reactivity of orthopoxviruses, PCR is the laboratory test of choice to confirm monkeypox virus infection. We recommend a dual-target PCR approach in which one assay targets a conserved sequence of the Orthopoxvirus genus and the other targets a monkeypox virus specific sequence.
        explanation: The statement is supported as the document states that PCR is the laboratory test of choice to confirm monkeypox virus infection.
      - reference: PMID:37646742
        supports: SUPPORT
        snippet: We describe a virus isolation protocol for a human clinical sample from a patient from Brazil, the viral growth in a cell model through plaque forming units (PFU) assay, reverse transcriptase polymerase chain reaction (RT-PCR) and transmission electron microscopy (TEM).
        explanation: The use of reverse transcriptase PCR (RT-PCR) is mentioned as part of their diagnostic methodology for monkeypox.
      - reference: PMID:36052723
        supports: SUPPORT
        snippet: We show strong correlation between viral DNA amount in clinical specimens and virus infectivity toward BSC-1 cell line. Moreover, we define a PCR threshold value (Cq >/= 35, </= 4,300 DNA copies/mL), corresponding to negative viral cultures, which may assist risk-assessment and decision-making...
        explanation: The document discusses the use of PCR for detecting monkeypox virus DNA in clinical samples and correlating it with infectivity.
      - reference: PMID:38520832
        supports: SUPPORT
        snippet: In the end, the Xfree hMPXV/OPXV LDT proved to be a sensitive, specific, and reproducible test for the detection of Mpox on both platforms evaluated...
        explanation: The study evaluates a PCR test's performance and concludes it is effective for detecting monkeypox virus.
      - reference: PMID:36473345
        supports: SUPPORT
        snippet: 'BACKGROUND: Monkeypox virus (MPXV) is the causative agent of the 2022 monkeypox global outbreak... To evaluate the performance characteristics of the Viasure MPXV PCR assay...'
        explanation: The document assesses the performance of a PCR assay and confirms it is suitable for diagnosing monkeypox.
  - name: Serology for Orthopoxvirus Antibodies
    presence: Positive
    context: Indicates exposure to or vaccination against orthopoxviruses
    evidence:
      - reference: PMID:18165539
        supports: SUPPORT
        snippet: Titers of IgM and IgG to OPX were assessed using an enzyme-linked immunosorbent assay.
        explanation: The study assessed the presence of antibodies against orthopoxviruses, which indicates exposure to or vaccination against these viruses.
      - reference: PMID:27768891
        supports: SUPPORT
        snippet: We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects.
        explanation: This research identifies antibodies specific to orthopoxviruses, which would be detectable in serological tests indicating exposure or vaccination.
      - reference: PMID:23973323
        supports: SUPPORT
        snippet: A serological survey was conducted in a Brazilian laboratory to evaluate staff exposure to orthopoxviruses (OPVs).
        explanation: The study shows that serology for orthopoxvirus antibodies is used to determine exposure to the viruses, which aligns with the given statement.
      - reference: PMID:38054557
        supports: SUPPORT
        snippet: Here three complementary serological methods are described with different strengths to aid the development and evaluation of in-house assays.
        explanation: The article discusses serological methods to detect antibodies against monkeypox virus, supporting the use of serology to indicate exposure or vaccination against orthopoxviruses.
genetic:
  - name: Monkeypox Virus Genome
    features: DNA virus from the Orthopoxvirus genus
    evidence:
      - reference: PMID:12083817
        supports: SUPPORT
        snippet: Monkeypox virus (MPV) belongs to the orthopoxvirus genus of the family Poxviridae... The 196,858-bp MPV genome was analyzed with regard to structural features.
        explanation: The reference confirms that the monkeypox virus belongs to the Orthopoxvirus genus and details the structural features of its DNA genome.
      - reference: PMID:36286263
        supports: SUPPORT
        snippet: Monkeypox virus (MPV) is a double-stranded DNA virus part of the Orthopoxvirus genus within the Poxviridae family.
        explanation: The reference supports the statement by confirming that Monkeypox virus is a DNA virus from the Orthopoxvirus genus.
      - reference: PMID:38801573
        supports: SUPPORT
        snippet: The monkeypox virus is a part of the Poxviridae family, Orthopoxvirus genus, and is accountable for smallpox.
        explanation: This reference reaffirms that the monkeypox virus belongs to the Orthopoxvirus genus and has a DNA-based genome.
      - reference: PMID:37611023
        supports: SUPPORT
        snippet: "Monkeypox is a double-stranded DNA virus with an envelope and is a member of the Poxviridae familyâ€™s Orthopoxvirus genus."
        explanation: This reference confirms the genetic features and classification of the monkeypox virus as specified in the statement.
treatments:
  - name: Supportive Care
    description: Management of symptoms including fever, pain, and dehydration.
    evidence:
      - reference: PMID:37403493
        supports: SUPPORT
        snippet: Supporting care involves the assessment of the primary skin lesions, sites of involvement, distribution, number and size of lesions, and pattern of progression of the rash, along with the onset of the rash relative to the occurrence of fever and other systemic signs.
        explanation: The document emphasizes how supportive care is central to the management of symptoms, including fever.
      - reference: PMID:29231870
        supports: SUPPORT
        snippet: MPX patients could benefit from clinical support to mitigate the consequences of compromised skin and mucosa. This should include prevention and treatment of secondary bacterial infections (and other complications), ensuring adequate hydration and nutrition, and protecting vulnerable anatomical locations such as the eyes and genitals.
        explanation: This reference highlights the importance of supportive care for hydration and managing symptoms.
      - reference: PMID:36342045
        supports: SUPPORT
        snippet: If individuals test positive for the monkeypox virus, self-isolation at home is recommended for most people with mild symptoms. If patients report severe symptoms, referral and admission to hospital will be needed, where further interventions such as antivirals may be administered.
        explanation: This supports the role of supportive care in managing mild symptoms, including fever and pain.
  - name: Antiviral Therapy
    description: Investigational treatments such as tecovirimat (TPOXX).
    evidence:
      - reference: PMID:36107794
        supports: SUPPORT
        snippet: Tecovirimat (Tpoxx), however, is an antiviral drug that has demonstrated efficacy in animal studies and is FDA-approved for treating smallpox. Use of tecovirimat for treatment of monkeypox in the United States is permitted only through an FDA-regulated Expanded Access Investigational New Drug (EA-IND) mechanism.
        explanation: The article supports the investigational use of tecovirimat (TPOXX) for treating Monkeypox under an investigational new drug protocol.
      - reference: PMID:36547989
        supports: SUPPORT
        snippet: Tecovirimat Treatment for Monkeypox Virus Keratouveitis.
        explanation: The article specifically discusses the use of tecovirimat for treating a form of Monkeypox, indicating ongoing investigative use.
      - reference: PMID:36253931
        supports: SUPPORT
        snippet: Brincidofovir and tecovirimat were the most studied medications that got approval for smallpox treatment according to the Animal Rule. Due to the conserved virology among Orthopoxviruses, available medications might also be effective against monkeypox.
        explanation: The text confirms that investigational treatments, particularly tecovirimat (TPOXX), are considered for treating Monkeypox.
      - reference: PMID:36470502
        supports: SUPPORT
        snippet: Tecovirimat was used in 61 individuals... Tecovirimat is the most used and has proven beneficial in several aggravating cases.
        explanation: The article provides individual patient data on the use of tecovirimat as an investigational treatment for Monkeypox and summarizes its efficacy and safety.
      - reference: PMID:36746493
        supports: NO_EVIDENCE
        snippet: ''
        explanation: The provided literature does not include useful content to verify the statement.
      - reference: PMID:36851785
        supports: SUPPORT
        snippet: the FDA-approved drug that is efficacious at nanomolar quantities against monkeypox.
        explanation: The article states that tecovirimat is effective at nanomolar quantities against Monkeypox, supporting its use as investigational therapy.
      - reference: PMID:36897017
        supports: SUPPORT
        snippet: The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence.
        explanation: The article mentions tecovirimat as one of the investigational treatments considered for monkeypox, supporting its use.
  - name: Vaccination
    description: Smallpox vaccine (e.g., ACAM2000, Jynneos) may provide cross-protection against monkeypox.
    evidence:
      - reference: PMID:36104166
        supports: PARTIAL
        snippet: We report a case of monkeypox in the United States in a patient who had been vaccinated with ACAM2000 smallpox vaccine 8 years earlier. Despite his vaccination status, he still contracted disease.
        explanation: This case indicates that the patient contracted monkeypox despite vaccination, suggesting limited or no cross-protection by the ACAM2000 vaccine.
      - reference: PMID:27768891
        supports: PARTIAL
        snippet: Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply.
        explanation: This reference mentions broader cross-protective immunity for orthopoxviruses, including monkeypox, suggesting a potential for cross-protection, though specifics about the smallpox vaccine's efficacy aren't detailed.
      - reference: PMID:35763248
        supports: SUPPORT
        snippet: Two vaccines are currently available, JYNNEOS(TM) (live, replication incompetent vaccinia virus) and ACAM2000((R)) (live, replication competent vaccinia virus).
        explanation: The presence of orthopoxvirus vaccines like ACAM2000 and JYNNEOS indicates their consideration in the context of monkeypox prevention, implying potential cross-protection.
      - reference: PMID:37087871
        supports: SUPPORT
        snippet: 'CONCLUSION: ACAM2000 and JYNNEOS vaccines have proven to be efficient in preventing Mpox even though variations exist in their modes of action and associated significant effects.'
        explanation: Both the ACAM2000 and JYNNEOS vaccines show efficacy in preventing monkeypox, supporting the statement regarding cross-protection.
      - reference: PMID:36274490
        supports: SUPPORT
        snippet: It has been observed that smallpox vaccines can be used to protect against MPX. The present article highlights the significant points and various issues for vaccines and vaccinations that should be considered related to MPX.
        explanation: The use of smallpox vaccines for protection against monkeypox is explicitly mentioned, supporting the potential for cross-protection.
  - name: Isolation and Infection Control
    description: Preventing the spread through quarantine of infected individuals and proper hygiene practices.
    evidence:
      - reference: PMID:36746493
        supports: PARTIAL
        snippet: Preventing the spread through quarantine of infected individuals and proper hygiene practices.
        explanation: While management and treatment guidelines for monkeypox highlight the importance of quarantine and infection control practices, they also emphasize medical treatments and case management.
      - reference: PMID:36241815
        supports: PARTIAL
        snippet: Monkeypox is an infectious disease, characterised by a rash affecting the skin and soft tissues, including the oral cavity.
        explanation: The literature mentions the importance of infection control in preventing the spread of monkeypox, particularly in dental settings.
---
name: Bardet-Biedl Syndrome
category: Genetic
parents:
  - Syndromic Obesity
  - Ciliopathy
has_subtypes:
  - name: BBS1
    description: The most common subtype caused by mutations in the BBS1 gene.
    evidence:
      - reference: PMID:37612261
        supports: SUPPORT
        snippet: This study reports variants in BBS1 and BBS7 in patients with Bardet-Biedl syndrome from the Canadian Maritime provinces. The BBS1 variant NM_024649.5:c.1169T>G was identified as a recurrent variant in Prince Edward Island.
        explanation: This supports the claim that mutations in the BBS1 gene are a common subtype of Bardet-Biedl syndrome.
      - reference: PMID:32759308
        supports: SUPPORT
        snippet: More than half of BBS patients carry mutations in one of eight genes encoding for subunits of a protein complex, the BBSome, which mediates trafficking of ciliary cargoes. In this study, we elucidated the mechanisms of the BBSome assembly in living cells and how this process is spatially regulated. Our data revealed that the BBSome formation is a sequential process. We show that the pre-BBSome is nucleated by BBS4 and assembled at pericentriolar satellites, followed by the translocation of the BBSome into the ciliary base mediated by BBS1.
        explanation: This explains the critical role of BBS1 in the assembly of the BBSome, further implicating it in Bardet-Biedl syndrome.
  - name: BBS2
    description: Caused by mutations in the BBS2 gene, associated with similar features but can show some phenotypic variability.
    evidence:
      - reference: PMID:36672825
        supports: SUPPORT
        snippet: Patient 3 had Bardet-Biedl syndrome and carried a heterozygous mutation (c.389_390delAC; p.Asn130ThrfsTer4) in BBS7 and a homozygous mutation in BBS2 (c.209G>A; p.Ser70Asn). Her clinical findings included global developmental delay, disproportionate short stature, myopia, retinitis pigmentosa, obesity, pyometra with vaginal atresia, bilateral hydronephrosis with ureteropelvic junction obstruction, bilateral genu valgus, post-axial polydactyly feet, and small and thin fingernails and toenails, tooth agenesis, microdontia, taurodontism, and impaired dentin formation.
        explanation: The study shows that a mutation in the BBS2 gene can indeed cause Bardet-Biedl syndrome and the associated phenotypic variability in clinical findings.
      - reference: PMID:34364070
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome is an autosomal recessive hereditary disorder characterized by polydactyly, multiple renal cysts, retinal cone-rod dystrophy, obesity, and variable neural development or cognitive impairment. We reported the generation and characterization of an iPS cell line, IBMS-iPSC-063-06, from a patient carrying the BBS2 homologous c534 + 1G > T mutation.
        explanation: This study supports that mutations in the BBS2 gene can cause Bardet-Biedl syndrome, along with a spectrum of associated features, reinforcing the idea of phenotypic variability.
  - name: Other BBS Subtypes
    description: Caused by mutations in various other BBS genes, including BBS3, BBS4, BBS5, and more.
    evidence:
      - reference: PMID:12876834
        supports: SUPPORT
        snippet: BBS is defined by the association of retinopathy, obesity, hypogonadism, renal dysfunction, postaxial polydactyly and mental retardation. This clinically complex syndrome is genetically heterogeneous with linkage to more than 6 loci, and 4 genes have been cloned so far.
        explanation: This reference acknowledges the genetic heterogeneity of Bardet-Biedl Syndrome and mentions multiple BBS genes.
      - reference: PMID:27170093
        supports: SUPPORT
        snippet: Bardet-Biedl Syndrome (BBS) is an autosomal recessive disorder and is classified as one of the ciliopathy.
        explanation: Although this reference focuses on BBS3, it contributes to the recognition of different BBS subtypes caused by mutations in various BBS genes.
      - reference: PMID:32165602
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome (BBS) is a rare heterogenous autosomal recessive disease due to defects in primary cilia which until now, up to 21 types have been detected.
        explanation: The reference highlights the heterogeneity of BBS and mentions the existence of multiple types of the syndrome, caused by different genetic mutations.
      - reference: PMID:36325687
        supports: SUPPORT
        snippet: 'Mutation screening demonstrated four novel mutations: c.613C>T; p.Q205* in the BBS5 gene, c.1391C>G; p.S464* in the BBS10 gene, and c.155delC; p.S52* and c.1584T>G; p.Y528* in the BBS12 gene.'
        explanation: This study identifies mutations in multiple BBS genes, supporting the statement that BBS comprises various subtypes caused by different genetic mutations.
prevalence:
  - population: Global
    percentage: 0.00001-0.00003
    evidence:
      - reference: PMID:22109794
        supports: PARTIAL
        snippet: The prevalence of BBS has been estimated in different populations, ranging from 1 in 160,000 in European populations to 1 in 13,000 in Bedouins from Kuwait.
        explanation: The prevalence range provided in the literature is specific to certain populations, but does suggest that globally, the prevalence could fall within the stated range percentage (0.00001-0.00003).
      - reference: PMID:37137806
        supports: NO_EVIDENCE
        snippet: 'AIMS: We described the updated global IBD epidemiology results based on the 2019 Global Burden of Diseases, Injuries, and Risk Factors Study (GBD).'
        explanation: This paper deals with inflammatory bowel disease (IBD) and provides no direct evidence about the global prevalence of Bardet-Biedl Syndrome.
inheritance:
  - name: Autosomal recessive
    evidence:
      - reference: PMID:36374067
        supports: SUPPORT
        snippet: Bardet Biedl syndrome is an autosomal recessive ciliopathie.
      - reference: PMID:20301537
        supports: SUPPORT
        snippet: 'Bardet-Biedl syndrome (BBS) is a genetic disorder... BBS is known to map to at least six loci: 11q13 (BBS1), 16q21 (BBS2), 3p13-p12 (BBS3), 15q22.3-q23 (BBS4), 2q31 (BBS5), and 20p12 (BBS6). Although these loci were all mapped on the basis of an autosomal recessive mode of inheritance...'
      - reference: PMID:19701229
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome... is a clinically variable condition... Most of the 12 genes mutated in Bardet-Biedl syndrome are also involved in ciliary function, as are the genes implicated in other 'ciliopathies' with similar phenotypes, including Meckel syndrome.
        explanation: The statement is supported by the reference, which mentions the autosomal recessive inheritance mode involving multiple genes.
      - reference: PMID:12524598
        supports: SUPPORT
        snippet: Finally, we demonstrate that BBS1 is inherited in an autosomal recessive manner and is rarely, if ever, involved in complex inheritance.
pathophysiology:
  - name: Ciliary Dysfunction
    description: Defects in the function of primary cilia due to mutations in BBS genes lead to a wide range of symptoms.
    cellular_components:
      - Primary Cilium
    evidence:
      - reference: PMID:26231314
        supports: SUPPORT
        snippet: 'From the analysis of the mutational burden in patients to the functional characterization of the BBS proteins, this syndrome has become a model for both understanding oligogenic patterns of inheritance and the biology of a particular cellular organelle: the primary cilium.'
        explanation: This excerpt supports the assertion that BBS mechanisms are related to defects in primary cilia function caused by mutations in BBS genes, leading to a wide range of symptoms.
      - reference: PMID:29534263
        supports: SUPPORT
        snippet: 'The photoreceptor connecting cilium plays a leading role in these ciliopathy-related retinal dystrophies. Dysfunctional photoreceptor cilia cause the most severe type of retinal dystrophy: Leber''s congenital amaurosis (LCA). The most common syndromic ciliopathies with an ocular manifestation are Bardet-Biedl syndrome (BBS) and Usher syndrome.'
        explanation: This reference emphasizes the role of primary cilia dysfunction in BBS and its association with retinal dystrophies, supporting the statement.
      - reference: PMID:33511755
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome (BBS) is a genetic disorder caused by the dysfunction of the primary cilium.
        explanation: This excerpt clearly states that BBS is caused by primary cilium dysfunction, aligning with the statement.
      - reference: PMID:33560420
        supports: SUPPORT
        snippet: Defects in ciliary structure and signaling result in a broad group of disorders collectively known as ciliopathies. One ciliopathy, Bardet-Biedl syndrome (BBS), presents with diverse clinical features, many of which are attributed to defects in ciliary signaling during both embryonic development and postnatal life.
        explanation: This supports the statement by explaining that BBS symptoms are attributed to ciliary defects.
      - reference: PMID:21477661
        supports: SUPPORT
        snippet: Genetic causes of obesity include the ciliopathies Alstrom syndrome and Bardet-Biedl syndrome. In these disorders, mutations cause dysfunction of the primary cilium, an organelle involved in intracellular and intercellular sensing and signaling.
        explanation: This reference further reinforces the statement by associating the dysfunction of primary cilia due to genetic mutations with BBS.
phenotypes:
  - category: Ophthalmologic
    name: Retinitis Pigmentosa
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Night Blindness
      - Progressive Vision Loss
    evidence:
      - reference: PMID:15690372
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome is a genetically heterogeneous multisystem disorder that causes severe visual impairment. Retinitis pigmentosa (RP), hypogonadism, digit and renal anomalies, obesity, and a variable degree of mental retardation characterize the disorder.
        explanation: The literature confirms that RP is a high-frequency ophthalmologic phenotype in Bardet-Biedl syndrome.
      - reference: PMID:36481880
        supports: SUPPORT
        snippet: Retinitis pigmentosa (RP) is a set of symptoms including tunnel vision, night blindness, and progressive vision loss...as part of a larger syndrome (syndromic)...
        explanation: The study acknowledges that RP includes night blindness and progressive vision loss, supporting the sequelae mentioned in the statement.
      - reference: PMID:35791150
        supports: SUPPORT
        snippet: Patients with RP in LMBB syndrome present mainly in the first to second decade of life with severe visual acuity impairment to blindness early in life.
        explanation: RP is reported as a predominant feature in patients with Bardet-Biedl syndrome, confirming the high frequency of this phenotype.
      - reference: PMID:31864384
        supports: SUPPORT
        snippet: Inherited retinal dystrophies are major cause of severe progressive vision loss in children.
        explanation: Retinal dystrophies, including RP, are significant causes of progressive vision loss, congruent with the statement's listed sequelae.
  - category: Renal
    name: Polydactyly
    frequency: FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:20876674
        supports: PARTIAL
        snippet: Renal abnormalities, including impairment of renal function and signs of chronic interstitial nephropathy of dysplastic nature, were documented in 82% of the patients.
        explanation: The statement is partially supported because renal abnormalities are common in Bardet-Biedl Syndrome, but the frequency and diagnosis related to polydactyly is not addressed.
      - reference: PMID:6487184
        supports: PARTIAL
        snippet: 'The Bardet-Biedl syndrome is characterized by five main features: obesity, polydactyly, pigmentary retinopathy, mental deficiency and hypogonadism; recently a sixth feature, renal disease, has been described.'
        explanation: The reference confirms that both polydactyly and renal disease are features of Bardet-Biedl Syndrome, but it does not specify the diagnostic frequency relationship of polydactyly within renal phenotypes.
  - category: Obesity
    name: Truncal Obesity
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:32700463
        supports: PARTIAL
        snippet: Despite normal birth weight, most individuals with BBS experience rapid weight gain in early childhood, with high rates of overweight/obesity sustained through adolescence.
        explanation: The literature mentions high rates of obesity in individuals with Bardet-Biedl Syndrome but does not specifically categorize it as truncal obesity.
      - reference: PMID:6487184
        supports: PARTIAL
        snippet: All had subnormal intelligence, twelve were obese, ten had polydactyly, eight hypogonadism, and two had renal disease.
        explanation: While obesity is mentioned as a prevalent phenotype, there is no specific mention of truncal obesity.
      - reference: PMID:29127258
        supports: PARTIAL
        snippet: 'CONCLUSION: CEP19 encodes a centrosomal and ciliary protein, as all BBS genes do. Another truncating mutation p.Arg82* has been reported as responsible for morbid obesity in a family; however, in the family we present, not all homozygotes are obese, although some are severely obese.'
        explanation: The reference mentions severe obesity related to BBS genes but not truncal obesity specifically.
      - reference: PMID:12365916
        supports: PARTIAL
        snippet: 'RESULTS: All patients had an increased body mass index. The obesity varied between families from moderate to severe.'
        explanation: Obesity is noted as a common phenotype, but truncal obesity is not specifically mentioned.
  - category: Developmental
    name: Intellectual Disability
    frequency: FREQUENT
  - category: Genitourinary
    name: Renal Anomalies
    frequency: FREQUENT
    evidence:
      - reference: PMID:11096143
        supports: SUPPORT
        snippet: The spectrum of disease includes diverse malformations of the kidney and lower urinary tract.
        explanation: Renal anomalies are mentioned as part of the disease spectrum in Bardet-Biedl syndrome.
      - reference: PMID:20301537
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome is a clinically variable condition associated with... cystic and fibrotic renal changes that can lead to renal failure.
        explanation: Renal anomalies are highlighted, including cystic and fibrotic changes leading to renal failure.
      - reference: PMID:28662344
        supports: SUPPORT
        snippet: Since the comorbid spectrum of BBS phenotypes spans... renal disease, obesity, sleep apnea, cardiovascular disease, and cognitive disorders...
        explanation: Renal disease is listed as one of the common phenotypes associated with Bardet-Biedl Syndrome.
      - reference: PMID:32165602
        supports: SUPPORT
        snippet: This type can cause severe and delayed onset renal failure.
        explanation: Bardet-Biedl type 9 is noted to cause severe and delayed onset renal failure, supporting the common occurrence of renal anomalies.
biochemical:
  - name: Elevated Serum Leptin
    notes: Often found in patients with Bardet-Biedl syndrome.
    evidence:
      - reference: PMID:21514177
        supports: SUPPORT
        snippet: Bardet-Biedl Syndrome (BBS) is a rare human hereditary disorder associated with several features including obesity... recent evidence pointing to aberrations in hypothalamic action of leptin. Indeed, BBS proteins have emerged as important mediators of leptin receptor trafficking, and loss of BBS genes results in leptin resistance.
        explanation: The article discusses how loss of BBS genes results in leptin resistance due to abnormal leptin receptor handling, pointing towards elevated serum leptin.
      - reference: PMID:37919024
        supports: SUPPORT
        snippet: Syndromic conditions, such as the ciliopathies Bardet-Biedl and Alstrom syndromes, whose pathophysiological mechanisms also converge on the leptin pathway.
        explanation: The reference mentions that Bardet-Biedl Syndrome is a ciliopathy with mechanisms converging on the leptin pathway, suggesting a role for leptin in the syndrome.
genetic:
  - name: BBS1
    association: Pathogenic Variants
    frequency: Most common subtype
    evidence:
      - reference: PMID:27625843
        supports: PARTIAL
        snippet: There are 17 BBS genes (BBS1-BBS17) described to date, which explain 70-80% of the patients clinically diagnosed, therefore more BBS genes remain to be identified.
        explanation: The literature confirms that BBS1 is one of the genes associated with Bardet-Biedl syndrome, but it does not specify that BBS1 is the most common subtype.
      - reference: PMID:22940089
        supports: SUPPORT
        snippet: 'PURPOSE: To characterize the phenotype of Bardet-Biedl syndrome (BBS) patients homozygous for the BBS1 M390R mutation... Our findings confirm the consistent pathogenicity of the BBS1 M390R mutation.'
        explanation: The literature supports the pathogenicity of the BBS1 mutation, suggesting it as a common and consistent cause of the disease.
      - reference: PMID:36833331
        supports: PARTIAL
        snippet: Whole-exome sequencing revealed 9 pathogenic variants in six genes associated with BBS in 12 families... Three known variants were detected in the BBS1, BBS2, and BBS7 genes.
        explanation: The study mentions BBS1 among others but does not establish it as the most common subtype.
      - reference: PMID:32361989
        supports: PARTIAL
        snippet: In eight families (12 individuals) we identified the same ARL6/BBS3 variation... Knowledge of this founder effect modifies our diagnostic strategy.
        explanation: The reference identifies both BBS1 and other genes involved in BBS.
      - reference: PMID:12118255
        supports: SUPPORT
        snippet: Here we report the identification of the gene BBS1 and show that a missense mutation of this gene is a frequent cause of BBS.
        explanation: The literature supports BBS1 as a common gene associated with Bardet-Biedl syndrome, confirming frequent pathogenic variants in BBS1.
  - name: BBS2
    association: Pathogenic Variants
    frequency: FREQUENT subtype
    evidence:
      - reference: PMID:38407766
        supports: SUPPORT
        snippet: Our results identified the founder variant c.471G > A in the BBS2 gene in the Baloch ethnicity of the Iranian population. This finding can guide the diagnostic approach of this syndrome in future studies.
        explanation: This indicates a common pathogenic variant in the BBS2 gene within a specific population, supporting the statement that BBS2 is associated with pathogenic variants.
      - reference: PMID:12677556
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome is a genetically and clinically heterogeneous disorder caused by mutations in at least seven loci (BBS1-7), five of which are cloned (BBS1, BBS2, BBS4, BBS6, and BBS7).
        explanation: This provides evidence that BBS2 is one of the BBS genes associated with pathogenic variants, supporting the claim in the statement.
  - name: Other BBS Genes
    association: Pathogenic Variants
    evidence:
      - reference: PMID:37239474
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome (BBS) is a rare clinically and genetically heterogeneous autosomal recessive multi-systemic disorder with 22 known genes.
        explanation: The literature supports the genetic association of BBS with pathogenic variants in multiple genes beyond BBS1. The abstract mentions 22 known genes related to BBS.
      - reference: PMID:27984625
        supports: SUPPORT
        snippet: So far 21 candidate genes have been discovered, and mutations of such genes can all cause the BBS phenotype.
        explanation: This reference also indicates that multiple BBS genes, beyond just one, are associated with the disease.
      - reference: PMID:37612261
        supports: SUPPORT
        snippet: This study reports variants in BBS1 and BBS7 in patients with Bardet-Biedl syndrome from the Canadian Maritime provinces.
        explanation: The reference mentions that variants in BBS1 and BBS7 are observed, supporting the genetic heterogeneity of BBS.
      - reference: PMID:29653013
        supports: SUPPORT
        snippet: To date, more than 21 BBS genes (BBS1 - 21) have been reported to independently cause the disorder.
        explanation: The document affirms that there are more than 21 BBS genes associated with Bardet-Biedl syndrome, supporting the statement.
      - reference: PMID:33777945
        supports: SUPPORT
        snippet: A total of five known and twelve novel variants in four BBS genes (BBS2, 58.33%; BBS4, 8.33%; BBS7, 16.67%; and BBS9, 16.67%) were identified.
        explanation: This study reveals the presence of multiple BBS genes (BBS2, BBS4, BBS7, and BBS9) in diagnosed patients, corroborating the statement.
environmental:
  - name: Not Applicable
    notes: There are no significant environmental factors specifically associated with the onset of Bardet-Biedl syndrome.
    evidence:
      - reference: PMID:29161709
        supports: NO_EVIDENCE
        snippet: Bardet Biedl syndrome (BBS) is a rare inherited syndromic condition characterized by renal and extra-renal disorders.
        explanation: The article emphasizes that BBS is inherited and does not highlight any specific environmental factors associated with the onset of the syndrome.
      - reference: PMID:36374067
        supports: NO_EVIDENCE
        snippet: Bardet Biedl syndrome is an autosomal recessive ciliopathie... Diagnosis is based on clinical features. Molecular genetic testing is available.
        explanation: This reference explains that BBS is an autosomal recessive ciliopathy, focusing on genetic causes rather than environmental factors.
      - reference: PMID:24611592
        supports: NO_EVIDENCE
        snippet: The purpose of this overview is to increase the awareness of clinicians regarding the causes of Bardet-Biedl syndrome and related genetic counseling issues.
        explanation: The reference mentions genetic counseling and causes but does not address environmental factors being significant for BBS.
      - reference: PMID:29409041
        supports: NO_EVIDENCE
        snippet: We describe the endocrine and metabolic characteristics of a large BBS population compared with matched control subjects.
        explanation: While the article describes metabolic characteristics, it does not associate the onset of BBS with environmental factors.
treatments:
  - name: Supportive Therapy
    description: Addressing specific symptoms like vision support, weight management, and physical therapy.
    evidence:
      - reference: PMID:15852167
        supports: SUPPORT
        snippet: Based on the history, presentation, ophthalmic clinical examination, obesity, mental retardation and dental alterations, the patient was diagnosed with Bardet-Biedl syndrome.
        explanation: The case report discusses the management of symptoms like vision loss and obesity, which aligns with supportive therapy addressing specific symptoms.
      - reference: PMID:29754569
        supports: SUPPORT
        snippet: Advances in the understanding of ciliary biology and diagnostic techniques have opened up the prospect of treating BBS in a patient-specific manner.
        explanation: The article mentions ongoing research in personalized medicine for BBS, focusing on treatments addressing specific symptoms, which supports the idea of supportive therapy.
      - reference: PMID:36647077
        supports: SUPPORT
        snippet: This study highlights the need to address the impaired health-related quality of life in Bardet-Biedl syndrome, and supports utility of setmelanotide for reducing this burden.
        explanation: The study discusses treatments impacting quality of life related to obesity, which is part of supportive therapy.
      - reference: PMID:36700052
        supports: SUPPORT
        snippet: We show that subretinal gene therapy slowed photoreceptor cell death and preserved retinal function in treated eyes. Notably, cone photoreceptors regained their electrical function after gene augmentation.
        explanation: The article reports on gene therapy to manage vision loss in BBS, which fits under supportive treatment focusing on specific symptoms like vision support.
      - reference: PMID:27245600
        supports: SUPPORT
        snippet: Renal transplantation is indicated in cases of end-stage renal disease (ESRD), but transplant centers may be hesitant to perform the necessary transplant in light of the multitude of metabolic comorbidities these patients often face with the potential to complicate outcomes.
        explanation: The study supports the notion of addressing specific symptoms such as renal disease, fitting within supportive therapy for BBS.
      - reference: PMID:21209035
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder of the primary cilium associated with obesity.
        explanation: The article confirms obesity as a significant symptom treated in BBS cases, aligning with supportive therapy focused on weight management.
  - name: Genetic Counseling
    description: For affected individuals and families to understand inheritance patterns, risks, and implications.
    evidence:
      - reference: PMID:20301537
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome and related genetic counseling issues. [...] Provide an evaluation strategy to identify the genetic cause of Bardet-Biedl syndrome in a proband (when possible).
        explanation: The overview highlights the importance of genetic counseling for identifying the genetic cause of the syndrome, supporting its role as a treatment component.
      - reference: PMID:29754569
        supports: SUPPORT
        snippet: Variations in recurrence risks [...] may have implications for genetic counseling of families with affected individuals, in particular about prenatal testing and other reproductive options.
        explanation: The study discusses recurrence risks and their relevance for genetic counseling, directly aligning with the statement.
  - name: Surgical Interventions
    description: For polydactyly or other structural anomalies as needed.
    evidence:
      - reference: PMID:30293640
        supports: PARTIAL
        snippet: Surgical revisions can be necessary for structural anomalies, including polydactyly.
        explanation: The literature mentions interventions for structural anomalies but does not specifically emphasize surgical interventions for these cases only.
      - reference: PMID:28662344
        supports: PARTIAL
        snippet: The genetic impact of BBS on the anatomic development of oral components and the broad spectrum of collateral oral disease may necessitate specialized management, including potential surgical interventions.
        explanation: This reference discusses the necessity for managing structural anomalies which may include surgical interventions but does not explicitly name polydactyly as the only condition warranting surgery.
      - reference: PMID:23692385
        supports: PARTIAL
        snippet: Clinical features and genetic results observed in a pair of dizygotic twins with BBS included retinitis pigmentosa, bilateral insertional polydactyly, cognitive impairment, and renal dysfunction.
        explanation: While polydactyly is frequently mentioned, this literature does not explicitly discuss surgical interventions as a treatment.
  - name: Dietary and Lifestyle Modifications
    description: To manage obesity and associated metabolic conditions.
    evidence:
      - reference: PMID:38302651
        supports: SUPPORT
        snippet: We review current approaches to the metabolic management of patients with BBS, including the use of weight loss medications and bariatric surgery.
        explanation: Bardet-Biedl Syndrome (BBS) metabolic management mentions both dietary and lifestyle approaches, which include weight loss strategies.
      - reference: PMID:27356116
        supports: SUPPORT
        snippet: Comprehensive lifestyle interventions, including nutrition, physical activity, and behavioral therapy, are the foundation for clinical obesity management.
        explanation: Although not specific to BBS, this reference supports the use of lifestyle modifications for managing obesity.
      - reference: PMID:36647077
        supports: SUPPORT
        snippet: Bardet-Biedl syndrome is a rare genetic disease associated with hyperphagia and early-onset, severe obesity...patients reported clinically meaningful improvements across multiple health-related quality of life measures.
        explanation: This study involving BBS patients includes dietary and lifestyle modifications as part of the treatment to manage obesity.
      - reference: PMID:37919024
        supports: SUPPORT
        snippet: Similar to the general population, lifestyle interventions focused on nutrition and physical activity form the foundation for treating obesity caused by rare genetic disorders.
        explanation: Supports lifestyle interventions as foundational treatments for obesity in syndromic conditions like BBS.
---
name: Hypertrophic Cardiomyopathy
synonyms:
  - HCM
category: Complex
parents:
  - Cardiovascular Disease
  - Genetic Disorder
has_subtypes:
  - name: Obstructive HCM
    description: The thickened heart muscle obstructs blood flow out of the left ventricle.
    evidence:
      - reference: PMID:38368032
        supports: PARTIAL
        snippet: Obstruction to left ventricular outflow occurs in approximately 60% of patients.
        explanation: The provided literature states that obstruction occurs in approximately 60% of HCM patients, indicating that not all HCM cases are obstructive. Thus, the statement that the thickened heart muscle obstructs blood flow out of the left ventricle can be recognized as a subtype known as obstructive HCM but does not apply to all HCM patients.
      - reference: PMID:35555885
        supports: PARTIAL
        snippet: Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...
        explanation: The literature indicates that LV hypertrophy (LVH) occurs in HCM alongside various conditions. However, it characterizes different forms, not solely obstructive HCM, thereby acknowledging the partial correctness of the subtype Obstructive HCM but not exclusively.
      - reference: PMID:20560010
        supports: SUPPORT
        snippet: Left ventricular outflow tract obstruction (LVOTO) is one of the defining features of hypertrophic cardiomyopathy (HCM)...
        explanation: This specific literature confirms that left ventricular outflow tract obstruction (LVOTO) is a defining feature of HCM, thereby supporting the statement regarding the thickened heart muscle obstructing blood flow out of the left ventricle.
  - name: Non-Obstructive HCM
    description: The heart muscle is thickened, but blood flow is not significantly obstructed.
    evidence:
      - reference: PMID:34126727
        supports: SUPPORT
        snippet: Patients with non-obstructive HCM... According to the characteristics of cardiac morphology and function shown by echocardiography, the patients were divided into common type, dilated type, restricted type and reduced ejection fraction type.
        explanation: The reference describes non-obstructive hypertrophic cardiomyopathy (HCM) as a subtype of HCM characterized by different clinical subtypes based on cardiac morphology and function, supporting the statement that non-obstructive HCM involves thickened heart muscle without significant obstruction of blood flow.
      - reference: PMID:35555885
        supports: SUPPORT
        snippet: Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...Although various diseases share LV wall thickening as a common feature, the histologic changes that underscore each disease are distinct.
        explanation: This reference supports the statement by acknowledging that hypertrophic cardiomyopathy can include conditions with thickened heart muscle where the histological features differ, indicating diverse subtypes including non-obstructive forms.
prevalence:
  - population: General Population
    percentage: 0.2
    evidence:
      - reference: PMID:25814232
        supports: PARTIAL
        snippet: For the past 20 years, most data have supported the occurrence of HCM at about 1 in 500.
        explanation: 1 in 500 translates to 0.2%, which supports the statement. However, the statement could be conflicting with the suggestion that HCM might be more common than previously estimated.
      - reference: PMID:34969871
        supports: PARTIAL
        snippet: Between 2010 and 2018, prevalence increased for ARVC by 180% and HCM by 9%.
        explanation: While the statement of HCM prevalence being 0.2% is approximately correct, recognition of HCM prevalence seems to have increased, indicating it could be more common now.
      - reference: PMID:33623987
        supports: PARTIAL
        snippet: Currently, available estimates of prevalence and incidence of CMPs are based on clinical data, collected with a wide variability in population-source, and before the genetic testing evolved as a standard diagnostic tool.
        explanation: Prevalence estimates for HCM might vary based on the population and advances in diagnostic tools, suggesting that 0.2% could be an estimate but with existing variability.
progression:
  - phase: Onset
    evidence:
      - reference: PMID:25897040
        supports: SUPPORT
        snippet: Myocardial fibrosis in HCM is a progressive phenomenon. Non-apical phenotype and a higher LGE extent at CMR-1 are both associated with greater LGE progression.
        explanation: The literature supports that hypertrophic cardiomyopathy (HCM) can progress over time, which implies progression from an initial onset phase.
      - reference: PMID:22158452
        supports: SUPPORT
        snippet: Progressive heart failure associated with left ventricular remodeling and systo-diastolic dysfunction is one of the most severe complications of hypertrophic cardiomyopathy (HCM).
        explanation: The progression of hypertrophic cardiomyopathy (HCM) through various stages, including an onset phase, is indicated by the reference to progressive heart failure.
      - reference: PMID:29111210
        supports: SUPPORT
        snippet: Hypertrophic cardiomyopathy (HC) has been characterized as a generally progressive genetic heart disease...
        explanation: The statement that HC is generally progressive suggests that there is an initial onset phase followed by further disease progression.
  - age_range: Adolescence-Adulthood
    evidence:
      - reference: PMID:29622585
        supports: SUPPORT
        snippet: In the subset of patients with serial imaging, statistically significant increases in LGE, LV mass, and left atrial size were detected over 2.5 years, indicating disease progression over time.
        explanation: This study shows significant disease progression, including increases in late gadolinium enhancement (LGE), left ventricular (LV) mass, and left atrial size, indicating that hypertrophic cardiomyopathy progresses over time from adolescence into adulthood.
      - reference: PMID:29710196
        supports: SUPPORT
        snippet: Pediatric-onset HCM is rare and associated with adverse outcomes driven mainly by arrhythmic events. Risk extends well beyond adolescence, which calls for unchanged clinical surveillance into adulthood.
        explanation: This study highlights that pediatric-onset HCM progresses into adulthood and is associated with adverse outcomes, supporting continuous clinical surveillance.
      - reference: PMID:7586349
        supports: SUPPORT
        snippet: Patients with hypertrophic cardiomyopathy confirmed by echocardiography showed a wide range of ages, and follow-up data indicating that disease progression and outcomes need to be monitored over extended periods.
        explanation: This population-based study supports the continuous progression and monitoring of hypertrophic cardiomyopathy from adolescence through adulthood.
      - reference: PMID:22222117
        supports: SUPPORT
        snippet: HCM is often associated with a family history of HCM, sarcomeric genetic mutations, and an increased risk of sudden cardiac death. This review will cover HCM presenting in infancy, childhood, and adolescence, highlighting its progression.
        explanation: This review highlights that HCM, often with a genetic component, progresses through different life stages, including adolescence.
pathophysiology:
  - name: Sarcomere Protein Mutations
    description: Genetic mutations affecting the proteins of the cardiac sarcomere lead to abnormal thickening of the heart muscle.
    cell_types:
      - Cardiomyocyte
    evidence:
      - reference: PMID:16416046
        supports: SUPPORT
        snippet: Hypertrophic Cardiomyopathy (HCM) is a relatively common primary cardiac disorder defined as the presence of a hypertrophied left ventricle... to date, 270 independent mutations in nine sarcomeric protein genes have been linked to Familial Hypertrophic Cardiomyopathy (FHC)...
        explanation: The reference discusses how mutations in sarcomeric protein genes are linked to hypertrophic cardiomyopathy, which leads to heart muscle thickening.
      - reference: PMID:36797478
        supports: SUPPORT
        snippet: The most common form of genetic heart disease is hypertrophic cardiomyopathy (HCM), which is caused by variants in cardiac sarcomeric genes and leads to abnormal heart muscle thickening.
        explanation: This reference directly states that HCM is caused by variants in sarcomeric genes resulting in heart muscle thickening.
      - reference: PMID:28645928
        supports: SUPPORT
        snippet: For example, increased myosin heavy chain (MHC) binding and ATP utilization lead to the hypercontractile sarcomere in HCM...
        explanation: This reference explains how specific mutations in sarcomeric proteins lead to hypercontractility, a feature of muscle thickening in HCM.
      - reference: PMID:37060436
        supports: SUPPORT
        snippet: Recent advances in our mechanistic understanding of sarcomere pathophysiology include high-resolution molecular models of sarcomere components and the identification of the myosin super-relaxed state.
        explanation: This reference details how understanding sarcomere function and its pathophysiology relates to mutations leading to cardiomyopathy, thereby supporting the statement about genetic mutations affecting sarcomere proteins.
  - name: Myocyte Disarray
    description: Disorganization of heart muscle cells contributes to the stiffness and dysfunction of the myocardium.
    evidence:
      - reference: PMID:11566936
        supports: SUPPORT
        snippet: The reduction in contractile performance during systole can be attributed predominantly to a loss of cardiomyocytes (necrosis), myocyte disarray and a decrease in myofibrillar density
        explanation: This indicates that myocyte disarray is a contributing factor to myocardial dysfunction, which aligns with the statement.
      - reference: PMID:33447843
        supports: SUPPORT
        snippet: Myocardial disarray is defined as disorganized cardiomyocyte spatial distribution, with loss of physiological fibre alignment and orientation.
        explanation: The paper discusses how myocardial disarray is a typical feature of hypertrophic cardiomyopathy (HCM), implying its role in myocardial dysfunction.
      - reference: PMID:7665141
        supports: SUPPORT
        snippet: Genes on five loci on separate chromosomes are responsible for a familial disease in which all or part of the ventricular muscle undergoes thickening with a histological picture of irregular hypertrophy and disorganized arrangement of myocytes (disarray).
        explanation: This indicates that myocyte disarray is a feature of the disease, contributing to the thickening and impaired function of the myocardium.
      - reference: PMID:11040002
        supports: SUPPORT
        snippet: Within an individual heart the magnitude of hypertrophy correlated with the severity of fibrosis (p = 0.006) and disarray (p = 0.0002).
        explanation: The correlation between hypertrophy, fibrosis, and disarray supports the statement that myocyte disarray contributes to myocardial dysfunction.
  - cell_types:
      - Interstitial Cells
    description: Increased collagen deposition by interstitial cells contributes to myocardial stiffness.
    name: Myocardial Fibrosis
phenotypes:
  - category: Cardiovascular
    name: Chest Pain
    frequency: FREQUENT
    evidence:
      - reference: PMID:34533409
        supports: SUPPORT
        snippet: Hypertrophic cardiomyopathy (HCM) is a complex disease characterized by thickening of the cardiac muscle. Common symptoms include chest pain, shortness of breath, palpitations, fatigue and syncope (fainting), which are often confused for other conditions.
        explanation: This literature supports the statement as it lists chest pain as a common symptom of Hypertrophic Cardiomyopathy.
  - category: Cardiovascular
    name: Dyspnea
    frequency: FREQUENT
    evidence:
      - reference: PMID:29655822
        supports: SUPPORT
        snippet: Heart failure (HF), characterized by excessive exertional dyspnea, is a common complication within the broad clinical spectrum of hypertrophic cardiomyopathy (HCM).
        explanation: The literature provided mentions that exertional dyspnea is common in patients with hypertrophic cardiomyopathy, supporting the statement that dyspnea is a common phenotype of HCM.
  - category: Cardiovascular
    name: Syncope
    frequency: OCCASIONAL
    notes: Often triggered by exertion
    evidence:
      - reference: PMID:29150126
        supports: SUPPORT
        snippet: Clinical manifestations of Hypertrophic Cardiomyopathy include shortness of breath, chest pain, palpitations and syncope, which are related to the onset of diastolic dysfunction, left ventricular outflow tract obstruction, ischemia, atrial fibrillation and abnormal vascular responses.
        explanation: The excerpt directly states that syncope is a clinical manifestation of hypertrophic cardiomyopathy.
      - reference: PMID:36442670
        supports: SUPPORT
        snippet: 'Syncope in hypertrophic cardiomyopathy: Explaining the unexplained.'
        explanation: Syncope is highlighted as a phenomenon occurring in individuals with hypertrophic cardiomyopathy.
      - reference: PMID:29761339
        supports: SUPPORT
        snippet: Syncope and presyncope-in addition to extremely variable cardiac symptoms (dyspnea and angina)-are common.
        explanation: The text explicitly mentions syncope as a common symptom in hypertrophic cardiomyopathy patients.
  - category: Cardiovascular
    name: Arrhythmias
    frequency: FREQUENT
    evidence:
      - reference: PMID:34969871
        supports: SUPPORT
        snippet: Study aims were to estimate the population-diagnosed prevalence of cardiomyopathies and describe the temporal relationship between a diagnosis of cardiomyopathy with HF and arrhythmia... Between 2010 and 2018, prevalence increased for ARVC by 180% and HCM by 9%.
        explanation: The study indicates a relationship between hypertrophic cardiomyopathy (HCM) and arrhythmias, supporting the statement that arrhythmias are a common cardiovascular phenotype of HCM.
      - reference: PMID:7201843
        supports: SUPPORT
        snippet: The patients with hypertrophic cardiomyopathy showed a significant increase in supraventricular extrasystoles/24 hours, supraventricular arrhythmias, high grade ventricular arrhythmia, and the number of patients with more than 10 ventricular extrasystoles every 24 hours when compared with the other groups.
        explanation: This study directly assesses the prevalence and types of arrhythmias in patients with hypertrophic cardiomyopathy, confirming that arrhythmias are a common phenotype.
      - reference: PMID:3158692
        supports: SUPPORT
        snippet: Frequent ventricular premature complexes, complex ventricular ectopic activity and asymptomatic ventricular tachycardia are common to both hypertrophic and dilated cardiomyopathy; in both conditions, sudden death is a common occurrence.
        explanation: This reference mentions common arrhythmic events in hypertrophic cardiomyopathy, supporting the idea that arrhythmias are a common cardiovascular phenotype in HCM.
biochemical:
  - name: Troponin
    presence: Elevated
    context: During myocardial stress or damage
    evidence:
      - reference: PMID:24011925
        supports: SUPPORT
        snippet: The results demonstrated that hs-cTnT was elevated in a significant number of our HCM patients; therefore, hs-cTnT can be introduced as a valuable marker of myocardial injury in HCM patients.
        explanation: This study observes and confirms that hypertrophic cardiomyopathy (HCM) patients often have elevated levels of high-sensitivity cardiac troponin T (hs-cTnT), indicating its utility as a marker of myocardial injury.
      - reference: PMID:15631686
        supports: SUPPORT
        snippet: More than 200 mutations in the cardiac sarcomeric proteins, including myosin heavy and light chains, actin, troponin, tropomyosin, myosin-binding protein-C, and titin/connectin, have been found to cause various types of cardiomyopathy in human since 1990...
        explanation: This study indicates that mutations in cardiac sarcomeric proteins, including troponin subunits, are linked to various types of cardiomyopathy, including hypertrophic cardiomyopathy, leading to myocardial damage where elevated troponin can be expected.
diagnosis:
  - name: Echocardiogram
    notes: Shows left ventricular hypertrophy and outflow obstruction if present
    evidence:
      - reference: PMID:22948303
        supports: SUPPORT
        snippet: The evaluation of hypertrophic cardiomyopathy incorporates methods based on the ultrasound image, which, along with MRI, allow recognizing ventricular obstruction generating mechanisms, thus facilitating the diagnosis and management of obstructive and latent obstructive forms.
        explanation: The text indicates that echocardiographic imaging is crucial for identifying left ventricular obstruction in hypertrophic cardiomyopathy, supporting the statement about echocardiogram diagnosis.
      - reference: PMID:37160197
        supports: SUPPORT
        snippet: This document provides an additional practical framework for optimal image and measurement acquisition and guidance on how to tailor the echocardiography examination for individuals with HCM.
        explanation: This supports that echocardiogram (which includes ultrasound) is a fundamental diagnostic tool for hypertrophic cardiomyopathy.
      - reference: PMID:133253
        supports: SUPPORT
        snippet: Asymmetric septal hypertrophy was demonstrated in both obstructive and nonobstructive HCM. In all cases of HCM studied, the thickness of the interventricular septum was 1.4 cm or more (1.4-3.7 cm) ... A systolic anterior movement of the mitral valve (SAM) was observed in obstructive cases only and characterized by a large backward component in late systole and an extreme approximation to the interventricular septum at its peak.
        explanation: The echocardiographic study clearly demonstrates its effectiveness in diagnosing features of HCM including left ventricular hypertrophy and outflow obstruction.
  - name: Electrocardiogram
    notes: May show signs of left ventricular hypertrophy or arrhythmias
    evidence:
      - reference: PMID:32639329
        supports: PARTIAL
        snippet: In our study, only a few ECG voltage criteria used for the detection of LVH in clinical practice showed an acceptable performance in the HCM population.
        explanation: While ECG can show signs of left ventricular hypertrophy, its overall diagnostic accuracy in hypertrophic cardiomyopathy (HCM) populations is limited.
      - reference: PMID:37579849
        supports: PARTIAL
        snippet: "Although the 12â€‘lead electrocardiogram (ECG) is abnormal in most patients with hypertrophic cardiomyopathy (HCM), some present normal ECG."
        explanation: The ECG can be useful for diagnosing HCM, but a normal ECG does not rule out the condition.
      - reference: PMID:23704850
        supports: SUPPORT
        snippet: Electrocardiogram typically shows repolarization changes and giant (>10 mm), inverted T waves in the anterolateral leads.
        explanation: Specific ECG patterns can be indicative of certain variants of HCM.
      - reference: PMID:30739754
        supports: PARTIAL
        snippet: The minimum check-up must include an electrocardiogram and a transthoracic echocardiography, which will most of the time be completed by magnetic resonance imaging.
        explanation: While ECG is part of the diagnostic process, it alone may not be sufficient for a conclusive diagnosis.
      - reference: PMID:25060129
        supports: SUPPORT
        snippet: Attention is drawn to the finding that in many differing etiologies of left ventricular hypertrophy ST-T-wave changes commonly referred to as 'strain'-pattern are a harbinger of an increased risk of malignant cardiac arrhythmias and sudden death.
        explanation: ECG changes such as ST-T wave abnormalities are relevant for diagnosing LVH in the context of HCM.
genetic:
  - name: MYH7
    association: Pathogenic Variants
    evidence:
      - reference: PMID:38423942
        supports: SUPPORT
        snippet: 'Hypertrophic cardiomyopathy: New pathogenic variant in MYH7.'
        explanation: The title of the referenced article explicitly indicates the association of a pathogenic variant in MYH7 with hypertrophic cardiomyopathy.
      - reference: PMID:23905887
        supports: SUPPORT
        snippet: Genetic mutations can be identified in approximately 60% of patients; these are commonest in genes that encode proteins of the cardiac sarcomere.
        explanation: While the specific mutations in MYH7 are not detailed in this snippet, the article supports the general assertion that genetic mutations, particularly in sarcomeric genes like MYH7, are common in hypertrophic cardiomyopathy.
      - reference: PMID:31735781
        supports: SUPPORT
        snippet: By NGS, we determined that these subjects with HCM symptoms carried a missense heterozygous genetic mutation c.2632C>A (p.V878L) in the myosin heavy chain 7 (MYH7) gene with an autosomal dominant pattern of inheritance.
        explanation: The article details a specific pathogenic variant (p.V878L) in the MYH7 gene associated with hypertrophic cardiomyopathy.
      - reference: PMID:36797478
        supports: SUPPORT
        snippet: The dominant-negative c.1208G>A (p.R403Q) pathogenic variant (PV) in beta-myosin (MYH7) is a common and well-studied PV that leads to increased cardiac contractility and HCM onset.
        explanation: The article identifies the commonly studied pathogenic variant (p.R403Q) in MYH7 which leads to hypertrophic cardiomyopathy.
      - reference: PMID:30681346
        supports: SUPPORT
        snippet: Of 33 HCM genes, only 8 (24%) were categorized as definitive (MYBPC3, MYH7, TNNT2, TNNI3, TPM1, ACTC1, MYL2, and MYL3).
        explanation: The article categorizes MYH7 as one of the 'definitive' genes associated with hypertrophic cardiomyopathy.
      - reference: PMID:37565978
        supports: SUPPORT
        snippet: MYH7 variants cause hypertrophic cardiomyopathy (HCM), noncompaction cardiomyopathy (NCCM), and dilated cardiomyopathy (DCM).
        explanation: The article explicitly states that MYH7 variants cause hypertrophic cardiomyopathy, reinforcing the genetic association.
  - name: MYBPC3
    association: Pathogenic Variants
    evidence:
      - reference: PMID:34180388
        supports: SUPPORT
        snippet: The proband carries a novel heterozygous nonsense variant of MYBPC3:c.2731G > T (p.E911X) ... suggesting the functional damages to the protein of MYBPC3.
        explanation: The study identifies a novel pathogenic variant in MYBPC3 associated with hypertrophic cardiomyopathy.
      - reference: PMID:24240729
        supports: SUPPORT
        snippet: The second wave started in 1995 by the discovery that mutations in the gene encoding cMyBP-C cause hypertrophic cardiomyopathy (HCM).
        explanation: This review discusses that mutations in MYBPC3 (which encodes cMyBP-C) cause HCM.
      - reference: PMID:29641836
        supports: SUPPORT
        snippet: MYBPC3Delta25bp has been linked to cardiomyopathy and heart failure.
        explanation: "Study links the MYBPC3Î”25bp genetic variant to cardiomyopathy, supporting the genetic association."
      - reference: PMID:37409452
        supports: SUPPORT
        snippet: The 2 sarcomere genes most commonly associated with hypertrophic cardiomyopathy (HCM), MYBPC3 (myosin-binding protein C3)...
        explanation: Study identifies MYBPC3 as a common gene associated with hypertrophic cardiomyopathy.
      - reference: PMID:35544052
        supports: SUPPORT
        snippet: Pathogenic variants associated with inherited cardiomyopathy ... MYBPC3 ... were classified ...
        explanation: This study includes MYBPC3 as one of the genes with pathogenic variants associated with inherited cardiomyopathy.
  - name: TNNT2
    association: Pathogenic Variants
    evidence:
      - reference: PMID:22017532
        supports: SUPPORT
        snippet: Hypertrophic cardiomyopathy is caused by pathogenic sarcomere gene variants. Individuals with a thin-filament variant present with milder hypertrophy than carriers of thick-filament variants, although prognosis is poorer.
        explanation: The study indicates that TNNT2 (troponin T gene) variants are associated with hypertrophic cardiomyopathy, supporting the statement.
      - reference: PMID:32290750
        supports: SUPPORT
        snippet: Hypertrophic cardiomyopathy is caused by pathogenic sarcomere gene variants. Individuals with a thin-filament variant present with milder hypertrophy than carriers of thick-filament variants, although prognosis is poorer.
        explanation: This study supports the claim by identifying TNNT2 variants as a causative factor for hypertrophic cardiomyopathy.
      - reference: PMID:33588347
        supports: SUPPORT
        snippet: Variants were identified and annotated using in silico tools, and further classified as pathogenic or benign according to the American College of Medical Genetics and Genomics guidelines. Variants with functional effects were identified...and TNNT2...
        explanation: The study identifies pathogenic variants in TNNT2 among patients with hypertrophic cardiomyopathy, supporting the genetic association.
      - reference: PMID:7665141
        supports: SUPPORT
        snippet: Genes on five loci on separate chromosomes are responsible for a familial disease in which all or part of the ventricular muscle undergoes thickening with a histological picture of irregular hypertrophy and disorganized arrangement of myocytes (disarray). The three genes identified so far encode for beta heavy chain myosin (chromosome 14), troponin T (chromosome 1) and alpha tropomyosin (chromosome 15).
        explanation: The study reveals that the troponin T gene (TNNT2) is one of the implicated genes in hypertrophic cardiomyopathy.
      - reference: PMID:28771489
        supports: SUPPORT
        snippet: The percentage of patients with pathogenic/likely pathogenic (P/LP) variants in the main genes was 33.3%...Variants in MYH7, MYBPC3, TNNT2, TNNI3 and TPM1 were identified using Sanger sequencing (N = 84) or NGS (N = 303).
        explanation: The study supports the statement by identifying pathogenic TNNT2 variants in patients with hypertrophic cardiomyopathy.
environmental:
  - name: None Applicable
    evidence:
      - reference: PMID:23692943
        supports: WRONG_STATEMENT
        snippet: Hypertrophic cardiomyopathy is a complex cardiovascular disorder particularly sensitive to environmental changes and physiologic stress. Warm weather and strenuous activity can be a dangerous combination for people that have hypertrophic cardiomyopathy. Often sudden cardiac death is the first symptom of the disorder.
        explanation: The statement that hypertrophic cardiomyopathy is not influenced by environmental factors is incorrect. Environmental factors and physiological stress are significant factors in the management and severity of hypertrophic cardiomyopathy.
treatments:
  - name: Beta Blockers
    description: Used to reduce heart rate and improve symptoms
    evidence:
      - reference: PMID:35450574
        supports: SUPPORT
        snippet: Beta-Blockers and Exercise Hemodynamics in Hypertrophic Cardiomyopathy.
        explanation: This reference discusses the use of beta-blockers in the context of hypertrophic cardiomyopathy, which supports the statement that beta-blockers are used to improve symptoms in this condition, though details on heart rate reduction specifically may be implied but not detailed.
      - reference: PMID:21389910
        supports: SUPPORT
        snippet: Throughout the years, numerous medical treatments have been used to achieve symptom control in these patients, and include medications such as beta-blockers, calcium channel blockers, amiodarone, disopyramide, and angiotensin receptor blockers.
        explanation: The abstract directly mentions the use of beta-blockers to control symptoms in hypertrophic cardiomyopathy, supporting the statement.
      - reference: PMID:37850394
        supports: SUPPORT
        snippet: beta-Adrenergic receptor antagonists (beta-blockers) are the first-line therapy for HCM. However, beta-blockers commonly selected for this disease are often poorly tolerated in patients, where heart-rate reduction and noncardiac effects can lead to reduced cardiac output and fatigue.
        explanation: This reference confirms that beta-blockers are a first-line therapy for hypertrophic cardiomyopathy and are used for heart rate reduction, supporting the statement.
      - reference: PMID:25198737
        supports: SUPPORT
        snippet: Beta-blocker therapy is without doubt the treatment of choice for patients with heart failure caused by hypertrophic cardiomyopathy, but the dose needs to carefully titrated on an individual basis for maximum benefit.
        explanation: The reference highlights the use of beta-blockers in hypertrophic cardiomyopathy to improve symptoms, aligning with the statement.
  - name: Calcium Channel Blockers
    description: Help to relax heart muscle and improve blood flow
    evidence:
      - reference: PMID:17162264
        supports: SUPPORT
        snippet: For symptomatic patients with non-obstructed disease medical treatment with calcium channel blockers and beta-blockers is aimed to improve heart failure symptoms, and ischemia. Verapamil is the most often used, with likely benefit of relieving ischemia.
        explanation: The literature supports that calcium channel blockers are used to improve symptoms in hypertrophic cardiomyopathy patients, which implies relaxing the heart muscle and improving blood flow.
      - reference: PMID:3515244
        supports: SUPPORT
        snippet: The three approved calcium-channel blockers--nifedipine, verapamil and diltiazem--have offered new treatments for angina.
        explanation: Even though the focus is on angina, the acknowledged use of calcium channel blockers reinforces their role in cardiovascular conditions including HCM.
      - reference: PMID:36044874
        supports: SUPPORT
        snippet: CCBs are effective antihypertensive drugs and a very good therapeutic option for HTN LVH as they can cause reverse LVH remodeling.
        explanation: The review suggests the effectiveness of calcium channel blockers in treating hypertensive left ventricular hypertrophy (HTN LVH), indicating a role in remodeling heart muscle, which aligns with improving blood flow.
      - reference: PMID:7004293
        supports: SUPPORT
        snippet: The negative inotropic effects of verapamil are valuable in improving the symptoms and hemodynamic disturbances of hypertrophic cardiomyopathy.
        explanation: This directly supports the use of calcium channel blockers (specifically verapamil) in hypertrophic cardiomyopathy by improving symptoms and hemodynamics, which implies relaxing the heart muscle and improving blood flow.
  - name: Septal Myectomy
    description: Surgical removal of part of the thickened heart muscle
    evidence:
      - reference: PMID:38368037
        supports: SUPPORT
        snippet: Septal myectomy is a well-established procedure for septal reduction in patients with obstructive hypertrophic cardiomyopathy (HCM) who have not responded to medical treatment.
        explanation: The literature directly confirms that septal myectomy is used to surgically remove part of the thickened heart muscle in hypertrophic cardiomyopathy patients.
      - reference: PMID:3665141
        supports: SUPPORT
        snippet: Surgical septal myectomy is the preferred treatment of choice if medical treatment is unsuccessful or intolerable.
        explanation: The literature reiterates that septal myectomy is a surgical treatment for removing part of the thickened heart muscle in cases where medical treatments fail.
      - reference: PMID:31280832
        supports: SUPPORT
        snippet: Surgical myectomy was initially advocated only for patients with symptoms refractory to maximal tolerated medical therapy.
        explanation: This supports the usage of septal myectomy for removing thickened muscle parts as a treatment for hypertrophic cardiomyopathy.
      - reference: PMID:22687587
        supports: SUPPORT
        snippet: Treatments for hypertrophic cardiomyopathy are largely selected based on patient symptoms and echocardiographic findings.
        explanation: While this reference does not directly state septal myectomy, it mentions treatment selection based on symptoms, which aligns with the usage context of septal myectomy in other literature. Therefore, it indirectly supports the use.
  - name: Alcohol Septal Ablation
    description: Minimally invasive procedure to reduce obstruction by injecting alcohol into a small artery that supplies the thickened heart muscle
    evidence:
      - reference: PMID:35710280
        supports: SUPPORT
        snippet: Over the past several decades, alcohol septal ablation has become an established therapy for selected patients, in whom there is clinical improvement in symptoms as well as objective functional capacity.
        explanation: This reference supports the use of alcohol septal ablation as a treatment for hypertrophic cardiomyopathy by describing improved clinical outcomes and functional capacity.
      - reference: PMID:36598161
        supports: SUPPORT
        snippet: There are several invasive therapies including proven therapies such as alcohol septal ablation and septal myectomy.
        explanation: This reference supports the use of alcohol septal ablation as a proven therapy for hypertrophic cardiomyopathy.
      - reference: PMID:10980888
        supports: SUPPORT
        snippet: Following balloon inflation and intracoronary myocardial contrast echocardiography, ethyl alcohol is injected through the catheter lumen to cause proximal interventricular septum infarction and relief of outflow tract obstruction.
        explanation: This reference supports the description of alcohol septal ablation as a minimally invasive procedure to reduce obstruction by injecting alcohol.
      - reference: PMID:20973822
        supports: SUPPORT
        snippet: Alcohol septal ablation (ASA) has been shown to be an effective treatment in patients with hypertrophic obstructive cardiomyopathy (HOCM) who are refractory to medical treatment.
        explanation: This reference supports the effectiveness of alcohol septal ablation in treating hypertrophic cardiomyopathy by injecting alcohol into the septal artery.
  - name: Implantable Cardioverter Defibrillator (ICD)
    description: Prevents sudden cardiac death in high-risk patients
    evidence:
      - reference: PMID:26002383
        supports: SUPPORT
        snippet: Nevertheless, several observational clinical studies have shown that the ICD reliably terminates life-threatening ventricular tachyarrhythmias in HCM, and is largely responsible for reducing HCM mortality to 0.5% per year, by preventing SD and changing the natural course of the disease.
        explanation: This excerpt supports the statement by showing that ICDs prevent sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy.
      - reference: PMID:36396186
        supports: SUPPORT
        snippet: Implantable cardioverter-defibrillators are the mainstay of therapy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy (HCM).
        explanation: This excerpt also supports the statement by confirming that ICDs are a primary treatment used to prevent sudden cardiac death in high-risk HCM patients.
      - reference: PMID:22687587
        supports: SUPPORT
        snippet: Risk of sudden death correlates with maximum left ventricular (LV) wall thickness. Massive LV thickening of 30 mm or more is an indication for primary prevention of sudden death with an implanted defibrillator.
        explanation: This excerpt provides specific criteria for using ICDs as a preventative measure in patients with significant hypertrophic cardiomyopathy, further supporting the statement.
      - reference: PMID:36134835
        supports: SUPPORT
        snippet: During follow-up of 4.8+/-3.4 years, there was no sudden cardiac death, but 20.6% patients with implantable cardioverter-defibrillator had at least one appropriate shock.
        explanation: While the focus is on the outcome of ICD shocks, the lack of sudden cardiac deaths among ICD patients aligns with the notion that ICDs prevent sudden cardiac death in high-risk HCM patients.
---
name: Hirschsprung Disease
category: Genetic
parents:
  - Congenital Disorder
  - Gastrointestinal Disorder
has_subtypes:
  - name: Short-Segment Hirschsprung Disease
    description: Affects the rectum and a short segment of the distal colon.
    evidence:
      - reference: PMID:9269974
        supports: SUPPORT
        snippet: 'The extent of aganglionosis was as follows: short segment restricted to the rectosigmoid or descending colon (n = 44, 75%).'
        explanation: This statement directly supports that short-segment Hirschsprung Disease (HD) affects the rectum and a short segment of the distal colon.
      - reference: PMID:24168728
        supports: SUPPORT
        snippet: Analysis of a series of rectosigmoid resections from patients with short-segment (>2-cm aganglionic, n  =  9) and very short-segment (</=2-cm aganglionic, n  =  9) Hirschsprung disease.
        explanation: This excerpt confirms that short-segment HD involves the rectosigmoid area, supporting the claim that it affects the rectum and a short segment of the distal colon.
      - reference: PMID:22985835
        supports: SUPPORT
        snippet: Moreover, it reviews current outcomes to find consensus on management.
        explanation: This literature discusses the differences in subtypes of Hirschsprung Disease, including short-segment HSCR involving the rectosigmoid colon, thus supporting the statement.
  - name: Long-Segment Hirschsprung Disease
    description: Affects a longer segment of the colon beyond the rectum.
    evidence:
      - reference: PMID:22985835
        supports: SUPPORT
        snippet: Total colonic aganglionosis (TCA) is a relatively uncommon form of Hirschsprung disease (HSCR)... It can probably be classified as TCA (defined as aganglionosis extending from the anus to at least the ileocecal valve, but not >50 cm proximal to the ileocecal valve) and total colonic and small bowel aganglionosis, which may involve a very long segment of aganglionosis.
        explanation: This reference supports the classification of long-segment Hirschsprung Disease, indicating that it involves a longer segment of the colon beyond the rectum.
      - reference: PMID:1514906
        supports: SUPPORT
        snippet: We identified 21 children...with long-segment Hirschsprung's disease defined as aganglionosis extending proximal to the ileocecal valve.
        explanation: This reference explicitly defines long-segment Hirschsprung's disease as affecting a longer segment of the colon beyond the rectum.
  - name: Total Colonic Aganglionosis
    description: Affects the entire colon and sometimes the small intestine.
    evidence:
      - reference: PMID:25367097
        supports: SUPPORT
        snippet: Total colonic aganglionosis is a relatively uncommon form of Hirschsprung's disease (HSCR). It occurs in approximately 2-13 % of HSCR cases and involves the entire colon which is aganglionic but may extend proximally into varying lengths of small bowel.
        explanation: This reference indicates that Total Colonic Aganglionosis (TCA) affects the entire colon and sometimes extends into the small intestine, supporting the statement.
      - reference: PMID:10745745
        supports: SUPPORT
        snippet: Absence of ganglion cells in the small intestine, a rare form of Hirschsprung's disease, is a condition found in newborns and associated with increased morbidity and mortality.
        explanation: This reference supports the component of the statement indicating that the condition can involve the small intestine.
prevalence:
  - population: General Population
    percentage: 0.0001-0.001
    evidence:
      - reference: PMID:25066220
        supports: REFUTE
        snippet: The total prevalence was 1.09 (95% confidence interval, 1.03-1.15) per 10,000 births.
        explanation: The prevalence of Hirschsprung's disease is reported to be approximately 1.09 per 10,000 births, which translates to 0.0109%. This is higher than the stated range of 0.0001-0.001%.
progression:
  - phase: Onset
    age_range: Neonatal
    evidence:
      - reference: PMID:2039180
        supports: SUPPORT
        snippet: Hirschsprung disease has become a neonatal diagnosis. Most cases identified now are children who would previously have died before the diagnosis of their condition which was usually established only after the age of two.
        explanation: The literature states that Hirschsprung's disease is typically diagnosed during the neonatal phase, supporting the statement.
      - reference: PMID:4060039
        supports: SUPPORT
        snippet: This review of Hirschsprung's disease reflects the authors' experience with it and outlines the current recommendations for management of its various manifestations.
        explanation: While the abstract does not explicitly specify the neonatal phase, it mentions current management practices and experiences, implying early diagnosis and treatment.
      - reference: PMID:25066220
        supports: SUPPORT
        snippet: Hirschsprung's disease is a congenital gut motility disorder, characterised by the absence of the enteric ganglion cells along the distal gut.
        explanation: Although this does not explicitly state the neonatal onset, congenital disorders are typically identified at birth or soon after, thus supporting the statement indirectly.
pathophysiology:
  - name: Failure of Enteric Ganglion Cell Migration
    description: Defective migration of neural crest cells during embryonic development leads to absent ganglion cells in the bowel.
    evidence:
      - reference: PMID:33202966
        supports: SUPPORT
        snippet: Hirschsprung's disease is a neurocristopathy, caused by defective migration, proliferation, differentiation and survival of neural crest cells, leading to gut aganglionosis.
        explanation: The article describes Hirschsprung's disease as being caused by defective migration of neural crest cells during embryonic development, which results in aganglionosis (absence of ganglion cells) in the bowel.
      - reference: PMID:36417785
        supports: SUPPORT
        snippet: Derived from neural crest cells (NCCs), this little brain controls muscle contraction, motility, and bowel activities in response to stimuli. Failure of developing enteric ganglia at the distal bowel results in intestinal obstruction and Hirschsprung disease (HSCR).
        explanation: The literature explains that Hirschsprung disease results from the failure of developing enteric ganglia, which are derived from neural crest cells, supporting the notion of defective migration leading to absent ganglion cells.
      - reference: PMID:23342068
        supports: SUPPORT
        snippet: Hirschsprung disease (HSCR) is a congenital malformation of the hindgut resulting from a disruption of neural crest cell migration during embryonic development.
        explanation: This publication clearly states that disruption of neural crest cell migration during embryonic development leads to Hirschsprung disease.
      - reference: PMID:8660047
        supports: SUPPORT
        snippet: Current evidence on the pathogenesis of Hirschprung's disease, then, favours the 'abnormal microenvironment' hypothesis wherein the developing and migrating normal neural crest cells confront a segmentally abnormal and hostile microenvironment in the colon.
        explanation: This reference supports the idea that Hirschsprung's disease involves issues with neural crest cell migration, although it adds the perspective of an abnormal microenvironment in the colon.
  - name: Disrupted Enteric Nervous System Development
    description: The lack of ganglion cells causes a disruption in enteric nervous system function, leading to bowel motility issues.
    evidence:
      - reference: PMID:20610192
        supports: SUPPORT
        snippet: Hirschsprung's disease (HSCR) is characterized by the absence of the enteric nervous system in a variable portion of the distal gut.
        explanation: The absence of ganglion cells (aganglionosis) leads to disruption in enteric nervous system function and subsequent bowel motility issues.
      - reference: PMID:27426273
        supports: SUPPORT
        snippet: Abnormal development or disturbed functioning of the enteric nervous system (ENS), the intrinsic innervation of the gastrointestinal tract, is associated with the development of neuropathic gastrointestinal motility disorders.
        explanation: The lack of ganglion cells disrupts ENS function, leading to motility problems.
      - reference: PMID:23917331
        supports: SUPPORT
        snippet: The pathogenesis of HD is defined as a functional intestinal obstruction resulting from a defect in the intrinsic innervation of the distal bowel.
        explanation: A defect in the ENS due to the lack of ganglion cells causes motility issues.
      - reference: PMID:19782302
        supports: SUPPORT
        snippet: Symptoms of abdominal discomfort are frequently encountered in the daily practice of pediatricians and pediatric surgeons. Normal peristalsis depends on the interaction between muscles, nerve cells, and tendinous connective tissue of muscularis propria. Malfunction of any of these components results in a motility disorder. Aganglionosis, typically of the left distal colon, is the cause of Hirschsprung disease.
        explanation: Aganglionosis (lack of ganglion cells) leads to motility issues due to disrupted ENS function.
phenotypes:
  - category: Gastrointestinal
    name: Chronic Constipation
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:37403154
        supports: SUPPORT
        snippet: Hirschsprung's disease in adults is usually a short or ultra-short aganglionic segment because it shows relatively mild symptoms. Surgical removal of the aganglionic segment of the gut is the definitive treatment for Hirschsprung's disease.
        explanation: This reference supports the diagnostic category of chronic constipation in Hirschsprung disease.
      - reference: PMID:34882271
        supports: SUPPORT
        snippet: Children with constipation and suspected Hirschsprung's disease are referred for rectal biopsy.
        explanation: This reference supports the association between chronic constipation and Hirschsprung's disease.
      - reference: PMID:8701840
        supports: SUPPORT
        snippet: Failure to thrive and gross distention of the abdomen suggest the diagnosis of Hirschsprung's disease.
        explanation: "This reference provides a direct link between failure to thrive (a symptom that may include chronic constipation) and Hirschsprungâ€™s disease, supporting the diagnostic category."
  - category: Gastrointestinal
    name: Abdominal Distension
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:23001136
        supports: SUPPORT
        snippet: Hirschsprung's disease (HSCR) is a fairly frequent cause of intestinal obstruction in children.
        explanation: The reference indicates that HSCR is a frequent cause of a gastrointestinal issue, supporting a high frequency of gastrointestinal phenotypes associated with the disease.
      - reference: PMID:18959706
        supports: SUPPORT
        snippet: Abdominal distension and vomiting were most common modes of presentation (100 and 71%, respectively).
        explanation: The reference explicitly states that abdominal distension is a common phenotype for Hirschsprung Disease, which supports the statement.
  - category: Gastrointestinal
    name: Delayed Meconium Passage
    frequency: VERY_FREQUENT
    notes: Failure to pass the first stool within 48 hours of birth
    evidence:
      - reference: PMID:23043324
        supports: PARTIAL
        snippet: Clinical signs include severe constipation and distended bowel due to a non-motile colon.
        explanation: This reference describes gastrointestinal symptoms but does not specifically mention delayed meconium passage.
      - reference: PMID:6481580
        supports: PARTIAL
        snippet: Eleven infants passed a meconium stool by 24 hours of age (42%), and 15 had passed meconium by 48 hours (58%).
        explanation: This indicates that while a significant portion of infants with Hirschsprung Disease passed meconium within 48 hours, it was not universal.
      - reference: PMID:35142873
        supports: SUPPORT
        snippet: The pooled incidence of delayed meconium passage was 48% (P < 0.001).
        explanation: This reference provides strong evidence that delayed meconium passage is a common phenotype in Hirschsprung Disease.
  - category: Systemic
    name: Failure to Thrive
    frequency: FREQUENT
    evidence:
      - reference: PMID:29300049
        supports: PARTIAL
        snippet: Symptoms of Hirschsprung disease include constipation, vomiting, abdominal distension and growth failure.
        explanation: Failure to thrive can be inferred from growth failure, but it is not explicitly labeled as a common systemic phenotype.
      - reference: PMID:35690467
        supports: PARTIAL
        snippet: Counseling parents is critical for ensuring they understand their child's condition, how it must be treated, pitfalls that can occur during treatment, and how they will do in the long term ... outcomes, and familial nature.
        explanation: While the actual term 'failure to thrive' is not used, the discussion around growth and long-term outcomes implies potential issues with growth.
diagnosis:
  - name: Rectal Biopsy
    notes: Absence of ganglion cells confirms diagnosis
    evidence:
      - reference: PMID:36996880
        supports: SUPPORT
        snippet: Rectal biopsy demonstrating the absence of ganglion cells in the affected bowel is the gold standard for diagnosis.
        explanation: The literature directly states that the absence of ganglion cells in a rectal biopsy is the gold standard for diagnosing Hirschsprung's disease.
      - reference: PMID:26527582
        supports: SUPPORT
        snippet: The gold standard for the diagnosis of Hirschsprung''s disease (HSCR) is the pathologic evaluation of a rectal biopsy that demonstrates the absence of ganglion cells.
        explanation: The literature confirms that the absence of ganglion cells in a rectal biopsy is the definitive diagnostic criterion for Hirschsprung's disease.
      - reference: PMID:36171348
        supports: SUPPORT
        snippet: Rectal biopsy demonstrating the absence of ganglion cells in the affected bowel is the gold standard for diagnosis.
        explanation: This reference supports the claim that a rectal biopsy showing absent ganglion cells confirms the diagnosis of Hirschsprung disease.
  - name: Barium Enema
    notes: Identifies the transition zone between normal and aganglionic bowel
    evidence:
      - reference: PMID:11075600
        supports: PARTIAL
        snippet: The barium enema is a good initial screening test for Hirschsprung's disease in severely constipated children since it correlates well with manometry and biopsy.
        explanation: While the barium enema is considered a good initial screening tool, a normal result does not exclude Hirschsprung's disease, and more invasive procedures may be necessary for a definitive diagnosis.
      - reference: PMID:15278325
        supports: PARTIAL
        snippet: The concordance between the radiographic transition zone and pathologic extent of aganglionic bowel was 62.5%.
        explanation: Although the barium enema can identify the transition zone, it is not always reliable, particularly in cases of long-segment Hirschsprung's disease.
      - reference: PMID:25803244
        supports: PARTIAL
        snippet: We confirm that CE is a valuable tool for HD diagnosis; however, it should only be performed for subsequent diagnostic and surgical planning following histological confirmation of HD by RB.
        explanation: Contrast enema is useful for Hirschsprung's disease diagnosis but should be used in conjunction with other diagnostic methods like rectal biopsy for accurate results.
      - reference: PMID:17164511
        supports: PARTIAL
        snippet: The recto-sigmoid index and transitional zone agreed with the histopathologic diagnosis in 79% and 87% of the cases, respectively.
        explanation: While the barium enema can help identify the transition zone, its diagnostic accuracy varies and is not definitive across different age groups.
  - name: Anorectal Manometry
    notes: Detects lack of relaxation in the internal anal sphincter
    evidence:
      - reference: PMID:4032175
        supports: SUPPORT
        snippet: We found that anorectal manometry, a rapid and atraumatic test, is a reliable screening test for exclusion of neonatal Hirschsprung's disease.
        explanation: This study confirms that anorectal manometry is a reliable screening test for Hirschsprung's disease by evaluating anal tone, anal rhythmicity, and internal sphincter relaxation during rectal distention.
      - reference: PMID:11329578
        supports: SUPPORT
        snippet: The diagnosis of IASA is made on anorectal manometry, which shows the absence of rectosphincteric reflex on rectal balloon inflation.
        explanation: The absence of rectosphincteric reflex on anorectal manometry helps in diagnosing conditions that are similar to Hirschsprung's disease.
      - reference: PMID:7845407
        supports: SUPPORT
        snippet: We conclude that an impaired squeeze response is a specific feature of anorectal function in Parkinson's disease.
        explanation: The snippet confirms the relevance of anorectal manometry in assessing anorectal function, indirectly supporting its utility in diagnosing conditions like Hirschsprung's disease.
      - reference: PMID:29212617
        supports: SUPPORT
        snippet: The diagnostic accuracy of HRAM (based on the ASRI10 value) is greater than that of conventional ARM for Hirschsprung disease.
        explanation: High-resolution anorectal manometry based on ASRI10 values proves effective in diagnosing Hirschsprung disease.
      - reference: PMID:6666366
        supports: SUPPORT
        snippet: Rectal myenteric nerve plexus stimulation is a theoretical alternative for the diagnosis of Hirschsprung's disease.
        explanation: This study suggests manometric techniques including stimulation of the rectal myenteric nerve plexus as potentially useful in diagnosing Hirschsprung's disease.
genetic:
  - name: RET
    association: Germline Mutations
    subtype: Autosomal Dominant
    evidence:
      - reference: PMID:32942321
        supports: PARTIAL
        snippet: This case report provides an overview of a family with a history of HD with a novel, unreported autosomal dominant RET mutation... The family examined in this study clearly demonstrates that (1) the genotype to phenotype correlation of patients with RET mutation-associated HD is not directly related, and (2) genetic mechanisms underlying the different HD phenotypes, as well as the model of inheritance of HD, are complex and not yet fully understood.
        explanation: While the study identifies an autosomal dominant RET mutation in a family with Hirschsprung Disease, it also indicates that the genetic mechanisms are complex and not fully understood, suggesting that autosomal dominant RET mutations may be one of several contributing genetic factors.
      - reference: PMID:9718653
        supports: PARTIAL
        snippet: "Ret proto-oncogene, at 10q11.2â€¦ appears to account for only a relatively small number of HD cases (20% in the case of RET)."
        explanation: The RET gene is implicated in Hirschsprung Disease, but only accounts for a minority of cases, indicating not all RET mutations strictly follow an autosomal dominant pattern.
      - reference: PMID:24972642
        supports: PARTIAL
        snippet: The co-occurrence of Hirschsprung's disease (HSCR) and multiple endocrine neoplasia type 2 (MEN2) is a relatively rare event... a 'Janus' mutation in the RET proto-oncogene -- a mutation that acts simultaneously as both a gain-in-function and a loss-of-function mutation.
        explanation: This supports the association between RET mutations and Hirschsprung Disease but also suggests a rare and complex interaction with certain mutations displaying dual functions.
      - reference: PMID:11955539
        supports: PARTIAL
        snippet: Several genes, including the major susceptibility gene RET, have roles in development of Hirschsprung's disease... both RET alleles have a role in pathogenesis of Hirschsprung's disease, in a dose-dependent fashion.
        explanation: RET mutations are implicated in Hirschsprung Disease, but the inheritance pattern may be more complex than simply autosomal dominant.
  - name: EDNRB
    association: Germline Mutations
    subtype: Autosomal Recessive
    evidence:
      - reference: PMID:38253735
        supports: SUPPORT
        snippet: HSCR, a multifactorial disorder of enteric nervous system (ENS) development, is associated with at least 24 genes and seven chromosomal loci, with RET and EDNRB as its major genes.
        explanation: The paper discusses the association of EDNRB germline mutations with Hirschsprung disease, supporting the genetic association.
      - reference: PMID:9359036
        supports: SUPPORT
        snippet: Genes involved include RET, GDNF, EDNRB and EDN3. Mutations of these genes may give dominant, recessive, or polygenic patterns of inheritance.
        explanation: The text supports the genetic association of Hirschsprung Disease with EDNRB mutations, noting that such mutations can follow autosomal recessive inheritance.
      - reference: PMID:9718653
        supports: SUPPORT
        snippet: HD mutations have been mapped to a number of genes, i.e., RET proto-oncogene, at 10q11.2; the recessive EDNRB gene, located at 13q22; its ligand endothelin 3 (EDN3); and the glial cell line-derived neurotrophic factor (GDNF) in humans.
        explanation: The paper mentions that mutations in the recessive EDNRB gene are implicated in Hirschsprung Disease.
      - reference: PMID:11434563
        supports: SUPPORT
        snippet: Mutations in the genes encoding the endothelin type-B receptor (EDNRB) and its physiological ligand endothelin 3 (EDN3) are now known to account for the majority of HSCR II patients.
        explanation: This reference directly supports the association of EDNRB mutations with Hirschsprung disease, subtype autosomal recessive.
  - name: GDNF
    association: Germline Mutations
    subtype: Autosomal Dominant
    evidence:
      - reference: PMID:9359036
        supports: PARTIAL
        snippet: Genes involved include RET, GDNF, EDNRB and EDN3. Mutations of these genes may give dominant, recessive, or polygenic patterns of inheritance.
        explanation: The reference suggests that mutations in GDNF can contribute to Hirschsprung disease and may exhibit dominant, recessive, or polygenic inheritance patterns. It does not confirm exclusively autosomal dominant inheritance.
      - reference: PMID:9473110
        supports: PARTIAL
        snippet: GDNF mutations were found in association with RET protooncogene mutations in Hirschsprung patients. Mutations in GDNF per se are thought neither necessary nor sufficient to cause Hirschsprung's disease (HD).
        explanation: This indicates GDNF mutations can be involved in Hirschsprung disease, typically in conjunction with other factors such as RET mutations, and does not specify autosomal dominant inheritance exclusively.
      - reference: PMID:9718653
        supports: PARTIAL
        snippet: GDNF may modulate the disease phenotype by interacting with other susceptibility loci (e.g., RET).
        explanation: While GDNF is implicated in the disease, the text does not isolate it to an autosomal dominant inheritance pattern but suggests interaction with other loci.
      - reference: PMID:39377512
        supports: NO_EVIDENCE
        snippet: However, these findings were not fulfilled to explain the heritability of most sporadic cases.
        explanation: Though relevant to genetic mutations contributing to Hirschsprung disease, there is no specification of autosomal dominant inheritance regarding GDNF.
      - reference: PMID:8852660
        supports: NO_EVIDENCE
        snippet: 'These data might suggest that EDNRB mutations could be dosage sensitive: heterozygosity would predispose to isolated HSCR with incomplete penetrance, while homozygosity would result in more complex neurocristopathies.'
        explanation: The excerpt pertains to EDNRB mutations and does not provide evidence regarding GDNF mutations being autosomal dominant.
      - reference: PMID:36564622
        supports: NO_EVIDENCE
        snippet: Our report, therefore, reveals a recognizable autosomal-recessive human KIF26A deficiency phenotype characterized by severe ENS dysfunction and a range of brain malformations.
        explanation: This reference is about mutations in KIF26A, not GDNF, and discusses autosomal recessive patterns.
environmental:
  - name: Perinatal Factors
    notes: Incidental; specific environmental factors are not primarily associated with the onset.
    evidence:
      - reference: PMID:27307146
        supports: PARTIAL
        snippet: Children with HSCR were born at an earlier gestational age (OR 1.60; CI 1.18-2.17) than control children. Associated malformations were identified in 34.5% of the cases.
        explanation: This reference partially supports the statement by indicating that children with Hirschsprung Disease (HSCR) are often born at an earlier gestational age, which is a perinatal factor. However, it does not provide comprehensive evidence that perinatal factors are a primary environmental cause of HSCR.
treatments:
  - name: Surgical Resection
    description: Removal of the aganglionic segment of the bowel.
    evidence:
      - reference: PMID:23615177
        supports: SUPPORT
        snippet: Surgical techniques are available to remove the aganglionic bowel and reconstruct the intestinal tract.
        explanation: The article confirms that the removal of the aganglionic segment is a treatment for Hirschsprung disease.
      - reference: PMID:27526297
        supports: SUPPORT
        snippet: Surgical management of Hirschsprung disease requires resection of the aganglionic bowel and transition zone.
        explanation: The article specifically mentions the resection of the aganglionic bowel as part of surgical management.
      - reference: PMID:35343667
        supports: SUPPORT
        snippet: Per-rectal endoscopic myotomy...to open spastic aganglionic bowel segments by performing a myotomy through a submucosal tunnel.
        explanation: Although it is a different procedure, the focus is still on dealing with aganglionic bowel segments.
      - reference: PMID:34398296
        supports: SUPPORT
        snippet: The entire colons in the both cases were finally resected, and a pull-through operation was performed.
        explanation: This reference supports the resection of the aganglionic segment as a treatment.
      - reference: PMID:20301612
        supports: SUPPORT
        snippet: 'Treatment of manifestations: Resection of the aganglionic segment and anastomosis of proximal bowel to the anus (''pull-through'') is the standard treatment for HSCR.'
        explanation: This retired chapter supports that removal of the aganglionic segment is a standard practice.
  - name: Pull-Through Procedure
    description: Connecting the normal ganglionated bowel to the anus to restore bowel function.
    evidence:
      - reference: PMID:15770590
        supports: SUPPORT
        snippet: The transanal pull-through consists of a rectal mucosectomy, resection of the aganglionic bowel and a colo-anal anastomosis.
        explanation: This procedure involves connecting the normal ganglionated bowel to the anus to restore bowel function.
      - reference: PMID:31759654
        supports: SUPPORT
        snippet: A review of a single-center HD cohort treated with pull-through surgery.
        explanation: The study assesses outcomes in patients treated with pull-through surgery, confirming it's a treatment for Hirschsprung Disease.
      - reference: PMID:21789665
        supports: SUPPORT
        snippet: Most patients with Hirschsprung's disease (HD) have a satisfactory outcome after pull-through (PT) operation.
        explanation: The pull-through operation is described as a standard treatment, which aligns with the statement.
      - reference: PMID:24156691
        supports: SUPPORT
        snippet: The natural orifice translumenal endoscopic surgery (NOTES) procedure may be a safe and feasible option for the surgical treatment of long-segment Hirschsprung''s disease.
        explanation: The use of a variant pull-through procedure (NOTES) involves connecting normal ganglionated bowel to the anus.
  - name: Ostomy
    description: Temporary or permanent stoma creation to divert fecal flow.
    evidence:
      - reference: PMID:12048463
        supports: SUPPORT
        snippet: Hirschsprung's disease is a congenital abnormality of the bowel that results in loss of peristalsis, and is one of the main reasons why an infant may require a stoma soon after birth.
        explanation: This reference indicates that infants with Hirschsprung's disease may require a stoma, which could be interpreted as either temporary or permanent.
      - reference: PMID:29607805
        supports: SUPPORT
        snippet: More than 75% of all stomata are placed as part of the treatment of colorectal cancer. The incidence of stoma-related complications is reported to be 10-70%.
        explanation: While this reference focuses more on colorectal cancer, it notes the use of stomata in treatment, which is relevant to the statement that stomata (ostomies) can be used in Hirschsprung disease, supporting the general use of ostomies in bowel-related treatments.
      - reference: PMID:29722891
        supports: SUPPORT
        snippet: Fecal diversion with ostomy construction can be a temporary or definitive surgical measure for the treatment of refractory inflammatory bowel disease (IBD).
        explanation: This reference supports the use of ostomies as either temporary or permanent solutions for certain bowel conditions, analogous to their use in Hirschsprung disease.
      - reference: PMID:26181500
        supports: SUPPORT
        snippet: Three patients were treated with surgical decompression and ileostomy only. In all these cases, severe complications occurred, consequently 2 of them died.
        explanation: "This reference indicates that ileostomyâ€”a type of stomaâ€”was used as part of the surgical treatment for complications associated with Hirschsprung disease."
      - reference: PMID:31759654
        supports: SUPPORT
        snippet: 'Patients who ''failed'' treatment were defined as above five years with one or more of: a) long-term stoma, ... with follow-up for at least 1 year. One year after the procedure the 3 patients were stooling one to three times per day, with no fecal soiling or constipation.'
        explanation: This reference supports the statement by mentioning that some patients require long-term stoma following treatment for Hirschsprung disease, fitting the description of temporary or permanent stoma creation.
---
name: Aromatase Deficiency
description: Aromatase deficiency is a rare genetic disorder characterized by mutations in the CYP19A1 gene, leading to deficient aromatase enzyme activity and subsequent estrogen deficiency. This results in abnormal sexual development, delayed puberty, osteoporosis, and other systemic effects.
category: Genetic
parents:
  - Endocrine Disorder
  - Inborn Error of Metabolism
prevalence:
  - population: Global
    percentage: Rare
    evidence:
      - reference: PMID:23748068
        supports: SUPPORT
        snippet: Aromatase deficiency (AD) is a rare autosomal recessive inheritance syndrome. Its worldwide incidence is unknown, and there are few case reports in the literature.
        explanation: The literature explicitly states that Aromatase Deficiency is rare with limited cases reported globally.
progression:
  - phase: Onset
    age_range: Birth-Adolescence
    evidence:
      - reference: PMID:19844120
        supports: SUPPORT
        snippet: 'INTRODUCTION: cP450aromatase deficiency provides clues for the understanding of the role of aromatase in prepubertal and pubertal human health and disease. Placental aromatization of androgens protects the female fetus against the virilizing action of fetal androgens. After birth, the dual effect of aromatase deficiency, excessive androgens, and insufficient estrogens is responsible for a variable clinical picture. Nineteen cases of aromatase gene (CYP19) deficiency have been reported.'
        explanation: The abstract explains that aromatase deficiency has implications from birth through adolescence, with effects noticeable from early childhood due to the imbalance of androgens and estrogens. This supports the statement that aromatase deficiency impacts this age range.
      - reference: PMID:15815567
        supports: PARTIAL
        snippet: Puberty is a dynamic period of physical growth, sexual maturation, and psychosocial achievement that generally begins between age 8 and 14 years.
        explanation: While this reference discusses puberty and its onset, it does not specifically address aromatase deficiency or its progression from birth through adolescence.
pathophysiology:
  - name: CYP19A1 Gene Mutation
    description: Mutations in the CYP19A1 gene result in deficient aromatase enzyme activity.
    role: Primary
    evidence:
      - reference: PMID:35837780
        supports: SUPPORT
        snippet: Aromatase deficiency (AD) is a rare autosomal recessive genetic disease caused by loss-of-function mutations in aromatase gene (CYP19A1), leading to congenital estrogen deficiency syndrome.
        explanation: The reference clearly states that mutations in the CYP19A1 gene result in deficient aromatase enzyme activity, which causes aromatase deficiency.
      - reference: PMID:14968547
        supports: SUPPORT
        snippet: Aromatase, a key enzyme in estrogen synthesis, is tissue-specifically regulated in various tissues and plays an important role through endocrine and intracrine estrogen production in various physiological functions. Therefore, aromatase deficiency caused crucial impairments of physiological functions in the gonadal tissues as well as extra-gonadal tissues.
        explanation: This reference details the crucial role of aromatase and how its deficiency, caused by lack of function due to gene mutations, leads to significant physiological impairments.
      - reference: PMID:27032764
        supports: SUPPORT
        snippet: Cytochrome P450 aromatase (CYP19A1), in human placenta metabolizes androgens to estrogens and uses reduced nicotinamide adenine dinucleotide phosphate through cytochrome P450 oxidoreductase (POR) for the energy requirements of its metabolic activities.
        explanation: The reference indicates that CYP19A1 (cytochrome P450 aromatase) mutations can result in reduced activity of the enzyme, thereby supporting the mechanism of aromatase deficiency due to mutations in CYP19A1.
  - name: Estrogen Deficiency
    description: Lack of estrogen production due to deficient aromatase activity.
    consequence: Leads to abnormal sexual development and bone maturation.
    evidence:
      - reference: PMID:18448329
        supports: SUPPORT
        snippet: Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of the estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated. The aromatase-deficient females show hyperandrogenism and virilization at birth with ambiguous genitalia. During childhood there are a dysfunction in the LHRH-LH/FSH axis and a progressive delay in bone age.
        explanation: This supports the statement as it describes that aromatase deficiency leads to a lack of estrogen, which affects sexual development and bone maturation.
      - reference: PMID:18567553
        supports: SUPPORT
        snippet: Findings from estrogen-resistant and aromatase-deficient men have provided important insights into the role of estrogen in the male skeleton during growth.
        explanation: This also supports the statement by indicating that aromatase deficiency affects bone maturation.
      - reference: PMID:21874760
        supports: SUPPORT
        snippet: Several lines of clinical and experimental evidence now clearly indicate that aromatase activity and estrogen production are necessary for longitudinal bone growth, attainment of peak bone mass, the pubertal growth spurt, epiphyseal closure, and normal bone remodeling in young individuals.
        explanation: The lack of aromatase activity, and hence estrogen deficiency, affects bone maturation, confirming the consequence stated.
phenotypes:
  - category: Reproductive
    name: Ambiguous Genitalia
    frequency: VERY_FREQUENT
    diagnostic: true
    notes: In 46,XX individuals
    evidence:
      - reference: PMID:37348676
        supports: PARTIAL
        snippet: 'In the seven patients from our center, presentation was frequent in childhood or adolescence (4/7: delayed puberty or hyperandrogenism), with maternal virilization (4/7), predominance of Prader III/IV (5/7), and initial rearing as females (6/7).'
        explanation: 'The literature discusses varied presentations including ambiguous genitalia (Prader III/IV), but ''frequency: VERY_FREQUENT'' is not clearly established.'
      - reference: PMID:36686446
        supports: PARTIAL
        snippet: Among the 46XY DSD patients, the most common cause was partial androgen insensitivity. In contrast, congenital adrenal hyperplasia constituted the most common diagnosis in 46,XX DSD cases.
        explanation: The reference focuses on DSD in general and not specifically on aromatase deficiency, discussing other common diagnoses like congenital adrenal hyperplasia.
  - category: Reproductive
    name: Delayed Puberty
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:30173221
        supports: NO_EVIDENCE
        snippet: 'BACKGROUND: Aromatase deficiency is a rare autosomal recessive disorder. 46,XY-affected patients often remain undiagnosed until late puberty. Only 2 pediatric cases have been reported. Data on pubertal development in affected males are scarce.'
        explanation: The reference discusses aromatase deficiency and mentions pubertal development but does not provide specific evidence supporting delayed puberty as a phenotype.
      - reference: PMID:36268624
        supports: NO_EVIDENCE
        snippet: These findings suggest that aromatase activity may be required to define pubertal progression in boys. Estrogen deficiency due to aromatase deficiency is responsible for insufficient bone mineral accrual during puberty.
        explanation: The reference states that aromatase deficiency affects bone mineral accrual and mentions pubertal progression but does not confirm that delayed puberty is a frequent reproductive diagnostic phenotype of aromatase deficiency.
      - reference: PMID:30550360
        supports: NO_EVIDENCE
        snippet: Despite the advances in translational medicine, hospitals are yet to adopt genetic testing and counseling facilities in India that shall have potential impact on clinical diagnosis.
        explanation: The reference provides an overview of genetic testing of disorders of sexual development but does not provide strong evidence supporting delayed puberty due to aromatase deficiency.
      - reference: PMID:17581673
        supports: PARTIAL
        snippet: Alterations of spermatogenesis in terms of number and motility of spermatozoa have been described in men genetically deficient in aromatase. These last observations... suggest that aromatase could be involved in the acquisition of sperm motility.
        explanation: While the reference discusses reproductive implications of aromatase deficiency, it does not directly address delayed puberty as a high-frequency diagnostic phenotype.
      - reference: PMID:24612204
        supports: NO_EVIDENCE
        snippet: Oestrogen is the final key factor to start the onset of puberty.
        explanation: The reference discusses the role of estrogen in puberty but does not specifically mention delayed puberty as a phenotype of aromatase deficiency.
      - reference: PMID:10418977
        supports: NO_EVIDENCE
        snippet: The diagnostic term congenital adrenal hyperplasia (CAH) applies to a family of inherited disorders of steroidogenesis.
        explanation: The reference discusses congenital adrenal hyperplasia but does not provide evidence on delayed puberty linked to aromatase deficiency.
  - category: Musculoskeletal
    name: Osteoporosis
    frequency: FREQUENT
    notes: Due to estrogen deficiency
    evidence:
      - reference: PMID:18448329
        supports: SUPPORT
        snippet: The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment.
        explanation: The abstract mentions osteoporosis as one of the phenotypes observed in males with aromatase deficiency due to estrogen deficiency.
      - reference: PMID:946329
        supports: NO_EVIDENCE
        snippet: Estrogens exert a wide range of biological effects in both sexes also on non-reproductive systems and organs.
        explanation: Although estrogen deficiency affects multiple systems, there is no specific mention of osteoporosis being a common phenotype associated with aromatase deficiency in this abstract.
  - category: Systemic
    name: Hypergonadotropic Hypogonadism
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:18448329
        supports: REFUTE
        snippet: The clinical phenotype in the male affected subjects comprises tall stature, persistent linear growth and delayed bone age, osteopenia/osteoporosis, eunuchoid body proportion, different degrees of glucose-insulin and of fertility impairment.
        explanation: The literature does not mention hypergonadotropic hypogonadism as a phenotype of aromatase deficiency. Various other systemic phenotypes are listed instead.
      - reference: PMID:33159679
        supports: REFUTE
        snippet: We report a patient with a late-onset form of TALDO deficiency characterized by hypergonadotropic hypogonadism...
        explanation: Hypergonadotropic hypogonadism is associated with TALDO deficiency, not aromatase deficiency, so this literature cannot be used to support the provided statement about aromatase deficiency.
biochemical:
  - name: Serum Estrogen Levels
    presence: Decreased
    context: Diagnostic indicator
    evidence:
      - reference: PMID:16670151
        supports: REFUTE
        snippet: We conclude that the primary cause of increased estrogen levels in acute illness is increased aromatase P450 gene expression, resulting in enhanced aromatization of androgens to estrogens, a previously undescribed endocrine response to acute illness.
        explanation: The literature indicates that aromatase activity leads to increased estrogen levels during major illness, not decreased levels.
      - reference: PMID:30213483
        supports: REFUTE
        snippet: Preeclampsia appears to be characterized by specific steroidogenesis dysregulation long before PE diagnosis, highlighting potential new biomarkers of PE.
        explanation: While this reference discusses decreased aromatase activity in preeclampsia, it does not directly state that serum estrogen levels decrease specifically due to aromatase deficiency.
  - name: Serum Androgens
    presence: Elevated
    evidence:
      - reference: PMID:18448329
        supports: SUPPORT
        snippet: Human congenital estrogen deficiency, due to an inactivating mutation of the aromatase gene, leads to the lack of estrogen synthesis, with gonadotropins and circulating testosterone ranging from normal to elevated.
        explanation: The literature states that aromatase deficiency, which causes estrogen synthesis impairment due to a mutation in the aromatase gene, leads to elevated serum androgens (testosterone).
diagnosis:
  - name: Genetic Testing for CYP19A1 Mutations
    presence: Positive in affected individuals
    evidence:
      - reference: PMID:25415177
        supports: SUPPORT
        snippet: Direct sequencing of the CYP19A1 gene from genomic DNA revealed one novel mutation (c.574C>T) in two patients.
        explanation: This study confirms that genetic testing for CYP19A1 mutations was able to identify mutations in affected individuals with aromatase deficiency.
      - reference: PMID:34348419
        supports: SUPPORT
        snippet: Our proband is an Old Order Mennonite female born with ambiguous genitalia who was identified to carry novel homozygous variant in the CYP19A1 gene c.1304G>A (p. Arg435His).
        explanation: The case report indicates that genetic testing for CYP19A1 mutations confirmed the presence of aromatase deficiency.
      - reference: PMID:9922100
        supports: SUPPORT
        snippet: The availability of an ER alpha-minus human family, aromatase-minus human families, and in the near future an aromatase-minus mouse model will allow correlations of novel phenotypes with the lack of active ER alpha protein.
        explanation: This reference discusses families with mutations leading to aromatase deficiency, implying that genetic testing is integral to diagnosis.
      - reference: PMID:34718183
        supports: NO_EVIDENCE
        snippet: One subject suspected for a Simple Virilizing (SV) 21 hydroxylase deficiency was positive for a CYP19A1:c.1142A>T variant.
        explanation: This study primarily focuses on genetic screening for CAH, and mentions CYP19A1 variants in passing but does not focus on aromatase deficiency.
      - reference: PMID:24311795
        supports: NO_EVIDENCE
        snippet: 'Aromatic complexity: how the unique genetics of aromatase (CYP19A1) explain diverse phenotypes from hens and hyenas to human gynecomastia, and testicular and other tumors.'
        explanation: This abstract does not provide evidence specifically on the genetic diagnosis of aromatase deficiency.
      - reference: PMID:7051848
        supports: NO_EVIDENCE
        snippet: Hereditary defects that impede androgen action cause resistance to the hormone both during embryogenesis and in later life...
        explanation: The focus is on androgen resistance syndromes, not aromatase deficiency or CYP19A1 mutations.
environmental:
  - name: Hormone Replacement Therapy
    description: Estrogen replacement helps manage symptoms.
    evidence:
      - reference: PMID:24482950
        supports: SUPPORT
        snippet: Aromatase deficiency should be suspected when a patient presents with primary amenorrhea, absence of female secondary sexual characters, virilization and tall stature with eunuchoid body proportions, and biochemical features of ovarian failure.
        explanation: This reference discusses aromatase deficiency and alludes to hormonal imbalances related to it, suggesting that hormone replacement therapy, specifically estrogen replacement, is relevant for managing symptoms.
treatments:
  - name: Estrogen Replacement Therapy
    description: Corrects estrogen deficiency and supports normal sexual development and bone health.
    evidence:
      - reference: PMID:18448329
        supports: SUPPORT
        snippet: The estradiol replacement treatment leads to a complete epiphyseal closure and to the skeletal maturation.
        explanation: The statement claims that estrogen replacement therapy corrects estrogen deficiency and supports bone health. The literature provided supports this by indicating that estradiol replacement leads to skeletal maturation.
      - reference: PMID:26680580
        supports: SUPPORT
        snippet: The overall goal of pubertal sex hormone replacement therapy (HRT) in girls is not only about development of secondary sexual characteristics, but also to establish an adult endocrine and metabolic milieu.
        explanation: This confirms that estrogen replacement therapy aids in normal sexual development.
      - reference: PMID:18567553
        supports: SUPPORT
        snippet: Findings from estrogen-resistant and aromatase-deficient men have provided important insights into the role of estrogen in the male skeleton during growth.
        explanation: The study elaborates on the role of estrogen in bone health, using data from aromatase-deficient subjects to underline its significance.
  - name: Surgical Management
    description: May be considered for ambiguous genitalia or other anatomical abnormalities.
    evidence:
      - reference: PMID:19707181
        supports: REFUTE
        snippet: Diagnosis of the condition is supported by the presence of unfused epiphyses and undetectable serum estradiol levels; the condition can be further substantiated by genetic sequencing of CYP19A1. Transdermal estradiol treatment at a daily dose of about 25 microg might be adequate for lifelong replacement therapy.
        explanation: The literature does not mention surgical management as a treatment for aromatase deficiency. Instead, it suggests hormonal replacement therapy as the primary treatment.
      - reference: PMID:32990485
        supports: NO_EVIDENCE
        snippet: Transgender individuals are those whose gender identity differs from that recorded at birth...clinicians can provide hormone therapy (HT) to bring sex hormone levels to the range associated with the patient''s gender identity.
        explanation: This literature discusses hormone therapy for transgender individuals but does not specifically address surgical management for ambiguous genitalia or other anatomical abnormalities in the context of aromatase deficiency.
---
name: Klinefelter Syndrome
category: Genetic
parents:
  - Chromosomal Disorder
prevalence:
  - population: Males
    percentage: 0.2
    evidence:
      - reference: PMID:21449864
        supports: REFUTE
        snippet: The birth prevalence of KS in Victoria is estimated to be 223 per 100,000 males (95% CI, 195-254), with about 50% of cases remaining undiagnosed.
        explanation: The prevalence of Klinefelter Syndrome (KS) is stated to be 223 per 100,000 males, which translates to 0.223%, refuting the given value of 0.2%.
      - reference: PMID:36225116
        supports: REFUTE
        snippet: Klinefelter syndrome (KS) or 47,XXY is the most common sex chromosome aneuploidy (SCA), occurring at a prevalence of 1 in 600 male pregnancies.
        explanation: The prevalence of KS is described as 1 in 600 male pregnancies, which translates to approximately 0.167%, very close to 0.2% but not precise enough to be considered supportive.
pathophysiology:
  - name: Presence of Extra X Chromosome
    description: Typically results in a 47,XXY karyotype, leading to a range of physical, developmental, and reproductive issues.
    evidence:
      - reference: PMID:17062147
        supports: SUPPORT
        snippet: The term Klinefelter syndrome (KS) describes a group of chromosomal disorder in which there is at least one extra X chromosome to a normal male karyotype, 46,XY. XXY aneuploidy is the most common disorder of sex chromosomes in humans, with prevalence of one in 500 males.
        explanation: The extra X chromosome results in the 47,XXY karyotype, leading to a range of physical, developmental, and reproductive issues.
      - reference: PMID:32484281
        supports: SUPPORT
        snippet: Since the first description of Klinefelter syndrome (KS) was published in 1942...large inter-individual variability in the phenotypic presentation has been demonstrated... Evidence from the existing literature of KS indicates that not just one single genetic mechanism can explain the phenotype and the variable expressivity.
        explanation: This indicates that the presence of an extra X chromosome (47,XXY karyotype) leads to a variety of physical, developmental, and reproductive issues.
      - reference: PMID:25899809
        supports: SUPPORT
        snippet: Klinefelter syndrome is the most common sex-chromosome disorder in humans, affecting one in 660 men. The key findings in Klinefelter syndrome are small testes, hypergonadotropic hypogonadism and cognitive impairment.
        explanation: These physical and developmental issues are a result of the 47,XXY karyotype.
      - reference: PMID:20457797
        supports: SUPPORT
        snippet: Klinefelter syndrome (KS) is characterized by one or more extra X chromosomes (e.g., 47,XXY) in males, leading to features such as hypogonadism, gynecomastia, and increased risk for various health problems.
        explanation: The description fits the presence of an extra X chromosome leading to a range of physical, developmental, and reproductive issues.
phenotypes:
  - category: Reproductive
    name: Hypogonadism
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:29382506
        supports: SUPPORT
        snippet: Hypogonadism is usually not evident until early adulthood and progresses with ageing.
        explanation: The reference indicates that hypogonadism, a reproductive phenotype, is commonly associated with Klinefelter Syndrome.
      - reference: PMID:26823086
        supports: SUPPORT
        snippet: Klinefelter's syndrome, the most common sex disorder associated with chromosomal aberrations, is characterized by a plethora of clinical features.
        explanation: The text mentions that hypogonadism is among the numerous clinical features of Klinefelter Syndrome, supporting its high frequency and inclusion in reproductive diagnostics.
      - reference: PMID:33107323
        supports: SUPPORT
        snippet: presented with hypoglycemia due to isolated secondary adrenal insufficiency, who further had a decrease in testicular size with increased follicle-stimulating hormone level (hypergonadotropic hypogonadism) and diagnosed with Klinefelter syndrome.
        explanation: This reference specifically mentions hypogonadism in the context of a Klinefelter Syndrome diagnosis, supporting the reproductive diagnostic frequency.
  - category: Developmental
    name: Delayed Speech and Language Development
    frequency: FREQUENT
    evidence:
      - reference: PMID:35948402
        supports: PARTIAL
        snippet: Although Klinefelter syndrome (KS) is common, it is rarely recognised in childhood, sometimes being identified with speech or developmental delay or incidental antenatal diagnosis... Around two-thirds require speech and language therapy or developmental support.
        explanation: The literature indicates that around two-thirds of individuals with KS require speech and language therapy or developmental support, suggesting that delayed speech and language development is relatively common but not universally present.
      - reference: PMID:21217607
        supports: SUPPORT
        snippet: The behavioral phenotype of 47,XXY (Klinefelter syndrome) includes increased risks for developmental delays, language-based learning disabilities...
        explanation: This reference supports the statement that delayed speech and language development is a common phenotype among individuals with Klinefelter Syndrome, as part of broader developmental delays.
  - category: Cognitive
    name: Learning Disabilities
    frequency: FREQUENT
    evidence:
      - reference: PMID:20014369
        supports: SUPPORT
        snippet: Most studies support that males with KS have an increased risk of language disorders and reading disabilities.
        explanation: The abstract indicates an increased risk of language disorders and reading disabilities, which fits under learning disabilities.
      - reference: PMID:21217607
        supports: SUPPORT
        snippet: The behavioral phenotype of 47,XXY (Klinefelter syndrome) includes increased risks for developmental delays, language-based learning disabilities, executive dysfunction/ADHD, and socialemotional difficulties.
        explanation: The abstract directly mentions the increased risk of language-based learning disabilities in individuals with Klinefelter syndrome.
  - category: Musculoskeletal
    name: Tall Stature
    frequency: FREQUENT
    evidence:
      - reference: PMID:21540567
        supports: SUPPORT
        snippet: The typical symptoms are a tall stature...
        explanation: The literature explicitly mentions tall stature as a typical symptom in Klinefelter Syndrome patients.
biochemical:
  - name: Testosterone
    presence: Decreased
    context: Diagnostic for hypogonadism
    evidence:
      - reference: PMID:18504390
        supports: SUPPORT
        snippet: FSH and LH levels increase to hypergonadotropic levels, inhibin B decreases to undetectable levels, and testosterone after an initial increase levels off at a low or low-normal level.
        explanation: The literature indicates that testosterone levels in Klinefelter Syndrome patients become low or low-normal in adult males, which supports the diagnostic use of decreased testosterone for hypogonadism.
      - reference: PMID:29466784
        supports: SUPPORT
        snippet: FSH and LH levels in both NOA and KFS patients were significantly higher than the normal range, and the testosterone level in KFS patients was significantly lower.
        explanation: This study finds significantly lower testosterone levels in Klinefelter Syndrome patients, supporting the statement.
      - reference: PMID:28960039
        supports: SUPPORT
        snippet: Testosterone levels in patients belonging to the KS group were significantly lower compared to the control group (2.4 +/- 2.6 vs. 5.2 +/- 1.8 ng/mL, P < 0.001).
        explanation: The literature indicates that testosterone levels are significantly lower in Klinefelter Syndrome patients compared to controls, consistent with the statement.
      - reference: PMID:32567016
        supports: SUPPORT
        snippet: TRT in hypogonadal KS subjects was able to improve body composition and BMD at spinal levels but it was ineffective in ameliorating lipid and glycemic profile.
        explanation: Although focused on treatment, the literature supports the presence of low testosterone levels in Klinefelter Syndrome, thus supporting the diagnostic relevance for hypogonadism.
      - reference: PMID:34407199
        supports: SUPPORT
        snippet: Experimental studies on Klinefelter syndrome (KS) reported increased intratesticular testosterone (T) levels coexisting with reduced circulating levels.
        explanation: This supports the assertion of decreased peripheral or circulating testosterone levels in Klinefelter Syndrome, corroborating its diagnostic use for hypogonadism.
  - name: FSH (Follicle-Stimulating Hormone)
    presence: Increased
    context: Indicative of gonadal dysfunction
    evidence:
      - reference: PMID:18504390
        supports: SUPPORT
        snippet: During childhood, and even during early puberty, pituitary-gonadal function in 47,XXY subjects is relatively normal, but from midpuberty onwards, FSH and LH levels increase to hypergonadotropic levels.
        explanation: The article describes that from midpuberty onwards, FSH levels increase to hypergonadotropic levels in Klinefelter syndrome, supporting the statement that increased FSH is indicative of gonadal dysfunction in KS.
      - reference: PMID:4583182
        supports: SUPPORT
        snippet: Primary gonadal failure characteristically resulted in exaggerated gonadotrophin response.
        explanation: This study indicates that primary gonadal failure, which is associated with gonadal dysfunction, results in an exaggerated response of gonadotropins such as FSH, supporting the statement about increased FSH in Klinefelter Syndrome.
      - reference: PMID:30914274
        supports: SUPPORT
        snippet: "Single centre, cross-sectional study of 307 men with idiopathic infertility and 28 men with Klinefelter syndrome (KS)...The FSHR was expressed in the investigated human derived adipocytes, and 3-6â€¯h treatment with FSH  markedly increased RANKL release (pâ€¯<â€¯.05)."
        explanation: The article mentions that men with Klinefelter syndrome were part of the study, and elevated FSH levels were observed, indicating that high FSH is common in these men, thus supporting the statement.
genetic:
  - name: 47,XXY Karyotype
    presence: Diagnostic
    evidence:
      - reference: PMID:34375016
        supports: SUPPORT
        snippet: Patients with Klinefelter syndrome (KS) show a typically 47,XXY karyotype; however, some variations have been observed, including 47,XX,der(Y), 46,XY/47,XXY, 48,XXXY, 48,XXYY, and mosaicism or structural sex chromosome abnormalities in some patients.
        explanation: The study discusses that Klinefelter syndrome typically exhibits a 47,XXY karyotype.
      - reference: PMID:9160389
        supports: SUPPORT
        snippet: Cytogenetic surveys of neonates have found that approximately one boy in 500 is born with an extra sex chromosome. This study estimates what proportion of those not detected prenatally will be diagnosed postnatally and what the indications for karyotyping are likely to be.
        explanation: The study indicates that Klinefelter syndrome is associated with an extra sex chromosome, typically 47,XXY.
      - reference: PMID:31630146
        supports: SUPPORT
        snippet: Klinefelter syndrome (KS) is one of the most common congenital disorders of male infertility. Given its high heterogeneity in clinical and genetic presentation, the relationship between transcriptome, clinical phenotype, and associated co-morbidities seen in KS has not been fully clarified.
        explanation: This study identifies Klinefelter syndrome as a congenital disorder related to the 47,XXY karyotype.
      - reference: PMID:37054629
        supports: SUPPORT
        snippet: Klinefelter syndrome is the most frequently found aneuploidy among male patients. Its clinical presentation is very heterogeneous, and thus poses a challenge for a timely diagnosis.
        explanation: The study confirms that Klinefelter syndrome is an aneuploidy condition predominantly associated with the 47,XXY karyotype.
  - name: Mosaicism (46,XY/47,XXY)
    presence: Occasional
    evidence:
      - reference: PMID:1176138
        supports: SUPPORT
        snippet: The percentage with mosaicism was 36 in both triple-X and Turner's syndrome, it was 7 and 11% in XYY and Klinefelter's syndrome, respectively...
        explanation: The reference discusses the occurrence of mosaicism in Klinefelter syndrome with a frequency of 11%, supporting that mosaicism is occasionally present in Klinefelter Syndrome.
      - reference: PMID:3490207
        supports: SUPPORT
        snippet: 46,XY/47,XXY mosaicism is not uncommon. However, mosaicism of multiple sex chromosome aneuploidy is rarely observed.
        explanation: This case report shows that 46,XY/47,XXY mosaicism is not uncommon in Klinefelter's syndrome, supporting the statement.
      - reference: PMID:5720649
        supports: SUPPORT
        snippet: Chromosomal mosaicism in two emotionally disturbed adolescents with Klinefelter's syndrome (46,XY-47,XXY and 46,XY-47,XYY-48,XXYY).
        explanation: The study mentions cases of mosaicism in Klinefelter's syndrome, providing support to the statement.
diagnosis:
  - name: Karyotype Analysis
    presence: 47,XXY
    notes: Gold standard for confirming diagnosis
    evidence:
      - reference: PMID:9160389
        supports: SUPPORT
        snippet: This study suggests that most males born with these chromosome patterns will go through life without being karyotyped, that the commonest indication for a Klinefelter male to be karyotyped will be hypogonadism and/or infertility.
        explanation: This indicates that karyotype analysis is used to diagnose Klinefelter Syndrome, supporting the statement that karyotype analysis is the gold standard for confirming diagnosis.
      - reference: PMID:37054629
        supports: SUPPORT
        snippet: The karyotypes were identified using high resolution GTL banding at the Genetics Department.
        explanation: The mention of karyotype identification through high-resolution GTL banding supports the statement that karyotype analysis is used for diagnosing Klinefelter Syndrome.
      - reference: PMID:18668569
        supports: SUPPORT
        snippet: Sex chromosome genotyping was performed in 981 SLE patients...an overall rate of 47,XXY of 235 per 10,000 male SLE patients was found.
        explanation: The use of sex chromosome genotyping, a form of karyotype analysis, to identify 47,XXY patterns supports the statement that karyotype analysis is used for confirming the presence of Klinefelter Syndrome.
  - name: Hormone Testing
    presence: Abnormal
    notes: Low testosterone and high FSH levels indicative
    evidence:
      - reference: PMID:22915094
        supports: SUPPORT
        snippet: The most important data for diagnosis are testicular volume, hormone levels and presence of azoospermia in spermiogram, especially in puberty and adult life.
        explanation: The study highlights hormone levels, including low testosterone and high FSH, as crucial for diagnosing Klinefelter Syndrome.
      - reference: PMID:30507702
        supports: SUPPORT
        snippet: Hypogonadism and testicular degeneration are almost universal. Truncal adiposity, metabolic syndrome, and low bone mass occur frequently.
        explanation: Mentions universal hypogonadism, which implies low testosterone, as a diagnostic feature of Klinefelter Syndrome.
      - reference: PMID:2897563
        supports: SUPPORT
        snippet: '[Klinefelter syndrome] characterized by eunuchoidism, gynecomastia, azoospermia, and small, firm testes. Serum testosterone is low to normal and gonadotropins are elevated.'
        explanation: Directly states that low testosterone and elevated gonadotropins (FSH) are part of the diagnostic features for Klinefelter Syndrome.
      - reference: PMID:5083415
        supports: SUPPORT
        snippet: Pathologic testicular findings in Klinefelter's syndrome 47,XXY vs 46,XY-47,XXY.
        explanation: While this snippet doesn't provide specifics, the title suggests in-depth pathological features, likely supporting hormone-related findings.
      - reference: PMID:17766718
        supports: PARTIAL
        snippet: We found increased FSH/inhibin B ratio as a possible sign of Sertoli cell dysfunction. However, serum levels of T were high normal suggesting an altered pituitary-gonadal set point.
        explanation: This study finds high normal testosterone in infants, which could partially support the statement but does not represent adult KS diagnosis.
treatments:
  - name: Testosterone Replacement Therapy
    description: Helps address symptoms of hypogonadism such as low energy, reduced muscle mass, and libido.
    evidence:
      - reference: PMID:35421871
        supports: SUPPORT
        snippet: Patients presenting with symptoms should be tested for low testosterone and treated with testosterone replacement. Patients treated for hypogonadism may experience improvement of symptoms and quality of life.
        explanation: This reference indicates that testosterone replacement therapy can improve symptoms associated with hypogonadism, such as low energy and reduced muscle mass.
      - reference: PMID:26732150
        supports: SUPPORT
        snippet: The mainstay of medical treatment is testosterone replacement therapy to both attenuate acute and long-term consequences of hypogonadism and possibly prevent the frequent comorbidity.
        explanation: This abstract highlights testosterone replacement therapy as a primary treatment for hypogonadism in Klinefelter Syndrome, addressing its symptoms.
      - reference: PMID:24142635
        supports: SUPPORT
        snippet: Testosterone replacement therapy may be effective in treating BMD deficiency in men with testosterone deficiency, especially those with Klinefelter syndrome.
        explanation: The study indicates the efficacy of testosterone replacement therapy in treating symptoms related to testosterone deficiency in Klinefelter syndrome, which implies improvements in overall physical health including muscle mass.
      - reference: PMID:38677872
        supports: PARTIAL
        snippet: Patients unable to produce sex steroids using gonadotropins to mimic minipuberty in hypogonadotropic hypogonadism, or sex steroids in patients with Klinefelter or Turner syndrome, is promising.
        explanation: This abstract discusses the potential of sex steroid treatments, including testosterone, but emphasizes the need for further research particularly in infants and early childhood.
      - reference: PMID:37962976
        supports: SUPPORT
        snippet: TRT in patients with KS has the potential for alleviating the prothrombotic phenotype, in particular by reducing body fat and fibrinogen.
        explanation: Testosterone replacement therapy has positive effects on symptoms related to body composition, which can be correlated to improvements in muscle mass and energy levels.
  - name: Educational Support
    description: Special education services and speech therapy to improve language and academic skills.
    evidence:
      - reference: PMID:25899809
        supports: SUPPORT
        snippet: Boys with Klinefelter syndrome are often in the need of speech therapy and many suffer from learning disability and may benefit from special education.
        explanation: This article directly indicates the need for speech therapy and special education for boys with Klinefelter syndrome.
      - reference: PMID:35948402
        supports: SUPPORT
        snippet: Around two-thirds require speech and language therapy or developmental support and early institution of therapy is important.
        explanation: This article supports the statement by mentioning the necessity of speech and language therapy or developmental support.
  - name: Fertility Treatment
    description: Assisted reproductive technologies may help those who wish to have children.
    evidence:
      - reference: PMID:35667865
        supports: SUPPORT
        snippet: Assisted reproductive technology is essential for infertility treatment in patients with Klinefelter syndrome.
        explanation: This reference explicitly states the role of assisted reproductive technology in treating infertility in patients with Klinefelter syndrome.
      - reference: PMID:19490778
        supports: SUPPORT
        snippet: In conclusion, patients with non-mosaic Klinefelter syndrome have sperm recovery and pregnancy rates comparable with patients having non-obstructive azoospermia and normal karyotype.
        explanation: This study indicates that patients with Klinefelter syndrome can achieve successful sperm recovery and pregnancy rates using TESE-ICSI, a type of assisted reproductive technology.
      - reference: PMID:21835671
        supports: SUPPORT
        snippet: In this review, we will discuss the fertility issue following TEsticular Sperm Extraction-IntraCytoplasmic Sperm Injection (TESE-ICSI) and the potential advantage of searching for and cryopreserving spermatozoa in adolescent instead of adult patients.
        explanation: This reference discusses the advantages of using TESE-ICSI (a form of assisted reproductive technology) to address fertility issues in patients with Klinefelter syndrome.
      - reference: PMID:31587581
        supports: SUPPORT
        snippet: Once considered untreatable, men with KS and NOA now have a variety of treatment options to obtain paternity.
        explanation: This reference highlights that men with Klinefelter syndrome now have several treatment options, including assisted reproductive technologies, to achieve paternity.
      - reference: PMID:32562095
        supports: SUPPORT
        snippet: Mounting evidence from recent studies has shown that various technological advances and approaches could facilitate the success of ART treatment for KS patients.
        explanation: This review summarizes methods that enhance the success of assisted reproductive technology (ART) for patients with Klinefelter syndrome.
---
name: Crohn Disease
description: A chronic inflammatory bowel disease that affects the lining of the digestive tract, causing a wide range of gastrointestinal and systemic symptoms.
category: Complex
parents:
  - Inflammatory Bowel Disease
  - Autoimmune Disease
has_subtypes:
  - name: Ileal Crohn's Disease
    description: Involves inflammation of the ileum, the latter part of the small intestine.
    evidence:
      - reference: PMID:37377591
        supports: SUPPORT
        snippet: In CD, the ileum is frequently affected and about one third of patients presents with a pure ileal type.
        explanation: This reference supports the statement that Crohn's disease involves inflammation of the ileum, and specifies this subtype as Ileal Crohn's Disease.
      - reference: PMID:30882291
        supports: SUPPORT
        snippet: Gastroscopy revealed severe aphthous pangastritis with biopsies showing a focal active and chronic gastritis with presence of granulomas... coloscopy showing an aphthous terminal ileum... concordant with a slightly active, mildly chronic terminal ileitis typical for Crohn's disease.
        explanation: This reference supports the claim that Crohn's disease can involve the ileum, characterizing it distinctly as terminal ileitis which is a known feature of Ileal Crohn's Disease.
      - reference: PMID:31960900
        supports: SUPPORT
        snippet: Crohn''s disease patients with unequivocal imaging findings of ileal inflammation at enterography despite negative ileoscopy and biopsy are likely to have active inflammatory Crohn''s disease.
        explanation: This reference highlights that Crohn's disease can manifest as inflammation of the ileum, aligning with the subtype of Ileal Crohn's Disease.
  - name: Colonic Crohn's Disease
    description: Affects the colon (large intestine) with skip lesions.
    evidence:
      - reference: PMID:38437854
        supports: PARTIAL
        snippet: Commonly affecting the terminal ileum and proximal colon, Crohn's disease inflammation is often discontinuous and patchy, segmental, and transmural.
        explanation: The literature indicates that Crohn's disease can affect the colon and often presents with discontinuous, patchy inflammation. However, it is typically not limited to the colon and often involves the terminal ileum.
      - reference: PMID:11271896
        supports: SUPPORT
        snippet: The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient. Typical small intestinal CD occurred in four of seven patients with marked aphthous lesions of the small intestine, whereas colonic CD occurred in two of eight patients with such aphthous lesions of the colon.
        explanation: This study shows that Crohn's disease can indeed affect the colon specifically, supporting the subtype known as Colonic Crohn's Disease.
      - reference: PMID:26906301
        supports: PARTIAL
        snippet: Although ileitis can be seen in HSP, terminal ileitis is virtually pathognomonic for Crohn disease.
        explanation: "The focus is on terminal ileitis, commonly seen in Crohnâ€™s disease. It suggests that Crohn's disease frequently involves the ileum, but does not refute that the colon can also be involved."
      - reference: PMID:33278326
        supports: PARTIAL
        snippet: Inflammation in the small intestine affects the absorptive capacity and alters various physiological aspects.
        explanation: "This study focuses on small intestine involvement in Crohnâ€™s disease but does not refute colonic involvement with skip lesions."
      - reference: PMID:28379745
        supports: SUPPORT
        snippet: Nearly half (36/73, 49%) of the patients with normal or nonspecific findings at ileocolonoscopy had radiologically active disease with a median length of SB involvement of 20 cm (range, 1 to > 100 cm).
        explanation: Findings indicate that Crohn's Disease can have varying and discontinuous involvement, including potentially just the colon, thereby supporting the subtype.
  - name: Ileocolonic Crohn's Disease
    description: Involves both the small intestine (ileum) and the colon.
    evidence:
      - reference: PMID:33712743
        supports: PARTIAL
        snippet: Crohn's disease can affect any part of the gastrointestinal tract; however, current European and national guidelines worldwide do not differentiate between small-intestinal and colonic Crohn's disease for medical treatment.
        explanation: Although the literature acknowledges different manifestations of Crohn's disease involving the ileum and colon, it primarily discusses the broader differentiation between small-intestinal and colonic Crohn's Disease without naming or detailing specific subtypes such as Ileocolonic Crohn's Disease.
      - reference: PMID:11271896
        supports: PARTIAL
        snippet: The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient.
        explanation: This provides clinical evidence of Crohn's Disease affecting both the ileum and colon in patients but does not explicitly label it as Ileocolonic Crohn's Disease.
      - reference: PMID:38294885
        supports: SUPPORT
        snippet: The terminal ileum and small bowel (SB) are involved in 30-45% of patients with Crohn's disease, while 20% have both small and large bowel involvement.
        explanation: This literature reference supports the statement by noting that 20% of Crohn's disease cases involve both the small and large intestines, which corresponds to the description of Ileocolonic Crohn's Disease.
prevalence:
  - population: Global
    percentage: 0.2-0.3
    evidence:
      - reference: PMID:37137806
        supports: WRONG_STATEMENT
        snippet: The crude prevalence of IBD increased by 47% in 2019 globally.
        explanation: The available literature does not provide specific data on the percentage prevalence of Crohn's Disease alone globally; it talks about the prevalence of IBD as a whole.
      - reference: PMID:35930087
        supports: NO_EVIDENCE
        snippet: This prospective, observational registry study was conducted at 19 tertiary centers in Japan. Patients newly diagnosed with Crohn''s disease after June 2016 (age >/= 16 years at informed consent) were enrolled between December 17, 2018 and June 30, 2020.
        explanation: This study focuses on the prevalence and characteristics of Crohn's Disease specifically in Japan, not globally.
progression:
  - phase: Onset
    age_range: 15-35
    evidence:
      - reference: PMID:33587489
        supports: SUPPORT
        snippet: Patients were divided into a derivation (80%) cohort and a validation (20%) cohort. The primary outcome was progressive disease... In our final model, age at diagnosis older than 60 years was significantly associated with a lower risk of developing progressive disease... In patients with CD.
        explanation: The study indicates that younger patients, particularly those aged less than 60 years, are at higher risk of developing progressive Crohn's disease.
      - reference: PMID:37384664
        supports: REFUTE
        snippet: Logistic regression analysis of the initial characteristics showed that the age at diagnosis, gender, initial location and initial extra-intestinal manifestation are not associated with the progression of the disease.
        explanation: This study states that the progression of Crohn's disease is not linked to the initial age of diagnosis among children and adolescents.
      - reference: PMID:37266570
        supports: PARTIAL
        snippet: The best predictive model (PREDICT-EPIMAD) included the location at diagnosis, pANCA, and 6 single nucleotide polymorphisms. This model showed good discrimination... Decision curve analysis confirmed the clinical utility of the model.
        explanation: Though the exact age range of 15-35 is not specifically discussed, the predictive model includes various factors that can affect disease progression, which might encompass age-related variations.
      - reference: PMID:28051217
        supports: NO_EVIDENCE
        snippet: Our aim was to identify the phenotype evolution of Crohn's disease over time according to the Montreal Classification and to precise predictive factors of the need for immunosuppressant treatment or surgery... without association with age, sex or smoking habits.
        explanation: This study did not find evidence associating age with the progression of Crohn's disease, focusing instead on phenotype and specific disease markers.
pathophysiology:
  - name: Dysregulated Immune Response
    description: The immune system attacks the gastrointestinal tract, leading to chronic inflammation.
    evidence:
      - reference: PMID:32242028
        supports: SUPPORT
        snippet: Several factors have been implicated in the cause of Crohn's disease, including a dysregulated immune system... The uncontrolled activation of the immune system toward antigens contained in the gut lumen in genetically predisposed subjects is believed to be the leading cause of inflammatory bowel disease.
        explanation: The statement is supported as one of the major factors causing Crohn's Disease is the dysregulated immune system attacking the gastrointestinal tract.
      - reference: PMID:36720220
        supports: SUPPORT
        snippet: Crohn's disease (CD) is a chronic gastrointestinal disease that is increasing in prevalence worldwide. CD is multifactorial, involving the complex interplay of genetic, immune, and environmental factors... we mapped markers of disease-associated myofibroblast activation and identified CHMP1A, TBX3, and RNF168 as regulators of fibrotic complications.
        explanation: This study supports the mechanism involving the immune system leading to inflammation and chronic disease in the gastrointestinal tract.
      - reference: PMID:21543977
        supports: SUPPORT
        snippet: The lymphatic system is re-emerging as a critical player in inflammatory and immune processes... Recent studies reporting lymphangitis, lymphangiogenesis, bacterial infiltration and lymph node infection, immune cell trafficking, and fat-wrapping in Crohn's disease suggest altered lymph drainage and lymphatic pumping, implicating the lymphatic system as a likely player in inflammatory disorders and IBDs.
        explanation: The literature acknowledges the immune system's involvement in Crohn's Disease through various mechanisms, including lymphatic system dysfunction.
  - name: Microbiome Imbalance
    description: Alterations in gut microbiota contribute to the disease mechanisms.
    evidence:
      - reference: PMID:34313550
        supports: SUPPORT
        snippet: Crohn's disease (CD) is a major form of inflammatory bowel disease characterized by transmural inflammation along the alimentary tract. Changes in the microbial composition and reduction in species diversity are recognized as pivotal hallmarks in disease dynamics, challenging the gut barrier function and shaping a pathological immune response in genetically influenced subjects.
        explanation: This study details changes in microbial composition and reduction in species diversity as key factors in the dynamics of Crohn's Disease, thereby supporting the statement.
      - reference: PMID:18810765
        supports: SUPPORT
        snippet: The pathogenesis of both disease phenotypes is complex, the likely primary defect lies in the innate rather than adaptive immunity, particularly in the chemical antimicrobial barrier of the mucosa. This ileal and colonic defect in innate defense mediated by a deficiency of the protective alpha- and beta-defensins may enable the luminal microbes to invade the mucosa and trigger the inflammation.
        explanation: This study indicates that defects in innate defense mechanisms allow microbial invasion, which triggers inflammation, supporting the involvement of microbiota alterations in Crohn's Disease.
      - reference: PMID:23971750
        supports: SUPPORT
        snippet: Inflammatory bowel disease includes ulcerative colitis and Crohn's disease, which are both inflammatory disorders of the gastrointestinal tract. Both types of inflammatory bowel disease have a complex etiology, resulting from a genetically determined susceptibility interacting with environmental factors, including the diet and gut microbiota.
        explanation: This article mentions the role of gut microbiota as an environmental factor in the etiology of Crohn's Disease, supporting the contribution of microbiome imbalance to disease mechanisms.
phenotypes:
  - category: Gastrointestinal
    name: Abdominal Pain
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:29246562
        supports: SUPPORT
        snippet: The most frequent symptoms are abdominal pain and diarrhoea, which can seriously affect patients' quality of life.
      - reference: PMID:33946069
        supports: SUPPORT
        snippet: In Crohn's disease, inflammation causes pain.
      - reference: PMID:35380673
        supports: SUPPORT
        snippet: The prevalence of pain [83.6% vs 59.1%; p < 0.001] and abdominal pain [68.7% vs 48.5%; p = 0.006] was higher in CD patients than in ulcerative colitis [UC] patients.
      - reference: PMID:33836648
        supports: SUPPORT
        snippet: Using the patients'' self-reported information, we identified two subpopulations of Crohn's disease; these subpopulations differ in disease severity, associations with smoking, and genetic transmission patterns.
        explanation: "While this reference focuses on identifying subpopulations with varying disease severity, it underscores the heterogeneity of Crohnâ€™s disease symptoms, indirectly supporting that abdominal pain is a frequent symptom."
  - category: Gastrointestinal
    name: Diarrhea
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Weight Loss
      - Malnutrition
    evidence:
      - reference: PMID:22230271
        supports: PARTIAL
        snippet: Patients may experience diarrhea, abdominal pain, fever, weight loss, abdominal masses, and anemia.
        explanation: This reference supports the presence of diarrhea and weight loss as frequent symptoms of Crohn's disease. However, it does not explicitly discuss malnutrition as a common sequela or confirm that these phenotypes are highly frequent.
      - reference: PMID:38036713
        supports: PARTIAL
        snippet: Malnutrition might play a key role in the prognosis of patients with Crohn's disease (CD) ... Forty-one patients (24.8%) had body weight loss whereas 124 patients (75.2%) had no body weight loss.
        explanation: This reference mentions weight loss and suggests a role for malnutrition in Crohn's disease prognosis, but does not confirm high frequency of gastrointestinal symptoms like diarrhea.
  - category: Systemic
    name: Fatigue
    frequency: FREQUENT
    evidence:
      - reference: PMID:23111414
        supports: SUPPORT
        snippet: A high percentage of CD patients suffer from fatigue.
        explanation: This reference confirms that fatigue is a common symptom among Crohn's disease patients.
      - reference: PMID:37569413
        supports: SUPPORT
        snippet: Despite high prevalence and importance, the symptom is often underestimated in clinical practice.
        explanation: The reference articulates the high prevalence of fatigue in inflammatory diseases, supporting the statement that fatigue is common among Crohn's disease patients.
biochemical:
  - name: C-Reactive Protein (CRP)
    presence: Elevated
    evidence:
      - reference: PMID:24635486
        supports: SUPPORT
        snippet: C-reactive protein (CRP) is an important acute-phase marker, produced mainly in the liver. Its production by mesenteric adipocytes has been recently stressed in Crohn's disease (CD).
        explanation: The literature indicates that CRP is a relevant marker for inflammation in Crohn's Disease.
      - reference: PMID:22868800
        supports: SUPPORT
        snippet: 'MDA/TBARS were the best predictor of CD, comparable to CRP, with high specificity (MDA/TBARS sensitivity and specificity: 75% and 90%; CRP: 76% and 93%). Combined assessment of MDA/TBARS and CRP improved sensitivity (94%) corresponding with acceptable specificity (81%).'
        explanation: The study highlights that CRP is a reliable biochemical marker for Crohn's Disease, confirming its elevated presence.
      - reference: PMID:36550821
        supports: SUPPORT
        snippet: The aim of this study was to ascertain serum vitamin B12 and folate levels in order to investigate the correlation among these vitamin levels and disease activation, localization, duration and age at the onset of the disease. [...] C-reactive protein, vitamin B12, folate levels were studied along with hemogram analyses.
        explanation: This study further supports that CRP levels are relevant in the context of Crohn's Disease.
    context: General inflammation
  - name: Fecal Calprotectin
    presence: Elevated
    context: Intestinal inflammation
    evidence:
      - reference: PMID:31088326
        supports: SUPPORT
        snippet: Calprotectin, a cytosolic protein derived predominantly from neutrophils, is now widely used in this capacity. Calprotectin is found in various bodily fluids at concentrations proportional to the degree of inflammation, including in feces at levels roughly six times higher than in the blood. Fecal calprotectin (FCP) therefore reflects intestinal inflammation.
        explanation: The statement is supported by the literature, which indicates that fecal calprotectin levels are elevated in the context of intestinal inflammation, consistent with the presence of Crohn's Disease.
      - reference: PMID:37999894
        supports: SUPPORT
        snippet: Fecal calprotectin was negatively correlated with glycolithocholic acid (GLCA) and hyodeoxycholic acid (HDCA) in UC. These bile acids were reduced in stool of UC patients with fecal calprotectin levels > 500 microg/g compared to UC patients with low calprotectin levels.
        explanation: Although this study focuses on ulcerative colitis, it corroborates the finding that fecal calprotectin levels are elevated in the context of intestinal inflammation.
genetic:
  - name: NOD2
    association: Risk Factor
    evidence:
      - reference: PMID:29358789
        supports: SUPPORT
        snippet: 'BACKGROUND AND OBJECTIVES: Crohn''s disease is a multifactorial inflammatory disease affecting mainly the gastrointestinal tract. The genetic factors that are involved in the disease include mainly three mutations of the gene NOD2/CARD15 (R702W, G908R, 3020insC).'
        explanation: This reference states that NOD2 mutations are involved in Crohn's disease, supporting the association as a risk factor.
      - reference: PMID:23352252
        supports: SUPPORT
        snippet: NOD2 gene mutations are associated with several diseases, and some of the mutations are of diagnostic value in Blau disease and NAID... The NOD2 variants located in the leucine-rich repeat (LRR) region are susceptible to Crohn disease.
        explanation: This reference confirms the association of NOD2 gene mutations with Crohn's disease.
      - reference: PMID:16773683
        supports: SUPPORT
        snippet: Investigations into the inheritance of the three risk alleles R702W, G908R and 1007fsInsC in NOD2 associated with susceptibility to Crohn's disease have demonstrated a remarkable amount of heterogeneity across ethnicities and populations.
        explanation: This reference clearly establishes the association of specific NOD2 mutations with susceptibility to Crohn's disease.
      - reference: PMID:12851870
        supports: SUPPORT
        snippet: The NOD2 gene, which is strongly associated with susceptibility to Crohn's disease (CD) of the terminal ileum, interacts with bacterial lipopolysaccharide (LPS), inducing cellular activation.
        explanation: This study supports the role of NOD2 as a genetic risk factor for Crohn's disease.
      - reference: PMID:32476786
        supports: SUPPORT
        snippet: While NOD2 mutations represent well established risk factors of CD, the role of other genes is incompletely understood.
        explanation: This confirms that NOD2 is a well-established genetic risk factor for Crohn's disease.
      - reference: PMID:11385577
        supports: SUPPORT
        snippet: Here we show, by using the transmission disequilibrium test and case-control analysis, that a frameshift mutation caused by a cytosine insertion, 3020insC, which is expected to encode a truncated NOD2 protein, is associated with Crohn's disease.
        explanation: This study provides evidence of a specific NOD2 mutation associated with Crohn's disease.
      - reference: PMID:17206682
        supports: SUPPORT
        snippet: The association of NOD2/CARD15 mutations with CD and BS, and possibly also early onset sarcoidosis, suggests a role for the gene in the development of granulomata and granulomatous diseases.
        explanation: This statement supports the association of NOD2 with Crohn's disease (CD).
      - reference: PMID:16987083
        supports: SUPPORT
        snippet: The mapping to CD of Nod2 variants that alter protein function represents one of the earliest, most well-established, associations in complex genetic disorders.
        explanation: This reference emphasizes that the NOD2 association with Crohn's disease is well-established.
      - reference: PMID:27076762
        supports: SUPPORT
        snippet: The highest accuracy, AUC of 0.78 was achieved with GRS combining 33 SNPs with optimal sensitivity and specificity of 75.0% and 72.7%, respectively... This includes variants in NOD2.
        explanation: This study confirms the role of NOD2 variants as part of a genetic risk score for Crohn's disease.
  - name: ATG16L1
    association: Risk Factor
    evidence:
      - reference: PMID:27698206
        supports: SUPPORT
        snippet: Conclusion In this meta-analysis, the ATG16L1 genotype was significantly associated with the risk of developing Crohn''s disease.
      - reference: PMID:25906181
        supports: SUPPORT
        snippet: Of interest, single-nucleotide polymorphisms in ATG16L1 (autophagy-related 16-like 1 [S. cerevisiae]), a key component in the autophagic response to invading pathogens, have been associated with an increased risk of developing Crohn disease.
      - reference: PMID:12840668
        supports: NO_EVIDENCE
        snippet: CARD15 mutations are present in 30-50% of CD patients compared to 7-20% of healthy controls. Interestingly, CD patients often carry mutations on their two chromosomes suggesting a mutation dose effect.
        explanation: "The reference focuses on the association between CARD15 mutations and Crohnâ€™s Disease, with no information regarding ATG16L1."
      - reference: PMID:29795570
        supports: NO_EVIDENCE
        snippet: we find that ten rare genetic risk factors in NOD2 and LRRK2 are enriched in AJ (p < 0.005), including several novel contributing alleles, show evidence of association to CD.
        explanation: "The reference highlights genetic risk factors in NOD2 and LRRK2 for Crohnâ€™s Disease, not ATG16L1."
      - reference: PMID:27076762
        supports: PARTIAL
        snippet: We generated genetic risk scores (GRS) based on the number of risk alleles using weighted additive model. Discriminatory accuracy was measured by area under ROC curve (AUC)....The highest accuracy, AUC of 0.78 was achieved with GRS combining 33 SNPs with optimal sensitivity and specificity of 75.0% and 72.7%, respectively.
        explanation: The study involves identification of SNPs for risk prediction, however ATG16L1 is not mentioned explicitly. Thus, it only partially supports the statement.
  - name: IL23R
    association: Risk Factor
    evidence:
      - reference: PMID:17068223
        supports: SUPPORT
        snippet: We found a highly significant association between Crohn's disease and the IL23R gene on chromosome 1p31, which encodes a subunit of the receptor for the proinflammatory cytokine interleukin-23.
        explanation: This study identifies IL23R as a gene significantly associated with Crohn's disease, supporting the statement that IL23R is a genetic risk factor for the condition.
      - reference: PMID:24989722
        supports: SUPPORT
        snippet: The study aimed to assess the contribution of the interleukin 23 receptor (IL23R) in determining disease susceptibility in two independent cohorts of CD. We demonstrate a strong increased CD risk for smokers and an additive interaction between IL23R SNPs and cigarette smoking.
        explanation: This study supports the association between IL23R and Crohn's disease, while also highlighting the interaction between IL23R variants and environmental factors like smoking.
environmental:
  - name: Smoking
    notes: Increases the risk and severity of Crohn's disease.
    evidence:
      - reference: PMID:27016849
        supports: SUPPORT
        snippet: Smoking increases the risk of complications, recurrences and resort of surgery, corticosteroids or immunosuppressants.
        explanation: The provided literature clearly states that smoking increases the risk and severity of Crohn's disease, aligning with the statement.
      - reference: PMID:31014995
        supports: SUPPORT
        snippet: 'We identified 9 factors that increase risk of IBD: smoking (CD)...'
        explanation: The review identifies smoking as a significant environmental risk factor that increases the risk of Crohn's disease.
      - reference: PMID:38238335
        supports: SUPPORT
        snippet: Compared to never smoking, current and previous smoking habits are associated with increased CD (P = 7.09 x 10(-10)) and UC (P < 2 x 10(-16)) risk, respectively.
        explanation: This prospective cohort study finds that both current and previous smoking habits are associated with increased risk of CD, which supports the statement.
      - reference: PMID:28838409
        supports: SUPPORT
        snippet: Understanding the potential environmental risk factors and natural history of CD in a given patient guides the physician when counseling the patient and selecting a treatment strategy.
        explanation: The review discusses smoking as an important environmental risk factor, thereby supporting the statement.
  - name: Diet
    notes: Western diet with high-fat, low-fiber content may exacerbate symptoms.
    evidence:
      - reference: PMID:33574618
        supports: SUPPORT
        snippet: Fiber-poor Western diets fuel inflammation.
        explanation: This indicates that a Western diet, which is low in fiber, can contribute to inflammation, suggesting a potential exacerbation of symptoms in Crohn's Disease.
      - reference: PMID:34010595
        supports: SUPPORT
        snippet: In mouse models, consumption of a Western diet for as little as 4 weeks led to Paneth cell dysfunction... Our findings provide a mechanistic link between poor diet and inhibition of gut innate immunity.
        explanation: This study provides a direct mechanistic link between a Western diet and compromised gut immunity, which could exacerbate Crohn's disease symptoms.
      - reference: PMID:33159156
        supports: SUPPORT
        snippet: Patients with IBD often believe certain foods influence their disease symptoms and consequently may alter their diet considerably... The association between diet and symptoms in patients with IBD and the mechanism(s) involved warrant further research.
        explanation: This indicates that patients with inflammatory bowel disease, including Crohn's disease, often find that diet influences their symptoms, supporting the statement.
      - reference: PMID:35595417
        supports: PARTIAL
        snippet: most patients report minimal nutritional education from their provider, and providers report few nutritional resources to help them educate patients.
        explanation: While this indicates the importance of diet, it also highlights a lack of resources and education surrounding the dietary management of Crohn's disease, providing partial support.
  - name: Stress
    notes: Can trigger flare-ups and worsen symptoms.
    evidence:
      - reference: PMID:15288007
        supports: NO_EVIDENCE
        snippet: Stress is also associated with IBD, but more as a modifier than an inducing factor, and its contribution is more obvious in IBD animal models than human IBD.
        explanation: The literature suggests that stress is associated with IBD as a modifier and not necessarily as a direct trigger.
      - reference: PMID:31574072
        supports: SUPPORT
        snippet: The unpredictable course of the disease, impaired function due to fatigue, and lack of bowel control were the most prominent causes of worry. The worries created feelings of stress, guilt, and frustration. The participants expressed a need to talk about their worries, to make them visible and recognized, and to be understood.
        explanation: The study indicates that stress related to the disease itself is significant among Crohn's disease patients, which supports the claim that stress can worsen symptoms.
treatments:
  - name: Aminosalicylates
    description: Anti-inflammatory drugs used for mild to moderate disease.
    evidence:
      - reference: PMID:12786608
        supports: SUPPORT
        snippet: The mainstay of current medical treatment for mild to moderately active stages of Crohn's disease includes aminosalicylates, antibiotics, glucococorticosteroids and immunomodulators.
        explanation: This reference states that aminosalicylates are included in the main treatments for mild to moderately active Crohn's disease.
      - reference: PMID:34797442
        supports: SUPPORT
        snippet: 5-aminosalicylates (5-ASA) are frequently used in the management of Crohn's disease.
        explanation: This reference supports the use of aminosalicylates for Crohn's disease treatment.
      - reference: PMID:17339853
        supports: REFUTE
        snippet: Sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease.
        explanation: This reference explicitly states that aminosalicylates have no clinical effect on Crohn's disease.
  - name: Corticosteroids
    description: Used for short-term control during flare-ups to reduce inflammation.
    evidence:
      - reference: PMID:24532122
        supports: SUPPORT
        snippet: Corticosteroids have been used for decades to treat active Crohn's disease and remain the mainstay in the management of moderate-to-severe relapses in Crohn's disease.
        explanation: This indicates that corticosteroids are indeed a primary treatment option for managing flare-ups in Crohn's disease.
      - reference: PMID:32653651
        supports: SUPPORT
        snippet: "corticosteroids are crucial for the induction of remission of moderateâ€‘toâ€‘severe flares in both UC and Crohn's disease."
        explanation: This strengthens the claim that corticosteroids are used for short-term control during flare-ups to reduce inflammation in Crohn's disease.
      - reference: PMID:18239408
        supports: SUPPORT
        snippet: The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by a long-term maintenance therapy. [...] The drugs described in this article include [...] corticosteroids [...].
        explanation: This reinforces that corticosteroids are part of the short-term treatment strategy to control flare-ups in Crohn's disease.
  - name: Immunomodulators
    description: Drugs like azathioprine and methotrexate to suppress the immune response.
    evidence:
      - reference: PMID:17105689
        supports: SUPPORT
        snippet: The immunomodulatory drugs in the IBD arsenal include azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and tacrolimus.
        explanation: The provided literature supports the statement that drugs like azathioprine and methotrexate are used as immunomodulators to manage Crohn's Disease.
      - reference: PMID:35115294
        supports: SUPPORT
        snippet: Our results show that parenteral use of methotrexate is efficacious in inducing and maintaining remission as a step-up agent in azathioprine refractory Crohn's disease patients.
        explanation: The study shows the use of methotrexate in patients who are refractory to azathioprine, supporting the statement that these drugs are used to treat Crohn's Disease by mitigating immune response.
      - reference: PMID:16245637
        supports: SUPPORT
        snippet: First line immunosuppressants are Azathioprine and 6-Mercaptopurine while Methotrexate, Infliximab, Mycophenolatmofetil and other compounds represent alternative or rescue medications.
        explanation: This reference confirms that Azathioprine and Methotrexate are used as immunosuppressants in the treatment of Crohn's Disease.
      - reference: PMID:24913384
        supports: SUPPORT
        snippet: The only other long term disease-modifying options are the immunomodulators, methotrexate, azathioprine and mercaptopurine.
        explanation: This review supports the use of methotrexate and azathioprine as immunomodulators for long-term management of Crohn's Disease.
  - name: Biologics
    description: Anti-TNF agents (infliximab, adalimumab) and integrin inhibitors (vedolizumab) for moderate to severe disease.
    evidence:
      - reference: PMID:18034589
        supports: PARTIAL
        snippet: Infliximab and adalimumab are currently the only biological agents approved for induction and maintenance treatment in adults (infliximab and adalimumab) and children (infliximab) with Crohn's disease.
        explanation: This reference supports the use of anti-TNF agents (infliximab and adalimumab) for the treatment of moderate to severe Crohn's disease but does not mention vedolizumab directly.
      - reference: PMID:26195652
        supports: PARTIAL
        snippet: Vedolizumab is an integrin-receptor antagonist for the treatment of CD and UC in adults with moderately to severely active disease.
        explanation: This reference supports the use of vedolizumab (an integrin inhibitor) for the treatment of Crohn's disease but does not provide details on anti-TNF agents (infliximab and adalimumab).
      - reference: PMID:26616476
        supports: SUPPORT
        snippet: Anti-TNF-alpha therapy is a novel approach that has transformed the way moderate-to-severe Crohn's disease (CD) is treated and has significantly improved clinical outcomes of patients.
        explanation: This reference supports the use of anti-TNF agents for moderate to severe Crohn's disease.
  - name: Nutritional Therapy
    description: Dietary modifications and enteral nutrition to manage symptoms and maintain nutrition.
    evidence:
      - reference: PMID:19244154
        supports: SUPPORT
        snippet: Nutrition therapy of Crohn's disease is considered the first-line of treatment for Crohn's disease in children, especially in Europe.
        explanation: "This article supports the use of nutrition therapy as a treatment for managing symptoms and maintaining nutrition in Crohnâ€™s disease."
      - reference: PMID:38276922
        supports: SUPPORT
        snippet: New data in Crohn's disease supports the use of enteral liquid nutrition to help induce remission and correct malnutrition in patients heading for surgery.
        explanation: This article supports the use of enteral nutrition as an effective therapy to induce remission and manage malnutrition in Crohn's disease.
      - reference: PMID:36558412
        supports: SUPPORT
        snippet: Both under-and over-nutrition are prevalent in patients with Crohn's Disease (CD).
        explanation: The study highlights the importance of dietary modifications to manage nutritional status in Crohn's disease patients.
      - reference: PMID:35595414
        supports: SUPPORT
        snippet: The primary agents used in the treatment of Crohn's disease are aminosalicylates, corticosteroids, immunomodulators, and biologics. Each agent has different roles in the induction and maintenance of remission of disease.
        explanation: While this primarily focuses on pharmacologic therapy, it does acknowledge the role of different agents in maintaining remission.
      - reference: PMID:22410431
        supports: SUPPORT
        snippet: Although an elemental diet might lead to disease remission, reintroducing real foods and sustainable diets in patients with Crohn's disease is currently difficult, and would benefit from the sensitivity and rapid feedback provided by the field of nutrigenomics.
        explanation: This reference suggests that dietary modifications can lead to remission and maintenance of Crohn's disease, validating the role of nutritional therapy.
  - name: Surgery
    description: Removal of affected bowel segments, typically reserved for complications like strictures or fistulas.
    evidence:
      - reference: PMID:21901520
        supports: SUPPORT
        snippet: The indications for surgery include the failure of medical management, especially the persistence or worsening of symptoms in spite of proper treatment and complications of the disease process. These complications include intestinal obstruction, intestinal perforation with fistula formation or abscess, free perforation, gastrointestinal bleeding, urologic complications, cancer, and perianal disease.
        explanation: The excerpt indicates that surgery is reserved for complications such as strictures or fistulas among others, thus supporting the statement.
      - reference: PMID:32279173
        supports: SUPPORT
        snippet: Therefore, current therapy of fibrotic strictures relies mainly on endoscopic and surgical procedures.
        explanation: The statement mentions surgery for complications like strictures, which is supported by the snippet indicating that fibrotic strictures rely on surgical procedures for treatment.
      - reference: PMID:21975159
        supports: SUPPORT
        snippet: Intestinal resection is almost always needed for the closure of symptomatic non-perianal fistulas.
        explanation: The statement links surgery to the complication of fistulas, which is supported by the snippet explaining the need for intestinal resection to manage symptomatic non-perianal fistulas.
      - reference: PMID:29462390
        supports: SUPPORT
        snippet: When isolated to the colon, and patients become medically refractory, there are several surgical options - segmental resection, subtotal colectomy with ileorectal anastomosis, or a total proctocolectomy and end ileostomy. Unfortunately, surgery does not cure CD, and, regardless of the extent of bowel removed, recurrence may be seen in the small bowel.
        explanation: The snippet supports the statement by discussing various surgical options for patients who are medically refractory, involving the removal of affected bowel segments.
      - reference: PMID:36926950
        supports: SUPPORT
        snippet: A partial resection of 3rd and 4th portion of the duodenum and the first loop of jejunum was performed, with duodenojejunal anastomosis.
        explanation: The provided case demonstrates a scenario where surgery was performed due to refractory disease and complications, supporting the statement.
---
name: Familial Mediterranean Fever
category: Genetic
parents:
  - Autoinflammatory Disease
  - Inherited Disorder
has_subtypes:
  - name: Type 1
    description: Classic form presenting with recurrent episodes of fever and serositis.
    evidence:
      - reference: PMID:25649364
        supports: NO_EVIDENCE
        snippet: Familial Mediterranean Fever is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis.
        explanation: Although the literature describes Familial Mediterranean Fever having episodic fever and serositis, it does not define subtypes or a 'Type 1' specifically.
      - reference: PMID:23823268
        supports: NO_EVIDENCE
        snippet: Periodic fevers are acquired or inherited disorders of innate immunity, which were first described in the 1940s. ... This clinical review focuses on a sample of autoinflammatory disorders including familial Mediterranean fever...
        explanation: There is a general discussion of Familial Mediterranean Fever but no mention of subtypes or a classification system involving the term 'Type 1'.
      - reference: PMID:36889987
        supports: NO_EVIDENCE
        snippet: MEFV gene mutation spectrum in patients with familial mediterranean fever.
        explanation: This study discusses the gene mutations associated with FMF but does not describe subtypes of the disease.
  - name: Type 2
    description: A variant characterized by continuous subclinical inflammation, leading to amyloidosis without overt episodes.
    evidence:
      - reference: PMID:21358337
        supports: SUPPORT
        snippet: Familial Mediterranean fever type 2 is characterized by amyloidosis as the first clinical manifestation of familial Mediterranean fever in an otherwise asymptomatic individual.
        explanation: The literature directly states that FMF type 2 is characterized by amyloidosis without prior overt inflammatory episodes, aligning with the given statement.
      - reference: PMID:11053071
        supports: PARTIAL
        snippet: Phenotype II in familial Mediterranean fever (FMF) is the onset of amyloidosis before the onset of FMF with its typical attacks, or as an isolated finding in a member of an FMF family.
        explanation: While this states Type 2 can involve amyloidosis without typical attacks, it does not directly mention continuous subclinical inflammation.
      - reference: PMID:36161616
        supports: PARTIAL
        snippet: Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis.
        explanation: Reference to subclinical inflammation in amyloidosis supports part of the statement, but does not specifically mention Type 2 FMF.
      - reference: PMID:37496356
        supports: PARTIAL
        snippet: Recent studies have shown that cases of amyloidosis in patients with familial Mediterranean fever are decreasing...However, familial Mediterranean fever is the most common cause of systemic amyloidosis.
        explanation: Though it implies a relationship between FMF and amyloidosis, it does not clearly distinguish between subtypes or mention continuous subclinical inflammation.
prevalence:
  - population: Mediterranean Populations
    percentage: 0.1-0.2
    evidence:
      - reference: PMID:32608308
        supports: REFUTE
        snippet: The predominant ethnicities were Turkish (41.8%), Lebanese (15.8%), Syrian (6.5%), South-West Asian (7.9%), and South-East Asian (3.0%).
        explanation: The prevalence in Mediterranean populations, such as Turkish (41.8%) and Lebanese (15.8%), is much higher than 0.1-0.2%.
      - reference: PMID:11053071
        supports: NO_EVIDENCE
        snippet: Phenotype II is uncommon among the relatives of patients with FMF and amyloidosis.
        explanation: This study does not provide direct evidence on the overall prevalence of FMF in the Mediterranean populations.
      - reference: PMID:3306755
        supports: REFUTE
        snippet: Recurrent hereditary polyserositis (RHP) or familial Mediterranean fever (FMF) is a chronic inherited illness of obscure aetiology... and predominantly affects Sephardic Jews, Arabs, Turks and Armenians.
        explanation: The article suggests that FMF predominantly affects specific Mediterranean populations, implying a higher prevalence than 0.1-0.2% among these groups.
      - reference: PMID:34363075
        supports: NO_EVIDENCE
        snippet: The aim of this study was to determine the prevalence of FMF in children with cryptogenic cirrhosis and it was high.
        explanation: The study focused on children with cryptogenic cirrhosis and does not provide general prevalence data for Mediterranean populations.
progression:
  - phase: Onset
    age_range: Childhood-Adolescence
    evidence:
      - reference: PMID:31999206
        supports: SUPPORT
        snippet: Of 1687 patients, 761 had first FMF attack at </=3 years of age while 926 patients presented with their first manifestation of FMF at >3 years.
        explanation: The study provides evidence that FMF onset can occur in childhood.
      - reference: PMID:23194659
        supports: SUPPORT
        snippet: Median age at first symptoms was 4 years (range 3 month-37 years) and at diagnosis 10 years (range 2-44 years).
        explanation: This reference supports the statement by indicating that the majority of FMF cases have an onset in childhood.
      - reference: PMID:1433029
        supports: SUPPORT
        snippet: The only efficient treatment to prevent this amyloidosis is regular administration of colchicine, from early childhood.
        explanation: This study highlights that managing FMF from early childhood is crucial to prevent complications.
pathophysiology:
  - name: MEFV Gene Mutation
    description: Mutations in the MEFV gene lead to dysfunctional pyrin, causing excessive inflammation.
    gene: MEFV
    evidence:
      - reference: PMID:28154935
        supports: SUPPORT
        snippet: Familial Mediterranean fever (FMF) is caused by mutations within the Mediterranean fever (MEFV) gene. These gain of function mutations lead to an increased activation of the inflammasome pyrin with a subsequent disproportional proinflammatory reaction.
        explanation: Mutations in the MEFV gene result in increased activation of pyrin, causing excessive inflammation.
      - reference: PMID:25307949
        supports: SUPPORT
        snippet: Mutations in the MEFV gene are associated with the human autoinflammatory disease familial Mediterranean fever (FMF). Pyrin can interact with the inflammasome adaptor ASC and induce inflammatory caspase-1 activation in monocytic cells.
        explanation: This article discusses the role of pyrin in inducing inflammatory responses, supporting the effect of MEFV gene mutations in causing excessive inflammation.
      - reference: PMID:36889987
        supports: SUPPORT
        snippet: The MEFV gene mutation spectrum in patients with familial Mediterranean fever links to the role of pyrin in disease pathogenesis.
        explanation: The mutation spectrum in the MEFV gene is related to the pathogenesis involving pyrin and inflammation, supporting the given statement.
  - name: Autoinflammatory Pathway Activation
    description: Dysregulated inflammatory response due to pyrin dysfunction, leading to recurrent inflammatory episodes.
    pathways:
      - "IL-1Î²"
      - inflammasome
    evidence:
      - reference: PMID:16344627
        supports: SUPPORT
        snippet: The spectrum of reported genetic mutations and susceptible ethnicities for the hereditary periodic fever subset of the autoinflammatory diseases has continued to expand. At the same time, the pathogeneses of many of these diseases are now understood to involve different aspects of a common pathway, largely affecting inflammatory cascades related to IL-1 or tumor necrosis factor-alpha.
        explanation: This reference supports the involvement of IL-1 and inflammatory pathways in autoinflammatory diseases, including Familial Mediterranean Fever (FMF).
      - reference: PMID:29148036
        supports: SUPPORT
        snippet: Pyrin, encoded by the MEFV gene, is an intracellular pattern recognition receptor that assembles inflammasome complexes in response to pathogen infections. Mutations in the MEFV gene have been linked to autoinflammatory diseases such as familial Mediterranean fever (FMF) or pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND).
        explanation: This reference describes the role of pyrin in inflammasome activation and its link to FMF, supporting the statement about dysregulated inflammatory responses and recurrent inflammatory episodes.
      - reference: PMID:33026080
        supports: SUPPORT
        snippet: FMF is an autoinflammatory disease characterized by recurrent attacks and increased IL-1 synthesis owing to activation of the pyrin inflammasome. Although knowledge of the mechanisms leading to the activation of pyrin inflammasome is increasing, it is still unknown why the disease is characterized by attacks.
        explanation: This reference directly mentions recurrent attacks and increased IL-1 synthesis due to pyrin inflammasome activation, supporting the mechanisms described in the statement.
      - reference: PMID:32601469
        supports: SUPPORT
        snippet: Familial Mediterranean fever (FMF) is an autoinflammatory disease caused by homozygous or compound heterozygous gain-of-function mutations in MEFV, which encodes pyrin, an inflammasome protein. Heterozygous carrier frequencies for multiple MEFV mutations are high in several Mediterranean populations, suggesting that they confer selective advantage.
        explanation: This reference supports the genetic basis of FMF involving mutations in MEFV, which leads to the dysregulated inflammatory response observed in FMF.
      - reference: PMID:29051974
        supports: SUPPORT
        snippet: Familial Mediterranean fever (FMF) is an autoinflammatory disease manifested by inflammatory attacks of peritonitis, pleuritis, pericarditis accompanied by fever and arthritis. Mutations of MEFV gene results in pyrin dysfunction, which causes uncontrolled interleukin-1 beta production and triggers the inflammatory attacks.
        explanation: This reference supports the mechanism described in the statement, emphasizing pyrin dysfunction and the uncontrolled production of interleukin-1 beta.
phenotypes:
  - category: Systemic
    name: Recurrent Fever
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:21358337
        supports: PARTIAL
        snippet: Familial Mediterranean fever type 1 is characterized by recurrent short episodes of inflammation and serositis, including fever, peritonitis, synovitis, pleuritis, and, rarely, pericarditis.
        explanation: The literature supports that recurrent fever is a common feature of Familial Mediterranean Fever type 1, but it does not fully support that FMF should be categorized solely under systemic phenotypes.
      - reference: PMID:25832989
        supports: PARTIAL
        snippet: Familial Mediterranean fever...presents with recurrent and self-limited inflammatory attacks of fever and polyserositis along with high acute-phase reactants.
        explanation: The literature supports that recurrent fever is a common diagnostic feature of FMF and systemically involves fever and inflammation, but it does not confirm all specified aspects of the statement.
      - reference: PMID:36688581
        supports: PARTIAL
        snippet: Higher Pras scores, earlier age of symptoms and diagnosis, more frequent arthritis and erysipelas-like erythema, and higher colchicine dose are closely associated with M694V homozygous familial Mediterranean fever patients. These patients also have mostly moderate and severe disease severity.
        explanation: It supports the systemic nature and severity aspects but does not fully align with the complete statement's focus.
      - reference: PMID:34606655
        supports: PARTIAL
        snippet: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease manifesting with phenotypic heterogeneity. It is a clinically diagnosed disease supported by Mediterranean fever gene mutation analysis.
        explanation: While fever is a prominent symptom, FMF is known for phenotypic heterogeneity, indicating varied systemic manifestations.
  - category: Musculoskeletal
    name: Arthritis
    frequency: FREQUENT
    notes: Transient, affecting large joints
    evidence:
      - reference: PMID:11411958
        supports: SUPPORT
        snippet: The arthritis was transient, monoarticular, nonerosive, and nondeforming in the majority of cases. Four patients (5.4%) had chronic arthritis, with one requiring total hip replacement. As in previous reports on arthritis of FMF, the majority of FMF patients studied in Lebanon had a transient monoarticular nonerosive and nondeforming type of arthritis affecting predominantly the large joints of the lower extremities.
        explanation: This reference supports the statement that arthritis is a common phenotype in FMF, is transient, and affects large joints.
      - reference: PMID:33124556
        supports: SUPPORT
        snippet: More patients had arthritis in the ELE group than in the other group (p=0.011). Arthritis occurred in the ankle (77.4%), knee (19.3%) and hip (3.2%) joints.
        explanation: This reference confirms the presence of arthritis in FMF patients, especially in large joints, supporting the statement.
  - category: Gastrointestinal
    name: Peritonitis
    frequency: VERY_FREQUENT
    notes: Recurrent abdominal pain due to inflammation of the peritoneum
    evidence:
      - reference: PMID:36082189
        supports: PARTIAL
        snippet: FMF is characterised by dysregulation of the inflammatory process in the body, presenting as recurrent episodes of serositis. Patients with FMF commonly present with episodes of fever, peritonitis, synovitis, pleuritis, arthritis, and occasionally pericarditis.
        explanation: This reference supports that peritonitis, which involves abdominal pain due to inflammation of the peritoneum, is a phenotype of FMF. However, it does not explicitly indicate a high frequency of gastrointestinal phenotypes.
      - reference: PMID:37723615
        supports: PARTIAL
        snippet: Familial Mediterranean fever (FMF) is the most prevalent hereditary autoinflammatory disease among children. Abdominal pain and various gastrointestinal system (GIS) manifestations may arise directly from FMF or concomitantly with FMF.
        explanation: This reference supports that gastrointestinal manifestations, including abdominal pain, are phenotypes of FMF. However, it does not specify the high frequency of peritonitis.
      - reference: PMID:9562837
        supports: SUPPORT
        snippet: When a patient complains of episodic fever accompanied by unexplained arthritis, peritonitis, pleurisy, or skin rash, this disorder should be considered.
        explanation: This reference supports that peritonitis is a common phenotype of FMF, aligning well with the statement.
      - reference: PMID:35737103
        supports: SUPPORT
        snippet: The key feature of familial Mediterranean fever is relapsing episodes of fever and serositis including peritonitis, pleurisy, or arthritis.
        explanation: This reference clearly supports that peritonitis, involving abdominal pain due to inflammation of the peritoneum, is a key feature of FMF and occurs frequently.
      - reference: PMID:31308342
        supports: SUPPORT
        snippet: Considering the history of recurrent abdominal pain, Familial Mediterranean Fever (FMF) was considered.
        explanation: This reference supports that recurrent abdominal pain is a phenotype associated with FMF.
  - category: Thoracic
    name: Pleuritis
    frequency: FREQUENT
    notes: Recurrent chest pain due to inflammation of the pleura
  - category: Renal
    name: Amyloidosis
    frequency: OCCASIONAL
    notes: Can lead to kidney failure if untreated
    evidence:
      - reference: PMID:12832747
        supports: SUPPORT
        snippet: Amyloidosis, causing renal failure, is one of the most severe complications of the disease.
        explanation: The literature confirms that amyloidosis can lead to kidney failure in patients with Familial Mediterranean Fever (FMF), supporting the statement.
      - reference: PMID:23548761
        supports: SUPPORT
        snippet: Familial Mediterranean Fever and tuberculosis were the most frequent causes of amyloidosis.
        explanation: The statement is supported as FMF is listed as one of the frequent causes of renal amyloidosis.
      - reference: PMID:3416182
        supports: SUPPORT
        snippet: Splenic and renal involvement is more likely in FMF-associated systemic amyloidosis.
        explanation: The presence of renal amyloidosis in FMF, leading potentially to kidney failure, supports the statement.
      - reference: PMID:21360109
        supports: SUPPORT
        snippet: The most frequent cause [of renal amyloidosis in children] is now autoinflammatory diseases. Among this group of diseases, the most frequent one throughout the world is familial Mediterranean fever (FMF).
        explanation: This confirms that FMF is a frequent cause of renal amyloidosis, thereby supporting the statement.
      - reference: PMID:33052444
        supports: SUPPORT
        snippet: Amyloidosis [...] stands out as a major complication of familial Mediterranean fever (FMF). Splenic and renal involvement is more likely in FMF-associated systemic amyloidosis.
        explanation: The literature confirms the renal involvement in FMF-associated amyloidosis, thus supporting the statement.
diagnosis:
  - name: Genetic Testing
    results: Identifies MEFV mutations
    evidence:
      - reference: PMID:29314663
        supports: PARTIAL
        snippet: Even though clinical assessment is accepted to be the most important factor in the diagnosis of FMF... MEFV gene assessment, unlike other diagnostic procedures, might support physicians in the early diagnosis of FMF.
        explanation: The literature acknowledges the importance of genetic testing for MEFV mutations but emphasizes that clinical evaluation remains crucial for diagnosis overall.
      - reference: PMID:25649364
        supports: SUPPORT
        snippet: Genetic mutation of the disease is on MEFV gene located on short arm of Chromosome 16. The disease is diagnosed based on clinical evaluation.
        explanation: This reference supports the statement that MEFV mutations are identified through genetic testing, although it specifies that the diagnosis is based on clinical evaluation.
      - reference: PMID:12168253
        supports: SUPPORT
        snippet: This strategy allows definitive confirmation of periodic disease if one mutation is detected on each of the two chromosomes...
        explanation: This reference directly supports the use of genetic testing to identify MEFV mutations for diagnosing familial Mediterranean fever.
      - reference: PMID:33037005
        supports: SUPPORT
        snippet: Its diagnosis relies on a set of clinical criteria and a genetic confirmation on identification of biallelic pathogenic MEFV variants.
        explanation: The reference confirms that genetic testing for MEFV mutations is a key part of diagnosing familial Mediterranean fever.
  - name: Inflammatory Markers
    presence: Elevated
    markers: CRP, ESR, SAA
    evidence:
      - reference: PMID:31524848
        supports: SUPPORT
        snippet: Median values of acute phase reactants during FMF attacks were 433.5 mg/L for serum amyloid A (SAA), 56.7 mg/L for C-reactive protein (CRP), and 37.5 mm/h for erythrocyte sedimentation rate (ESR).
        explanation: The study shows that SAA, CRP, and ESR are elevated during FMF attacks.
      - reference: PMID:23794006
        supports: SUPPORT
        snippet: We found that the NLR values of the patients were significantly higher than those of the control group, and C-reactive protein values were correlated with NLR.
        explanation: CRP is confirmed as an elevated marker in FMF patients in this study as well.
environmental:
  - name: Physical Stress
    effect: May trigger episodes
    evidence:
      - reference: PMID:22234484
        supports: PARTIAL
        snippet: Multiple stressful life events predicted FMF attacks 2 days following the event. Physical exertion and high-fat diet did not increase the likelihood of FMF attacks.
        explanation: The study found that emotional stress could trigger FMF attacks, but physical stress did not show a significant effect. Therefore, while stress in general may trigger episodes, physical stress specifically does not.
  - name: Emotional Stress
    effect: Potential trigger for flare-ups
    evidence:
      - reference: PMID:22234484
        supports: SUPPORT
        snippet: Multiple stressful life events predicted FMF attacks 2 days following the event. After adjustment for treatment, an additional stressful event was associated with an estimated 70% increase in the odds of having an FMF attack on the second day.
        explanation: The study indicates a clear association between emotional stress and the triggering of FMF attacks, supporting the statement.
      - reference: PMID:33026080
        supports: SUPPORT
        snippet: The emergence of FMF attacks after emotional stress and the induction of attacks with metaraminol in previous decades suggested that stress-induced sympathoadrenal system activation might play a role in inflammasome activation and triggering attacks.
        explanation: The literature provides evidence that emotional stress can trigger FMF attacks through the activation of the inflammasome pathway.
treatments:
  - name: Colchicine
    description: First-line treatment to prevent and reduce the frequency of attacks and the risk of amyloidosis.
    evidence:
      - reference: PMID:19797919
        supports: SUPPORT
        snippet: The study demonstrated that colchicine treatment is effective in preventing amyloidosis among Armenian patients with FMF and that earlier initiation and continuous therapy at an adequate dose of 1.2-1.8 mg/day may be associated with a decreased amyloidosis risk among Armenian patients with FMF.
        explanation: The study directly supports the statement that colchicine is a first-line treatment for preventing amyloidosis, a common complication of FMF.
      - reference: PMID:25649364
        supports: SUPPORT
        snippet: The only agent that decreases the development of amyloidosis and the frequency and severity of the episodes is colchicine, which has been used for about 40 years.
        explanation: This reference clearly supports the claim that colchicine reduces the frequency of attacks and prevents amyloidosis, affirming its role as a first-line treatment.
      - reference: PMID:25791871
        supports: SUPPORT
        snippet: Early studies reported colchicine as a potential drug for preventing attacks of familial Mediterranean fever.
        explanation: This indicates that colchicine is considered effective for preventing FMF attacks, supporting its position as a first-line treatment.
      - reference: PMID:17242135
        supports: SUPPORT
        snippet: The daily application of colchicine is the standard therapy for prophylaxis of attacks and amyloid deposition in familial Mediterranean fever.
        explanation: This statement corroborates that colchicine is the standard, or first-line, therapy for preventing FMF attacks and amyloidosis.
      - reference: PMID:15720245
        supports: SUPPORT
        snippet: Since 1972 colchicine has become the drug of choice for prophylaxis against FMF attacks and amyloidosis FMF-associated.
        explanation: This reference supports the idea that colchicine is the primary treatment for preventing FMF attacks and associated amyloidosis.
  - name: Anti-IL-1 Therapy
    description: Used in colchicine-resistant cases to control inflammation (e.g., anakinra, canakinumab).
    evidence:
      - reference: PMID:28362189
        supports: SUPPORT
        snippet: The accumulating data indicates that anti IL-1 drugs are effective in treating colchicine resistant FMF cases and improving their quality of life.
        explanation: The reference supports the use of anti-IL-1 therapy for treating colchicine-resistant FMF cases.
      - reference: PMID:30338514
        supports: SUPPORT
        snippet: For those people who are colchicine-resistant or intolerant, drugs such as rilonacept, anakinra, canakinumab, etanercept, infliximab, thalidomide and interferon-alpha might be beneficial.
        explanation: The reference lists several anti-IL-1 therapies as beneficial for colchicine-resistant or intolerant FMF patients.
      - reference: PMID:36161616
        supports: SUPPORT
        snippet: Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance.
        explanation: The study supports the effectiveness of anti-IL-1 therapy in managing inflammation in colchicine-resistant FMF patients.
      - reference: PMID:27860460
        supports: SUPPORT
        snippet: In this randomized controlled trial, anakinra appears to be an effective and safe treatment for colchicine-resistant FMF.
        explanation: The reference provides evidence from a randomized controlled trial supporting the effectiveness of anakinra, an anti-IL-1 therapy, in colchicine-resistant FMF patients.
  - name: NSAIDs
    description: Used for symptom relief during acute attacks
    evidence:
      - reference: PMID:37752496
        supports: REFUTE
        snippet: 'These provide the basis for stratifying patients into the following treatment paths: continue colchicine, persisting attacks / inflammation, colchicine intolerance, persisting arthritis, colchicine reduction and adjustment/reduction of biologics.'
        explanation: The literature does not mention NSAIDs as a treatment path for symptom relief during acute attacks of Familial Mediterranean Fever. The focus is on colchicine and biological therapy.
      - reference: PMID:36945975
        supports: NO_EVIDENCE
        snippet: Mean age of the overall group was 38.2 +/- 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%, 6.64% in order).
        explanation: There is no mention of NSAIDs being used for symptom relief during acute attacks in FMF patients. The treatments focus on colchicine and IL-1 antagonist.
  - name: Lifestyle Modifications
    description: Avoiding known triggers such as stress and infections where possible
    evidence:
      - reference: PMID:38488998
        supports: PARTIAL
        snippet: Patients can significantly decrease the number of familial Mediterranean fever attacks they experience by managing psychological stress and avoiding physical factors such as cold exposure and fatigue.
        explanation: The literature supports the management of psychological stress and avoiding physical factors as triggers but does not explicitly mention infections.
      - reference: PMID:26324575
        supports: PARTIAL
        snippet: Triggers of this illness include many things, such as cold or stress.
        explanation: The literature mentions stress as a trigger but does not provide exhaustive confirmation about infections as triggers or other preventive lifestyle modifications.
---
name: Transient Neonatal Pustular Melanosis
category: Skin Disorder
parents:
  - Neonatal Condition
prevalence:
  - population: Newborns
    percentage: Rare
    evidence:
      - reference: PMID:22037857
        supports: SUPPORT
        snippet: ' ...one case each of transient neonatal pustular melanosis... (2.3% each) were enrolled in this study...'
        explanation: The literature indicates that transient neonatal pustular melanosis is quite rare with only one case identified out of a cohort, supporting the statement that it has a rare prevalence in newborns.
progression:
  - phase: Onset
    age_range: Birth
    evidence:
      - reference: PMID:22884507
        supports: SUPPORT
        snippet: Transient neonatal pustular melanosis is a skin condition commonly seen in newborns.
        explanation: The article mentions that Transient Neonatal Pustular Melanosis (TNPM) is observed in newborns, supporting the statement regarding its onset at birth.
      - reference: PMID:33609325
        supports: SUPPORT
        snippet: In this study, newborns born between 2018 and 2019 were evaluated prospectively. Along with demographic findings, temporary neonatal skin manifestations, congenital spots, benign neonatal pustulosis, congenital anomalies and other lesions were statistically evaluated.
        explanation: The reference specifies the evaluation of neonatal skin manifestations in newborns, including Transient Neonatal Pustular Melanosis, thus supporting the statement about its onset phase at birth.
      - reference: PMID:11422167
        supports: SUPPORT
        snippet: It must be distinguished from other causes of a pustular eruption in neonates, including infection and erythema toxicum neonatorum, and rare disorders such as transient neonatal pustular melanosis...
        explanation: The article includes transient neonatal pustular melanosis in the differential diagnosis of pustular eruptions in neonates, indicating its occurrence from birth.
  - phase: Resolution
    age_range: Weeks
    evidence:
      - reference: PMID:22884507
        supports: NO_EVIDENCE
        snippet: Transient neonatal pustular melanosis.
        explanation: The reference title mentions the condition transient neonatal pustular melanosis, but it does not provide any specific information about its progression, age range, or resolution phase.
      - reference: PMID:37340913
        supports: NO_EVIDENCE
        snippet: A Neonate With a Rash.
        explanation: Though discussing various neonatal conditions involving rashes, the abstract does not mention specific details about transient neonatal pustular melanosis or its progression and resolution age range.
      - reference: PMID:29974501
        supports: NO_EVIDENCE
        snippet: Management of afebrile neonates with pustules and vesicles in a pediatric emergency department.
        explanation: The study mentions vesicles and pustules in afebrile neonates but doesn't provide information specifically about transient neonatal pustular melanosis and its progression or resolution phase.
      - reference: PMID:31553864
        supports: NO_EVIDENCE
        snippet: A neonatal pustule:Langerhans cell histiocytosis.
        explanation: Discusses Langerhans cell histiocytosis and its presentation in neonates, but does not cover transient neonatal pustular melanosis.
      - reference: PMID:11422167
        supports: NO_EVIDENCE
        snippet: Neonatal eosinophilic pustular folliculitis.
        explanation: Mentions eosinophilic pustular folliculitis and compares it to other pustular neonatal conditions, including transient neonatal pustular melanosis, but does not provide details on the progression, age range, or resolution phase of transient neonatal pustular melanosis.
pathophysiology:
  - name: Melanocyte Activation
    description: An unknown trigger, possibly related to the transition from intrauterine to extrauterine life, leads to the activation of melanocytes in the skin.
    cell_types:
      - Melanocyte
    downstream:
      - Melanin Accumulation
  - name: Melanin Accumulation
    locations:
      - Epidermis
    description: Activated melanocytes produce and release excessive amounts of melanin, which accumulates in the superficial layers of the skin.
    downstream:
      - Pustule Formation
  - name: Pustule Formation
    locations:
      - Epidermis
    description: The accumulation of melanin in the epidermis leads to the formation of small, superficial pustules that are characteristically present at birth or develop within the first few days of life.
    downstream:
      - Hyper pigmentation
      - Desquamation
  - name: Hyper pigmentation
    locations:
      - Skin
    description: As the pustules resolve, they may leave behind areas of hyper pigmentation or dark spots on the skin, representing the sites of melanin accumulation.
  - name: Desquamation
    locations:
      - Skin
    description: In some cases, the resolution of pustules may be followed by a period of superficial skin peeling or desquamation.
  - name: Spontaneous Resolution
    description: Transient Neonatal Pustular Melanosis is a self-limited condition that typically resolves spontaneously within a few weeks to months without any sequelae.
  - name: Benign Course
    description: Despite the presence of pustules and skin changes, Transient Neonatal Pustular Melanosis is a benign condition that does not affect the overall health of the neonate.
phenotypes:
  - category: Dermatologic
    name: Pustules
    frequency: VERY_FREQUENT
    diagnostic: true
    evidence:
      - reference: PMID:7091064
        supports: SUPPORT
        snippet: Transient neonatal pustular melanosis.
        explanation: The title confirms that transient neonatal pustular melanosis is indeed a dermatologic condition.
      - reference: PMID:12113648
        supports: SUPPORT
        snippet: Generalized pustular eruptions in neonates include erythema toxicum neonatorum and transient neonatal pustular melanosis, both of which are non-infectious.
        explanation: This snippet supports the statement by confirming that transient neonatal pustular melanosis falls under generalized pustular eruptions in neonates.
      - reference: PMID:27192509
        supports: SUPPORT
        snippet: The majority of neonatal skin pustules is not infectious, comprising the benign neonatal pustulosis. The most common ones are erythema toxicum neonatorum, the transient neonatal pustular melanosis and the benign cephalic pustulosis.
        explanation: This snippet supports the statement by indicating transient neonatal pustular melanosis is a common and benign pustular condition in newborns.
      - reference: PMID:511427
        supports: SUPPORT
        snippet: Transient neonatal pustular melanosis.
        explanation: The title confirms that transient neonatal pustular melanosis is a recognized dermatologic condition.
      - reference: PMID:28543629
        supports: SUPPORT
        snippet: Erythema toxicum neonatorum (ETN) and transient neonatal pustular melanosis (TNPM) are benign pustular skin conditions that are relatively common in newborns.
        explanation: This snippet supports the statement by confirming that transient neonatal pustular melanosis is a common benign pustular skin condition in newborns.
  - category: Dermatologic
    name: Hyperpigmented Macules
    frequency: VERY_FREQUENT
    evidence:
      - reference: PMID:511427
        supports: PARTIAL
        snippet: A Mexican-American boy presented at birth with an extensive eruption consisting of 0.5 to 1.0 cm hyperpigmented macules with a distinct peripheral scale involving primarily the forearms, abdomen and lower back.
        explanation: The reference supports the presence of hyperpigmented macules as a phenotype of transient neonatal pustular melanosis. However, it does not provide support for the frequency being 'High'.
      - reference: PMID:22884507
        supports: PARTIAL
        snippet: Transient neonatal pustular melanosis.
        explanation: The title indicates a relation to transient neonatal pustular melanosis, but the document itself does not specify the frequency of occurrence of hyperpigmented macules or confirm that it is a 'High' frequency phenotypic characteristic.
diagnosis:
  - name: Dermatologic Examination
    notes: Observation of typical pustules, ruptured lesions, and resultant hyperpigmented macules.
    evidence:
      - reference: PMID:24318488
        supports: SUPPORT
        snippet: The clinical aspect and time of onset are generally sufficient to make the correct diagnosis. Nevertheless, peculiar clinical presentations may require additional work-up to rule out life-threatening conditions, and dermatological consultation and histological examination are required for the final diagnosis.
        explanation: The literature mentions that clinical recognition through observation of typical skin changes can be sufficient for diagnosis, suggesting that a dermatological examination is key in diagnosing Transient Neonatal Pustular Melanosis.
      - reference: PMID:33397568
        supports: SUPPORT
        snippet: An accurate diagnosis is primarily based on the distinct morphologic features of the pustules and the characteristic hyperpigmented macules left behind.
        explanation: This supports the value of dermatologic examination in diagnosing Transient Neonatal Pustular Melanosis by observing the specific morphologic features.
  - name: Skin Smear
    notes: May reveal neutrophils and absence of microorganisms.
    evidence:
      - reference: PMID:511427
        supports: SUPPORT
        snippet: Gram stains of the pustules showed numerous neutrophils but no bacteria.
        explanation: The use of skin smears in diagnosing transient neonatal pustular melanosis is supported as it reveals neutrophils and an absence of bacteria.
      - reference: PMID:9144701
        supports: SUPPORT
        snippet: The Tzanck smear is a very easy, rapid, and sensitive test for detection of a herpetic infection (multinucleated giant cells) as well as noninfectious pustular eruptions (eosinophils, neutrophils). Therefore the Tzanck smear should be the first test performed.
        explanation: The statement is supported as the use of skin smears to detect neutrophils in noninfectious pustular eruptions is recommended.
treatments:
  - name: None Required
    description: Condition is self-limiting and resolves without treatment.
    evidence:
      - reference: PMID:7091064
        supports: SUPPORT
        snippet: Transient neonatal pustular melanosis.
        explanation: The literature specifically covers transient neonatal pustular melanosis, implying it is self-limiting and does not require treatment.
      - reference: PMID:27192509
        supports: SUPPORT
        snippet: However, the majority of neonatal skin pustules is not infectious, comprising the benign neonatal pustulosis. Benign neonatal pustuloses are a group of clinical disease characterized by pustular eruptions in which a contagious agent is not responsible for its etiology. The most common ones are erythema toxicum neonatorum, the transient neonatal pustular melanosis and the benign cephalic pustulosis. These dermatoses are usually benign, asymptomatic and self-limited.
environmental:
  - name: Not Applicable
    evidence:
      - reference: PMID:7091064
        supports: NO_EVIDENCE
        snippet: No environmental factors are mentioned in relation to Transient Neonatal Pustular Melanosis in the provided literature.
        explanation: The provided literature does not discuss environmental causes or factors related to the condition.
notes: No known environmental factors are associated with this condition.
---
name: Nephronophthisis
category: Genetic
parents:
  - Tubulointerstitial Kidney Disease
  - Ciliopathy
has_subtypes:
  - name: Infantile Nephronophthisis
    description: Early onset in infancy characterized by rapid progression to end-stage renal disease.
    evidence:
      - reference: PMID:16966065
        supports: SUPPORT
        snippet: Infantile nephronophtisis is a recessive autosomic tubulo-interstitial nephritis with cortical microcysts which progress to end stage renal failure before age 5.
        explanation: The source indicates that infantile nephronophthisis is characterized by early onset and rapid progression to end-stage renal disease, supporting the statement.
  - name: Juvenile Nephronophthisis
    description: Most common form with onset in childhood and progressive renal failure by adolescence.
    evidence:
      - reference: PMID:16966065
        supports: SUPPORT
        snippet: Juvenile nephronophthisis, the most frequent, progresses to end stage renal failure before age 15.
        explanation: The provided excerpt states that juvenile nephronophthisis is the most frequent subtype and typically progresses to end-stage renal failure by adolescence.
      - reference: PMID:35570616
        supports: SUPPORT
        snippet: Nephronophthisis is the most common genetic cause of kidney failure in childhood... outcomes of kidney transplant recipients with primary diagnosis of juvenile nephronophthisis...
        explanation: The excerpt indicates that juvenile nephronophthisis is a common pediatric kidney failure cause, aligning with 'most common form with onset in childhood'.
  - name: Adolescent Nephronophthisis
    description: Later onset in teenage years with slower progression to renal failure.
    evidence:
      - reference: PMID:16966065
        supports: SUPPORT
        snippet: Adolescent nephronophtisis is a less frequent form of nephronophtisis.
        explanation: The term 'adolescent nephronophthisis' is noted, and it is described as a less frequent form of nephronophthisis which is consistent with later onset.
      - reference: PMID:16966065
        supports: SUPPORT
        snippet: Medullary cystic disease is transmitted as an autosomic dominant trait. Clinical and histological signs are similar to nephronophthisis, but the disease progress later to terminal renal failure and is not accompanied by extra-renal symptoms.
        explanation: Medullary cystic disease presents similar signs but progresses later, implying a slower progression to renal failure, corroborating the adolescent nephronophthisis description.
prevalence:
  - population: Global
    percentage: 0.1-1.0
    evidence:
      - reference: PMID:29717526
        supports: NO_EVIDENCE
        snippet: Nephronophthisis is an autosomal recessive cystic kidney disease and one of the most common genetic disorders causing end-stage renal disease in children. Nephronophthisis is a genetically heterogenous disorder with more than 25 identified genes. In 10%-20% of cases, there are additional features of a ciliopathy syndrome, such as retinal defects, liver fibrosis, skeletal abnormalities, and brain developmental disorders.
        explanation: The provided literature discusses the genetic heterogeneity and associated features of nephronophthisis but does not provide information about its global prevalence.
      - reference: PMID:25514144
        supports: NO_EVIDENCE
        snippet: According to the official health statistics, Taiwan has the highest prevalence of end stage renal disease (ESRD) in the world. Each year, around 60,000 ESRD patients in Taiwan consume 6% of the national insurance budget for dialysis treatment. The prevalence of chronic kidney disease (CKD) has been climbing during 2008-2012.
        explanation: The article discusses the prevalence of end-stage renal disease in Taiwan but does not provide specific prevalence rates for nephronophthisis.
pathophysiology:
  - name: Ciliary Dysfunction
    description: Mutations in NPHP genes disrupt the structure and function of primary cilia, which are essential for cell signaling and homeostasis.
    genes:
      - NPHP
    cellular_components:
      - Primary Cilium
    downstream:
      - Impaired Cell Signaling
    evidence:
      - reference: PMID:19118152
        supports: SUPPORT
        snippet: Nephronophthisis (NPHP), a recessive cystic kidney disease... Mutations in NPHP genes cause defects in signaling mechanisms that involve the noncanonical Wnt signaling pathway and the sonic hedgehog signaling pathway, resulting in defects of planar cell polarity and tissue maintenance.
        explanation: The provided snippet indicates that mutations in NPHP genes affect mechanisms that disrupt cellular functions related to cilia, supporting the statement that these mutations lead to impaired cilia.
      - reference: PMID:34183231
        supports: SUPPORT
        snippet: Mutations in genes encoding centriolar or ciliary proteins cause diseases collectively known as 'ciliopathies'.
        explanation: This statement refers to how ciliary protein gene mutations cause related ciliopathies, aligning with impaired cilia as seen in Nephronophthisis.
      - reference: PMID:21113628
        supports: SUPPORT
        snippet: Ciliary dysfunction has emerged as a common factor underlying the pathogenesis of both syndromic and isolated kidney cystic disease, an observation that has contributed to the unification of human genetic disorders of the cilium, the ciliopathies.
        explanation: The excerpt affirms that ciliary dysfunction is fundamental to the development of various cystic kidney diseases, including Nephronophthisis, caused by mutations affecting cilia.
  - name: Impaired Cell Signaling
    description: Defective primary cilia lead to disrupted signaling pathways, such as the Wnt and Hedgehog pathways, affecting cell differentiation and proliferation.
    pathways:
      - Wnt Pathway
      - Hedgehog Pathway
    downstream:
      - Abnormal Cell Proliferation
  - name: Renal Tubular Dysfunction
    locations:
      - Renal Tubule
    downstream:
      - Polyuria
      - Polydipsia
      - Electrolyte Imbalance
      - Interstitial Fibrosis
    description: Ciliary dysfunction in renal tubular epithelial cells impairs fluid and electrolyte balance, leading to polyuria and polydipsia.
  - name: Interstitial Fibrosis
    locations:
      - Kidney Interstitium
    description: Chronic tubular dysfunction and inflammation lead to the accumulation of extracellular matrix and progressive interstitial fibrosis.
  - name: Renal Cyst Formation
    locations:
      - Renal Tubule
    downstream:
      - Renal Insufficiency
    description: Abnormal cell proliferation and differentiation result in the formation of cysts in the kidney tubules, contributing to the loss of renal function.
  - name: Renal Insufficiency
    description: The combination of tubular dysfunction, interstitial fibrosis, and cyst formation leads to a gradual decline in renal function and eventual end-stage renal disease (ESRD).
  - name: Extrarenal Manifestations
    subtypes:
      - "Senior-LÃ¸ken syndrome"
    locations:
      - Liver
      - Retina
      - Brain
    description: "Some forms of nephronophthisis, such as Senior-LÃ¸ken syndrome, may involve other organs due to the presence of primary cilia in various tissues."
  - name: Progression and Severity
    description: The age of onset and rate of progression vary depending on the specific NPHP gene mutations and the type of nephronophthisis.
inheritance:
  - name: Autosomal Recessive
    evidence:
      - reference: PMID:29717526
        supports: SUPPORT
        snippet: Nephronophthisis is an autosomal recessive cystic kidney disease and one of the most common genetic disorders causing end-stage renal disease in children.
        explanation: The literature clearly states that nephronophthisis follows an autosomal recessive inheritance pattern.
      - reference: PMID:31810733
        supports: SUPPORT
        snippet: There is increasing appreciation of nephronophthisis (NPHP) as an autosomal recessive cause of kidney failure and earlier stages of chronic kidney disease among adults.
        explanation: The literature confirms that nephronophthisis is inherited in an autosomal recessive manner, even in cases diagnosed in adults.
  - name: Tubulointerstitial Fibrosis
    description: Progressive fibrosis of the kidney's tubulointerstitial region.
    evidence:
      - reference: PMID:35533128
        supports: SUPPORT
        snippet: Nephronophthisis is an autosomal recessive cystic kidney disease... resulting in kidney disease and extrarenal manifestations such as retinal degeneration and liver fibrosis.
        explanation: The literature indicates that nephronophthisis involves chronic tubulointerstitial changes compatible with fibrosis.
      - reference: PMID:27169608
        supports: PARTIAL
        snippet: Chronic tubulointerstitial nephritis (CTN) is characterized by interstitial scarring, fibrosis and tubule atrophy, resulting in progressive chronic kidney disease.
        explanation: While the article discusses tubulointerstitial nephritis in general, it supports the idea that fibrosis occurs in this region, although it does not specifically discuss nephronophthisis.
phenotypes:
  - category: Renal
    name: Progressive Renal Failure
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - End-Stage Renal Disease
    evidence:
      - reference: PMID:16966065
        supports: SUPPORT
        snippet: Nephronophthisis is a chronic tubulo-interstitial nephritis which progresses to terminal renal failure.
        explanation: This abstract describes nephronophthisis as a progressive renal disease leading to end-stage renal failure, supporting the idea that progressive renal failure is a frequent and diagnostic feature.
      - reference: PMID:33323469
        supports: SUPPORT
        snippet: Nephronophthisis-related ciliopathies (NPHP-RC) account for the majority of cases of monogenetically caused end-stage renal disease (ESRD) in children.
        explanation: This reference states that nephronophthisis-related ciliopathies are a common cause of end-stage renal disease in children, confirming that progressive renal failure and progression to ESRD is common.
      - reference: PMID:20969579
        supports: SUPPORT
        snippet: A Mendelian inheritance underlies a nonnegligible proportion of hereditary kidney diseases, suggesting that the encoded proteins are essential for maintenance of the renal function.
        explanation: While the abstract primarily discusses hereditary kidney diseases in general, it emphasizes the importance of kidney function maintenance in genetic diseases, indirectly supporting the frequency and importance of progressive renal failure in conditions like nephronophthisis.
  - category: Cardiovascular
    name: Hypertension
    frequency: FREQUENT
    evidence:
      - reference: PMID:17647025
        supports: NO_EVIDENCE
        snippet: Among the causes of secondary hypertension are a group of disorders with a Mendelian inheritance pattern. Recent advances in molecular biology have unveiled the pathogenesis of hypertension in many of these conditions.
        explanation: While this reference mentions Mendelian forms of hypertension, there is no specific mention of Nephronophthisis resulting in hypertension or cardiovascular phenotypes generally.
      - reference: PMID:20969579
        supports: NO_EVIDENCE
        snippet: A Mendelian inheritance underlies a nonnegligible proportion of hereditary kidney diseases, suggesting that the encoded proteins are essential for maintenance of the renal function.
        explanation: This reference discusses hereditary kidney diseases and the genetic mutations involved but does not mention Nephronophthisis or its cardiovascular phenotypes including hypertension.
      - reference: PMID:12589180
        supports: NO_EVIDENCE
        snippet: Defective transduction of the dopamine receptor signal in the kidney...
        explanation: The article discusses the role of dopamine in the kidney and its involvement in hypertension, but it does not address Nephronophthisis or whether hypertension is a common cardiovascular phenotype in this condition.
      - reference: PMID:23402468
        supports: NO_EVIDENCE
        snippet: Hypertension is the most common modifiable risk factor for cardiovascular disease. Antihypertensive treatment substantially reduces the risk of heart failure, stroke, and myocardial infarction.
        explanation: This article offers a general overview of hypertension and its management but does not specifically mention Nephronophthisis or any associated cardiovascular phenotypes.
      - reference: PMID:16336577
        supports: NO_EVIDENCE
        snippet: Nephrosclerosis, benign nephrosclerosis, and hypertensive kidney disease are terms that clinicians use when renal damage is thought to be secondary to essential hypertension.
        explanation: While the article discusses hypertension in the context of renal diseases, it does not specify an association between Nephronophthisis and hypertension as a cardiovascular phenotype.
      - reference: PMID:37910243
        supports: NO_EVIDENCE
        snippet: Hypertension is common in children with CAKUT and increases the risk of CKD.
        explanation: This study focuses on congenital anomalies of the kidney and urinary tract (CAKUT) and their association with hypertension, but it does not discuss Nephronophthisis.
  - category: Hepatic
    name: Fibrosis
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:35533128
        supports: SUPPORT
        snippet: Nephronophthisis is an autosomal recessive cystic kidney disease caused by mutations in genes that encode proteins involved in the primary cilia function, resulting in kidney disease and extrarenal manifestations such as retinal degeneration and liver fibrosis.
        explanation: The literature mentions liver fibrosis as an extrarenal manifestation of nephronophthisis, supporting the statement that hepatic fibrosis is an occasional phenotype category of nephronophthisis.
  - category: Ophthalmologic
    name: Retinitis Pigmentosa
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:16966065
        supports: SUPPORT
        snippet: 'Some children present with extrarenal symptoms: tapetoretinal degeneration (Senior-Loken syndrome)...'
        explanation: This reference indicates that tapetoretinal degeneration, synonymous with retinitis pigmentosa in the context of this disease, is an occasional extrarenal symptom of nephronophthisis.
      - reference: PMID:25161209
        supports: SUPPORT
        snippet: The renal lesions were characterized by diffuse renal cyst development with tubulointerstitial nephropathy...These renal and retinal lesions are most similar to those associated with nephronophthisis (NPHP) and retinitis pigmentosa in humans.
        explanation: This reference directly confirms the association between nephronophthisis and retinitis pigmentosa as occasional ophthalmologic phenotypes.
      - reference: PMID:37644229
        supports: SUPPORT
        snippet: At least 10% of NPHP cases present with extrarenal conditions, which most often include retinal degeneration.
        explanation: This indicates that ophthalmologic phenotypes, including retinitis pigmentosa, occur occasionally in cases of nephronophthisis.
biochemical:
  - name: Serum Creatinine
    presence: Elevated
    evidence:
      - reference: PMID:37930417
        supports: PARTIAL
        snippet: NPHP is an autosomal recessive cystic kidney disease and is one of the most frequent genetic causes for kidney failure (KF) in children and adolescents... Persistently elevated serum creatinine and albuminuria are diagnostic and prognostic hallmarks of chronic kidney disease.
        explanation: The reference indicates elevated serum creatinine as a hallmark for chronic kidney disease, which includes nephronophthisis. However, the direct association with nephronophthisis specifically is not explicitly detailed, hence 'PARTIAL' support.
  - name: Elevated Blood Urea Nitrogen (BUN)
    presence: Elevated
    evidence:
      - reference: PMID:7272960
        supports: PARTIAL
        snippet: Irreversible and progressive renal parenchymal damage and functional impairment occurred in the majority of patients receiving at least six courses (200 mg/m2 of BCNU and/or methyl CCNU at eight-week intervals) of nitrosoureas for therapy of malignant brain tumors. Seventeen of 18 patients who received at least six courses and all nine patients who received more than ten courses developed impaired renal function as judged by elevation of blood urea nitrogen and/or serum creatinine or decrease in filtration rate as determined by inulin clearance.
        explanation: The literature supports elevated BUN as a marker of renal damage but does not specify nephronophthisis. Thus, it's partially supporting elevated BUN in cases of renal impairment.
      - reference: PMID:26769764
        supports: PARTIAL
        snippet: 'CONCLUSIONS: We showed that elevation of BUN at discharge significantly modified the relation between eGFR at discharge and the risk of all-cause mortality after discharge, suggesting that the association between eGFR and outcomes may be largely dependent on concomitant elevation of BUN.'
        explanation: While the study highlights the relevance of elevated BUN in patients with heart failure, it does not specifically address nephronophthisis. Therefore, it partially supports the biochemical value.
      - reference: PMID:21722602
        supports: PARTIAL
        snippet: 'CONCLUSION: Semiquantitative dipstick measurements of SUN can reliably identify CKD patients with elevated BUN levels.'
        explanation: This supports BUN as an indicator in chronic kidney disease (CKD) but not specifically nephronophthisis. Hence, it gives partial support.
genetic:
  - name: NPHP1
    association: Pathogenic Variants
    evidence:
      - reference: PMID:15138899
        supports: SUPPORT
        snippet: Two siblings affected with a mild form of JS were found to have a homozygous deletion of the NPHP1 gene identical, by mapping, to that in subjects with NPHP alone.
        explanation: The NPHP1 gene deletion is associated with juvenile nephronophthisis, confirming the genetic link between NPHP1 and nephronophthisis.
      - reference: PMID:36990420
        supports: SUPPORT
        snippet: Patients with pathogenic variants in CEP290 or IQCB1 presented early with retinopathy, whereas other patients with INVS, NPHP3, or NPHP4 variants first developed nephropathy.
        explanation: This reference supports the genetic association of nephronophthisis with variants in several genes, highlighting NPHP1 among the genes associated with nephropathy.
  - name: NPHP3
    association: Pathogenic Variants
    evidence:
      - reference: PMID:34212438
        supports: SUPPORT
        snippet: we detected a homozygous predicted synonymous allele in NPHP3 in two children with hepatorenal fibrocystic disease from a consanguineous family.
      - reference: PMID:26184788
        supports: SUPPORT
        snippet: Eight of 17 (47.1%) patients detected were identified to have mutations in NPHP3.
      - reference: PMID:36990420
        supports: SUPPORT
        snippet: Patients with pathogenic variants in CEP290 or IQCB1 presented early with retinopathy, whereas other patients with INVS, NPHP3, or NPHP4 variants first developed nephropathy.
  - name: NPHP4
    association: Pathogenic Variants
    evidence:
      - reference: PMID:14750102
        supports: SUPPORT
        snippet: 'Nephronophthisis (NPH) is an autosomal recessive kidney disease... Four genes responsible for different types of NPH have been identified: NPHP1, NPHP2, NPHP3, and NPHP4.'
        explanation: The literature identifies NPHP4 as one of the genes responsible for different types of Nephronophthisis.
      - reference: PMID:34591160
        supports: SUPPORT
        snippet: Nephronophthisis (NPHP) 4 gene encoding nephrocystin-4... contributes to end-stage renal disease in children and young adults.
        explanation: The literature indicates that NPHP4 is associated with end-stage renal disease in Nephronophthisis, highlighting its pathogenic role.
      - reference: PMID:36990420
        supports: SUPPORT
        snippet: Senior-Loken syndrome (SLSN) is an autosomal recessive disorder characterized by retinopathy and nephronophthisis... Patients with pathogenic variants in CEP290 or IQCB1 presented early with retinopathy, whereas other patients with INVS, NPHP3, or NPHP4 variants first developed nephropathy.
        explanation: The literature mentions that patients with NPHP4 variants develop nephropathy in the context of Nephronophthisis.
environmental:
  - name: Not Applicable
    notes: Nephronophthisis is primarily driven by genetic mutations.
    evidence:
      - reference: PMID:15917209
        supports: REFUTE
        snippet: There has been tremendous progress in the past few years in understanding the molecular basis of nephronophthisis, and it is now evident that the disease is characterized by both clinical and genetic heterogeneity.
        explanation: This indicates that Nephronophthisis is primarily driven by genetic mutations, not environmental factors.
      - reference: PMID:20844548
        supports: REFUTE
        snippet: Nephronophthisis (NPHP) 4 gene coding nephrocystin-4 is involved in the development of renal tubules and its congenital mutations cause juvenile end-stage renal disease, NPHP.
        explanation: This further supports that Nephronophthisis is caused by genetic mutations and not by environmental factors.
      - reference: PMID:29869359
        supports: REFUTE
        snippet: The patient had elevated liver enzymes and biopsy-proven liver fibrosis. As liver synthesis was acceptable, only KT was performed. However, liver fibrosis progressed at 1.5 years after transplantation, manifested with portal hypertension and hypersplenism.
        explanation: This case study describes genetic mutations as the cause of disease progression, reinforcing that Nephronophthisis is genetically driven.
treatments:
  - name: Renal Replacement Therapy
    description: Dialysis or kidney transplantation for end-stage renal disease.
    evidence:
      - reference: PMID:32906116
        supports: SUPPORT
        snippet: Nephronophthisis (NPHP) is an autosomal recessive disease manifesting as tubulointerstitial nephritis uniformly progressing to ESRD in approximately 5-10% patients in childhood. Living donor transplantation is the most beneficial mean of renal replacement therapy compared to other methods.
        explanation: The abstract discusses that Nephronophthisis often leads to end-stage renal disease (ESRD) and mentions living donor transplantation as a beneficial renal replacement therapy option.
      - reference: PMID:15715116
        supports: SUPPORT
        snippet: 'Diabetes and ESRD receiving Renal Replacement Therapy (RRT)... The main choices of modalities are: 1) haemodialysis (HD), 2) Peritoneal dialysis (PD), 3) Kidney transplantation alone (KTA) or 4) simultaneous kidney and pancreas transplantation (SPKT).'
        explanation: Although this reference focuses on diabetic nephropathy, it supports the statement that renal replacement therapies for ESRD include dialysis and kidney transplantation.
  - name: Antihypertensive Therapy
    description: Management of blood pressure with medications.
    evidence:
      - reference: PMID:36224286
        supports: PARTIAL
        snippet: Chronic kidney disease (CKD) is one of the strongest risk factors for hypertension, and hypertension can exacerbate the progression of CKD... therefore, one of the best strategies to slow the progression of CKD is to maintain the 'numbers' of these essential components necessary to preserve renal function. To this end, both the achievement of an optimal blood pressure and a maximum reduction in urinary protein excretion are essential.
        explanation: This source suggests that managing blood pressure is essential in the context of CKD, which is related to nephron function. However, it does not explicitly mention Nephronophthisis, a specific type of nephropathy.
      - reference: PMID:30354828
        supports: NO_EVIDENCE
        snippet: Resistant hypertension (RH) is defined as above-goal elevated blood pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug classes...evaluation includes identification of contributing lifestyle issues, detection of drugs interfering with antihypertensive medication effectiveness, screening for secondary hypertension, and assessment of target organ damage. Management of RH includes maximization of lifestyle interventions, use of long-acting thiazide-like diuretics (chlorthalidone or indapamide), addition of a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and, if BP remains elevated, stepwise addition of antihypertensive drugs with complementary mechanisms of action to lower BP.
        explanation: This source provides comprehensive information on the evaluation and management of resistant hypertension but does not discuss Nephronophthisis specifically.
  - name: Supportive Care
    description: Symptomatic treatment and monitoring to manage associated complications.
    evidence:
      - reference: PMID:35533128
        supports: SUPPORT
        snippet: At the moment there is no healing therapy, so early kidney transplant is a fundamental tool to improve prognosis.
        explanation: There is no curative treatment for nephronophthisis, indicating that supportive care, including symptomatic treatment and monitoring, is currently applied to manage associated complications.
---
name: Peroxisome Biogenesis Disorder
category: Genetic
parents:
  - Inborn Error of Metabolism
  - Peroxisomal Disorder
prevalence:
  - population: Global
    percentage: Very Rare
inheritance:
  - name: Autosomal recessive
pathophysiology:
  - name: Peroxisome Biogenesis Defect
    description: Mutations in PEX genes disrupt the assembly and function of peroxisomes, leading to impaired metabolic processes.
    cellular_components:
      - Peroxisome
  - name: Accumulation of Toxic Metabolites
    description: The inability to break down very long-chain fatty acids (VLCFAs) and other compounds leads to their accumulation in tissues.
    chemical_entities:
      - VLCFAs
      - Bile Acid Intermediates
      - Phytanic Acid
  - name: Deficiency of Essential Compounds
    description: Impaired synthesis of plasmalogens and other essential compounds disrupts normal cellular functions.
    chemical_entities:
      - Plasmalogen
  - name: Neurological Dysfunction
    locations:
      - central nervous system
    description: Accumulation of toxic metabolites and deficiency of essential compounds lead to demyelination, neuronal migration defects, and neurodegeneration.
  - name: Hepatic Dysfunction
    locations:
      - liver
    description: Accumulation of bile acid intermediates and VLCFAs, along with oxidative stress, cause hepatomegaly, fibrosis, and liver failure.
  - name: Skeletal Abnormalities
    locations:
      - bones
      - cartilage
    description: Plasmalogen deficiency disrupts normal bone formation, leading to rhizomelic shortening of limbs and chondrodysplasia punctata.
  - name: Multisystem Involvement
    description: The pervasive nature of peroxisomal dysfunction affects multiple organ systems, resulting in a wide range of clinical manifestations.
phenotypes:
  - category: Neurologic
    name: Hypotonia
    frequency: VERY_FREQUENT
  - category: Neurologic
    name: Developmental Delay
    frequency: VERY_FREQUENT
  - category: Hepatobiliary
    name: Hepatomegaly
    frequency: FREQUENT
  - category: Visual
    name: Retinopathy
    frequency: FREQUENT
  - category: Auditory
    name: Hearing Loss
    frequency: FREQUENT
  - category: Craniofacial
    name: Craniofacial Dysmorphism
    frequency: OCCASIONAL
biochemical:
  - name: Very Long Chain Fatty Acids (VLCFA)
    presence: Elevated
    context: Diagnostic marker
  - name: Plasmalogens
    presence: Decreased
    context: Diagnostic marker
  - name: Bile Acid Intermediates
    presence: Elevated
    context: Diagnostic marker
genetic:
  - name: PEX1
    association: Pathogenic Variants
  - name: PEX6
    association: Pathogenic Variants
  - name: Other PEX Genes
    association: Pathogenic Variants
environmental:
  - name: Not Applicable
treatments:
  - name: Symptomatic Management
    description: Supportive care addressing specific symptoms such as physical therapy for hypotonia and seizure management.
  - name: Nutritional Support
    description: Specialized diet and supplements to manage biochemical abnormalities.
  - name: Liver Transplant
    description: Considered in severe cases with significant liver dysfunction.
  - name: Genetic Counseling
    description: Providing information and support to families regarding inheritance and implications.
---
name: Type I Diabetes
category: Metabolic
parents:
  - Autoimmune Disease
  - Diabetes Mellitus
prevalence:
  - population: Global
    percentage: 0.1-0.2
progression:
  - phase: Onset
    age_range: Childhood-Adolescence
pathophysiology:
  - name: Genetic Susceptibility
    description: Certain HLA gene variants (HLA-DQ2, HLA-DQ8) and other susceptibility genes (INS) increase the risk of developing Type I Diabetes.
    genes:
      - HLA-DQ2
      - HLA-DQ8
      - INS
    downstream:
      - Autoimmune Destruction of Beta Cells
  - name: Environmental Triggers
    description: Viral infections or early dietary factors (cow's milk, gluten) may trigger the autoimmune response in genetically susceptible individuals.
    triggers:
      - Viral Infections
      - Early Dietary Factors
    downstream:
      - Autoimmune Destruction of Beta Cells
  - name: Autoimmune Destruction of Beta Cells
    description: The immune system mistakenly targets and destroys insulin-producing beta cells in the pancreas.
    cell_types:
      - Pancreatic Islet Beta Cell
    biological_processes:
      - T Cell-mediated Cytotoxicity
      - Autoantibody Production
    downstream:
      - Insulin Deficiency
  - name: Insulin Deficiency
    description: Loss of beta cells leads to a deficiency of insulin, a hormone required for glucose uptake.
    downstream:
      - Hyperglycemia
      - Impaired Glucose Utilization
      - Increased Lipolysis
  - name: Hyperglycemia
    description: Lack of insulin results in high blood glucose levels, as glucose cannot be efficiently taken up by cells.
    assays:
      - Elevated Blood Glucose
      - Elevated Hemoglobin A1c (HbA1c)
    downstream:
      - Glucosuria
      - Polyuria
      - Polydipsia
      - Diabetic Ketoacidosis (DKA)
  - name: Impaired Glucose Utilization
    description: Without insulin, cells are unable to utilize glucose for energy production, leading to cellular energy deficiency.
    downstream:
      - Weight Loss
      - Fatigue
  - name: Increased Lipolysis
    description: Insulin deficiency also leads to increased breakdown of fat (lipolysis) for energy, resulting in the production of ketones.
    downstream:
      - Diabetic Ketoacidosis (DKA)
  - name: Chronic Complications
    description: Persistent hyperglycemia over time can lead to damage in various tissues and organs.
    downstream:
      - Retinopathy
      - Neuropathy
      - Nephropathy
      - Cardiovascular Disease
phenotypes:
  - category: Endocrine
    name: Hyperglycemia
    frequency: VERY_FREQUENT
    diagnostic: true
    sequelae:
      - Diabetic Ketoacidosis
      - Chronic Complications (Retinopathy, Neuropathy)
  - category: Systemic
    name: Weight Loss
    frequency: FREQUENT
    notes: Due to inability to utilize glucose for energy
biochemical:
  - name: Blood Glucose
    presence: Elevated
    frequency: VERY_FREQUENT
  - name: Hemoglobin A1c (HbA1c)
    presence: Elevated
    frequency: VERY_FREQUENT
genetic:
  - name: HLA-DQ2
    association: Susceptibility
  - name: HLA-DQ8
    association: Susceptibility
  - name: INS
    association: Susceptibility
environmental:
  - name: Viral Infections
    notes: May trigger the autoimmune response in genetically susceptible individuals
  - name: Early Dietary Factors
    notes: Possible risk factors include early exposure to cow's milk and gluten
treatments:
  - name: Insulin Therapy
    description: Essential treatment to replace the missing insulin and regulate blood glucose levels.
  - name: Blood Glucose Monitoring
    description: Regular monitoring to manage glucose levels effectively.
  - name: Lifestyle Modifications
    description: Maintaining a balanced diet, regular physical activity, and adherence to treatment plans.
---
name: Dengue
category: Infectious Disease
parents:
  - Arbovirus Infection
infectious_agent:
  - name: Dengue Virus
transmission:
  - name: Aedes Mosquito Exposure
    effect: Vector for transmission
  - name: Tropical and Subtropical Regions
    notes: Endemic areas where transmission is most common
prevalence:
  - population: Global
    percentage: 40
progression:
  - phase: Incubation
    incubation_days: 3-14
    notes: Typically 4-7 days
  - phase: Febrile
    duration_days: 2-7
    notes: Sudden onset of high fever
  - phase: Critical
    duration_days: 3-7
    notes: Risk of severe complications, including hemorrhage and vascular leakage
  - phase: Recovery
    duration_days: 2-5
    notes: Gradual return to normal fluid balance
pathophysiology:
  - name: Dengue Virus (DENV) Infection
    description: A Flavivirus transmitted by Aedes mosquitoes, causing a wide range of symptoms from mild fever to severe hemorrhagic fever and shock.
    subtypes:
      - DENV-1
      - DENV-2
      - DENV-3
      - DENV-4
    biological_processes:
      - Viral Infection
    cell_types:
      - Dendritic Cell
      - Monocyte
      - Macrophage
      - Endothelial Cell
    downstream:
      - Viral Replication
      - Immune System Activation
  - name: Viral Replication
    description: DENV replicates primarily in dendritic cells, monocytes, and macrophages, leading to the release of new virions and the spread of infection.
    cell_types:
      - Dendritic Cell
      - Monocyte
      - Macrophage
    downstream:
      - Immune System Activation
      - Cytokine Release
      - Endothelial Dysfunction
  - name: Immune System Activation
    description: DENV infection triggers a robust immune response, involving both innate and adaptive immunity.
    cell_types:
      - Natural Killer Cell
      - T Cell
      - B Cell
    downstream:
      - Cytokine Release
      - Antibody-Dependent Enhancement (ADE)
  - name: Cytokine Release
    description: Infected cells and activated immune cells release a variety of cytokines and chemokines, contributing to the inflammatory response and disease pathogenesis.
    biological_processes:
      - TNF-alpha Production
      - IL-1beta Production
      - IL-6 Production
      - IL-8 Production
      - IFN-gamma Production
    downstream:
      - Endothelial Dysfunction
      - Vascular Leakage
      - Coagulopathy
  - name: Antibody-Dependent Enhancement (ADE)
    description: In secondary infections with a different DENV serotype, pre-existing antibodies can enhance viral entry into cells, leading to increased viral replication and more severe disease.
    mechanisms:
      - Fc Receptor-Mediated Uptake
      - Increased Viral Load
    downstream:
      - Severe Dengue
      - Dengue Hemorrhagic Fever (DHF)
      - Dengue Shock Syndrome (DSS)
  - name: Endothelial Dysfunction
    description: DENV infection and the resulting inflammatory response cause damage to the endothelial cells lining blood vessels, leading to increased permeability and fluid leakage.
    mechanisms:
      - Cytokine-Induced Damage
      - Endothelial Cell Apoptosis
    downstream:
      - Vascular Leakage
      - Plasma Leakage
      - Hemoconcentration
  - name: Coagulopathy
    description: DENV infection can disrupt the balance of the coagulation system, leading to abnormalities in platelet function and an increased risk of bleeding.
    mechanisms:
      - Thrombocytopenia
      - Platelet Dysfunction
      - Disseminated Intravascular Coagulation (DIC)
    downstream:
      - Hemorrhagic Manifestations
      - Petechiae
      - Epistaxis
      - Gum Bleeding
  - name: Organ Involvement
    description: In severe cases, DENV infection can affect various organs, leading to complications and potential organ failure.
    locations:
      - Liver
      - Kidneys
      - Brain
    downstream:
      - Hepatitis
      - Acute Kidney Injury
      - Encephalitis
      - Neurological Complications
phenotypes:
  - category: Systemic
    name: Fever
    frequency: VERY_FREQUENT
    diagnostic: true
    notes: Sudden onset, often high-grade
  - category: Musculoskeletal
    name: Severe Muscle and Joint Pain
    frequency: FREQUENT
    notes: Referred to as "breakbone fever"
  - category: Gastrointestinal
    name: Vomiting
    frequency: FREQUENT
  - category: Gastrointestinal
    name: Diarrhea
    frequency: OCCASIONAL
  - category: Hemorrhagic
    name: Petechiae
    frequency: FREQUENT
    notes: Small red or purple spots on the skin
  - category: Hemorrhagic
    name: Epistaxis
    frequency: FREQUENT
    notes: Nosebleeds
  - category: Hemorrhagic
    name: Gum Bleeding
    frequency: FREQUENT
  - category: Neurologic
    name: Severe Headache
    frequency: FREQUENT
    notes: Often retro-orbital (behind the eyes)
    diagnostic: true
  - category: Systemic
    name: Fatigue
    frequency: FREQUENT
biochemical:
  - name: Dengue NS1 Antigen
    presence: Positive
    notes: Early marker of infection
  - name: Dengue IgM Antibodies
    presence: Positive
    notes: Appears ~4-5 days after onset of symptoms
  - name: Dengue IgG Antibodies
    presence: Positive
    notes: Appears later and persists, indicative of secondary infection
  - name: Platelet Count
    presence: Decreased
    notes: Thrombocytopenia is common in dengue
  - name: Hematocrit
    presence: Elevated
    notes: Indicator of plasma leakage
diagnosis:
  - name: PCR for Dengue Virus RNA
    presence: Positive
    notes: Confirms active infection
  - name: NS1 Antigen Test
    presence: Positive
    notes: Useful in early diagnosis
  - name: Serological Testing for IgM/IgG Antibodies
    presence: Positive
    notes: IgM for recent infection, IgG for past or secondary infection
treatments:
  - name: Supportive Care
    description: Includes fluid management, fever control, and monitoring for complications
  - name: Platelet Transfusions
    description: May be required in cases of severe thrombocytopenia
  - name: Pain Relief
    description: Acetaminophen is preferred; NSAIDs should be avoided due to bleeding risk
  - name: Vector Control
    description: Measures to reduce mosquito populations and prevent bites
---
name: Tuberculosis
category: Infectious Disease
parents:
  - Bacterial Infection
infectious_agent:
  - name: Mycobacterium tuberculosis
    description: A bacterium that primarily affects the lungs but can affect other organs.
transmission:
  - name: Airborne Transmission
    description: Spread through the air when individuals with active TB cough, sneeze, or speak.
prevalence:
  - population: Global
    percentage: 0.1
progression:
  - phase: Latent
    duration: Variable
    notes: Non-contagious stage where the bacteria are present in the body but inactive.
  - phase: Active
    duration: Variable
    notes: Contagious stage where symptoms appear and the bacteria can be spread to others.
pathophysiology:
  - name: Phagocytosis
    description: Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.
    cell_types:
      - Macrophage
      - T Cell
    downstream:
      - Granuloma Formation
  - name: Granuloma Formation
    description: Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.
    cell_types:
      - Macrophage
      - T Cell
    downstream:
      - Tissue Damage
    locations:
      - Lung
  - name: Tissue Damage
    locations:
      - Lung
    description: Active TB can cause cavitation and destruction of lung tissue.
phenotypes:
  - category: Respiratory
    name: Chronic Cough
    frequency: VERY_FREQUENT
    diagnostic: true
  - category: Systemic
    name: Fever
    frequency: FREQUENT
  - category: Systemic
    name: Night Sweats
    frequency: FREQUENT
  - category: Systemic
    name: Weight Loss
    frequency: FREQUENT
    notes: Also known as consumption historically.
  - category: Hematologic
    name: Hemoptysis
    frequency: OCCASIONAL
    notes: Coughing up blood.
biochemical:
  - name: Tuberculin Skin Test (TST)
    presence: Positive
    notes: Indicates TB infection, not necessarily active disease.
  - name: Interferon-Gamma Release Assay (IGRA)
    presence: Positive
    notes: Blood test indicating TB infection.
diagnosis:
  - name: Sputum Microscopy
    presence: Positive
    notes: Detection of acid-fast bacilli.
  - name: Chest X-Ray
    notes: Shows cavitary lesions and other signs of active pulmonary TB.
  - name: Sputum Culture
    presence: Positive
    notes: Confirms TB diagnosis.
treatments:
  - name: Isoniazid
    description: First-line antibiotic for TB treatment.
    notes: It's important to note that resistance to isoniazid can develop through mutations in the katG gene, which reduces the activation of the drug, or in the inhA gene, which decreases the binding affinity of the activated drug to the InhA enzyme. To minimize the risk of resistance, isoniazid is typically used in combination with other antitubercular drugs, such as rifampicin, ethambutol, and pyrazinamide.
    mechanism:
      - name: Prodrug Activation
        description: Isoniazid is a prodrug that requires activation by the bacterial enzyme catalase-peroxidase (KatG). KatG couples the isonicotinic acyl with NADH to form an isonicotinic acyl-NADH complex.
      - name: Inhibition of InhA
        description: The activated form of isoniazid binds to and inhibits the enoyl-acyl carrier protein reductase (InhA), an enzyme involved in the fatty acid synthase II (FAS-II) pathway. This pathway is essential for the synthesis of mycolic acids.
      - name: Depletion of mycolic acids
        description: By inhibiting InhA, isoniazid prevents the synthesis of mycolic acids, which are long-chain fatty acids that make up a significant portion of the mycobacterial cell wall. Mycolic acids provide structural integrity and help the bacteria resist the host's immune response.
      - name: Cell wall disruption
        description: The depletion of mycolic acids leads to the weakening and disruption of the bacterial cell wall. This makes the bacteria more susceptible to the host's immune defenses and other antibiotics.
      - name: Reactive oxygen species
        description: In addition to inhibiting mycolic acid synthesis, the isoniazid-NAD adduct can also generate reactive oxygen species (ROS) and nitric oxide (NO) within the bacteria. These reactive species can cause damage to various bacterial components, including DNA, proteins, and lipids, contributing to the bactericidal effect.
      - name: Bactericidal action
        description: The combination of cell wall disruption and the production of reactive oxygen and nitrogen species ultimately leads to the death of the M. tuberculosis bacteria.
  - name: Rifampicin
    description: Bactericidal antibiotic used for TB treatment.
    notes: Rifampicin is a broad-spectrum antibiotic that is particularly effective against mycobacteria, including M. tuberculosis, as it can easily penetrate the lipid-rich cell wall.
    mechanism:
      - name: Inhibition of bacterial RNA polymerase
        description: Rifampicin binds to the beta subunit of DNA-dependent RNA polymerase, preventing the initiation of RNA synthesis.
      - name: Disruption of bacterial transcription
        description: By inhibiting RNA polymerase, rifampicin disrupts bacterial transcription, which is essential for protein synthesis and bacterial survival.
  - name: Ethambutol
    description: Bacteriostatic antibiotic used for TB treatment.
    notes: Ethambutol is specific to mycobacteria and is often used in combination with other antitubercular drugs to prevent the emergence of drug resistance.
    mechanism:
      - name: Inhibition of arabinogalactan synthesis
        description: Ethambutol interferes with the biosynthesis of arabinogalactan, a key component of the mycobacterial cell wall.
      - name: Inhibition of arabinosyl transferase
        description: Ethambutol inhibits the enzyme arabinosyl transferase, which is responsible for the polymerization of arabinose into arabinan, a precursor of arabinogalactan.
      - name: Compromised cell wall integrity
        description: By disrupting the synthesis of arabinogalactan, ethambutol compromises the integrity of the cell wall, making the bacteria more susceptible to host defenses and other antibiotics.
  - name: Directly Observed Therapy (DOT)
    description: Health worker observes and records patients taking their medication to ensure adherence.
  - name: Latent TB Treatment
    description: Isoniazid or rifapentine used to prevent latent TB from becoming active.
notes: TB is a significant global health issue, particularly in low-income and developing countries.
